WO2003102134A2 - Pancreatic acinar cells into insulin producing cells - Google Patents

Pancreatic acinar cells into insulin producing cells Download PDF

Info

Publication number
WO2003102134A2
WO2003102134A2 PCT/US2003/016124 US0316124W WO03102134A2 WO 2003102134 A2 WO2003102134 A2 WO 2003102134A2 US 0316124 W US0316124 W US 0316124W WO 03102134 A2 WO03102134 A2 WO 03102134A2
Authority
WO
WIPO (PCT)
Prior art keywords
cells
unchanged
unchanged low
protein
insulin
Prior art date
Application number
PCT/US2003/016124
Other languages
French (fr)
Other versions
WO2003102134A3 (en
Inventor
Sharon C. Presnell
Neil Robbins
Mohammad Heidaran
Perry Haaland
Paul P. Latta
David W. Scharp
Margaret Coutts
Catherine Mcintyre
Original Assignee
Becton, Dickinson And Company
Novocell, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Becton, Dickinson And Company, Novocell, Inc. filed Critical Becton, Dickinson And Company
Priority to AU2003228255A priority Critical patent/AU2003228255A1/en
Priority to BR0311413A priority patent/BR0311413A/en
Priority to BR0311360A priority patent/BR0311360A/en
Priority to US10/515,421 priority patent/US20060122104A1/en
Priority to EP03726954A priority patent/EP1578925A4/en
Priority to JP2004510376A priority patent/JP2006512046A/en
Priority to CA 2487094 priority patent/CA2487094A1/en
Publication of WO2003102134A2 publication Critical patent/WO2003102134A2/en
Publication of WO2003102134A3 publication Critical patent/WO2003102134A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0676Pancreatic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018Culture media for cell or tissue culture
    • C12N5/0037Serum-free medium, which may still contain naturally-sourced components
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/05Inorganic components
    • C12N2500/10Metals; Metal chelators
    • C12N2500/20Transition metals
    • C12N2500/24Iron; Fe chelators; Transferrin
    • C12N2500/25Insulin-transferrin; Insulin-transferrin-selenium
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/38Vitamins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/46Amines, e.g. putrescine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/105Insulin-like growth factors [IGF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/11Epidermal growth factor [EGF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/113Acidic fibroblast growth factor (aFGF, FGF-1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/115Basic fibroblast growth factor (bFGF, FGF-2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/117Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/12Hepatocyte growth factor [HGF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/135Platelet-derived growth factor [PDGF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/15Transforming growth factor beta (TGF-β)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/16Activin; Inhibin; Mullerian inhibiting substance
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/165Vascular endothelial growth factor [VEGF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • C12N2501/235Leukemia inhibitory factor [LIF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30Hormones
    • C12N2501/315Prolactin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30Hormones
    • C12N2501/335Glucagon; Glucagon-like peptide [GLP]; Exendin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30Hormones
    • C12N2501/34Calcitonin; Calcitonin-gene related peptide [CGRO]; Amylin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30Hormones
    • C12N2501/345Gastrin; Cholecystokinins [CCK]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30Hormones
    • C12N2501/35Vasoactive intestinal peptide [VIP]; Pituitary adenylate cyclase activating polypeptide [PACAP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30Hormones
    • C12N2501/37Parathyroid hormone [PTH]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30Hormones
    • C12N2501/38Hormones with nuclear receptors
    • C12N2501/39Steroid hormones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30Hormones
    • C12N2501/38Hormones with nuclear receptors
    • C12N2501/39Steroid hormones
    • C12N2501/392Sexual steroids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40Regulators of development
    • C12N2501/41Hedgehog proteins; Cyclopamine (inhibitor)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/80Neurotransmitters; Neurohormones
    • C12N2501/83Tachykinins, e.g. substance P
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/85Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998Proteins not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/22Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from pancreatic cells
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates to compositions and methods whereby, e.g., human pancreatic acinar cells are cultured under conditions that support expansion and transdifferentiation into glandular epithelial cells and subsequently into insulin-producing cells.
  • the challenges presented by these approaches are related to maintenance of function of islets over long periods of culture, and of the relative rarity of stem-like cells that can be harnessed for insulin production from the bone marrow and pancreas.
  • the ductular precursor stem-like cells derived from the pancreas are reported to be more efficient than bone-marrow derived cells at differentiation into insulin-producing cells, and this may reflect their site of origin (i.e., pancreas) where they are certainly exposed to many differentiation signals related to the pancreatic microenvironment.
  • the most abundant cell type in the pancreas is the acinar cell, which comprises about 85% of the pancreas.
  • the acinar cells serve to produce and secrete digestive enzymes and, like islet cells, arise during development from the ductular cell compartment.
  • insulin-producing cells can be produced upon further differentiation of the duct cells in the ligated portion of the pancreas.
  • the acinar cells are also reported to be of limited survivability in primary culture, with some culture conditions leading to loss of at least 50% of cells within a week. While primary duct cells have been demonstrated in vitro to convert into insulin-producing cells under some culture conditions (e.g. Bonner Weir, 2000, U.S. Pat. No. 6,011,647), there are no reports of cells that arose from acinar cells in vitro differentiating further to produce islet-like cells.
  • pancreatic acinar cells Prior to the development of the present system, primary pancreatic acinar cells were expanded without differentiation into insulin-producing cells, either in serum- containing medium (undesirable both because of the risk and the uncertainty associated with the use of serum), or in complex serum free media formulations. Likewise, primary pancreatic acinar cells have been transdifferentiated into insulin-producing cells without expansion, producing cells with an insulin-producing phenotype in small numbers. Furthermore, it has not been previously possible to obtain insulin-producing cells in good numbers using acinar cells as starting material.
  • the present invention provides compositions and methods whereby, e.g., acinar cells can be cultivated successfully in vitro, undergoing a 3-4 fold increase in cell number over time, and giving rise to a cell population that co-expresses acinar and ductal markers early during the culture (2-3 days ex vivo), then ultimately (e.g., about 7-8 days ex vivo) acquires a modified phenotype characterized by expression of some acinar-associated genes, as well as some liver-associated genes.
  • genes expressed by these modified cells at about 7-8 days ex vivo include, e.g., ductular cytokeratins (CK7, CK8, CK18 and CK19), hepatic nuclear factor 1 (HNF1), alpha-1 antitrypsin, pi-glutathione s transferase (pi-GST), liver-specific (basic helix-loop-helix (bHLH) transcription factor, Thy-1, CCAAT/enhancer-binding protein (C/EBP)-alpha and C/EBP-beta.
  • ductular cytokeratins CK7, CK8, CK18 and CK19
  • HNF1 hepatic nuclear factor 1
  • pi-GST hepatic nuclear factor 1
  • pi-GST hepatic nuclear factor 1
  • pi-GST hepatic nuclear factor 1
  • pi-GST hepatic nuclear factor 1
  • pi-GST hepatic nuclear
  • IP intermediate progenitor
  • the expanded/transdifferentiated acinar cells can be produced using a general serum-containing media, or, in a preferred method, can be produced without serum on a surface comprising one or more extracellular matrix molecules (ECMs) in the presence of one or more soluble active factors.
  • ECMs can be presented in 2 dimensional or 3 dimensional culture systems in the presence of soluble active factors.
  • IP cells generated from these cultures are expected to be useful directly in certain medical applications. For example, there is evidence that such cells may under certain conditions become functioning insulin-producing cells when implanted in diabetic patients.
  • the cells can also be used for drug discovery and toxicity studies.
  • the IP cells can be cultivated further, in a serum-free medium composed of any standard serum-free base medium (DMEM:HamsF12, for example) with BSA and combinations of factors, including ECMs, small molecules, and growth factors.
  • DMEM serum-free base medium
  • the IP cells undergo additional steps of differentiation, culminating in the formation of cell aggregates that express pro-insulin and C-peptide. Challenge of these cultures with a high-glucose medium causes release of insulin and C-peptide into the medium, indicating the production in these cultures of functional islet-like cells.
  • the present invention provides a cell culture system comprising a superior cell attachment surface that also stimulates cellular expansion, and a simple culture medium including effective amounts of one or more soluble active factors, or serum (e.g. fetal bovine serum), added to a base medium composition.
  • the cell culture system will be particularly useful for primary culture of mammalian epithelial cells, particularly human epithelial cells.
  • the cell culture system is used for the expansion and transdifferentiation of primary acinar cells, especially human pancreatic acinar cells.
  • the cell attachment surface for this cell culture system is any surface to which the cells can attach and expand, including both 2 dimensional (e.g. plates, flasks, roller bottles, petri dishes, wells etc.) and 3 dimensional (e.g. scaffold) environments.
  • the surface comprises at least one type of ECM, or a peptide fragment thereof. Cells may, in some circumstances, detach from these surfaces and form self-supporting aggregates. Suitable fragments include peptides consisting of a sequence of three of more amino acid residues that are identical to any portion of the amino acid sequence of the ECM. Such fragments can be easily made and tested by means known to those of skill in the art.
  • the surface is a layer of collagen I. Many other surfaces known in the art are also suitable, such as Collagen VI, Collagen IV, Vitronectin, or Fibronectin. Collagen I is preferred due to ease and cost.
  • the base medium to which the soluble active factors are added may be any cell culture medium appropriate for growth and differentiation of epithelial cells. These include, but are not limited to, DMEM, Hams F12, MEM, M-199 and RPMI. The general requirements for such culture media and many suitable examples are known to those of skill in the art.
  • serum such as fetal bovine serum
  • BSA bovine serum albumin
  • the medium is preferably serum-free.
  • Soluble active factors for the expansion and transdifferentiation of primary pancreatic acinar cells into IP cells include growth factors such as HGF receptor activators and EGF receptor activators.
  • Preferred soluble active factors include one or more of EGF and Transforming Growth Factor- ⁇ , IGF1, HGF, betacellulin, prolactin and gastrin 1.
  • HGF, EGF and/or Transforming Growth Factor- ⁇ are particularly preferred.
  • Also preferred is the combination of IGF1 and betacellulin.
  • the base medium contains a 1:1 mixture of DMEM and Hams F12.
  • the base medium is completed with the addition of glutamine to a final concentration of ⁇ 4 mM, insulin (-0.1-10 ⁇ g/ml, preferably -0.01 mg/ml), transferrin (-0.5-10 ⁇ g/ml, preferably -0.0055 mg/ml), selenium (-0.25-5.0 ng/ml, preferably -0.0067 ⁇ g/ml of sodium selenite), and Epidermal Growth Factor (EGF) (-1-20 ng/ml, preferably -10 ng/ml); this medium is hereafter referred to as pancreatic cell medium, or PCM.
  • PCM Epidermal Growth Factor
  • Fetal Bovine Serum (or other serum), preferably between -10 — 15% fetal bovine serum, most preferably about 10% or up to about 15% fetal bovine serum) may be added, or, to create a serum-free culture environment, the following components are added in place of serum: heat-inactivated bovine serum albumin (0.1-2%), Hepatocyte growth factor (HGF) (1-20 ng/ml), and/or Transforming Growth Factor Alpha (TGF ⁇ )(l-10 ng/ml).
  • HGF Hepatocyte growth factor
  • TGF ⁇ Transforming Growth Factor Alpha
  • the medium may contain Betacellulin (0.5-20 ng/ml), Gastrin 1 (0.05-10 ng/ml), Prolactin (1.0-10 ng/ml), and/or IGF-1 (5-100 ng/ml).
  • Betacellulin 0.5-20 ng/ml
  • Gastrin 1 0.05-10 ng/ml
  • Prolactin 1.0-10 ng/ml
  • IGF-1 5-100 ng/ml.
  • greater or lesser amounts of these components may be added in order to achieve a formulation that is effective in supporting the expansion and transdifferentiation of the cells. Persons of skill in the art will appreciate that determining effective amounts of the components will require no more than routine experimentation.
  • the cell culture system is a combination of collagen I coated tissue culture surface (presented in a 2 dimensional or 3 dimensional form) and a serum-free medium containing BSA, insulin, transferrin, selenium, Hepatocyte growth factor (HGF), Epidermal Growth Factor (EGF) and Transforming Growth Factor Alpha (TGFA).
  • BSA serum-free medium containing BSA, insulin, transferrin, selenium, Hepatocyte growth factor (HGF), Epidermal Growth Factor (EGF) and Transforming Growth Factor Alpha (TGFA).
  • HGF Hepatocyte growth factor
  • EGF Epidermal Growth Factor
  • TGFA Transforming Growth Factor Alpha
  • the cell culture system enables superior attachment in vitro of primary pancreatic epithelial cells for adherent culture compared to prior methods, while creating a cellular environment that promotes expansion of the epithelial component of primary pancreatic cultures with concomitant transdifferentiation of the acinar cells present in the starting material into IP cells, while minimizing emergence of undesired fibroblasts.
  • Advantages of this culture system are ease of construction, few components needed, and that all components are readily available and easily used in the required manner.
  • the components of this aspect of the invention may be conveniently packaged in the form of a kit.
  • the kit may include, for example, 1) a cell culture medium such as DMEM: 2) a serum-free medium supplement containing BSA, insulin, transferrin, selenium, HGF, EGF and TGFA, in suitable amounts to yield the concentrations noted above in the completed medium; and 3) at least one collagen I coated substrate, such as a vessel for tissue culture (e.g., dish(es) with at least one collagen-1 coated tissue culture surface), or collagen-1 coated inserts for use in culture dishes or other laboratory ware.
  • the kit may also optionally include a tissue culture dish or other cell culture accessories and additional reagents that may be required to carry out epithelial cell culture and differentiation.
  • Culture systems consisting of scaffolds, collagen coated flasks or other vessels and serum-free base medium may be packaged along with the soluble active factors as a separate vial that would be added to the culture medium just prior to use.
  • the active factor combination can be added to a variety of base media to accomplish the same end, e.g., growth and differentiation of primary pancreatic acinar cells in vitro.
  • Such culture systems should also be useful for other cell types, particularly glandular epithelial cells derived from other organs and tissues, including those from liver, pancreas, intestine, prostate, and breast.
  • the collagen I surface provides superior cell attachment (thereby increasing the number of cells that adhere during initial culture and thus enhancing culture efficiency), while the collagen I and the combination of soluble active factors (e.g., HGF, TGFA and EGF) promote continued proliferation of cells over time, leading to an increase in cell number above what has been previously reported for primary pancreatic acinar cells. Furthermore, the expansion of the acinar cells is accompanied by a transdifferentiation in the majority of cells to an IP phenotype, which is potentially a therapeutically useful cell phenotype for the treatment of diseases such as diabetes. This likely occurs due to convergence of the intracellular signaling pathways associated with collagen I, HGF, TGFA and EGF, creating a synergistic response.
  • soluble active factors e.g., HGF, TGFA and EGF
  • the cell culture system of the present invention has unexpected advantages over systems previously in use.
  • Collagen I, IV, NI, Vitronectin and Fibronectin were expected to enhance cell attachment.
  • other extracellular matrix molecules that yielded equivalent attachment of cells during the initial 18 hours of culture did not promote consistent growth of the cells over time in the serum-free medium containing HGF/EGF/TGFA.
  • the most efficient and cost-effective method of achieving cell expansion AND differentiation into IP cells is to utilize a collagen-I surface and a medium containing reduced serum (preferably less than 20%, more preferably less than 15%, 10%, or 5%, most preferably 2%).
  • mammalian epithelial cell any cell of a tissue or organ with an epithelial cell phenotype, defined by the presence of expression of cytokeratins and often through the presence of markers that suggest a tissue-specific function (i.e., epithelial cells of the skin make keratin, epithelial cells of the intestine make mucin, epithelial cells of the prostate make PSA).
  • the cells are primary pancreatic cells, particularly human pancreatic cells.
  • Suitable temperature for mammalian cells is usually in the range of about 37°C, but may be varied somewhat according to cell type.
  • the atmosphere can be ordinary air, or other specialized mixtures of gasses suitable for maintaining cells, as will be familiar to persons of skill in the art. Expansion of pancreatic acinar cells can be maximized by decreasing the oxygen tension in the culture atmosphere to less than 21%, while transdifferentiation to IP cells can be enhanced by increasing oxygen tension to greater than 5%.
  • a preferred range of oxygen tension is between about 5% and about 21%.
  • the invention also provides methods and compositions for transforming glandular epithelial cells that have acquired expression of markers characteristic of an intermediate progenitor (IP) phenotype as described above into insulin-producing cells.
  • glandular epithelial cell is meant an epithelial cell that is a component of a gland. Glands are tissues that have a specific function related to secretion of key molecules - most organs in the body have glandular function (liver, intestine, pancreas, prostate, breast, pituitary, adrenal, kidney) whereby they produce and release hormones, digestive enzymes, or other life-essential fluids.
  • Glandular epithelial cells from endoderm-derived organs e.g., liver, intestine, pancreas
  • endoderm-derived organs e.g., liver, intestine, pancreas
  • glandular epithelial cells from pancreas for example acinar cells.
  • the terms "express” and “expression” generally refer to nucleic acids (e.g., mRNAs) or to protein gene products that are detectable by standard immunocytochemical methods.
  • the invention provides a second cell culture system comprising a cell attachment surface and a culture medium that supports and promotes the transformation of glandular epithelial cells into insulin-producing cells.
  • the cell attachment surface is similar to and may be identical to the attachment surface for expanding primary pancreatic acinar cells. It may be presented in the form of a flat surface coated on a vessel or in the form of a scaffold or other surface adapted for cell culture. It can be comprised of, or coated with, any composition that is capable of maintaining cells or supporting cell growth. In a preferred embodiment, it comprises at least one ECM, such as Collagen I, Collagen VI, Collagen IV, Vitronectin or Fibronectin. In a particularly preferred embodiment, the cell attachment surface is Collagen-I.
  • the invention provides a further culture medium comprising at least one differentiation promoting factor (“DPF") that promotes the transformation of glandular epithelial cells into insulin producing cells.
  • DPFs for the transformation of glandular epithelial cells into insulin producing cells can be one or more of Activin A, acidic FGF, basic FGF, C-Natriuretic Peptide (CNP), Calcitonin Gene Related Peptide, Cholera Toxin B Subunit, Dexamethasone, Gastrin-Releasing Peptide, Glucagon-like Peptide-1 (GLP-1), Glucose, IGF1, IGF2, Insulin, Laminin, LIF, Met-Enkephalin, PDGFAA+PDGFBB, Prolactin, Sonic Hedgehog, Substance P, TGF-alpha, Trolox (alpha-tocopherol derivative), or VEGF.
  • PPFs for the transformation of glandular epithelial cells into insulin producing cells can be one or more of Activin A, acid
  • the culture medium comprises at least one (or as many as all 10) of the following differentiation promoting DPFs:. C-Natriuretic Peptide (CNP), Calcitonin Gene Related Peptide, Cholera Toxin B Subunit, Dexamethasone, Gastrin-Releasing Peptide, Laminin, Met-Enkephalin, PDGFAA+PDGFBB, Sonic Hedgehog, and Substance P.
  • CNP C-Natriuretic Peptide
  • Calcitonin Gene Related Peptide Cholera Toxin B Subunit, Dexamethasone, Gastrin-Releasing Peptide, Laminin, Met-Enkephalin, PDGFAA+PDGFBB, Sonic Hedgehog, and Substance P.
  • the culture medium that promotes the transformation of glandular epithelial cells into insulin producing cells consists of a 1:1 mixture of DMEM and Hams F12 plus the components listed in Table 2. This medium is sometimes referred to herein as "Media or Medium G9
  • the components of this aspect of the invention may also be conveniently packaged in the form of a kit.
  • the kit may include, for example, 1) a cell culture medium such as DMEM, Hams F12, or a combination thereof; 2) a serum-free medium supplement containing: BSA and the DPFs Activin A, acidic FGF, basic FGF, C- Natriuretic Peptide (CNP), Calcitonin Gene Related Peptide, Cholera Toxin B Subunit, Dexamethasone, Gastrin-Releasing Peptide, Glucagon-like Peptide-1 (GLP-1), Glucose, IGF1, IGF2, Insulin, Laminin, LIF, Met-Enkephalin, PDGFAA+PDGFBB, Prolactin, Sonic Hedgehog, Substance P, TGF-alpha, Trolox (alpha-tocopherol derivative), or VEGF, or two or more of these components in combination, in suitable amounts to yield the concentrations noted in Table 1 in the completed
  • Culture systems consisting of scaffolds, collagen coated flasks or other vessels and serum-free base medium may be packaged along with the DPF(s) as a separate vial that would be added to the culture medium just prior to use.
  • the DPF combination can be added to a variety of base media to accomplish the same end, e.g., growth and differentiation of primary pancreatic acinar cells in vitro.
  • Such culture systems may also be useful for other cell types, particularly other epithelial cells derived from glandular tissues, including those from liver, pancreas, intestine, prostate, and breast.
  • the invention also provides a method for converting glandular epithelial cells into insulin-producing cells comprising culturing the glandular epithelial cells in the cell culture system described above.
  • the method may further comprise removing the culture medium from the cell culture, re-feeding the cell culture with a serum-free medium with glucose, and measuring proinsulin production C-peptide production, or insulin release.
  • the invention provides an isolated population of insulin-producing cells containing cytoplasmic granules with immunodetectable proinsulin, insulin, and/or c-peptide that is derived from a population of cells of which a subset of cells expressed at least one marker associated with IP cells (e.g., expressed some acinar-associated genes, as well as some liver-associated genes, including, e.g., ductular cytokeratins (CK7, CK8, CK18 and CK19), HNF1, alpha-1 antitrypsin, pi-glutathione s transferase (pi-GST), liver- specific bHLH transcription factor, Thy-1, C/EBP-alpha and C/EBP-beta, and expressed little if any of the pancreas-associated genes carbonic anhydrase, cystic fibrosis transmembrane conductance regulator (CFTR), elastase and amylase).
  • IP cells e.g., expressed some acina
  • an “isolated" cell or population of cells is meant herein that the cell or cell population is removed from its original environment (e.g., the natural environment if it is naturally occurring), and isolated or separated from at least one other component with which it is naturally associated.
  • a naturally-occurring cell present in its natural living host is not isolated, but the same cell, separated from some or all of the coexisting materials in the natural system, is isolated.
  • Such cell or cell populations could be part of a cell culture or cell population, and still be isolated in that such culture or population is not part of its natural environment.
  • the insulin-producing cells are derived from glandular epithelial cells obtained from mammalian pancreas, such as primary acinar cells.
  • the data disclosed in the examples below are generated from freshly isolated human pancreatic cells.
  • the expansion of primary human pancreatic cells in these conditions produces cultures with a mixed epithelial IP phenotype, suitable for in vitro studies of IP cells for a variety of purposes, and suitable for transplantation in vivo for cell therapy for the treatment of diseases such as diabetes.
  • the IP cells generated by these methods may also be useful in the study of pancreatic cell biology, as normal controls in the study of pancreatic epithelial cancers, and to test the effects of drugs/compounds on normal pancreatic epithelial cells (ductal or acinar).
  • the cells may be further cultured to yield insulin-producing cells as demonstrated below.
  • Figures 1 A-D show microscopic images after treatment of starting material with antibodies to amylase (Fig. 1A), insulin (Fig. IB), and CK19 (Fig. 1C) and the composition of the cell pellet of freshly isolated primary human pancreatic cells (Fig.
  • Figure 2 shows growth curves constructed from primary human pancreatic cultures grown in commercial medium (with serum) or in the described pancreatic cell medium (PCM) with serum.
  • Figure 3 shows a comparison of cell expansion in the base medium composition described vs. base medium + soluble growth factors (serum-free formula) vs. base medium + fetal bovine serum.
  • Figures 4A-B shows the effect of different culture surfaces on total cell number (Fig. 4 A) and cell phenotype (Fig. 4B) after expansion.
  • Figures 5A-B show a comparison of cell phenotype after expansion in serum- containing (5 A) and serum-free (5B) medium containing all soluble active factors.
  • Figure 6 shows high power images of cell cultures expanded in various conditions, including serum-free base media supplemented with 3 soluble active factors, HGF, EGF & TGFA. Note epithelial morphology.
  • Figure 7 shows a demonstration of growth of IP cells on ECM-coated surfaces as determined by metabolic activity assay over time. Note superior growth when Collagen I surface is combined with the media formulation described herein, yielding results superior to the combination of Matrigel and commercial media with serum.
  • Figure 8A shows expression of amylase by acinar cells after two days of culture (red staining)
  • Figure 8B shows expression of CK19 (green staining)
  • Figure 8C shows an overlay of the two images, showing co-expression (yellow) in a large proportion of cells.
  • Figure 9 shows changing phenotype of primary acinar cells in culture over 5 days. Amylase is red, CK19 is green. Note appearance of yellow (amylase + CK19) on Day 2 and 3.
  • Figures 10A and 10B show primary human pancreatic cells that were expanded in serum-containing medium on Collagen I coated surface. Images were analyzed to determine total cells (Figure 10A, blue nuclei) and total positive cells (Figure 10B, blue nuclei surrounded by green staining for CK19).
  • Figure 11 shows light microscopic (200X) appearance of pancreatic acinar cells cultured on a collagen I surface with all DPFs (Activin A, 0.5 ng/ml; acidic FGF, 2.5 ng/ml; basic FGF, C-Natriuretic Peptide (CNP), 0.11 ⁇ g/ml; Calcitonin Gene Related Peptide, 0.19 ⁇ g/ml; Cholera Toxin B Subunit, 12.5 ng/ml; Dexamethasone, 0.002 ⁇ g/ml; Gastrin-Releasing Peptide, 0.143 ⁇ g/ml; Glucagon-like Peptide- 1 (GLP-1), 0.033 ⁇ g/ml; Glucose, 1.08 ⁇ g/ml; IGF1, 0.0025 ⁇ g/ml; IGF2, 0.0025 ⁇ g/ml; Insulin, 9.5 ⁇ g/ml; Laminin, 2.25 ⁇ g/m
  • Figure 12A (top right panel) shows immunocytochemical analysis with CK19 antibodies (green).
  • Figure 12B shows immunocytochemical analysis with C- peptide antibodies (red).
  • Figure 12C shows an overlay image demonstrating the colocalization of CK19 and C-peptide (orange). Blue portions are DAPI stained nuclei.
  • Figure 13A shows insulin release upon glucose challenge in IP cells that have not been detached and relocated (subcultured) during the growth and differentiation process.
  • Figure 13B shows insulin release upon glucose challenge in IP cells that have been subcultured according to Example 10.
  • Figure 13C shows C-peptide release upon glucose challenge in IP cells that have not been subcultured according to Example 10.
  • Figure 14 shows the Insulin/DNA ratio in subcultured and nonsubcultured cells that are treated with Combinations 1, 2 and 3 of DFP media, as described in Example 11.
  • Figure 15 shows insulin release in response to base level glucose (5 mm) and a glucose challenge (22mm) over 10 days of culture in PCM and DPF media, as described in Example 13.
  • Figure 15A shows insulin release in response to base level glucose (5 mm) and a glucose challenge (22mm) over 14 days of culture in PCM and DMG9 media, as detailed in Example 14.
  • Figure 16 is a graphical representation of the characteristics of the 17 classes of genes shown in Table 6, as indicated in the last column of the Table, as detailed in Example 14.
  • BSA bovine serum albumin
  • BMP Bone Morphogenetic Protein bHLH basic helix loop helix
  • DMEM Dulbecco's Modified Eagle's Medium
  • TGFj ⁇ l Transforming Growth Factor ⁇ l
  • ECM extracellular matrix molecules; naturally occurring proteins produced by cells of a tissue that provide structural support as well as a source of cellular signals related to adhesion. Examples are collagen, vitronectin, fibronectin, laminin.
  • EGF Epidermal Growth Factor
  • HGF Hepatocyte growth factor
  • HNF-1 Hepatic nuclear factor 1
  • IGF1 Insulin-like growth factor 1
  • IGF-II Insulin-like growth factor 2
  • IP cells Intermediate progenitor cells derived from an epithelial cell, such as, e.g., a pancreatic acinar cell or a liver cell, wherein the derived cells express some acinar- associated genes, as well as some liver-associated genes, including, e.g., cytokeratins
  • pancreas-associated genes carbonic anhydrase, cystic fibrosis transmembrane conductance regulator (CFTR), elastase and amylase.
  • PDGF-A Platelet derived growth factor alpha
  • PDGF-B Platelet derived growth factor beta
  • culture system is intended to mean a system for growing and/or differentiating cells in culture, which comprises a cell attachment surface, preferably one that also stimulates cellular expansion, and a culture medium, which includes effective amounts of one or more factors, or serum (e.g. fetal bovine serum), added to a base medium composition.
  • a cell attachment surface preferably one that also stimulates cellular expansion
  • a culture medium which includes effective amounts of one or more factors, or serum (e.g. fetal bovine serum), added to a base medium composition.
  • serum e.g. fetal bovine serum
  • an effective amount means an amount that either alone or in combination with other included factors is effective in promoting either expansion and differentiation into IP cells, or into insulin- producing cells, as applicable.
  • Starting Material Primary human pancreatic acinar cells are collected as waste from standard COBE gradient preparation of islet cells for transplantation (Lake et al., 1989). After density gradient centrifugation, the islets are present as a layer between 1.063 density and 1.10 density, and the remaining cells are collected as the pellet that sediments to the bottom of the gradient based on density. Approximately 48 hours after collection of the cells at the transplant center are received by the inventors in non-tissue- culture treated polystyrene flasks and are suspended in RPMI + 10% fetal calf serum at a density of approximately 2.0 million cells/ml. Cell number and viability is assessed by trypan blue exclusion and enumeration on a hemacytometer by light microscopic observation.
  • Example 1 Characterization of cell culture conditions A. Serum-free medium
  • Figure 3 compares the results of expanding the cells for 6 days in base medium, base medium plus all of the soluble active factors [HGF, -1—20 ng/ml, preferably -5.0 ng/ml; TGFA, -1—10 ng/ ml, preferably -2 ng/ml; Betacellulin, -0.5—20 ng/ml, preferably ⁇ 10ng/ml; Gastrin 1, -0.05—10 ng/ml, preferably -0.06 ng/ml; Prolactin, -1.0—10 ng/ml, preferably -2.4 ng/ml; and IGF1, -5—100 ng/ml, preferably - 5 ng/ml] and base medium plus 10% serum.
  • the serum-free media formulation meets/exceeds expansion provided by media + serum.
  • the attachment of primary human pancreatic cells was evaluated by counting the number of attached cells vs. the number of cells initially seeded on a panel of ECM surfaces comprised of Collagen I (1 ⁇ g/cm 2 ), Fibronectin (3 ⁇ g/cm 2 ), Laminin (2 ⁇ g/cm 2 ), Vitronectin (1 ⁇ g/cm 2 ), Matrigel (1 ⁇ g/cm 2 ), Human ECM (1 ⁇ g/cm 2 ), or Poly- D-Lysine (3 ⁇ g/cm 2 ). In one condition, a mixture of Collagen IV, Laminin, and Fibronectin was utilized.
  • ECMs were placed into solution at the above concentrations and allowed to coat tissue culture-treated polystyrene surfaces according to manufacturer's suggestions of 1 hour at room temp. Excess ECM solution was then removed and surfaces were rinsed twice in water. Just before seeding cells, the water was aspirated, then cells were seeded onto the ECM surface at a density of 1 x 10 5 cells/cm 2 in growth medium (PCM) composed of DMEM:HamsF12 mixture (1:1) with 4mM glutamine, lx ITS supplement (GIBCO 51500-056), 10% Fetal Calf Serum (Inactivated, Qualified, GIBC 26140-079), and 10 ng/ml Epidermal Growth Factor (EGF) (BD 4001).
  • PCM growth medium
  • Cells were seeded onto tissue-culture polystyrene surface as a control. After 18 hours, unattached cells were washed away and remaining attached cells were re-fed with PCM and allowed to grow for 7 days prior to evaluation. Cultures were fixed in 10% formalin and subjected to immunocytochemistry with antibodies for CK19 and Amylase as described previously to determine phenotypic composition. Cells were counterstained with DAPI fluorescent blue nuclear stain to visualize individual cell nuclei for cell counting. The metabolic activity of cells subjected to the various conditions was determined by an MTS assay.
  • Viable cells were measured using the MTS assay (Promega CellTiter 96 Aqueous One Solution Cell Proliferation Assay), a colorimetric method for determining the number of viable cells in proliferation or cytotoxicity. The results of this analysis are shown in Figure 7.
  • MTS assay Promega CellTiter 96 Aqueous One Solution Cell Proliferation Assay
  • Collagens I, IV, Laminin, Fibronectin, and Matrigel provide a suitable surface for cell attachment and expansion
  • maintenance of acinar (amylase+) phenotype along with the presence of an increased proportion of cells with a glandular epithelial phenotype (CK19+) was superior on Collagen I. More than 50% of cells analyzed expressed amylase and more than 50% of cells analyzed expressed CK19, suggesting that a subpopulation of cells in these experimental conditions express both markers.
  • Tissue culture-treated polystyrene culture surfaces were coated with Collagen I as described above.
  • Tissue culture medium (PCM) was prepared as described above.
  • serum was replaced with Fraction V BSA (99% pure, heat inactivated, Sigma), along with combinations of soluble growth factors, including IGF1, IGF2, betacellulin, HGF, EGF, and TGF-alpha.
  • Optimal seeding density is between 10 4 and 10 5 cells/cm 2 , as demonstrated in Example 3. Cells were seeded onto collagen-coated flasks (150 cm 2 ) at 1.5 x 10 6 cells/flask in PCM.
  • the relative fraction of CK19+ cells was determined by quantitative image analysis as described above (see Example 4). After formalin was removed and monolayers were rinsed, cultures were subjected to immunocytochemistry as described in previous section for CK19 and vimentin (a marker of fibroblasts). Cells were also stained with amylase antibodies, but did not produce positive results due to release of digestive enzymes, such as amylase, by the cells over time in culture. The relative fraction of CK19+ cells was determined by quantitative image analysis as described above (see example 4). Acquisition of ductal markers by acinar cells was verified by demonstrating concomitant expression of CK19 and amylase in cell subpopulations during days 2-3 of culture (see example 5).
  • CK19 primary antibodies were reacted with formalin- fixed cell cultures, followed by visualization with Alexa488-conjugated Goat anti-mouse IgG (Molecular Probes). Then, cells were subjected to a blocking step (Protein Blocker, BioGenex), followed by application of the second primary antibody (anti-amylase). Visualization of the amylase was accomplished by application of Alexa594-conjugated Goat Anti-Mouse IgG. Images were collected as described above. At the end of a 7-day culture period in the conditions described herein, between 65-90% of the cells in the culture express CK19, while less than 20% express vimentin (see example 6). Variations in the relative proportion of CK19+ cells probably reflect heterogeneity due to age, gender, and other unique characteristics of individual patients.
  • Example 4 Cells were grown on a Collagen I surface, at 37°C in 21% oxygen, in PCM medium or in base medium with 2 % BSA, 2 ng/ml TGF- ⁇ , 10 ng/ml EGF, and 10 ng/ml HGF. After 7 days, cultures were fixed in 10% formalin and subjected to immunocytochemical analysis with fluorescent detection, followed by automated image collection and analysis. The results are shown in Figures 5 A and 5B. Fibroblast (vimentin+) fraction, glandular epithelial cell fraction (CK19+), and fraction of unlabeled cells (Other) are similar after expansion. This suggests that replacement of serum with the serum-free medium maintains fraction of CK19+ cells without overgrowth of fibroblasts as compared to cells grown in serum-containing media.
  • Example 5 Primary pancreatic acinar cells were cultured for several days in a 1:1 ratio of DMEM and HamsF12, with 10% fetal bovine serum, 0.01 mg/ml insulin, 0.0055mg/ml transferrin, 0.0067 ⁇ g/ml sodium selenite, 10 ng/ml EGF, 4mmol liter glutamine and antibiotics. After 2 days of culture (4 days ex vivo), expression of amylase by the acinar cells is still strong ( Figure 8A, upper left panel, red staining) as determined by immunocytochemistry. Expression of CK19 is also apparent ( Figure 8B, lower left panel, green staining).
  • Example 6 After 7 days of growth in PCM / Collagen I surface, cells were fixed, stained with antibodies to CK19, and counterstained with nuclear DAPI. Total cell number was evaluated by automated image analysis (Figure 10A left panel, blue-stained cell nuclei), while CK19+ cells were counted ( Figure 10B, right panel, green-stained cell cytoplasm). Of 378 total cells, 342 were immunopositive for CK19 (90%). After approximately 7 days of culture using conditions described herein, the acinar cells have concrete ductular characteristics, now referred to as IP cells. For most primary human cultures, more than 80%) of cells in the culture after about 7 days express markers such as CK19 that are associated with ductular cells from a variety of tissues.
  • Example 7 Gene Expression Analysis of 7-Day Cultures (IP Cells).
  • IP cells were obtained by culturing primary acinar cells in a cell culture system comprising PCM and a Collagen I surface. Monolayer cultures were rinsed 2x with PBS, then detached from the flasks with 0.25% trypsin. Cells were pelleted by centrifugation at 1,200 RPM for 3 minutes in a swinging bucket centrifuge. Cell pellets were resuspended and washed 2x in PBS before a final centrifugation at 1,200 RPM for 3 minutes as described above.
  • the supernatant was discarded and gently aspirated to remove as much liquid as possible from the cell pellet, which was then quick-frozen in a dry-ice/ethanol bath and stored at -80°C until transfer to BD Clontech where gene expression analysis was performed, using conventional techniques.
  • Labelled P-33 cDNA probes were prepared from the 30 ⁇ g of total RNA from each sample by first enriching for poly A + RNA using a streptavidin-magnetic bead separation method that is part of the Atlas Pure Total RNA Labeling system.
  • the labeled probes from each sample were hybridized with the plastic human 8 K gene arrays for about 16 hours, the arrays were washed and imaged according to the Atlas array protocols.
  • the Atlas image 2.7 software was used to align array images with the array grid template and to exclude false background signals or false signals due to strong signal bleedover.
  • the transcript signals were then extracted from these aligned arrays using the Atlas Image 2.7 software and further statistical analysis of the changes in gene expression were performed.
  • mRNA transcription was assayed, by hybridization to suitable oligonucleotide probes.
  • the protein expression product was measured, using conventional methods of immunohistochemistry.
  • Table 4 contains a list of genes expressed in IP cells and a comparison of expression patterns in primary acinar cells and primary ductal cells. Gene products identified as "+” were expressed; those identified as "++” were strongly expressed. Gene products designated ® are found in regenerating pancreas.
  • PAP Protein
  • IP cultures can be utilized to generate insulin-producing cells by placing the cells in a second phase of culture that includes a surface, such as Collagen I, that promotes attachment of the IP cells combined with a defined medium formula that lacks serum but contains combinations of the following differentiation promoting factors: Activin A, acidic FGF, basic FGF, C-Natriuretic Peptide (CNP), Calcitonin Gene Related Peptide, Cholera Toxin B Subunit, Dexamethasone, Gastrin-Releasing Peptide, Glucagon-like Peptide- 1 (GLP-1), Glucose, IGF1, IGF2, Insulin, Laminin, LIF, Met- Enkephalin, PDGFAA+PDGFBB, Prolactin, Sonic Hedgehog, Substance P, TGF-alpha, Trolox (alpha-tocopherol derivative), and VEGF.
  • Activin A acidic FGF
  • basic FGF basic FGF
  • CNP C-Natriuretic Peptide
  • the base medium is composed of a 1:1 mixture of HamsF12 and DMEM with antibiotics and 0.2%> Bovine Serum Albumin (Fraction V, heat inactivated 99%> pure).
  • the base medium contained Cholera Toxin B, Dexamethasone, GRP, GLP-1, Glucose, IGF-1, IGF-2, Insulin, Prolactin, Sonic Hedgehog, Trolox, aFGF, and bFGF.
  • the base medium contained Activin A, CGRP-alpha, CNP, Glucose, GLP-1, IGF-2, Insulin, LIF, Met-Enkephalin, Prolactin, Sonic Hedgehog, aFGF, and vEGF.
  • the base medium contains Activin A, CGRP-alpha, Cholera Toxin B, Dexamethasone, Glucose, GLP-1, Insulin, LIF, Laminin, Met-Enkephalin, PDGFAA BB, Sonic Hedgehog, Substance P, TGF-alpha, aFGF, and VEGF.
  • concentrations of these media supplements are listed in Table 1.
  • AD cells were placed into culture by either: 1) trypsinizing the cells from the surface on which they were generated, and redistribution onto a fresh attachment- promoting surface at a density of -5 x 10 cells/cm , or 2) removing the medium, washing 2x in PBS to remove traces of old medium, and cultures re-fed with the new medium (described above) containing differentiation promoting factors.
  • Cells are cultured for a period of 4-10 days at 37°C and 21% oxygen. On Day 5, half of the medium is removed and replaced with an equal volume of fresh medium containing differentiation promoting factors.
  • IP cells cultured in differentiation conditions described above were captured by light microscopy (see Example 8, below).
  • the cellular phenotype of the cells comprising these cultures was assessed by immunocytochemistry as described above using monoclonal antibodies to vimentin, pro-insulin, C-peptide, MUC-1, and CK19 (See Example 10, below). Briefly, cultures were fixed with 10% formalin for 1 hour at room temperature, then washed with PBS and subjected to immunocytochemical protocol. (See Example 9, below).
  • the ability of the aggregated cell clusters to release insulin and C-peptide was assessed by subjecting the cultured cells to a glucose challenge as follows. Cells that had been cultured in differentiation medium for 7-10 days were washed 3x in PBS, then re- fed with either 1) base medium (described above) with 5mM Glucose, or 2) base medium with 22mM glucose. After 18 hours, the cell-conditioned medium was collected and subjected to ELISA analysis for insulin and C-peptide release (Diagnostic Systems Laboratories (DSL)). ELISAs were conducted using the standard range assay procedure according to manufacturer's specifications. Plates were incubated on a shaker during the assay and results were read in a Tecan specfrophotometric plate reader. Total ng of insulin or C-peptide per well were calculated for each media condition, for both 5mM glucose media and 22mM glucose media (See Example 10).
  • Example 8 Pancreatic acinar cells were cultured in Base Medium + ITS + Serum (10%>) for 1 week, then trypsinized (treated with 0.25% Trypsin without EDTA for 10 minutes at 37°C) and transferred to a fresh collagen-1 coated surface and placed in a medium containing all 23 DFPs listed. Over a period of 3-5 days, the cells readily formed three-dimensional pod-like structures, clearly observable by light microscopy ( Figure 11). Some larger pods detached from the culture surface after about 4-6 days in culture, and remained viable, as determined by trypan blue exclusion. The pod-like structures were hypothesized to be aggregations of insulin-producing cells, and subjected to further analysis as described below.
  • Example 9 Pod-like structures, generated the same manner as described in the previous example, were fixed in 10% formalin and subjected to immunocytochemical analysis first with CK19 monoclonal antibodies, then with C-peptide monoclonal antibodies, as described above.
  • Figure 12A shows a group of cells (DAPI stained nuclei are blue), some of which are immunopositive for CK19 (green staining).
  • Figure 12B shows the same group of cells, many of which are positive for C-Peptide, which is produced when the proinsulin molecule synthesized within the cell is cleaved to yield mature insulin; the C-peptide stained cells are red, with a typical granular staining of the cytoplasm.
  • Figure 12C shows a higher power overlay image, demonstrating colocalization of CK19 and C-peptide in a small subset of cells. Co-stained cells appear yellow-orange on the overlay image.
  • Example 10 Cells cultured in base medium (negative control), or in Combinations 1, 2 and 3 of the differentiation promoting media, were evaluated for their ability to release insulin and C-peptide into the culture medium, hi addition, we assessed whether increasing concentrations of glucose led to the release of a greater quantity of insulin and C-peptide, indicating an islet-like functionality.
  • the cells were cultured for 1 week in base medium + EGF(10 ng/ml) + ITS + 10% fetal bovine serum (PCM). Then, cells were either subjected to a wash and medium change (non-subcultured), or to a wash, trypsinization detachment, reseeding, and medium change.
  • DNA was measured utilizing a standard Picogreen assay (Molecular Probes), while insulin was measured by ELISA assay. Total ng of Insulin was divided by total ⁇ g of DNA in the sample, thus providing the insulin:DNA ratio value, in order to calculate a ratio of the quantity of insulin present vs. the number of cells present (reflected by DNA content).
  • the results are shown in Figure 14.
  • the insulin:DNA ratio is increased compared to base medium, suggesting that more insulin is produced on a per cell basis in the presence of DPFs than when cultured without them.
  • the insulin:DNA ratio is increased slightly in some conditions upon glucose challenge (22mM glucose vs. 5mM), suggesting that the cells respond to glucose by releasing a greater quantity of insulin.
  • Example 12 Insulin-producing cells obtained by the preceding method were subjected to gene expression analysis as described above.
  • Table 5 contains a list of the highest expressed genes, their position on the Clontech atlas 8K gene array, and relative expression of these genes (after normalization). Table 5 is attached hereto as Appendix 1
  • Example 13 Primary human pancreatic cells were seeded at 0.5 x 10 5 cells/cm 2 in PCM on a collagen-1 surface and grown for 7 days. Insulin was measured at Days 1, 7, and 10 as follows: Growth medium was removed, wells were washed 3x in phosphate buffered saline. After a pre-incubation for 1 hour at 37C in base medium without insulin, with 5mM glucose, media was removed and replaced with either 1) base medium (without insulin) with 5mM glucose, or 2) base medium (without insulin) with 22mM glucose. Insulin was measured in cell-conditioned media after 18 hours at 37° C.
  • Example 14 Human pancreatic acinar cells were cultured on a collagen I surface in PCM from Day 1 to Day 7, thus generating a culture of IP cells at Day 7. On Day 1, the IP cells were washed and the PCM medium was replaced with the G09 differentiation medium containing the 30 factors listed in Table 2. At each time point (Days 1, 7, 10 and 14), insulin release was measured by washing the cultures three times with PBS, then challenging the cultures with a 1:1 mixture of DMEM and HAMs F12 containing either 5mM or 22mM glucose. After 18 hours of exposure to the glucose, supernatants were collected and insulin measured by ELISA. The results are shown in Figure 15 a.
  • Example 15 Three independent samples of primary human pancreatic acinar cells were seeded and expanded described above. From Day 0 to Day 8, cells were on collagen I surface, seeded at 10 cells/cm , in PCM. On Day 8, the medium was changed from PCM to the medium with the active factors shown in Table 2. Cells were fed twice with G09 (50%> of medium replaced) between days 8 and 16. The cells remained on the surface throughout the culture process. Cultures were harvested at 3 days after the initial plating (actively trans-differentiating acinar cells), 8 days after plating (IP cells) and 16 days after plating (putative insulin producing cells) and subjected to gene expression analysis, as described in Example 7. mRNA expression data were obtained with 12K microarrays from Clonetech.
  • RNAse free water was added per 9 ml of lysis solution in an Oak Ridge Cetrifuge tube.
  • chloroform was then added and the solution vigorously vortexed for 1 minute.
  • the aqueous and organic phases were then separated by cetrifugation at 4°C and the upper aqueous phase containing RNA was removed to a clean PET tube.
  • RNA was precipitated by isopropanol precipitation, washed with 70% ethanol and redissolved in 200 ⁇ l of RNAse free water.
  • a chaotrope lysis reagent was immediately added to the RNA and it was further purified using a Qiagen spin column method with a DNAse digestion step. The purified RNA was finally eluted in 80 ⁇ l RNAse free water and stored at -80°C.
  • Labelled P-33 cDNA probes were prepared from the 30 ⁇ g of total RNA from each sample by first enriching for poly A + RNA using a streptavidin-magnetic bead separation method that is part of the Atlas Pure Total RNA Labeeling system. The labeled probes from each sample were hybridized with the plastic human 12 K gene arrays for about 16 hours, the arrays were washed and imaged according to the Atlas array protocols. The Atlas image 2.7 software was used to alighn array images with the array grid template and to exclude false background signals or false signals due to strong signal bleedover. The transcript signals were then extracted from these aligned arrays using the Atlas Image 2.7 software and further statistical analysis of the changes in gene expression were performed.
  • the Table also shows the expression levels of these genes at Day 16, and the mean expression for all three condition/time points.
  • the Table also shows the ratios of expression at various times: "I to A” is the ratio of expression of putative insulin-producing cells (Day 16) to acinar (Day 8) cells; “hit to A” is the ratio of IP cells (Day 8) cells to acinar cells (Day 3).
  • Notch-3 Trace Trace Trace involved in differentiation of cells into pancreatic mesenchyme hepatic lineage and endothelium
  • BMPRclA Trace Mesenchyme c-kit Liver / Pancreas / Neuronal chromogranin A Trace Trace Trace Neuroendocrine / Liver/ Intestine
  • IP cells no longer expressed genes consistent with pancreatic acinar cells, nor did they express a complement of genes specific for pancreatic ductular cells.
  • the IP cells expressed low levels of some markers associated with pancreatic islets, including insulin, somatostatin and pancreatic polypeptide, suggesting that at least some cells in the population are competent to express endocrine genes of the pancreatic islets.
  • the IP cells also expressed several liver-specific transcription factors (e.g., C/EBP alpha, C-EBP-beta) and other markers of mature and developing liver, including low levels of Thy-1, a marker associated with hepatic "oval" stem cells.
  • C/EBP alpha C/EBP alpha
  • C-EBP-beta other markers of mature and developing liver, including low levels of Thy-1, a marker associated with hepatic "oval" stem cells.
  • Thy-1 a marker associated with hepatic "oval” stem cells.
  • the cells generated in this example resemble the cells that emerge from the pancreas of rodents that are fed a copper-deficient diet. (See, e.g. Rao et al., 1988).
  • Isolated cells generated by the methods of the present invention are to be distinguished from naturally occurring cells that may have some of the characteristics of IP cells, such as oval cells or cells isolated from the pancreas of a rodent on a copper-deficient diet.
  • IP cells having the characteristics of these IP cells may be useful for, e.g., therapeutic approaches in the treatment of diabetes.
  • the cells in this example were derived from pancreas, other epithelial tissues, or perhaps even any endoderm-derived tissue, may provide additional sources of cells that can be differentiated into cells having a similar phenotype. Suitable tissue types include, e.g., liver or intestine.
  • These IP cells express genes associated with pancreas, liver, intestine and neuronal tissues. For example, they express mucin, CK19 and CK7, which are common markers associated with duct cells in the pancreas, liver and intestine.
  • IP cells may serve as a predictive measure for cells derived from each of these tissues for the purpose of generating insulin-producing cells.
  • IP cells may, under appropriate conditions, give rise, not only to pancreatic islet cells, but also to hepatocytes or any endoderm-derived tissue.
  • C/EBP CCAAT/enhancer binding protein
  • RAS guanyl releasing protein 2 (calcium 8 8226622 1 1226633 1616 and DAG-regulated) cartilage paired-class homeoprotein 1 6 6667777 1 1116666 1241 paired-like homeodomain transcription 6 6880055 1 1111133 756 factor 1 transcription factor 21 7 7662211 1 1006633 801
  • CD3E antigen CD3E antigen, epsilon polypeptide (TiT3 88005544 999944 1113 complex)
  • calbindin 2 (29kD, calretinin) 7000 676 786 serine (or cysteine) proteinase inhibitor, 5214 668 678 clade A (alpha-1 antiproteinase, antitrypsin), member 1 retinal G protein coupled receptor 7972 653 696 myosin regulatory light chain 2, smooth 22449999 663388 561 muscle isoform butyrate response factor 1 (EGF-response 7 ⁇ 3v2>5 ⁇ 683300 646 factor 1 )
  • C/EBP CCAAT/enhancer binding protein
  • 7237 359 645 alpha paired box gene 9 5206 335 201 protein tyrosine phosphatase, receptor 8235 331 250 type, N keratin 8 7215 327 449 claudin 7 280 325 173 trophinin associated protein (tastin) 462 323 360 neuronal thread protein 8356 322 366 basic helix-loop-helix domain containing, 6734 318 215 class B, 2 annexin A2 4467 290 226 cathepsin D (lysosomal aspartyl protease) 7370 289 600
  • TNF receptor-associated factor 1 6037 269 270
  • LIM homeobox transcription factor 1 beta 8211 143 89 eukaryotic translation elongation factor 2 4536 134 150 mitogen-activated protein kinase kinase 5462 129 92 kinase 10
  • CD63 antigen (melanoma 1 antigen) 7769 124 91 nuclear receptor coactivator 3 4181 119 84
  • GATA-binding protein 4 659 80 110 transcription factor 1 , hepatic; LF-B1 , 712 80 136 hepatic nuclear factor (HNF1), albumin proximal factor heat shock transcription factor 1 6708 79 57 liver-specific bHLH-Zip transcription factor 765 77 188 liver-specific bHLH-Zip transcription factor 765 77 188 eukaryotic translation initiation factor 3, 6280 76 94 subunit 4 (delta, 44kD) eukaryotic translation initiation factor 3, 6280 76 94 subunit 4 (delta, 44kD) gamma-aminobutyric acid (GABA)
  • GABA gamma-aminobutyric acid
  • MAD1 mitotic arrest deficient, yeast, 1946 63 38 homolog
  • P05026 L22ab2 ATPase Na+/K+ transporting be 3965 733 5290 1976 367 3744 962 -1 OOE+00 4 16E-01 15 On A/lnt, Down I
  • RNA II DNA direct 1964282 155 2828549 211 5128 526E-01 -339E-01 20 Other
  • RNA II DNA direct 560 1066 892 821 9856 758 0427 553E-01 671E 01 20 Other
  • RNA II DNA direct 2157 353 3780 3657 763 3198285 762E-01 809E-01 3 Unchanged High
  • RNA II DNA direct 2161 398 2600 2709495 2489 343 326E-01 265E-01 3 Unchanged High

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

This invention relates, e.g., to a method for expanding mammalian acinar cells, comprising culturing the cells in a cell culture system comprising a cell culture medium and a cell attachment surface, under conditions wherein the acinar cells undergo a 3-4 fold expansion together with transdifferentiation into a modified cell phenotype (IP cells) showing characteristics of acinar cells and liver cells. The invention also relates to a method for transforming these IP cells to insulin-producing cells in vitro, comprising culturing the cells in a novel, defined medium. Also disclosed are suitable culture media for performing these methods, isolated cells having the phenotype of IP cells and/or produced by these methods, and kits for performing the methods.

Description

Methods for in Vitro Expansion and Transdifferentiation of Human Pancreatic Acinar Cells into Insulin-Producing Cells
This application claims the benefit of provisional application 60/384,000, filed May 28, 2002, which disclosure is incorporated by reference in its entirety herein.
BACKGROUND OF THE INVENTION
1. Field of the Invention
[0001] The invention relates to compositions and methods whereby, e.g., human pancreatic acinar cells are cultured under conditions that support expansion and transdifferentiation into glandular epithelial cells and subsequently into insulin-producing cells.
2.Background Information
[0002] The potential benefits of taking insulin-producing cells from organ donors and transplanting them into insulin-dependent, Type I diabetic patients is clear. In the Edmonton clinical trials, many patients have lived free from the delivery of exogenous insulin for approximately 2 years after being transplanted with intact islets from organ donor sources. However, current technology requires two organ donor pancreata to generate a sufficient number of islets (about 1 million islets, comprised of about 1,000 cells each) to transplant into one diabetic patient for cellular therapy. Thus, there has been emphasis in the diabetes field to identify new sources of insulin-producing cells for transplantation. Many avenues are being explored, including expansion of islets after harvest and before transplantation and the generation of new islets from stem-like cells derived from the bone marrow, or from precursor cells located in the pancreas. The challenges presented by these approaches are related to maintenance of function of islets over long periods of culture, and of the relative rarity of stem-like cells that can be harnessed for insulin production from the bone marrow and pancreas. The ductular precursor stem-like cells derived from the pancreas are reported to be more efficient than bone-marrow derived cells at differentiation into insulin-producing cells, and this may reflect their site of origin (i.e., pancreas) where they are certainly exposed to many differentiation signals related to the pancreatic microenvironment. The most abundant cell type in the pancreas is the acinar cell, which comprises about 85% of the pancreas. The acinar cells serve to produce and secrete digestive enzymes and, like islet cells, arise during development from the ductular cell compartment.
[0003] There have been reports that acinar cells, when cultivated in vitro, especially under conditions of stress, can undergo a 'transdifferentiation' into a cell type that resembles ductular cells, as determined by expression of CK19, CK7, and carbonic anhydrase (all reputed by the authors to be markers of duct cells) (Kerr-Conte, 1996; WO 02/29010 A2), Hall et al, 1992). Furthermore, Bouwens et al. (1998) have shown in vivo, in a model of pancreatic duct ligation, that acinar cells in the ligated portion of the pancreas undergo transdifferentiation into cells with a ductular phenotype. Further work has suggested that insulin-producing cells can be produced upon further differentiation of the duct cells in the ligated portion of the pancreas. The acinar cells are also reported to be of limited survivability in primary culture, with some culture conditions leading to loss of at least 50% of cells within a week. While primary duct cells have been demonstrated in vitro to convert into insulin-producing cells under some culture conditions (e.g. Bonner Weir, 2000, U.S. Pat. No. 6,011,647), there are no reports of cells that arose from acinar cells in vitro differentiating further to produce islet-like cells.
[0004] Prior to the development of the present system, primary pancreatic acinar cells were expanded without differentiation into insulin-producing cells, either in serum- containing medium (undesirable both because of the risk and the uncertainty associated with the use of serum), or in complex serum free media formulations. Likewise, primary pancreatic acinar cells have been transdifferentiated into insulin-producing cells without expansion, producing cells with an insulin-producing phenotype in small numbers. Furthermore, it has not been previously possible to obtain insulin-producing cells in good numbers using acinar cells as starting material.
[0005] Thus, there is a need for a simple cell culture system and method for rapidly generating large numbers of cells that can fiirther differentiate into, e.g., insulin- producing cells, through expansion and lifferentiation of the abundant pancreatic acinar cells. Further, there is a need for a cell culture system and method for culturing and transforming such cells into insulin-producing cells. One cell culture system and related method disclosed herein allows a simple, one-step approach that generates expanded cultures that contain at least 80% intermediate progenitor cells that can give rise to insulin-producing cells. A second cell culture system and related method allows the further culturing of these intermediate progenitor cells or other glandular epithelial cells to obtain insulin-producing cells. Both IP cells and insulin-producing cells will be useful for cell-based therapies for the treatment of diseases such as diabetes.
SUMMARY OF THE INVENTION
[0006] The present invention provides compositions and methods whereby, e.g., acinar cells can be cultivated successfully in vitro, undergoing a 3-4 fold increase in cell number over time, and giving rise to a cell population that co-expresses acinar and ductal markers early during the culture (2-3 days ex vivo), then ultimately (e.g., about 7-8 days ex vivo) acquires a modified phenotype characterized by expression of some acinar-associated genes, as well as some liver-associated genes. The genes expressed by these modified cells at about 7-8 days ex vivo include, e.g., ductular cytokeratins (CK7, CK8, CK18 and CK19), hepatic nuclear factor 1 (HNF1), alpha-1 antitrypsin, pi-glutathione s transferase (pi-GST), liver-specific (basic helix-loop-helix (bHLH) transcription factor, Thy-1, CCAAT/enhancer-binding protein (C/EBP)-alpha and C/EBP-beta. These cells exhibit little if any expression of the pancreas-associated genes carbonic anhydrase, cystic fibrosis transmembrane conductance regulator (CFTR), elastase and amylase. By "little if any" expression of a gene is meant herein that gene expression is generally undetectable under conventional methods, such as the hybridization and immunocytochemical methods described herein, but expression may be detected by extraordinarily sensitive methods, such as PCR-based analysis. This type of modified cell is referred to herein as an intermediate progenitor ("IP") cell. The expanded/transdifferentiated acinar cells (IP cells) can be produced using a general serum-containing media, or, in a preferred method, can be produced without serum on a surface comprising one or more extracellular matrix molecules (ECMs) in the presence of one or more soluble active factors. ECMs can be presented in 2 dimensional or 3 dimensional culture systems in the presence of soluble active factors.
[0007] The IP cells generated from these cultures are expected to be useful directly in certain medical applications. For example, there is evidence that such cells may under certain conditions become functioning insulin-producing cells when implanted in diabetic patients. The cells can also be used for drug discovery and toxicity studies.
[0008] In addition, according to a further aspect of the invention, the IP cells can be cultivated further, in a serum-free medium composed of any standard serum-free base medium (DMEM:HamsF12, for example) with BSA and combinations of factors, including ECMs, small molecules, and growth factors. After 5-10 days of culture, the IP cells undergo additional steps of differentiation, culminating in the formation of cell aggregates that express pro-insulin and C-peptide. Challenge of these cultures with a high-glucose medium causes release of insulin and C-peptide into the medium, indicating the production in these cultures of functional islet-like cells.
[0009] Thus, in a first aspect, the present invention provides a cell culture system comprising a superior cell attachment surface that also stimulates cellular expansion, and a simple culture medium including effective amounts of one or more soluble active factors, or serum (e.g. fetal bovine serum), added to a base medium composition. The cell culture system will be particularly useful for primary culture of mammalian epithelial cells, particularly human epithelial cells. In a preferred embodiment the cell culture system is used for the expansion and transdifferentiation of primary acinar cells, especially human pancreatic acinar cells.
[00010] The cell attachment surface for this cell culture system is any surface to which the cells can attach and expand, including both 2 dimensional (e.g. plates, flasks, roller bottles, petri dishes, wells etc.) and 3 dimensional (e.g. scaffold) environments. Preferably the surface comprises at least one type of ECM, or a peptide fragment thereof. Cells may, in some circumstances, detach from these surfaces and form self-supporting aggregates. Suitable fragments include peptides consisting of a sequence of three of more amino acid residues that are identical to any portion of the amino acid sequence of the ECM. Such fragments can be easily made and tested by means known to those of skill in the art. Most preferably the surface is a layer of collagen I. Many other surfaces known in the art are also suitable, such as Collagen VI, Collagen IV, Vitronectin, or Fibronectin. Collagen I is preferred due to ease and cost.
[00011] The base medium to which the soluble active factors are added may be any cell culture medium appropriate for growth and differentiation of epithelial cells. These include, but are not limited to, DMEM, Hams F12, MEM, M-199 and RPMI. The general requirements for such culture media and many suitable examples are known to those of skill in the art. To this base medium is added either serum (such as fetal bovine serum), or a stabilizing protein such as bovine serum albumin (BSA) along with effective amounts of soluble active factors. The medium is preferably serum-free.
[00012] Soluble active factors for the expansion and transdifferentiation of primary pancreatic acinar cells into IP cells include growth factors such as HGF receptor activators and EGF receptor activators. Preferred soluble active factors include one or more of EGF and Transforming Growth Factor-α, IGF1, HGF, betacellulin, prolactin and gastrin 1. HGF, EGF and/or Transforming Growth Factor-α are particularly preferred. Also preferred is the combination of IGF1 and betacellulin.
[00013] In one particularly preferred embodiment, the base medium contains a 1:1 mixture of DMEM and Hams F12. The base medium is completed with the addition of glutamine to a final concentration of ~4 mM, insulin (-0.1-10 μg/ml, preferably -0.01 mg/ml), transferrin (-0.5-10 μg/ml, preferably -0.0055 mg/ml), selenium (-0.25-5.0 ng/ml, preferably -0.0067 μg/ml of sodium selenite), and Epidermal Growth Factor (EGF) (-1-20 ng/ml, preferably -10 ng/ml); this medium is hereafter referred to as pancreatic cell medium, or PCM. To this base medium formulation, up to -20% Fetal Bovine Serum (or other serum), preferably between -10 — 15% fetal bovine serum, most preferably about 10% or up to about 15% fetal bovine serum) may be added, or, to create a serum-free culture environment, the following components are added in place of serum: heat-inactivated bovine serum albumin (0.1-2%), Hepatocyte growth factor (HGF) (1-20 ng/ml), and/or Transforming Growth Factor Alpha (TGFα)(l-10 ng/ml). In addition, the medium may contain Betacellulin (0.5-20 ng/ml), Gastrin 1 (0.05-10 ng/ml), Prolactin (1.0-10 ng/ml), and/or IGF-1 (5-100 ng/ml). In particular formulations, greater or lesser amounts of these components may be added in order to achieve a formulation that is effective in supporting the expansion and transdifferentiation of the cells. Persons of skill in the art will appreciate that determining effective amounts of the components will require no more than routine experimentation.
[00014] By the use of this attachment surface and medium, the expansion and transdifferentiation of primary pancreatic cells with the desired phenotype is simplified greatly.
[00015] hi a particularly preferred embodiment, the cell culture system is a combination of collagen I coated tissue culture surface (presented in a 2 dimensional or 3 dimensional form) and a serum-free medium containing BSA, insulin, transferrin, selenium, Hepatocyte growth factor (HGF), Epidermal Growth Factor (EGF) and Transforming Growth Factor Alpha (TGFA).
[00016] The cell culture system enables superior attachment in vitro of primary pancreatic epithelial cells for adherent culture compared to prior methods, while creating a cellular environment that promotes expansion of the epithelial component of primary pancreatic cultures with concomitant transdifferentiation of the acinar cells present in the starting material into IP cells, while minimizing emergence of undesired fibroblasts. Advantages of this culture system are ease of construction, few components needed, and that all components are readily available and easily used in the required manner.
[00017] The components of this aspect of the invention may be conveniently packaged in the form of a kit. The kit may include, for example, 1) a cell culture medium such as DMEM: 2) a serum-free medium supplement containing BSA, insulin, transferrin, selenium, HGF, EGF and TGFA, in suitable amounts to yield the concentrations noted above in the completed medium; and 3) at least one collagen I coated substrate, such as a vessel for tissue culture (e.g., dish(es) with at least one collagen-1 coated tissue culture surface), or collagen-1 coated inserts for use in culture dishes or other laboratory ware. The kit may also optionally include a tissue culture dish or other cell culture accessories and additional reagents that may be required to carry out epithelial cell culture and differentiation.
[00018] Culture systems consisting of scaffolds, collagen coated flasks or other vessels and serum-free base medium may be packaged along with the soluble active factors as a separate vial that would be added to the culture medium just prior to use. The active factor combination can be added to a variety of base media to accomplish the same end, e.g., growth and differentiation of primary pancreatic acinar cells in vitro. Such culture systems should also be useful for other cell types, particularly glandular epithelial cells derived from other organs and tissues, including those from liver, pancreas, intestine, prostate, and breast.
[00019] The collagen I surface provides superior cell attachment (thereby increasing the number of cells that adhere during initial culture and thus enhancing culture efficiency), while the collagen I and the combination of soluble active factors (e.g., HGF, TGFA and EGF) promote continued proliferation of cells over time, leading to an increase in cell number above what has been previously reported for primary pancreatic acinar cells. Furthermore, the expansion of the acinar cells is accompanied by a transdifferentiation in the majority of cells to an IP phenotype, which is potentially a therapeutically useful cell phenotype for the treatment of diseases such as diabetes. This likely occurs due to convergence of the intracellular signaling pathways associated with collagen I, HGF, TGFA and EGF, creating a synergistic response.
[00020] The cell culture system of the present invention has unexpected advantages over systems previously in use. Collagen I, IV, NI, Vitronectin and Fibronectin were expected to enhance cell attachment. However, other extracellular matrix molecules that yielded equivalent attachment of cells during the initial 18 hours of culture did not promote consistent growth of the cells over time in the serum-free medium containing HGF/EGF/TGFA. The most efficient and cost-effective method of achieving cell expansion AND differentiation into IP cells is to utilize a collagen-I surface and a medium containing reduced serum (preferably less than 20%, more preferably less than 15%, 10%, or 5%, most preferably 2%).
[00021] Another aspect of the invention is a method for culturing mammalian epithelial cells comprising adding said cells to the cell culture system described above, and maintaining them at suitable temperature and atmospheric conditions. By "mammalian epithelial cell" is meant any cell of a tissue or organ with an epithelial cell phenotype, defined by the presence of expression of cytokeratins and often through the presence of markers that suggest a tissue-specific function (i.e., epithelial cells of the skin make keratin, epithelial cells of the intestine make mucin, epithelial cells of the prostate make PSA). In a preferred embodiment, the cells are primary pancreatic cells, particularly human pancreatic cells. Suitable temperature for mammalian cells is usually in the range of about 37°C, but may be varied somewhat according to cell type. The atmosphere can be ordinary air, or other specialized mixtures of gasses suitable for maintaining cells, as will be familiar to persons of skill in the art. Expansion of pancreatic acinar cells can be maximized by decreasing the oxygen tension in the culture atmosphere to less than 21%, while transdifferentiation to IP cells can be enhanced by increasing oxygen tension to greater than 5%. A preferred range of oxygen tension is between about 5% and about 21%.
[00022] hi a second aspect, the invention also provides methods and compositions for transforming glandular epithelial cells that have acquired expression of markers characteristic of an intermediate progenitor (IP) phenotype as described above into insulin-producing cells. By "glandular epithelial cell" is meant an epithelial cell that is a component of a gland. Glands are tissues that have a specific function related to secretion of key molecules - most organs in the body have glandular function (liver, intestine, pancreas, prostate, breast, pituitary, adrenal, kidney) whereby they produce and release hormones, digestive enzymes, or other life-essential fluids. Glandular epithelial cells from endoderm-derived organs (e.g., liver, intestine, pancreas) share many characteristics, including the ability to express many of the same genes. Particularly preferred are glandular epithelial cells from pancreas, for example acinar cells. As used herein, the terms "express" and "expression" generally refer to nucleic acids (e.g., mRNAs) or to protein gene products that are detectable by standard immunocytochemical methods.
[00023] In this aspect, the invention provides a second cell culture system comprising a cell attachment surface and a culture medium that supports and promotes the transformation of glandular epithelial cells into insulin-producing cells. The cell attachment surface is similar to and may be identical to the attachment surface for expanding primary pancreatic acinar cells. It may be presented in the form of a flat surface coated on a vessel or in the form of a scaffold or other surface adapted for cell culture. It can be comprised of, or coated with, any composition that is capable of maintaining cells or supporting cell growth. In a preferred embodiment, it comprises at least one ECM, such as Collagen I, Collagen VI, Collagen IV, Vitronectin or Fibronectin. In a particularly preferred embodiment, the cell attachment surface is Collagen-I.
[00024] h this aspect, the invention provides a further culture medium comprising at least one differentiation promoting factor ("DPF") that promotes the transformation of glandular epithelial cells into insulin producing cells. The DPFs for the transformation of glandular epithelial cells into insulin producing cells can be one or more of Activin A, acidic FGF, basic FGF, C-Natriuretic Peptide (CNP), Calcitonin Gene Related Peptide, Cholera Toxin B Subunit, Dexamethasone, Gastrin-Releasing Peptide, Glucagon-like Peptide-1 (GLP-1), Glucose, IGF1, IGF2, Insulin, Laminin, LIF, Met-Enkephalin, PDGFAA+PDGFBB, Prolactin, Sonic Hedgehog, Substance P, TGF-alpha, Trolox (alpha-tocopherol derivative), or VEGF. Preferred concentrations in culture medium of each of these 23 DPFs are listed in Table 1. Although in some cases one DPF is sufficient, preferably two or more factors are used. As many as all 23 of the factors may be used. Table 1
Figure imgf000012_0001
[00025] In a preferred embodiment of this aspect of the invention, the culture medium comprises at least one (or as many as all 10) of the following differentiation promoting DPFs:. C-Natriuretic Peptide (CNP), Calcitonin Gene Related Peptide, Cholera Toxin B Subunit, Dexamethasone, Gastrin-Releasing Peptide, Laminin, Met-Enkephalin, PDGFAA+PDGFBB, Sonic Hedgehog, and Substance P. [00026] In a preferred embodiment, the culture medium that promotes the transformation of glandular epithelial cells into insulin producing cells consists of a 1:1 mixture of DMEM and Hams F12 plus the components listed in Table 2. This medium is sometimes referred to herein as "Media or Medium G9."
Table 2
Figure imgf000013_0001
17
18 19
20
21
22
23
24
25 26
27
28
29 30
Figure imgf000014_0001
[00027] The components of this aspect of the invention may also be conveniently packaged in the form of a kit. The kit may include, for example, 1) a cell culture medium such as DMEM, Hams F12, or a combination thereof; 2) a serum-free medium supplement containing: BSA and the DPFs Activin A, acidic FGF, basic FGF, C- Natriuretic Peptide (CNP), Calcitonin Gene Related Peptide, Cholera Toxin B Subunit, Dexamethasone, Gastrin-Releasing Peptide, Glucagon-like Peptide-1 (GLP-1), Glucose, IGF1, IGF2, Insulin, Laminin, LIF, Met-Enkephalin, PDGFAA+PDGFBB, Prolactin, Sonic Hedgehog, Substance P, TGF-alpha, Trolox (alpha-tocopherol derivative), or VEGF, or two or more of these components in combination, in suitable amounts to yield the concentrations noted in Table 1 in the completed medium; and 3) tissue culture dish(es) with at least one collagen-1 coated tissue culture surface (or collagen-1 coated inserts for use in culture dishes or other laboratory ware). The kit may also optionally include a tissue culture dish and/or other cell culture accessories and additional reagents that may be required to carry out epithelial cell culture and differentiation. In other embodiments, the kit may contain any of the media or media components discussed herein.
[00028] Culture systems consisting of scaffolds, collagen coated flasks or other vessels and serum-free base medium may be packaged along with the DPF(s) as a separate vial that would be added to the culture medium just prior to use. The DPF combination can be added to a variety of base media to accomplish the same end, e.g., growth and differentiation of primary pancreatic acinar cells in vitro. Such culture systems may also be useful for other cell types, particularly other epithelial cells derived from glandular tissues, including those from liver, pancreas, intestine, prostate, and breast.
[00029] The invention also provides a method for converting glandular epithelial cells into insulin-producing cells comprising culturing the glandular epithelial cells in the cell culture system described above. The method may further comprise removing the culture medium from the cell culture, re-feeding the cell culture with a serum-free medium with glucose, and measuring proinsulin production C-peptide production, or insulin release.
[00030] Furthermore, the invention provides an isolated population of insulin-producing cells containing cytoplasmic granules with immunodetectable proinsulin, insulin, and/or c-peptide that is derived from a population of cells of which a subset of cells expressed at least one marker associated with IP cells (e.g., expressed some acinar-associated genes, as well as some liver-associated genes, including, e.g., ductular cytokeratins (CK7, CK8, CK18 and CK19), HNF1, alpha-1 antitrypsin, pi-glutathione s transferase (pi-GST), liver- specific bHLH transcription factor, Thy-1, C/EBP-alpha and C/EBP-beta, and expressed little if any of the pancreas-associated genes carbonic anhydrase, cystic fibrosis transmembrane conductance regulator (CFTR), elastase and amylase).
[00031] By an "isolated" cell or population of cells is meant herein that the cell or cell population is removed from its original environment (e.g., the natural environment if it is naturally occurring), and isolated or separated from at least one other component with which it is naturally associated. For example, a naturally-occurring cell present in its natural living host is not isolated, but the same cell, separated from some or all of the coexisting materials in the natural system, is isolated. Such cell or cell populations could be part of a cell culture or cell population, and still be isolated in that such culture or population is not part of its natural environment.
[00032] In one preferred embodiment, the insulin-producing cells are derived from glandular epithelial cells obtained from mammalian pancreas, such as primary acinar cells.
[00033] The data disclosed in the examples below are generated from freshly isolated human pancreatic cells. The expansion of primary human pancreatic cells in these conditions produces cultures with a mixed epithelial IP phenotype, suitable for in vitro studies of IP cells for a variety of purposes, and suitable for transplantation in vivo for cell therapy for the treatment of diseases such as diabetes. The IP cells generated by these methods may also be useful in the study of pancreatic cell biology, as normal controls in the study of pancreatic epithelial cancers, and to test the effects of drugs/compounds on normal pancreatic epithelial cells (ductal or acinar). Furthermore, the cells may be further cultured to yield insulin-producing cells as demonstrated below.
BRIEF DESCRIPTION OF THE DRAWINGS
[00034] Figures 1 A-D show microscopic images after treatment of starting material with antibodies to amylase (Fig. 1A), insulin (Fig. IB), and CK19 (Fig. 1C) and the composition of the cell pellet of freshly isolated primary human pancreatic cells (Fig.
ID).
[00035] Figure 2 shows growth curves constructed from primary human pancreatic cultures grown in commercial medium (with serum) or in the described pancreatic cell medium (PCM) with serum. [00036] Figure 3 shows a comparison of cell expansion in the base medium composition described vs. base medium + soluble growth factors (serum-free formula) vs. base medium + fetal bovine serum.
[00037] Figures 4A-B shows the effect of different culture surfaces on total cell number (Fig. 4 A) and cell phenotype (Fig. 4B) after expansion.
[00038] Figures 5A-B show a comparison of cell phenotype after expansion in serum- containing (5 A) and serum-free (5B) medium containing all soluble active factors.
[00039] Figure 6 shows high power images of cell cultures expanded in various conditions, including serum-free base media supplemented with 3 soluble active factors, HGF, EGF & TGFA. Note epithelial morphology.
[00040] Figure 7 shows a demonstration of growth of IP cells on ECM-coated surfaces as determined by metabolic activity assay over time. Note superior growth when Collagen I surface is combined with the media formulation described herein, yielding results superior to the combination of Matrigel and commercial media with serum.
[00041] Figure 8A (upper left) shows expression of amylase by acinar cells after two days of culture (red staining), Figure 8B (lower left) shows expression of CK19 (green staining), Figure 8C (right) shows an overlay of the two images, showing co-expression (yellow) in a large proportion of cells.
[00042] Figure 9 shows changing phenotype of primary acinar cells in culture over 5 days. Amylase is red, CK19 is green. Note appearance of yellow (amylase + CK19) on Day 2 and 3.
[00043] Figures 10A and 10B show primary human pancreatic cells that were expanded in serum-containing medium on Collagen I coated surface. Images were analyzed to determine total cells (Figure 10A, blue nuclei) and total positive cells (Figure 10B, blue nuclei surrounded by green staining for CK19).
[00044] Figure 11 shows light microscopic (200X) appearance of pancreatic acinar cells cultured on a collagen I surface with all DPFs (Activin A, 0.5 ng/ml; acidic FGF, 2.5 ng/ml; basic FGF, C-Natriuretic Peptide (CNP), 0.11 μg/ml; Calcitonin Gene Related Peptide, 0.19 μg/ml; Cholera Toxin B Subunit, 12.5 ng/ml; Dexamethasone, 0.002 μg/ml; Gastrin-Releasing Peptide, 0.143 μg/ml; Glucagon-like Peptide- 1 (GLP-1), 0.033 μg/ml; Glucose, 1.08 μg/ml; IGF1, 0.0025 μg/ml; IGF2, 0.0025 μg/ml; Insulin, 9.5 μg/ml; Laminin, 2.25 μg/ml; LIF, 0.0025 μg/ml; Met-Enkephalin, 0.0030 μg/ml; PDGFAA+PDGFBB (0.0050 μg/ml: 0.0025 μg/ml of PDGFAA + 0.0025 μg/ml PDGFBB); Prolactin, 0.0012 μg/ml; Sonic Hedgehog, 0.025 μg/ml; Substance P, 5.0 μg/ml; TGF-alpha, 0.0010 μg/ml; Trolox (alpha-tocopherol derivative), 0.625 μg/ml; and VEGF, 0.0025 μg/ml).
[00045] Figure 12A (top right panel) shows immunocytochemical analysis with CK19 antibodies (green).
[00046] Figure 12B (lower right panel) shows immunocytochemical analysis with C- peptide antibodies (red).
[00047] Figure 12C (left panel) shows an overlay image demonstrating the colocalization of CK19 and C-peptide (orange). Blue portions are DAPI stained nuclei.
[00048] Figure 13A shows insulin release upon glucose challenge in IP cells that have not been detached and relocated (subcultured) during the growth and differentiation process.
[00049] Figure 13B shows insulin release upon glucose challenge in IP cells that have been subcultured according to Example 10. [00050] Figure 13C shows C-peptide release upon glucose challenge in IP cells that have not been subcultured according to Example 10.
[00051] Figure 14 shows the Insulin/DNA ratio in subcultured and nonsubcultured cells that are treated with Combinations 1, 2 and 3 of DFP media, as described in Example 11.
[00052] Figure 15 shows insulin release in response to base level glucose (5 mm) and a glucose challenge (22mm) over 10 days of culture in PCM and DPF media, as described in Example 13.
[00053] Figure 15A shows insulin release in response to base level glucose (5 mm) and a glucose challenge (22mm) over 14 days of culture in PCM and DMG9 media, as detailed in Example 14.
[00054] Figure 16 is a graphical representation of the characteristics of the 17 classes of genes shown in Table 6, as indicated in the last column of the Table, as detailed in Example 14.
DETAILED DESCRIPTION OF THE INVENTION
[00055] h describing preferred embodiments of the present invention, specific terminology is employed for the sake of clarity. However, the invention is not intended to be limited to the specific terminology so selected. It is to be understood that each specific element includes all technical equivalents, which operate in a similar manner to accomplish a similar purpose. Each reference cited here is incorporated by reference as if each were individually incorporated by reference.
[00056] The following abbreviations are used:
BSA: bovine serum albumin
BMP Bone Morphogenetic Protein bHLH: basic helix loop helix
DMEM: Dulbecco's Modified Eagle's Medium
TGFjδl : Transforming Growth Factor βl
ECM: extracellular matrix molecules; naturally occurring proteins produced by cells of a tissue that provide structural support as well as a source of cellular signals related to adhesion. Examples are collagen, vitronectin, fibronectin, laminin.
EGF: Epidermal Growth Factor
Hams F12: Ham's Nutrient Mixture F12
HGF: Hepatocyte growth factor
HNF-1: Hepatic nuclear factor 1
IGF1: Insulin-like growth factor 1
IGF-II: Insulin-like growth factor 2
IP cells: Intermediate progenitor cells derived from an epithelial cell, such as, e.g., a pancreatic acinar cell or a liver cell, wherein the derived cells express some acinar- associated genes, as well as some liver-associated genes, including, e.g., cytokeratins
(CK7, CK8, CK18 and CK19), HNF1, alpha- 1 antitrypsin, pi-glutathione s transferase
(pi-GST), liver-specific bHLH transcription factor, Thy-1, C/EBP-alpha and C/EBP-beta, and express little if any of the pancreas-associated genes carbonic anhydrase, cystic fibrosis transmembrane conductance regulator (CFTR), elastase and amylase).
PDGF-A: Platelet derived growth factor alpha
PDGF-B: Platelet derived growth factor beta
TGFA, TGF-α: Transforming Growth Factor
[00057] As used herein, the term "culture system" is intended to mean a system for growing and/or differentiating cells in culture, which comprises a cell attachment surface, preferably one that also stimulates cellular expansion, and a culture medium, which includes effective amounts of one or more factors, or serum (e.g. fetal bovine serum), added to a base medium composition.
[00058] When referring to active soluble factors and DPFs herein, "effective amount" means an amount that either alone or in combination with other included factors is effective in promoting either expansion and differentiation into IP cells, or into insulin- producing cells, as applicable.
EXAMPLES I. Expansion and transdifferentiation of primary acinar cells into glandular epithelial cells (Culture Phase I)
Materials and methods:
[00059] Starting Material: Primary human pancreatic acinar cells are collected as waste from standard COBE gradient preparation of islet cells for transplantation (Lake et al., 1989). After density gradient centrifugation, the islets are present as a layer between 1.063 density and 1.10 density, and the remaining cells are collected as the pellet that sediments to the bottom of the gradient based on density. Approximately 48 hours after collection of the cells at the transplant center are received by the inventors in non-tissue- culture treated polystyrene flasks and are suspended in RPMI + 10% fetal calf serum at a density of approximately 2.0 million cells/ml. Cell number and viability is assessed by trypan blue exclusion and enumeration on a hemacytometer by light microscopic observation.
[00060] Phenotypic Evaluation of Starting Material. A preparation of starting material was formalin fixed and paraffin-embedded as a cell pellet about 24 hours after initial harvest of the pancreatic cells. Paraffin sections were prepared, placed on slides, and subjected to immunocytochemical analysis with antibodies to insulin (Biogenex, San Ramon, CA), CK19 (Biogenex), and Amylase (Biogenex). A minimum of (3) sections per sample were assessed with each marker. All antibody staining was carried out according to the manufacturer's suggestion with pre-diluted commercial antibodies. For CK19, a 3 minute treatment with pepsin enzyme (Biogenex) preceded the blocking step for the purpose of antigen retrieval. Briefly, the sections were rehydrated through graded ethanols, followed by a 15 minute incubation in phosphate buffered saline (PBS) without calcium and magnesium. Protein Blocker (Biogenex) was added for 30 minutes prior to addition of primary antibodies. After (3) 5-minute washes, biotinylated secondary antibody (Biogenex) was added at a 1:100 dilution and sections were incubated for 30 minutes at room temperature. After (3) 5-minute washes, Alexa488 or Alexa-596- conjugated StreptAvidin (Molecular Probes, Eugene, Oregon) was added for fluorescent visualization. For each slide, a minimum of (3) 200x images were captured using a Nikon fluorescent microscope fitted with a SPOT camera (Diagnostic Systems, Inc., Webster, TX). The images were assessed quantitatively using image analysis software (MetaMorph/Universal Imaging Corporation, Downington, PA) to determine relative fraction of insulin-positive, CK19+, and amylase÷ cells. frιsulin+ cells are the beta cells of the islets, CK19+ cells are the primary ductal cells, and amylase+ cells are the acinar cells (see Example 1).
Example 1 : Characterization of cell culture conditions A. Serum-free medium
[00061] Freshly isolated primary human pancreatic cells were collected as a pellet from a COBE cell separator, fixed in formalin, paraffin-embedded, sectioned, and analyzed with antibodies to amylase, CK19, and Insulin. Images (Figures 1A and IB) were collected on a Universal Imaging System (Universal Imaging Corporation) and analyzed with MetaMorph Software. This cell pellet (Figure 1C) was comprised of 1.0% insulin+ cells (beta cells of the islet), 5.8% CK19+ cells (primary ductal cells), and 93.2% amylase+ and unlabeled (acinar cells and other cell types).
[00062] Primary human pancreatic cells were then seeded at 104 or 105 cells/ cm2 onto tissue culture treated polystyrene in either DMEM commercial medium plus 10% fetal bovine serum or in PCM plus 10% fetal bovine serum. Replicate cultures were harvested at 3 day intervals via trypsinization and live cells (as determined by trypan blue exclusion) and enumerated on a hemocytometer. The results (shown in Figure 2) demonstrate that the (serum-containing) medium formulation described herein is superior to commercial media formulation for growth and maintenance of primary pancreatic cells. Figure 3 compares the results of expanding the cells for 6 days in base medium, base medium plus all of the soluble active factors [HGF, -1—20 ng/ml, preferably -5.0 ng/ml; TGFA, -1—10 ng/ ml, preferably -2 ng/ml; Betacellulin, -0.5—20 ng/ml, preferably ~10ng/ml; Gastrin 1, -0.05—10 ng/ml, preferably -0.06 ng/ml; Prolactin, -1.0—10 ng/ml, preferably -2.4 ng/ml; and IGF1, -5—100 ng/ml, preferably - 5 ng/ml] and base medium plus 10% serum. The serum-free media formulation meets/exceeds expansion provided by media + serum.
[00063] The cell expansion experiment was repeated essentially as above, except that the base medium was supplemented with only three of the soluble active factors: TGF, HGF, and EGF. Figure 6D compares the results of expanding the cells in the various media; Figures 6A, 6B and 6C show high power images of the cell cultures expanded under the various media conditions.
B. ECM Surfaces
[00064] The attachment of primary human pancreatic cells was evaluated by counting the number of attached cells vs. the number of cells initially seeded on a panel of ECM surfaces comprised of Collagen I (1 μg/cm2), Fibronectin (3 μg/cm2), Laminin (2 μg/cm2), Vitronectin (1 μg/cm2), Matrigel (1 μg/cm2), Human ECM (1 μg/cm2), or Poly- D-Lysine (3 μg/cm2). In one condition, a mixture of Collagen IV, Laminin, and Fibronectin was utilized. ECMs were placed into solution at the above concentrations and allowed to coat tissue culture-treated polystyrene surfaces according to manufacturer's suggestions of 1 hour at room temp. Excess ECM solution was then removed and surfaces were rinsed twice in water. Just before seeding cells, the water was aspirated, then cells were seeded onto the ECM surface at a density of 1 x 105 cells/cm2 in growth medium (PCM) composed of DMEM:HamsF12 mixture (1:1) with 4mM glutamine, lx ITS supplement (GIBCO 51500-056), 10% Fetal Calf Serum (Inactivated, Qualified, GIBC 26140-079), and 10 ng/ml Epidermal Growth Factor (EGF) (BD 4001). Cells were seeded onto tissue-culture polystyrene surface as a control. After 18 hours, unattached cells were washed away and remaining attached cells were re-fed with PCM and allowed to grow for 7 days prior to evaluation. Cultures were fixed in 10% formalin and subjected to immunocytochemistry with antibodies for CK19 and Amylase as described previously to determine phenotypic composition. Cells were counterstained with DAPI fluorescent blue nuclear stain to visualize individual cell nuclei for cell counting. The metabolic activity of cells subjected to the various conditions was determined by an MTS assay. Viable cells were measured using the MTS assay (Promega CellTiter 96 Aqueous One Solution Cell Proliferation Assay), a colorimetric method for determining the number of viable cells in proliferation or cytotoxicity. The results of this analysis are shown in Figure 7.
Example 2: Further studies with ECM surfaces and various media components
[00065] Primary pancreatic cells, composed of >90% non-islet/non-duct cells, were plated onto various coated surfaces at a density of 28,900 cells/well (105 cells/cm2). Unattached cells were washed off after 18 hours, and cultures were re-fed and allowed to grow for 8 days. Cultures were fixed in formalin (10%) and subjected to phenotypic analysis with antibodies to CK19 and Amylase. The results are shown in Figure 4A-B. While Collagens I, IV, Laminin, Fibronectin, and Matrigel provide a suitable surface for cell attachment and expansion, maintenance of acinar (amylase+) phenotype along with the presence of an increased proportion of cells with a glandular epithelial phenotype (CK19+) was superior on Collagen I. More than 50% of cells analyzed expressed amylase and more than 50% of cells analyzed expressed CK19, suggesting that a subpopulation of cells in these experimental conditions express both markers.
[00066] Tissue culture-treated polystyrene culture surfaces were coated with Collagen I as described above. Tissue culture medium (PCM) was prepared as described above. In some cases, serum was replaced with Fraction V BSA (99% pure, heat inactivated, Sigma), along with combinations of soluble growth factors, including IGF1, IGF2, betacellulin, HGF, EGF, and TGF-alpha. Optimal seeding density is between 104 and 105 cells/cm2, as demonstrated in Example 3. Cells were seeded onto collagen-coated flasks (150 cm2) at 1.5 x 106 cells/flask in PCM. After an ~18hr attachment period, unattached cells were washed away with gentle aspiration/rinse, followed by re-feeding with fresh medium. Cultures were monitored over time by metabolic assay (MTT) and by trypsinization and cell counting, to establish cell number (see example 3). Cell phenotype at the end of the culture period was assessed as follows: small-scale cultures were set up simultaneously in 96-well plates. At the end of the culture phase, monolayer cells were fixed in 10% formalin for a minimum of 1 hour. After formalin was removed and monolayers were rinsed, cultures were subjected to immunocytochemistry as described in previous section for CK19, amylase, insulin, and vimentin (a marker of fibroblasts). The relative fraction of CK19+ cells was determined by quantitative image analysis as described above (see Example 4). After formalin was removed and monolayers were rinsed, cultures were subjected to immunocytochemistry as described in previous section for CK19 and vimentin (a marker of fibroblasts). Cells were also stained with amylase antibodies, but did not produce positive results due to release of digestive enzymes, such as amylase, by the cells over time in culture. The relative fraction of CK19+ cells was determined by quantitative image analysis as described above (see example 4). Acquisition of ductal markers by acinar cells was verified by demonstrating concomitant expression of CK19 and amylase in cell subpopulations during days 2-3 of culture (see example 5). For these experiments, CK19 primary antibodies were reacted with formalin- fixed cell cultures, followed by visualization with Alexa488-conjugated Goat anti-mouse IgG (Molecular Probes). Then, cells were subjected to a blocking step (Protein Blocker, BioGenex), followed by application of the second primary antibody (anti-amylase). Visualization of the amylase was accomplished by application of Alexa594-conjugated Goat Anti-Mouse IgG. Images were collected as described above. At the end of a 7-day culture period in the conditions described herein, between 65-90% of the cells in the culture express CK19, while less than 20% express vimentin (see example 6). Variations in the relative proportion of CK19+ cells probably reflect heterogeneity due to age, gender, and other unique characteristics of individual patients.
Example 3: Density of cell seeding
[00067] Primary pancreatic cells were seeded at (3) densities on tissue-culture treated polystyrene dishes (60mm) and fed with PCM. Light microcopic observations were made daily. At the 24-hour timepoint, dishes were sacrificed and stained with trypan blue to assess viability. The results are shown in Table 3. TABLE 3
Figure imgf000026_0001
[00068] Example 4. Cells were grown on a Collagen I surface, at 37°C in 21% oxygen, in PCM medium or in base medium with 2 % BSA, 2 ng/ml TGF-α, 10 ng/ml EGF, and 10 ng/ml HGF. After 7 days, cultures were fixed in 10% formalin and subjected to immunocytochemical analysis with fluorescent detection, followed by automated image collection and analysis. The results are shown in Figures 5 A and 5B. Fibroblast (vimentin+) fraction, glandular epithelial cell fraction (CK19+), and fraction of unlabeled cells (Other) are similar after expansion. This suggests that replacement of serum with the serum-free medium maintains fraction of CK19+ cells without overgrowth of fibroblasts as compared to cells grown in serum-containing media.
[00069] Example 5. Primary pancreatic acinar cells were cultured for several days in a 1:1 ratio of DMEM and HamsF12, with 10% fetal bovine serum, 0.01 mg/ml insulin, 0.0055mg/ml transferrin, 0.0067μg/ml sodium selenite, 10 ng/ml EGF, 4mmol liter glutamine and antibiotics. After 2 days of culture (4 days ex vivo), expression of amylase by the acinar cells is still strong (Figure 8A, upper left panel, red staining) as determined by immunocytochemistry. Expression of CK19 is also apparent (Figure 8B, lower left panel, green staining). Overlay of the two images (Figure 8C) demonstrates clear co- expression of amylase and CK19 in a large proportion of the cells, indicating that an intermediate cell exists from active conversion of amylase+ acinar cells to an amylase+/CK19+ mixed acinar/ductal phenotype (AD cells). Daily evaluation of cultures (Figure 9) demonstrated that onset of CK19 expression begins around Day 2 of culture and by Day 5 cultures have lost most immunodetectable amylase expression and CK19 expression is prevalent.
[00070] Example 6. After 7 days of growth in PCM / Collagen I surface, cells were fixed, stained with antibodies to CK19, and counterstained with nuclear DAPI. Total cell number was evaluated by automated image analysis (Figure 10A left panel, blue-stained cell nuclei), while CK19+ cells were counted (Figure 10B, right panel, green-stained cell cytoplasm). Of 378 total cells, 342 were immunopositive for CK19 (90%). After approximately 7 days of culture using conditions described herein, the acinar cells have concrete ductular characteristics, now referred to as IP cells. For most primary human cultures, more than 80%) of cells in the culture after about 7 days express markers such as CK19 that are associated with ductular cells from a variety of tissues.
[00071] Example 7: Gene Expression Analysis of 7-Day Cultures (IP Cells).
Two independent IP cell cultures were subjected to Clontech 8K Atlas Gene Array analysis. IP cells were obtained by culturing primary acinar cells in a cell culture system comprising PCM and a Collagen I surface. Monolayer cultures were rinsed 2x with PBS, then detached from the flasks with 0.25% trypsin. Cells were pelleted by centrifugation at 1,200 RPM for 3 minutes in a swinging bucket centrifuge. Cell pellets were resuspended and washed 2x in PBS before a final centrifugation at 1,200 RPM for 3 minutes as described above. The supernatant was discarded and gently aspirated to remove as much liquid as possible from the cell pellet, which was then quick-frozen in a dry-ice/ethanol bath and stored at -80°C until transfer to BD Clontech where gene expression analysis was performed, using conventional techniques.
[00072] Labelled P-33 cDNA probes were prepared from the 30 μg of total RNA from each sample by first enriching for poly A + RNA using a streptavidin-magnetic bead separation method that is part of the Atlas Pure Total RNA Labeling system. The labeled probes from each sample were hybridized with the plastic human 8 K gene arrays for about 16 hours, the arrays were washed and imaged according to the Atlas array protocols. The Atlas image 2.7 software was used to align array images with the array grid template and to exclude false background signals or false signals due to strong signal bleedover. The transcript signals were then extracted from these aligned arrays using the Atlas Image 2.7 software and further statistical analysis of the changes in gene expression were performed.
[00073] In general, mRNA transcription was assayed, by hybridization to suitable oligonucleotide probes. In a few cases, e.g., for CK19 and amylase, the protein expression product was measured, using conventional methods of immunohistochemistry. A summary of the expression by these cell populations of a selected set of genes is presented in Table 4. Table 4 contains a list of genes expressed in IP cells and a comparison of expression patterns in primary acinar cells and primary ductal cells. Gene products identified as "+" were expressed; those identified as "++" were strongly expressed. Gene products designated ® are found in regenerating pancreas.
TABLE 4:
Gene IP Cells Primary Ductal Cells Primary Acinar Cells
Aquaporin 1 + ++(mRNA)/+(protein) 0
Aquaporin 5 ++ +(mRNA)/-(protein)
Aquaporin 8 + - +
Insulin Receptor Substrate-2 + ++ ®
Protein Kinase B (AKT) 0 + +
Calpain (mu) ++ - ++
CFTR (Cystic Fibrosis 0 0 0
Transmembrane
Conductance Regulator)
Claudin 2 nd ++ -
Claudin 3 + + +
Claudin 4 + + +
Claudin 5 nd - ++
Carbonic Anhydrase II 0 0 0
Inositol 1 ,4,5 triphosphate ++ - ++
Re, Type 3
MUC-1 + ++ + MUC-6 ++ +
Cytokeratin 7 ++ ++ -
Cytokeratin 8 ++ +
Cytokeratin 18 + +
Cytokeratin 19 + ++ - alpha v integrin 0 + alpha 3 integrin ++ n/a beta 3 integrin 0 + beta 4 integrin + n/a beta 5 integrin 0 + fibronectin 0 + collagen IV + + vitronectin 0 + ®
MMP2 0 Trace
MMP9 + Trace
T1MP1 ++ Trace
TGF-alpha Trace ++ ®
Gastrin 0 ++ ®
ICAM-1 0 0
ICAM-2 0 0
ICAM-3 0 0
Pancreatitis Associated ++ + ® Trace
Protein (PAP)
Reg-1 + 0 Trace pyrimidinergic receptor P2Y + +
Syndecan + +(low) Trace
Glutathione S Transferase - + + -
Pi
II. Transformation of glandular epithelial cells into insulin producing cells - Generating insulin-producing cells by differentiation of IP cultures (Culture Phase II)
[00074] IP cultures can be utilized to generate insulin-producing cells by placing the cells in a second phase of culture that includes a surface, such as Collagen I, that promotes attachment of the IP cells combined with a defined medium formula that lacks serum but contains combinations of the following differentiation promoting factors: Activin A, acidic FGF, basic FGF, C-Natriuretic Peptide (CNP), Calcitonin Gene Related Peptide, Cholera Toxin B Subunit, Dexamethasone, Gastrin-Releasing Peptide, Glucagon-like Peptide- 1 (GLP-1), Glucose, IGF1, IGF2, Insulin, Laminin, LIF, Met- Enkephalin, PDGFAA+PDGFBB, Prolactin, Sonic Hedgehog, Substance P, TGF-alpha, Trolox (alpha-tocopherol derivative), and VEGF. In the following examples, the base medium is composed of a 1:1 mixture of HamsF12 and DMEM with antibiotics and 0.2%> Bovine Serum Albumin (Fraction V, heat inactivated 99%> pure). In one example (Combination 1), the base medium contained Cholera Toxin B, Dexamethasone, GRP, GLP-1, Glucose, IGF-1, IGF-2, Insulin, Prolactin, Sonic Hedgehog, Trolox, aFGF, and bFGF. In another example (Combination 2), the base medium contained Activin A, CGRP-alpha, CNP, Glucose, GLP-1, IGF-2, Insulin, LIF, Met-Enkephalin, Prolactin, Sonic Hedgehog, aFGF, and vEGF. In a third example (Combination 3), the base medium contains Activin A, CGRP-alpha, Cholera Toxin B, Dexamethasone, Glucose, GLP-1, Insulin, LIF, Laminin, Met-Enkephalin, PDGFAA BB, Sonic Hedgehog, Substance P, TGF-alpha, aFGF, and VEGF. The concentrations of these media supplements are listed in Table 1.
[00075] AD cells were placed into culture by either: 1) trypsinizing the cells from the surface on which they were generated, and redistribution onto a fresh attachment- promoting surface at a density of -5 x 10 cells/cm , or 2) removing the medium, washing 2x in PBS to remove traces of old medium, and cultures re-fed with the new medium (described above) containing differentiation promoting factors. Cells are cultured for a period of 4-10 days at 37°C and 21% oxygen. On Day 5, half of the medium is removed and replaced with an equal volume of fresh medium containing differentiation promoting factors.
Phenotypic Analysis of IP cells After Differentiation Culture.
[00076] Morphological assessment of IP cells cultured in differentiation conditions described above was captured by light microscopy (see Example 8, below). The cellular phenotype of the cells comprising these cultures was assessed by immunocytochemistry as described above using monoclonal antibodies to vimentin, pro-insulin, C-peptide, MUC-1, and CK19 (See Example 10, below). Briefly, cultures were fixed with 10% formalin for 1 hour at room temperature, then washed with PBS and subjected to immunocytochemical protocol. (See Example 9, below).
Functional Analysis of IP cells After Differentiation Culture.
[00077] The ability of the aggregated cell clusters to release insulin and C-peptide was assessed by subjecting the cultured cells to a glucose challenge as follows. Cells that had been cultured in differentiation medium for 7-10 days were washed 3x in PBS, then re- fed with either 1) base medium (described above) with 5mM Glucose, or 2) base medium with 22mM glucose. After 18 hours, the cell-conditioned medium was collected and subjected to ELISA analysis for insulin and C-peptide release (Diagnostic Systems Laboratories (DSL)). ELISAs were conducted using the standard range assay procedure according to manufacturer's specifications. Plates were incubated on a shaker during the assay and results were read in a Tecan specfrophotometric plate reader. Total ng of insulin or C-peptide per well were calculated for each media condition, for both 5mM glucose media and 22mM glucose media (See Example 10).
[00078] Example 8. Pancreatic acinar cells were cultured in Base Medium + ITS + Serum (10%>) for 1 week, then trypsinized (treated with 0.25% Trypsin without EDTA for 10 minutes at 37°C) and transferred to a fresh collagen-1 coated surface and placed in a medium containing all 23 DFPs listed. Over a period of 3-5 days, the cells readily formed three-dimensional pod-like structures, clearly observable by light microscopy (Figure 11). Some larger pods detached from the culture surface after about 4-6 days in culture, and remained viable, as determined by trypan blue exclusion. The pod-like structures were hypothesized to be aggregations of insulin-producing cells, and subjected to further analysis as described below.
[00079] Example 9. Pod-like structures, generated the same manner as described in the previous example, were fixed in 10% formalin and subjected to immunocytochemical analysis first with CK19 monoclonal antibodies, then with C-peptide monoclonal antibodies, as described above. Figure 12A shows a group of cells (DAPI stained nuclei are blue), some of which are immunopositive for CK19 (green staining). Figure 12B shows the same group of cells, many of which are positive for C-Peptide, which is produced when the proinsulin molecule synthesized within the cell is cleaved to yield mature insulin; the C-peptide stained cells are red, with a typical granular staining of the cytoplasm. Figure 12C shows a higher power overlay image, demonstrating colocalization of CK19 and C-peptide in a small subset of cells. Co-stained cells appear yellow-orange on the overlay image.
[00080] Example 10. Cells cultured in base medium (negative control), or in Combinations 1, 2 and 3 of the differentiation promoting media, were evaluated for their ability to release insulin and C-peptide into the culture medium, hi addition, we assessed whether increasing concentrations of glucose led to the release of a greater quantity of insulin and C-peptide, indicating an islet-like functionality. First, the cells were cultured for 1 week in base medium + EGF(10 ng/ml) + ITS + 10% fetal bovine serum (PCM). Then, cells were either subjected to a wash and medium change (non-subcultured), or to a wash, trypsinization detachment, reseeding, and medium change. Replicate cultures were re-fed with either base medium (serum-free), fresh PCM, or one of the three combinations of differentiation promoting media (all serum-free). After 10 days, differentiation media were removed, cultures were washed 3x with PBS, then re-fed with serum-free base medium containing either 5mM glucose or 22mM glucose (final concentration). After 18 hours, the conditioned media were collected and subjected to ELISA analysis with antibodies to either Insulin or C-Peptide (DSL laboratories). Figures 13 A, 13B and 13C, respectively, show insulin release by nonsubcultured cells, and insulin release and C-peptide release in response to glucose challenge. Since some of the cultures contain insulin, and cells can take insulin up from the medium, production of C- peptide is an important confirmation that the cells are synthesizing insulin de novo from the synthesis and processing of proinsulin. Furthermore, the production of insulin and C- peptide is increased in most cases with increasing glucose concentration, suggesting an islet-like function of cells within these cultures. Note that little insulin or C-peptide is produced in the base medium that contains no DPFs. [00081] Example 11. Both the quantity of insulin and the quantity of DNA were measured in IP cells subjected to differentiation culture with or without enzymatic detachment and subculturing. Cultures were carried out precisely as described in the previous paragraph. DNA was measured utilizing a standard Picogreen assay (Molecular Probes), while insulin was measured by ELISA assay. Total ng of Insulin was divided by total μg of DNA in the sample, thus providing the insulin:DNA ratio value, in order to calculate a ratio of the quantity of insulin present vs. the number of cells present (reflected by DNA content). The results are shown in Figure 14. In each of the differentiation media combinations, the insulin:DNA ratio is increased compared to base medium, suggesting that more insulin is produced on a per cell basis in the presence of DPFs than when cultured without them. Furthermore, the insulin:DNA ratio is increased slightly in some conditions upon glucose challenge (22mM glucose vs. 5mM), suggesting that the cells respond to glucose by releasing a greater quantity of insulin.
[00082] Example 12. Insulin-producing cells obtained by the preceding method were subjected to gene expression analysis as described above. Table 5 contains a list of the highest expressed genes, their position on the Clontech atlas 8K gene array, and relative expression of these genes (after normalization). Table 5 is attached hereto as Appendix 1
[00083] Example 13. Primary human pancreatic cells were seeded at 0.5 x 105 cells/cm2 in PCM on a collagen-1 surface and grown for 7 days. Insulin was measured at Days 1, 7, and 10 as follows: Growth medium was removed, wells were washed 3x in phosphate buffered saline. After a pre-incubation for 1 hour at 37C in base medium without insulin, with 5mM glucose, media was removed and replaced with either 1) base medium (without insulin) with 5mM glucose, or 2) base medium (without insulin) with 22mM glucose. Insulin was measured in cell-conditioned media after 18 hours at 37° C. After 7 days of culture, PCM medium was replaced with either 1) fresh PCM, 2) serum- free base medium, 3) serum free base medium with all 23 differentiating factors, 4) serum-free combination 1, or 5) serum-free combination 2. The results are shown in Figure 15. After 3 days exposure to the differentiating factors, increased insulin release is noted in presence of differentiating factors. The results on Day 1 argue against the presence of a significant number of insulin-producing cells in the starting material, demonstrating the de novo generation of insulin-producing cells from acinar cells in the primary culture. It can be seen in the Figure that at the end of 10 days, insulin release in response to a glucose challenge is much greater in the DFP media than in the PCM or base medium, verifying the stimulatory effect that the DFPs exert on transformation of glandular epithelial cells into insulin-producing cells.
[000841 Example 14. Human pancreatic acinar cells were cultured on a collagen I surface in PCM from Day 1 to Day 7, thus generating a culture of IP cells at Day 7. On Day 1, the IP cells were washed and the PCM medium was replaced with the G09 differentiation medium containing the 30 factors listed in Table 2. At each time point (Days 1, 7, 10 and 14), insulin release was measured by washing the cultures three times with PBS, then challenging the cultures with a 1:1 mixture of DMEM and HAMs F12 containing either 5mM or 22mM glucose. After 18 hours of exposure to the glucose, supernatants were collected and insulin measured by ELISA. The results are shown in Figure 15 a.
III. Expression studies at several time points of primary human acinar cells that are expanded, allowed to differentiate into IP cells and then allowed to differentiate further into insulin-producing cells
[00085] Example 15. Three independent samples of primary human pancreatic acinar cells were seeded and expanded described above. From Day 0 to Day 8, cells were on collagen I surface, seeded at 10 cells/cm , in PCM. On Day 8, the medium was changed from PCM to the medium with the active factors shown in Table 2. Cells were fed twice with G09 (50%> of medium replaced) between days 8 and 16. The cells remained on the surface throughout the culture process. Cultures were harvested at 3 days after the initial plating (actively trans-differentiating acinar cells), 8 days after plating (IP cells) and 16 days after plating (putative insulin producing cells) and subjected to gene expression analysis, as described in Example 7. mRNA expression data were obtained with 12K microarrays from Clonetech. [00086] Briefly, growth medium was removed from the culture flasks and cells were lysed in trizol LS (Invitrogen) chaotrope/phenol reagent for about 2 minutes by pipetting the lysis solution over the cell layer. Three ml of RNAse free water was added per 9 ml of lysis solution in an Oak Ridge Cetrifuge tube. 2.4 ml chloroform was then added and the solution vigorously vortexed for 1 minute. The aqueous and organic phases were then separated by cetrifugation at 4°C and the upper aqueous phase containing RNA was removed to a clean PET tube. The RNA was precipitated by isopropanol precipitation, washed with 70% ethanol and redissolved in 200 μl of RNAse free water. A chaotrope lysis reagent was immediately added to the RNA and it was further purified using a Qiagen spin column method with a DNAse digestion step. The purified RNA was finally eluted in 80μl RNAse free water and stored at -80°C.
[00087] Labelled P-33 cDNA probes were prepared from the 30 μg of total RNA from each sample by first enriching for poly A + RNA using a streptavidin-magnetic bead separation method that is part of the Atlas Pure Total RNA Labeeling system. The labeled probes from each sample were hybridized with the plastic human 12 K gene arrays for about 16 hours, the arrays were washed and imaged according to the Atlas array protocols. The Atlas image 2.7 software was used to alighn array images with the array grid template and to exclude false background signals or false signals due to strong signal bleedover. The transcript signals were then extracted from these aligned arrays using the Atlas Image 2.7 software and further statistical analysis of the changes in gene expression were performed.
[00088] The raw expression data were analyzed as follows: (1) We filtered out genes that were not expressed at any of the 3 conditions/time points; (2) We normalized all of the microarrays against each other to remove differences from array-to-array and the effects of variability in sample processing, hybridization, etc.; (3) We identified genes which showed a statistically significant difference among the conditions/time points; and (4) We clustered the genes based on their temporal patterns in a way that is consistent with the design of the study and the changes in phenotype. [00089] Table 6 shows expression data for the genes that were identified by the above analysis. This Table is attached hereto as Appendix 2. These identified genes were expressed at high levels at both Day 3 and Day 8, or their expression increased substantially between Day 3 and Day 8. The Table also shows the expression levels of these genes at Day 16, and the mean expression for all three condition/time points. The Table also shows the ratios of expression at various times: "I to A" is the ratio of expression of putative insulin-producing cells (Day 16) to acinar (Day 8) cells; "hit to A" is the ratio of IP cells (Day 8) cells to acinar cells (Day 3).
[00090] The data shown in Table 6 were further analyzed by clustering them into one of 17 "classes," whose features are summarized on the Table. A graphical representation of the characteristics of these 17 classes in presented in Figure 16.
[00091] The data from the Day 8 time points in Table 6 were also grouped with regard to whether the genes expressed at Day 8 in these cells belong to the classes of genes expressed normally in (1) liver and pancreas; (2) pancreas-associated genes; (3) liver- associated genes; or (4) progenitor-associated genes. The results are shown in Table 7.
Table 7 BDT Intermediate Cells
Genes Expressed in Liver and Sample 1 Sample 2 Sample 3 Hepatic Pattern of Expression Pancreatic Pattern of Pancreas Expression
CK18 + + + hepatic lineage acinar cells
CK8 + + + hepatic lineage acinar cells
CK19 + + + bile duct duct cells
CK7 + + + bile duct duct cells
HNF1 + + + liver tc factor in beta cells α-1 antitrypsin ++ ++ ++ produced in differentiated hepatocytes yes
Notch-1 - - Trace involved in differentiation of cells into developing pancreatic hepatic lineage epithelium α-fetoprotein - - - developing hepatocytes and hepatic developing pancreatic progenitors ducts
Notch-3 Trace Trace Trace involved in differentiation of cells into pancreatic mesenchyme hepatic lineage and endothelium
Notch-4 Trace Trace Trace- involved in differentiation of cells into pancreatic mesenchyme hepatic lineage and endothelium
Jagged-2 involved in differentiation of cells into yes hepatic lineage pi-glutathione s transferase (pi-GST) ++ developing liver duct cells and centroacin cells γ-glutamyl transferase developing bile duct acinar cells
Pancreas-Associated Genes Sample 1 Sample 2 Sample 3 Hepatic Pattern of Expression Pancreatic Pattern of Expression carbonic anhydrase - - Trace no duct cells
CF transmemb conductance regulator - - Trace no duct cells elastase - - - no acinar cells amylase - - - no acinar cells insulin + Trace Trace no islet somatostatin Trace Trace Trace no islet
Pancreatic Polypeptide + + Trace no islet
Glucagon - - - no Islet
Liver-Associated Genes Sample 1 Sample 2 Sample 3 Hepatic Pattern of Expression Pancreatic Pattern of Expression
Sialyltransferase-6 - - produced in differentiated hepatocytes no
Liver-specific bHLH transcrip factor + + + liver-specific Tc factor no
Thy-1 + + + hepatic oval cell marker no
Glucose-6-phosphatase - Trace hepatic lineage, progenitors and adult No
Glutamine synthetase - Trace hepatocyte No
Carbamoyl phosphate synthetase- 1 - - hepatocyte no
Dipeptidylpeptidase IV - - hepatocyte no
C/EBP-α ++ *-+ + liver-specific Tc factor *tumed on and upregul during hepatization of pancreas (copper-deficie diet)
C/EBP-beta ++ ++ ++ liver-specific Tc factor *tumed on and upregul during hepatization of pancreas (copper-deficie diet)
Progenitor Cell-Associated Genes Sample 1 Sample 2 Sample 3 Tissue
Musashi-1 Intestine
Nestin Pancreas / Neuronal
CD34 Hematopoietic
Thy-1 Hepatic progenitors
BMP-2 Neuronal
BMPRclA Trace Mesenchyme c-kit Liver / Pancreas / Neuronal chromogranin A Trace Trace Trace Neuroendocrine / Liver/ Intestine
PDX-1 + Pancreas
[00092] As can be seen, at Day 8 IP cells no longer expressed genes consistent with pancreatic acinar cells, nor did they express a complement of genes specific for pancreatic ductular cells. The IP cells expressed low levels of some markers associated with pancreatic islets, including insulin, somatostatin and pancreatic polypeptide, suggesting that at least some cells in the population are competent to express endocrine genes of the pancreatic islets.
[00093] Surprisingly, the IP cells also expressed several liver-specific transcription factors (e.g., C/EBP alpha, C-EBP-beta) and other markers of mature and developing liver, including low levels of Thy-1, a marker associated with hepatic "oval" stem cells. This suggests that the differentiating cells were not moving simply from pancreatic acinar to pancreatic ductal, but had developed into a cell with both hepatic and pancreatic characteristics, while not fitting into any single gene expression profile of one of these cell types. The cells generated in this example resemble the cells that emerge from the pancreas of rodents that are fed a copper-deficient diet. (See, e.g. Rao et al., 1988). The pancreas of such animals goes through an acute phase of pancreatitis followed by "hepatization" of liver (which means cells that begin to express hepatic genes rather than pancreatic genes). Liver-like cells have also been reported in human fetal pancreas (Tsanadis et al., 1995) Isolated cells generated by the methods of the present invention (e.g., by propagating primary acinar cells or other types of endodermal cells or progenitor cells by the methods of the invention) are to be distinguished from naturally occurring cells that may have some of the characteristics of IP cells, such as oval cells or cells isolated from the pancreas of a rodent on a copper-deficient diet.
[00094] Cells having the characteristics of these IP cells may be useful for, e.g., therapeutic approaches in the treatment of diabetes. Furthermore, although the cells in this example were derived from pancreas, other epithelial tissues, or perhaps even any endoderm-derived tissue, may provide additional sources of cells that can be differentiated into cells having a similar phenotype. Suitable tissue types include, e.g., liver or intestine. These IP cells express genes associated with pancreas, liver, intestine and neuronal tissues. For example, they express mucin, CK19 and CK7, which are common markers associated with duct cells in the pancreas, liver and intestine. Thus, the gene expression pattern seen in these IP cells may serve as a predictive measure for cells derived from each of these tissues for the purpose of generating insulin-producing cells. Furthermore, IP cells may, under appropriate conditions, give rise, not only to pancreatic islet cells, but also to hepatocytes or any endoderm-derived tissue.
[00095] The disclosures of the following references, cited above in part, relate to the present invention:
WO 02/29010 A2 (Kerr-Conte);
Bonner-Weir, S. et al., Proc. Natl. Acad. Sci. USA 97: 7999-8004 (2000),
Bouwens, L., Microsc. Res. Tech. 43: 332-6 (1998),
Bowens, L. et al. Diabetologia 41:629-33 (1998);
Gmyr, V. et al., Diabetes 49:1671-80 (2000);
Gmyr, V. et al. Cell Transplant 10:109-21 (2001),
Gmyr, V. et al. Diabetes 49:1671-80 (2000),
Hall, P.A. et al, J. Pathol. 166: 97-103 (1992);
Kerr-Conte, J. et al, Diabetes 45:1108-14 (1996);
Kerr-Conte, J. et al, Transplant Proc 27:3268 (1985);
Pattou F. et al., Bull. Acad. Natl. Med. 184:1887-99 (2000);
Rao, MS et al Biochem Biophys Res Comm. 156:131-6 (1988);
Rooman, Use et al., Diabetes 51: 686-90 (2002);
Rooman, I, et al. Diabetologia 43:907-14 (2000);
Rooman, I. et al., Gastroenterology 121: 940-9 (2001);
Trivedi, N. et al. Endocrinology 142:2115-22 (2001);
Tsanadis, G. et al. Histol. Histopathol. 10:1-10 (1995);
Wang, R.N. et al., Diabetologia 38:1405-11(1995);
USP 6,011,647 (Ammon Peck).
[00096] The embodiments illustrated and discussed in the present specification are intended only to teach those skilled in the art the best way known to the inventors to make and use the invention, and should not be considered as limiting the scope of the present invention. The exemplified embodiments of the invention may be modified or varied, and elements added or omitted, without departing from the invention, as appreciated by those skilled in the art in light of the above teachings. It is therefore to be understood that, within the scope of the claims and their equivalents, the invention may be practiced otherwise than as specifically described.
[00097] The entire disclosure of all applications, patents and publications, cited above and in the figures are hereby incoφorated in their entirety by reference.
GENE Position on Atlas 8K Array Relative Expression, Sample 1 Relative Expression, Sample 2 aquaporin 5 7 7554477 4 4553399 4550 actin, beta 3 3995522 3 3559988 3442 actin, beta 8 8117766 3 3004477 3747 growth hormone secretagogue receptor 6 6884466 2 2009922 1710 profilin 1 4 44488 1 1558800 1246 special AT-rich sequence binding protein 1 3 3003355 1 1443377 886 (binds to nuclear matrix/scaffold- associating DNA's) cardiac-specific homeo box 2 2005500 1 1339955 2850
CCAAT/enhancer binding protein (C/EBP), 1 1558888 1 1337744 1671 beta
RAS guanyl releasing protein 2 (calcium 8 8226622 1 1226633 1616 and DAG-regulated) cartilage paired-class homeoprotein 1 6 6667777 1 1116666 1241 paired-like homeodomain transcription 6 6880055 1 1111133 756 factor 1 transcription factor 21 7 7662211 1 1006633 801
CD3E antigen, epsilon polypeptide (TiT3 88005544 999944 1113 complex)
CD151 antigen 55 5666111333 99 9333555 808
ATPase, Ca++ transporting, plasma 77 7999444000 99 9111999 876 membrane 2 ficolin (collagen/fibrinogen domain- 88 8222444 99 9000111 829 containing) 3 (Hakata antigen) inositol polyphosphate phosphatase-like 1 55 5999888999 88 8333222 425 protein tyrosine phosphatase, receptor 8 88333666777 8 88000666 810 type, S integrin, alpha 3 (antigen CD49C, alpha 3 1 11777444333 7 77555888 647 subunit of VLA-3 receptor) syntaxin 1A (brain) 6 66888555111 7 77444333 658 parathymosin 7 77111333555 7 77222555 852 thymosin, beta 10 7 77444333666 7 77000999 1617 midkine (neurite growth-promoting factor 2) 2 22444777000 6 66888222 802 arylsulfatase A 3147 678 3084
calbindin 2, (29kD, calretinin) 7000 676 786 serine (or cysteine) proteinase inhibitor, 5214 668 678 clade A (alpha-1 antiproteinase, antitrypsin), member 1 retinal G protein coupled receptor 7972 653 696 myosin regulatory light chain 2, smooth 22449999 663388 561 muscle isoform butyrate response factor 1 (EGF-response 7 ι3v2>5κ 683300 646 factor 1 )
7583 589 394 type I transmembrane receptor (seizure- related protein) type I transmembrane receptor (seizure- 7583 589 394 related protein) procollagen C-endopeptidase enhancer 3593 576 713
7069 558 571 mitogen-activating protein kinase kinase kinase kinase 2 protease, serine, 1 (trypsin 1 ) 6323 558 656
4576 536 2177 pancreatitis-associated protein n receptor 1 B 4093 516 491 angiotensi
6489 503 581 stratifin
7903 500 364 keratin 17
6872 432 433 somatostatin receptor 3 ng protein H 4692 428 96 myosin-bindi
4202 411 381 ephrin-A5
1965 407 263
RAP1, GTPase activating protein 1 B1 6604 405 830 chymotrypsinogen ankyrin-like with transmembrane domains 3577 395 431 1 ted kinase 2439 391 341
Misshapen/NIK-rela
4492 381 308 bone morphogenetic protein 6
713 375 662 splicing factor proline/glutamine rich (poiypyrimidine tract-binding protein- associated)
2720 370 378 claudin 12 matrix metalloproteinase 23A 77449911 336ϋ8» 138 neurogranin (protein kinase C substrate, 4465 366 335 RC3)
dopamine receptor D2 1649 362 234 cardiotrophin 1 5283 359 507
CCAAT/enhancer binding protein (C/EBP), 7237 359 645 alpha paired box gene 9 5206 335 201 protein tyrosine phosphatase, receptor 8235 331 250 type, N keratin 8 7215 327 449 claudin 7 280 325 173 trophinin associated protein (tastin) 462 323 360 neuronal thread protein 8356 322 366 basic helix-loop-helix domain containing, 6734 318 215 class B, 2 annexin A2 4467 290 226 cathepsin D (lysosomal aspartyl protease) 7370 289 600
Bicaudal D (Drosophila) homolog 1 6822 284 217 lectin, galactoside-binding, soluble, 1 7331 280 310
(galectin 1) keratin 7 7171 278 481 glyceraldehyde-3-phosphate 3953 278 307 dehydrogenase aquaporin 6, kidney specific 7591 277 258
TNF receptor-associated factor 1 6037 269 270
Rho GDP dissociation inhibitor (GDI) alpha 5565 267 321 calcium channel, voltage-dependent, 3142 260 207 gamma subunit 4 glutamate receptor, ionotropic, kainate 1 4776 244 296
CCR4-NOT transcription complex, subunit 983 244 428
4 filamin A, alpha (actin-binding protein-280) 3457 241 233 peanut (Drosophila)-like 1 711 233 310 enhancer of rudimentary (Drosophila) 5921 231 405 homolog endothelin converting enzyme 1 7835 229 197
2483 223 Vϋ rotocadherin 17
7679 217 145 quaporin 8 ynapsin I 4871 216 164 ubulin, alpha, brain-specific 2827 212 345 D44 antigen (homing function and Indian 7848 207 141 ilood group system) erebral cavernous malformations 1 2731 205 116
.sulin-like 3 (Leydig cell) 666 202 365 idenylate cyclase activating polypeptide 1 4489 200 74 pituitary) lairless (mouse) homolog 5185 196 36
4427 190 44 isulin jranulin 928 184 201 jranulin 928 184 201 ϊarly growth response 1 2111 178 136 yclin-dependent kinase inhibitor 1A (p21 , 7852 175 108
-ip )
;tem cell growth factor; lymphocyte 1606 174 152
-ecreted C-type lectin
-JD4 antigen (p55) 5608 172 143
DCTAIRE protein kinase 1 6334 161 78 ho GTPase activating protein 6 1035 160 220
3 protein-coupled receptor 37 (endothelin 6318 158 35 eceptor type B-like) syndecan 4 (amphiglycan, ryudocan) 3154 157 147
3CTAIRE protein kinase 3 8050 155 159 smpty spiracles (Drosophila) homolog 2 2084 150 207 ransglutaminase 1 (K polypeptide 6674 150 101 spidermal type I, protein-glutamine-gamma- glutamyltransferase) potassium voltage-gated channel, 1335 147 62 subfamily G, member 2 aldehyde dehydrogenase 4 (glutamate 5985 147 207 gamma-semialdehyde dehydrogenase; pyrroline-5-carboxylate dehydrogenase)
E1 A binding protein p300 1433 144 197
LIM homeobox transcription factor 1 , beta 8211 143 89 eukaryotic translation elongation factor 2 4536 134 150 mitogen-activated protein kinase kinase 5462 129 92 kinase 10
PPAR(gamma) angiopoietin related protein 3074 129 56 homeo box Aδ 7037 128 87
CD63 antigen (melanoma 1 antigen) 7769 124 91 nuclear receptor coactivator 3 4181 119 84
CD68 antigen 443 118 256 transmembrane 4 superfamily member 7 1571 117 29 pancreatic polypeptide 2735 116 136 endothelin type b receptor-like protein 2 6656 114 74 neurogenin 1 5772 113 91 insulin receptor substrate 2 6016 110 130 glutamate receptor, ionotropic, N-methyl D- 4702 109 58 asparate-associated protein 1 (glutamate binding) neurotrophin 5 (neurotrophin 4/5) 8259 108 89 pyrimidinergic receptor P2Y, G-protein 3857 105 65 coupled, 6 empty spiracles (Drosophila) homolog 1 2040 103 87 chromobox homolog 2 (Drosophila Pc 2832 101 139 class) heart and neural crest derivatives 2146 92 129 expressed 1 transglutaminase 2 (C polypeptide, protein- 7731 92 74 glutamine-gamma-glutamyltransferase) enolase l , (alpha) 1389 92 205 thyroid transcription factor 1 4519 89 60 keratin 19 5923 88 223
Deleted in split-hand/split-foot 1 region 3641 87 104 glutathione peroxidase 4 (phospholipid 1874 84 72 hydroperoxidase) aristaless (Drosophila) homeobox 1783 81 103
GATA-binding protein 4 659 80 110 transcription factor 1 , hepatic; LF-B1 , 712 80 136 hepatic nuclear factor (HNF1), albumin proximal factor heat shock transcription factor 1 6708 79 57 liver-specific bHLH-Zip transcription factor 765 77 188 liver-specific bHLH-Zip transcription factor 765 77 188 eukaryotic translation initiation factor 3, 6280 76 94 subunit 4 (delta, 44kD) eukaryotic translation initiation factor 3, 6280 76 94 subunit 4 (delta, 44kD) gamma-aminobutyric acid (GABA) A 3720 70 178 receptor, alpha 6 retinoic acid receptor, gamma 5191 70 109 homeo box D9 1776 69 34
MAD1 (mitotic arrest deficient, yeast, 1946 63 38 homolog)-like 1 homeo box A4 7177 57 103
Thy-1 cell surface antigen 559 57 87 talin 603 53 84 bone morphogenetic protein receptor, type 332 53 45
II (serine/threonine kinase) hepatocyte nuclear factor 3, alpha 72 52 60 ryanodine receptor 2 (cardiac) 5244 47 40 signal transducer and activator of 3661 40 35 transcription 6, interleukin-4 induced
APPENDIX 2 • Table 6
SwissPro Spot geneName day3 day8 day16 allMean ratioltoA rationlntto. classic className
P04270 E19ab2 actin; alpha, cardiac muscle 1198 174 760 5955077 2637 676 2 31E+00 -657E-01 7 Equal A/lnt, Up Islets
095996 N17ab2 adenomatous polyposis coli like 2708 542 5180 7594 139 5161 464 1 49E+00 936E-01 7 Equal A/lnt, Up Islets
Q1 697 G02ef8 alpha glucosidaεe II alpha subun 3060691 350 7753358 4770123 1 34E+00 1 92E-01 7 Equal A/lnt, Up Islets
P1 209 G23ab7 antigen identified by monoclonal 389 822 507 1238 43 711 8924 1 67E+00 3 80E-01 7 Equal A/lnt, Up Islets
P30530 G14ef5 AXL receptor tyrosme kinase 3144639 288 6345658 4122115 1 01E+00 -1 29E-01 7 Equal A lnt, Up Islets
043770 I23ab3 B-cell CLL lymphoma 7C 700573 1050 150452 1085931 1 10E+00 587E-01 7 Equal A/lnt, Up Islets
043852 P08ab3 calumenin 801 582 1290 4720807 2269 921 2 56E+00 684E-01 7 Equal A lnt, Up Islets
075718 024cd6 cartilage associated protein 430 4432 256 1090 59 5922327 1 34E+00 -7 52E-01 7 Equal A/lnt, Up Islets
Q9Y3C0 G14ef2 CGI-116 protein 181 0293 301 4167246 2997237 1 20E+00 736E-01 7 Equal A lnt, Up Islets
P78369 G09cd6 claudin 10 1176 087 742 2598 595 1505471 1 14E+00 -665E-01 7 Equal A lnt, Up Islets
P08572 P08ef6 collagen, type IV, alpha 2 1130 23 1350 4684425 2389 488 205E + 00 260E-01 7 Equal A/lnt, Up Islets
P11802 B05ef5 cyclm-dependent kinase 4 914 1579 978 2342 994 1411 839 1 36E+00 979E-02 7 Equal A/lnt, Up Islets
Q16555 O07ab4 dihydropynmidinase-like 2 114 6165 164 921 1473 3998267 301E+00 5 14E-01 7 Equal A/lnt, Up Islets
P33316 H23ab5 dUTP pyrophosphatase 1772032 238 541 5382 3187836 1 61E+00 4 23E-01 7 Equal A/lnt, Up Islets
P07992 K20ef6 excision repair cross-complemen 362031 415 9077933 561 6388 1 33E+00 1 97E-01 7 Equal A lnt, Up Islets
075636 B14cd3 ficolin (collagen/fibπnogen domai 1081 127 1010 4327606 2139448 2 OOE+00 -987E-02 7 Equal A/lnt, Up Islets
Q9UBA6 B19ef4 G8 protein 3706842 578 1489206 8126378 201E+00 641E-01 7 Equal A/lnt, Up Islets
Q9Y5P5 P08ef7 GDP-mannose pyrophosphorylai 171 1216 198 4140862 261 0679 1 27E+00 2 10E-01 7 Equal A/lnt, Up Islets
075293 E02ef7 growth arrest and DNA-damage-l 1943626 203 386 6833 261 3841 992E-01 635E-02 7 Equal A/lnt, Up Islets
P50152 C05ab6 guanine nucleotide binding prote 204743 150 497 3097 283 8702 1 28E+00 -453E-01 7 Equal A/lnt, Up Islets
Q9NX09 C05gh3 HIF-1 responsive RTP801 348 8574 253 1032929 5450622 1 57E+00 -4 61E-01 7 Equal A/lnt, Up Islets
P05204 J22ab7 high-mobility group (πonhistone ( 2067 865 1120 6059 895 3082 818 1 55E+00 -884E-01 7 Equal A/lnt, Up Islets
Q9P0P2 C17ef3 homolog of yeast 0G1 325 8407 378 6827568 462 1583 1 07E+00 2 14E-01 7 Equal A lnt, Up Islets
Q9NWF8 L15gh2 hypothetical protein FLJ10055 172 167 241 3743 2626222 1 12E+00 488E-01 7 Equal A/lnt, Up Islets
Q9NWV4 B17gh2 hypothetical protein FLJ20580 221 4432 280 483 5381 3282481 1 13E+00 3 37E-01 7 Equal A/lnt, Up Islets
Q9P0S8 A21ef3 hypothetical protein HSPC195 153 824 165 330 9111 2164274 1 11E+00 972E-02 7 Equal A/lnt, Up Islets
Q9BWS9 P04gh5 hypothetical protein GC3234 1969154 161 4272066 261 7132 1 12E+00 -2 90E-01 7 Equal A/lnt, Up Islets
Q9BSK0 K21gh8 hypothetical protein GC4415 1564692 117 684 3425 319 1224 2 13E+00 -4 25E-01 7 Equal A lnt, Up Islets
Q9Y6M1 P09cd6 IGF-II mRNA-b ding protein 2 1352566 153 4085101 2322937 1 59E+00 1 79E-01 7 Equal A/lnt, Up Islets
Q9NQX7 H02gh7 integral membrane protein 3 4782728 481 1102244 687 2575 1 20E+ 00 897E-03 7 Equal A/lnt, Up Islets
P08648 E23ef7 integrin, alpha 5 (fibronectin rece 1834629 124 4787266 262 0713 1 38E+00 -565E-01 7 Equal A/lnt, Up Islets
000410 J24ab6 karyopheπn (importin) beta 3 326 6874 196 6297656 3842402 947E-01 -735E-01 7 Equal A/lπt, Up Islets
P07195 N16ab6 lactate dehydrogenase B 1003 971 1200 5593079 259905 248E + 00 2 57E-01 7 Equal A/lnt. Up Islets
P09382 N22ab6 lectin. galactoside-bmding, solub 19170 52 35400 7808675 44205 77 203E + 00 8 83E-01 7 Equal A/lnt, Up Islets
075427 P20ab6 leucme-πch repeat protein, neurc 174 9605 231 543 3883 316 5457 1 63E+00 4 03E-01 7 Equal A/lnt, Up Islets
Q16553 A15ab7 lymphocyte antigen 6 complex, lc 4258933 494 9384504 619 3701 1 14E+00 2 13E-01 7 Equal A/lnt, Up Islets
075900 O05cd4 matπx metalloproteinase 23A 381 2184 297 851 7221 510 1038 1 16E+00 -358E-01 7 Equal A/lnt, Up Islets
Q9UNF1 H16ef7 melanoma antigen, family D, 2 193 8125 219 6599701 357 6132 1 77E+00 1 77E-01 7 Equal A/lnt, Up Islets
P13995 J16cd6 methylene tetrahydrofolate dehyc 321 4878 226 7596021 4356746 1 24E+00 -509E-01 7 Equal A/lnt, Up Islets
000265 G19cd8 microtubule-assoclated protein, F 1897616 234 3775576 267 156 993E 01 3 03E-01 7 Equal A/lnt, Up Islets
P27361 B13ef5 mitogen-activated protein kinase 358 0872 382 720 3119 486 849 1 01E+00 938E-02 7 Equal A lnt, Up Islets
P24844 E18cd6 myosin, light polypeptide 9, regul 5480 451 7380 22518 95 1179309 204E + 00 4 29E-01 7 Equal A/lπt, Up Islets
Q9NVD4 J10gh2 N-acetylneuraminic acid phosph. 1534762 167 390 6642 237 1908 1 35E+00 1 26E-01 7 Equal A/lnt, Up Islets
Q9Y617 N22ef8 phosphosenne aminotransferase 1699503 250 1238 851 5530005 2 87E+00 558E-01 7 Equal A/lπt, Up Islets
095356 A11gh7 pituitary tumor-transforming 3 237 2126 192 2276 181 901 8229 326E+00 -305E-01 7 Equal A/lnt, Up Islets
Q9Y5X6 G04cd6 plasma glutamate carboxypeptid, 1696268 142 3666202 2260168 1 11E+00 -2 58E-01 7 Equal A/lnt, Up Islets
Q15113 G20abB procollagen C-eπdopeptidase en 4973967 402 2628947 1176046 2 40E+00 -308E-01 7 Equal A lnt, Up Islets
015460 D20cd4 procollagen-proline, 2-oxoglutars 262 1395 433 7564003 483 9569 1 53E+00 7 25E-01 7 Equal A/lnt, Up Islets
043556 I19gh1 sarcoglycan, epsilon 1727191 215 349304 245 5263 1 02E+00 3 13E-01 7 Equal A/lnt, Up Islets
P50454 M17ab6 seπne (or cysteiπe) protemase in 339 1762 612 4091 161 1680 942 3 59E+00 853E-01 7 Equal A/lnt, Up Islets
Q92853 A23cd8 similar to vaccinia virus Hindlll K 444062 553 997 4551 664 6951 1 17E+00 3 15E-01 7 Equal A/lnt, Up Islets
Q16658 P20cd1 singed-like (fascin homolog, sea 2627872 479 1472155 738014 249E+00 866E-01 7 Equal A/lnt, Up Islets
Q9Y4Y8 E18cd7 Sm protein F 2572026 278 5489705 361 3772 1 09E+00 1 12E-01 7 Equal A/lnt, Up Islets
Q9BVH9 D18gh7 thioredoxiπ related protein 5220262 481 1903964 968 9954 1 87E+00 -1 18E-01 7 Equal A/lnt, Up Islets
Q9HBB0 L08gh8 Thy-1 co-transcπbed 3273502 374 1110527 603 8101 1 76E+00 1 90E-01 7 Equal A/lπt, Up Islets
P01033 P09ef7 tissue inhibitor of metalloprotems 1236457 1500 1302941 5256 861 340E + 00 283E-01 7 Equal A/lnt, Up Islets
Q15582 L20ef6 transforming growth factor, beta-l 1221 083 2060 8540 86 393909 2 81E+00 751E-01 7 Equal A/lnt, Up Islets
Q01995 M07cd2 transgelln 3307 821 3880 18534 27 8573074 249E + 00 229E-01 7 Equal A lnt, Up Islets
Q13641 B05ab2 trophoblast glycoprotein 4796488 426 1399786 768 6158 1 55E+00 -1 70E-01 7 Equal A/lπt, Up Islets
P06468 G08cd2 tropomyosin 2 (beta) 3392292 589 1320305 4710 469 5 28E+00 7 96E-01 7 Equal A/lπt, Up Islets
P51784 21cd4 ubiquitin specific protease 11 1580478 194 491 1246 2809819 1 64E+00 294E-01 7 Equal A/lnt, Up Islets
P03996 E17ab2 actin, alpha 2, smooth muscle, a< 412 1187 1940 41801 34 14717 63 6 66E+00 2 23E+00 9 Increasing A/lnt/l
P08123 P02ef6 collagen, type I, alpha 2 1865666 576 14565 36 5109251 6 29E+00 1 63E+00 9 Increasing A/lnt/l
P24821 A05ef7 hexabrachion (tenascln C, cytota 355495 918 2371 983 1215 165 274E + 00 1 37E+00 9 Increasing A/lnt/l
Q9NVA2 F13gh3 hypothetical protein FLJ10849 374 1496 861 3471 789 1568 848 321E+00 1 20E+ 00 9 Increasing A/lnt/l
P40261 M09cd1 nicotinamide N-methyltraπsferas< 1060 579 2310 5683 533 3016993 242E+00 1 12E+00 9 Increasing A/lnt l
Q15063 C01ef7 osteoblast specific factor 2 (fasα 276634 795 8328222 3133301 491E+00 1 52E+00 9 Increasing A/lnt/l
P09486 A09ef7 secreted protein, acidic, cysteme 404 2839 2760 638372 2233348 730E + 00 277E + 00 9 Increasing A/lnt/l
P35625 K20ef5 tissue inhibitor of metalloprotein. 216254 619 10078 17 3637 823 5 54E + 00 1 52E+ 00 9 Increasing A/lπt/l
Q9H2L5 G06gh8 AD037 protein 361 2297 681 1588121 4004602 -1 19E+00 915E-01 19 lnt> (A,l)
P15121 C18ab2 aldo-keto reductase family 1 , mei 2342 744 5380 2337052 3354494 -351E-03 1 20E+00 19 lπt> (A,l)
P08582 B14ef5 antigen p97 (melanoma associa. 299 1375 595 80 80392 3249781 -1 89E+00 9 92E-01 19 lnt> (A,l)
P20292 E06ab2 arachidonate 5-llpoxygeπase-act 1000016 687 203 2911 330 0345 1 02E.00 278E + 00 19 lnt> (A,l)
015342 A13ab3 ATPase, H+ transporting, lysosoi 6063 171 16500 6160 831 9572914 2 31E-02 1 44E+00 19 lnt> (A,l)
Q9BXJ0 H18gh6 C1 q and tumor necrosis factor re 180 2978 350 154 1441 228 0109 -2 26E-01 955E-01 19 lnt> (A,l)
Q9NRJ3 P09gh4 CC chemokine CCL28 2500021 1830 7632866 9480274 1 61E+00 287E+00 19 lnt> (A,l)
P05305 F17ab5 endothelin 1 8664561 1810 403431 1026 992 -1 10E+00 1 06E+00 19 lnt> (A,l)
P09341 A04ab6 GR01 oncogene (melanoma gro 933 2938 4770 1006711 2236622 1 09E-01 235E+00 19 lπt> (A,l)
Q92730 014ef4 GTP-binding protein 653 8575 2760 5427528 1318 381 -269E-01 208E + 00 19 lnt> (A,l)
Q9H5K0 10gh5 hypothetical protein FLJ23360 151 2029 296 130 3196 1926442 -2 14E-01 97 E-01 19 lnt> (A,l) r- .acc-t «fl n1R9 1 .mi >-γκ nnRi. _. o .p+nn . -πp+nn .α n P42701 A06ef7 interleukin 12 receptor, beta 1 1227 347 22100 1333 521 8218 994 1 20E-01 4.17E+00 19 lnt> (A,l)
P09237 J15ef1 matrix metalloproteinase 7 (matri 9598545 87300 1984969 3890532 1 05E+00 3 18E+00 19 lnt> (A,l)
P16860 013ab8 natnuretic peptide precursor B 4340 214 12900 1260 906 6171 6 -1 78E+00 1 57E+00 19 lπt> (A,l)
P21359 L16ab7 neurofibromm 1 (neurofibromato: 132 483 292 1550822 193 3208 227E-01 1 14E+00 19 lnt> (A I)
P02775 B07ef7 pro-platelet basic protein (includf 3398656 1400 2652119 567 1992 296E+00 5 37E+00 19 lnt> (A,l)
Q9UDQ9 J22gh4 SBBI26 protein 121 5886 1080 238 8624 479 5908 974E-01 3 15E+00 19 lnt> (A,l)
075635 P14cd3 serine (or cystelπe) protelnase In 232 6336 3890 3262581 1483 169 4 88E-01 4 06E+00 19 lπt> (A,l)
P02735 A11cd3 serum amyloid A1 4969578 17400 957 6141 6295724 946E-01 5 13E+00 19 lnt> (A,l)
060635 F10cd5 tetraspan 1 321 8888 843 1776479 4475729 -858E-01 1 39E+00 19 lnt> (A,l)
P50591 C09cd4 tumor necrosis factor (ligand) su| 5367773 1550 4762305 8543061 -1 73E-01 1 53E+00 19 lnt> (A,l)
Q03169 I10ef7 tumor necrosis factor, alpha-indu 3667502 1260 3266536 650583 -1 67E-01 1 78E+00 19 lπt> (A I)
Q9C075 N11ef8 type I Intermediate filament cytok 848 9829 4200 401 4854 1818 182 -1 08E +00 2 31E+00 19 lnt> (A,l)
P02248 A01cd3 ubiquitin C 155 6735 892 6204595 369 9913 -1 33E +00 2 52E+00 19 lnt> (A,l)
095497 A15cd5 vanm 1 309 1556 1840 5107208 8870948 724E-01 2 57E+00 19 lnt> (A,l)
Q14202 B15cd5 199 6246 1040 2479161 496 3668 3 13E-01 2 38E+00 19 lnt> (A,l)
P15514 M02ef7 103 1419 405 6566087 191 2981 -6 52E-01 1 97E+00 18 Off A I. On lnt
Q9BZL9 121 gh8 1263951 211 8456927 140 8098 -5 80E-01 742E-01 18 Off A l, On lnt
P30991 D14efS 64 37115 260 1202328 148 3131 901E-01 2 02E+00 18 Off A l, On lnt
P29400 H13ab3 53 50943 374 141 1609 189 6904 1 40E+00 2 81E+00 18 Off A I. On lnt
Q9UK22 H22cd7 87 59822 217 1203781 141 6466 459E-01 1 31E+00 18 Off A/I, On Int
Q16769 015cd8 8990252 195 1130683 1327502 331E-01 1 12E+00 18 Off A/I, On Int
P02261 06gh6 6546028 263 126664 151 868 952E-01 2 01E+00 18 Off A/I, On Int
P20769 D03ef1 101 245 176 1025687 1267136 1 87E-02 800E-01 18 Off A I, On Int
P52945 I12ab6 7460504 351 8642558 1707555 2 12E-01 2 24E+00 18 Off A/I, On Int
Q14496 F21cd6 9927101 286 9828057 161 3017 -1 45E-02 1 53E+00 18 Off A/I, On Int
P01583 F15ef7 103386 375 666314 181 5566 -634E-01 1 86E+00 18 Off A/I On Int
P01584 F17ef7 1167675 415 1190156 216 8707 275E-02 1 83E+00 18 Off A/I, On Int
Q9GZM1 I20gh7 102 1328 348 101 569 183 8736 -799E-03 1 77E+00 18 Off A/I, On Int
P25105 G15ef5 9743121 356 8047935 177 9689 -276E-01 1 87E+00 18 Off A/I, On M
P58294 014gh8 7998286 241 137 5167 152 9437 782E-01 1 59E+00 18 Off A/I, On Int
P23471 A06ef6 8555935 3 6 9365845 1750253 1 30E-01 2 02E+00 18 Off A/I, On Int
088386 D10ef3 1232003 399 68 13944 1967342 -854E-01 1 69E+00 18 Off A/|, On lnt
P10826 I08gh6 6798871 241 120 9469 1433844 831E-01 1 83E+00 18 Off A/I, On Int
095786 I24ef3 112 9366 241 8932396 147 8829 -338E-01 1 10E+00 18 Off A/I, On Int
P02778 O10ef7 6503395 418 8609019 1896022 405E-01 2 68E+00 18 Off A/I, On Int
P80162 F14cd1 5400821 311 1292639 164 6594 1 26E+00 2 52E+00 18 Off A/I. On lnt
P43005 N23ef5 9930514 189 110 8119 133 1898 1 58E-01 9 32E-01 18 Off A/I, On Int
P01375 O09ef6 138 6153 386 75 13436 200 0804 -884E-01 1 48E+00 18 OffA/I. On lnt
Q16890 G04cd2 1035477 191 9801862 130885 -792E-02 8 84E-01 18 Off A/I. On lnt
Q9H949 K11gh5 111 8812 218 7954574 136 5769 -492E-01 9 64E-01 18 Off A/I. On lnt
Q9H4G4 O06gh5 8861746 223 5322979 281 2148 259E+00 1 33E+00 8 Off Acinar, Increasing Int/I
Q14040 B15ef1 3827203 209 4724413 1657 194 695E+00 245E+00 8 Off Acinar, Increasing Int/I
P12110 B17ef1 8800282 164 3835 637 1362487 545E+00 8 97E-01 8 Off Acinar, Increasing Int/I
P02751 K15ef1
Figure imgf000049_0001
4441362 152 4171 603 1442812 988E+00 5 10E+00 8 Off Acinar, Increasing Int/I
P14652 N23ab6 homeo box B2 6271629 291 3571 974 1308575 583E+00 2 21E+00 8 Off Acinar, Increasing Int/I
P08476 D15ef7 mhibin, beta A (activin A, activin 64 38161 318 854 6532 412 2794 373E+00 2 30E+00 8 Off Acinar, Increasing Int/I
P17936 D07ab6 Insulin -like growth factor binding 3822268 349 1302669 563 1937 509E+00 3 19E+00 8 Off Acinar, Increasing Int/I
Q9Y4K0 P18ab6 lysyl oxldase-like 2 75 91549 260 2525644 953 7036 506E+00 1 77E+00 8 Off Acinar, Increasing Int/I
P03956 N05ef7 matπx metalloproteinase 1 (inter, 1062193 203 5902622 2998442 247E+00 9 35E-01 8 Off Acinar, Increasing Int/I
P39900 N15ef7 matπx metalloproteinase 12 (mac 182367 381 1219 953 5397471 606E+00 4 39E+00 8 Off Acinar, Increasing Int/I
P55001 G09ab7 microfibπllar-assoclated protein - 99 33548 526 3302631 1309293 506E+00 240E+00 8 Off Acinar, Increasing Int/I
Q9NYR0 O07gh7 SH3-domam kinase binding proti 3469271 197 6564675 296 0285 424E+00 2 50E+00 8 Off Acinar, Increasing Int/I
043623 D06ef4 snail homolog 2 (Drosophila) 9688079 292 3028 508 1139 155 497E+00 1 59E+00 8 Off Acinar, Increasing Int I
P09936 I13cd4 ubiquitin carboxyl-termiπal ester- 4830052 219 1523 166 5967714 4 98E+00 2 18E+00 8 Off Acinar, Increasing Int I
Q02952 J11ab2 A kinase (PRKA) anchor protein 1039756 364 229 1446 232 3779 1 14E+00 1 81E+00 4 Off Acinar, On lnt=l
Q99541 I19ab2 adipose differentiation-related pr 6738509 182 146 1347 132005 1 12E+00 1 44E+00 4 Off Acinar, On lπt=l
P54284 N17ab3 calcium channel, voltage-depend 1063248 227 2549633 195985 1 26E+00 1 09E+00 4 Off Acinar, On lnt=l
Q13269 G14ab5 cAMP responsive element bindln 100 6639 193 2177521 170 529 1 11E+00 940E-01 4 Off Acinar, On lnt=l
Q9NPF2 02ef4 chondroitin 4-sulfotransferase 1338375 192 303 01 2097612 1 18E+00 524E-01 4 Off Acinar, On lnt=l
Q9H7A5 F12gh7 chromosome 20 open reading fra 9871521 179 2080134 161 8637 1 08E+00 8 58E-01 4 Off Acinar, On lπt=l
Q9H9Q2 L23gh5 C0P9 constitutive photomorphoς 8657682 115 184 3088 1287341 1 09E+00 4 14E-01 4 Off Acinar, On lπt=l
P42771 D17ef5 cyclin-dependent kinase inhibitor 4335217 471 3557426 290 1928 304E+00 3 44E+00 4 Off Acinar, On lnt=l
Q14650 J20ef4 cytoplasmic FMR1 interacting pre 132 5759 272 321 6348 2422271 1 28E+00 1 04E+00 4 Off Acinar, On lπt=l
Q96IK6 F14gh6 DKFZP434C245 protein 145 227 104 91 06477 113265 -673E-01 -4 89E-01 4 Off Acinar, On lπt=l
P12034 D05ef7 fibroblast growth factor 5 602377 259 317 6018 2122747 240E+00 2 10E+00 4 Off Acinar, On lπt=l
Q93079 M20gh6 H2B histone family, member J 144 6906 428 271 2983 281 3281 907E-01 1 56E+00 4 Off Acinar, On lnt=l
Q9P016 A10ef8 HSPC144 protein 1234601 348 3994935 2904476 1 69E+00 1 50E+00 4 Off Acinar, On lnt=l
Q9HBI5 09gh4 HT021 163605 276 3095798 233 835 1 41E+00 1 24E+00 4 Off Acinar, On lnt=l
Q9BY45 024gh8 HTPAP protein 7849388 109 177 2043 121 5622 1 17E+00 4 74E-01 4 Off Acinar, On lnt=l
P08397 G18ab6 hydroxymethylbllane synthase 1390B57 188 260 8417 196 1361 907E-01 4 38E-01 4 Off Acinar, On lnt=l
Q9BUV0 06gh4 hypothetical protein dJ465N24 2 6840543 152 167 5592 1293473 1 29E+00 1 15E+00 4 Off Acinar, On lnt=l
Q9H9A2 N22gh6 hypothetical protein DKFZp762LJ 82 54725 110 1695379 1207311 1 04E+00 4 6E-01 4 Off Acinar, On lnt=l
Q9NUV6 P09gh3 hypothetical protein FLJ11113 8743713 178 1366771 134 1021 644E-01 1 03E+00 4 Off Acinar, On lnt=l
Q9NXF7 C20gh2 hypothetical protein FLJ20280 6649705 143 170 7367 1267851 1 36E+00 1 11E+00 4 Off Acinar, On lnt=l
Q9H6V0 05gh5 hypothetical protein FLJ21839 1163704 258 3233964 232 5844 1 47E+00 1 15E+00 4 Off Acinar, On lnt=l
Q9BUW5 K21gh6 hypothetical protein MGC4707 8031127 170 2039516 151 3887 1 34E+00 1 08E+00 4 Off Acinar, On lnt=l
Q9H765 I15gh6 hypothetical protein MGC5540 1063949 220 2066405 177 6046 958E-01 1 05E+00 4 Off Acinar, On lπt=l
Q14157 N23gh1 KIAA0144 gene product 95 13957 147 147 7214 129 9305 635E-01 6 27E-01 4 Off Acinar, On lnt=l
Q9Y2D8 A07ef8 KIAA0923 protein 84 1225 237 206 8269 176 1358 1 30E+00 1 50E+00 4 Off Acinar, On lnt=l
Q9H6Z3 E24gh5 kmesin family member 13A 111 6382 206 238 8822 185 578 1 10E+00 885E-01 4 Off Acinar, On lnt=l
Q99748 J24ab8 neurturin 1237486 150 2464754 1732957 994E-01 2 74E-01 4 Off Acinar, On lnt=l
Q9NVD7 D11gh3 parvin, alpha 8267948 140 230 66 151 1753 1 48E+00 7 62E-01 4 Off Acinar, On lnt=l n--..7<. Q 3636 K19cd7 RAB31 , member RAS oncogene 7636263 118 170 0352 121 5169 1 15E+00 630E-01 4 Off Acinar, On lnt=l
Q9UIC2 L10ef2 RNB6 8078879 171 194 395 1487422 1 27E+00 1 08E+00 4 Off Acinar, On lnt=l
Q9NVQ7 K12gh3 Sec61 alpha form 2 82 6036 143 162 0674 129 1434 972E-01 7 89E-01 4 Off Acinar, On lπt=l
075368 J08cd1 SH3 domain binding glutamic acl 9282513 212 1968753 167 1823 1 08E+00 1 19E+00 4 Off Acinar, On lnt=l
095863 N01cd2 snail homolog 1 (Drosophila) 7658448 134 1579807 122 817 1 04E+00 8 06E-01 4 Off Acinar, On lnt=l
Q9UL01 H01cd8 squamous cell carcinoma antiger 8670353 111 1764557 124 5829 1 03E+00 3 51E-01 4 Off Acinar, On lnt=l
Q16226 N05cd6 thioredoxin interacting protein 111 1384 454 5292322 364 6675 225E+00 203E+00 4 Off Acinar, On lnt=l
P07996 A11ef7 thrombospondin 1 7900174 139 1832593 127 0819 1 05E+00 8 15E-01 4 Off Acinar, On lnt=l
Q99081 F10ef6 transcπption factor 12 (HTF4, he 1122294 181 256 0348 182 9347 1 19E+00 6 86E-01 4 Off Acinar, On lnt=l
095922 L06ef7 tubulin tyrosme ligase -like 1 73 12945 245 253 9213 190 8311 1 80E+00 1 75E+00 4 Off Acinar, On lnt=l
P15036 H18ef6 v-ets erythroblastosis virus E26 c 149 9259 114 83 55955 1158531 -843E-01 -3 94E-01 4 Off Acinar, On lnt=l
095337 D04ef8 weakly similar to glutathione perc 6955111 164 284 3593 1727489 203E+00 1 24E+00 4 Off Acinar, On lnt=l
Q9H B5 18gh5 xylosyltransferase II 81 87715 106 174 2539 120 5878 1 09E+00 3 68E-01 4 Off Acinar, On lπt=l
P55263 K07ab2 adeπosme kinase 891 6698 720 2996337 637 198 -1 57E+00 -308E-01 15 On A/lnt Down I
P51648 A22ab2 aldehyde dehydrogenase 3 famll 1955203 1390 5073786 1284046 -1 95E+00 -4 93E-01 15 On A/lnt, Down I
P50995 I08ab2 annexin A11 4888 71 3870 1773 94 3511 843 -1 46E+00 -3 36E-01 15 On A/lnt Down I
P12429 I14ab2 annexm A3 9711 235 10800 1720452 7424351 -250E+00 1 59E-01 15 On A/lnt, Down I
P05026 L22ab2 ATPase Na+/K+ transporting, be 3965 733 5290 1976 367 3744 962 -1 OOE+00 4 16E-01 15 On A/lnt, Down I
P00751 M07ab3 B factor properdm 2984 309 2460 1178473 2206 568 -1 34E+00 -2 81E-01 15 On A/lnt, Down 1
Q9HA23 E10gh6 calponin like transmembrane dor 480 5263 528 1930456 4005912 -1 32E+00 1 36E-01 15 On A/lnt, Down I
Q16170 17ab3 carαnoembryonic antlgen-r elatee 984 7628 1230 2127712 807 5766 -221E+00 3 15E-01 15 On A/lnt, Down I
P25774 P07ab5 cathepsm S 857 9751 776 228 9093 620 9386 -1 91E+00 -1 45E-01 15 On A/lnt, Down I
P21926 J13ef7 CD9 antigen (p24) 2011 966 3500 833 332 211574 -1 27E+00 8 00E-01 15 On A/lnt, Down I
Q9H2A7 M19gh5 chemokine (C-X-C motif) ligand 1 650 7961 842 235 8205 576 1228 -1 46E+00 3 71E-01 15 On A/lnt Down I
014493 G21ab4 claudin 4 1919 128 2480 799 5104 1732749 -1 26E+00 3 70E-01 15 On A/lnt Down I
P12277 06ab4 creatme kinase brain 373 8119 617 1930681 394 4895 -953E-01 7 22E-01 15 On A/lnt, Down I
Q9NYS7 E20ef4 CS box-containing WD protein 5966891 384 211 1821 397 3278 -1 50E+00 -6 35E-01 15 On A/lnt, Down I
P53355 D09ab5 death-associated protein kinase 1325243 1260 5589756 1048 818 -1 25E+00 -7 03E-02 15 On A lnt, Down I
015205 D17cd6 diubiqultin 7363 301 14700 2196 358 8102423 -1 75E+00 1 OOE+00 15 On A/lnt, Down I
Q9UFZ2 C23ef8 DKFZP564K247 protein 1325797 1060 313 5237 900 9109 -208E+00 -3 18E-01 15 On A/lnt, Down 1
P28562 M22ab5 dual specificity phosphatase 1 2077 188 1680 754 9876 1502864 -1 46E+00 -3 09E 01 15 On A/lnt Down I
Q16690 B21ab4 dual specificity phosphatase 5 485 6475 305 155 0161 3152743 -1 65E+00 -6 70E-01 15 On A/lnt, Down I
Q9UJW0 H10ef1 dynactiπ 4 (p62) 778 5079 662 3359831 592 1023 -1 21E+00 -2 34E-01 15 On A/lπt Down I
E13gh5 ectonucleotlde pyrophosphatase 2339728 378 1833797 2650097 -352E-01 6 91E-01 15 On A/lnt Down I
P00533 A06efS epidermal growth factor receptor 2632516 334 1824044 2597582 -529E-01 342E-01 15 On A/lnt Down I
Q13113 J02cd5 epithelial protein up-regulated in 13324 19 15500 2641 961 10494 6 -233E+00 220E-01 15 On A/lnt Down I
P28161 M09ab6 glutathione S-transferase 2 (mi 1020 341 690 2174433 6427437 -223E+00 -5 63E-01 15 On A/lnt Down I
Q03013 L06ab3 glutathione S-transferase M4 3332767 465 210 8696 336469 -660E-01 4 81E-01 15 On A/lnt, Down I
P52594 A18ab7 HIV-1 Rev binding protein 4394544 468 252 8058 386 6697 -798E-01 9 00E 02 15 On A/lnt, Down l
Q9NWT9 D09gh2 hypothetical protein FLJ20607 1062388 757 368 3558 7292943 -1 53E+00 -4 89E 01 15 On A/lnt Down I
Q9BZR4 L12gh7 hypothetical protein HT036 7480681 844 160 1449 584 0643 -2 22E+00 1 74E-01 15 On A/lnt, Down I
Q9BW25 A19gh6 hypothetical protein MGC3101 3154695 409 1504768 291 8079 -1 07E+00 376E-01 15 On A/lπt Down I
P16144 I16ab6 integrin, beta 4 4907243 672 157 31 4400464 -1 64E+00 4 54E-01 15 On A/lnt Down I
P10145 022ef7 interleukin 8 6902736 13300 1783339 7330 866 -1 95E+00 9 47E-01 15 On A/lnt Down I
Q05084 G10ab7 islet cell autoantigen 1 (69kD) 600 5671 588 209 1329 465 8994 -1 52E+00 -3 05E-02 15 On A/lnt Down I
Q9Y484 E14cd7 JM5 protein 1335218 2010 938 9827 1429625 -508E-01 5 93E-01 15 On A/lnt, Down I
P14923 23ef6 junction plakoglobin 1969949 2610 9123081 1831 613 -1 11E+00 4 07E-01 15 On A/lnt, Down I
P05783 N06ef6 keratin 18 1731724 12500 2306 177 10707 79 -2 91E+00 -4 70E-01 15 On A/lnt, Down I
P08727 L06ab6 keratin 19 4025258 2800 631 8404 248493 -2 67E+00 -525E-01 15 On A/lnt, Down I
P08729 N14ef6 keratin 7 1160548 11100 188838 8203 912 -2 62E+00 -6 19E-02 15 On A/lnt Down I
P05787 N16ef6 keratin 8 11031 01 7880 1694 024 6867 677 -270E+00 -4 86E-01 15 On A/lnt, Down I
014782 H22ab6 kiπesln family member 3C 366 3528 652 2422822 420 177 -597E-01 8 31E-01 15 On A/lnt, Down I
000515 D05ab7 ladinin 1 3562 632 2040 8242377 2140 683 -2 11E+00 -8 08E-01 15 On A/lnt, Down I
P80188 D13ab7 lipocalm 2 (oncogene 24p3) 5234435 9070 6640466 4989308 -2 98E+00 7 93E-01 15 On A/lnt, Down 1
Q9UQ53 G02ef3 mannosyl (alpha-1 ,3-)-glycopr ote 1485546 931 3985069 9382331 -1 90E+00 -675E-01 15 On A/lπt, Down I
P80294 D15gh6 metallothionein 1 H 327 8489 366 2088705 3007815 -650E-01 1 57E 01 15 On A/lnt, Down I
075394 M10cd5 mitochondπal πbosomal protein t 441 6574 646 2137295 433794 -1 05E+00 549E 01 15 On A/lnt Down I
Q9Y376 H18ef2 M025 protein 860 3225 1410 5500258 939 6431 -645E-01 7 11E-01 15 On A/lπt Down I
P15941 H22ab7 mucm 1 , transmembrane 2330 649 1250 487 1995 1357 116 -226E+00 -8 95E-01 15 On A/lπt, Down I
Q16301 H11cd4 myelm transcription factor 2 243302 2560 5450513 1844855 -2 16E+00 7 14E-02 15 On A/lnt, Down I
Q99836 M07ab7 myelold differentiation pπmary re 108839 1110 4134864 871 4196 -1 40E+00 3 15E-02 15 On A/lnt, Down I
P24001 H08cd4 natural killer cell transcript 4 49232 84 71300 13531 68 44684 13 -1 86E+00 534E-01 15 On A/lnt, Down I
Q9C002 012gh8 normal mucosa of esophagus spi 8605554 17700 4423686 1024228 -960E-01 1 04E+00 15 On A/lnt Down I
P25963 A16ef1 nuclear factor of kappa light poly 938908 1270 6056118 937 0159 -6 33E-01 4 32E-01 15 On A/lnt Down I
P00491 L18ab7 πucleoslde phosphorylase 8204015 500 2504586 5237383 -1 71E+00 -7 13E-01 15 On A/lnt, Down I
P49763 O20ef7 placental growth factor, vascular 5604053 12600 1723 953 6646258 -1 70E+00 1 17E+00 15 On A/lπt, Down I
Q9Y342 A13ef2 plasmollpiπ 942 5595 983 3002833 742 036 -1 65E+00 6 10E-02 15 On A/lnt, Down I
P43490 H04cd5 pre-B-cell colony-enhancing facti 2261 72 1730 651 3251 1546408 -1 80E+00 -3 90E-01 15 On A/lnt, Down I
Q99988 B23ef7 prostate differentiation factor 1470 061 2930 681 8854 1694813 -1 11E+00 996E-01 15 On A/lπt, Down I
Q9UJY1 B05ef3 protein kinase H11 1836 927 2080 544 441 1485828 -1 75E+00 1 77E-01 15 On A/lnt, Down I
Q9H1C7 O10gh8 putative nuclear protein 0RF1-FI 11454 74 14800 3062014 9771 26 -1 90E+00 3 69E-01 15 On A/lnt, Down 1
P51149 A21ef6 RAB7, member RAS oncogene f. 3422 13 5250 2267 107 3646784 -594E-01 6 18E-01 15 On A/lnt, Down I
P51151 J22cd4 RAB9A, member RAS oncogene 1882 687 1580 721 6194 1393904 -1 38E+00 -255E-01 15 On A/lnt, Down I
P15153 C17ef6 ras-r elated C3 botulinum toxin si 3830769 418 2130301 3380922 -847E-01 1 26E-01 15 On A/lnt, Down I
P52566 I19ef1 Rho GDP dissociation inhibitor (( 986 1501 788 3520789 708 6827 -1 49E+00 -324E-01 15 On A/lnt, Down I
P01011 I08ef7 seπne (or cysteine) protemase in 40450 89 43700 1017244 31439 89 -1 99E+00 1 11E-01 15 On A/lnt, Down I
P05120 P07ef7 serine (or cysteine) protelnase in 24922 82 38200 2879818 21999 69 -3 11E+00 6 16E-01 15 On A/lnt, Down I
014508 M13ef6 STAT induced STAT mhιbιtor-2 1511 844 1490 420453 113968 -1 85E+00 -2 42E-02 15 On A/lπt, Down I
Q9Y6N5 G13gh4 sulfide dehydrogenase like (yeas 8237665 871 2840637 659 5107 -1 54E+00 7 99E-02 15 On A/lnt, Down l
000161 C23cd4 synaptosomal-associated protein 1077 833 1340 6870432 1034 031 -650E-01 3 11E-01 15 On A/lnt, Down I
P31431 F24cd1 syndecan 4 (amphiglycan, ryudo 2109871 3080 887 6687 2026067 -1 25E+00 546E-01 15 On A/lnt, Down I
015533 B16ef7 TAP binding protein (tapasin) 313 1585 424 1623501 299 8834 -948E-01 4 38E-01 15 On A/lnt Down I
157 6175 317 0491 -1 65E+00 -7 35E-01 15 On A/lnt Dawn I Q16149 B15cd1 transporter 1 , ATP-bindmg casse 862 1561 1100 480 8685 8133307 -842E-01 347E-01 15 On A/lnt, Down I
Q9Y2A9 C22ef3 UDP-GlcNAo betaGal beta-1,3-N 774 5506 436 1539485 454 8446 2 33E+00 -8 29E-01 15 On A/lnt, Down I
060625 N10cd3 vesicle-associated membrane pn 2480 868 2680 584 39 1914 133 2 09E+00 1 10E-01 15 On A/lnt, Down I
P07948 A21ab7 v-yes-1 Yamaguchi sarcoma vira 512646 443 170 1742 375 1466 •1 59E+00 -2 12E-01 15 On A/lnt, Down I
Q9P2N4 M10gh4 a disintegπn-like and metalloprot 1597274 227 72 96867 153 1495 -1 13E+00 506E-01 14 On A/lnt, Off I
P47895 C04ab2 aldehyde dehydrogenase 1 famil 1247008 2370 146 6644 1254 954 -309E+00 927E-01 14 On A/lnt, Off I
P04233 G09ef1 CD74 antigen (invariant polypepl 2294566 174 8699566 1636002 -1 40E+00 -3 96E-01 14 On A/lnt, Off 1
Q9NZ31 L12gh4 chromosome 20 open reading fra 3454771 375 137 4415 285 9642 -1 33E+00 1 18E-01 14 On A/lnt, Off I
096002 G07cd5 chromosome X open reading frar 401 521 375 1307318 3024558 -1 62E+00 -981E-02 14 On A/lnt, Off I
094907 J15gh6 dickkopf homolog 1 (Xenopus las 150 3215 200 8453571 145 044 -8 30E-01 4 14E-01 14 On A/lnt, Off I
Q92796 K06ef5 discs, large (Drosophila) homolαi 161 9581 154 84 90819 1335184 -932E-01 -7 56E-02 14 On A/lnt, Off I
Q13115 017ab4 dual specificity phosphatase 4 5335415 730 146312 4698392 -1 87E+00 4 52E-01 14 On A/lnt, Off I
P29317 F02ef5 EphA2 267.722 279 82 15254 2095143 -1 70E+00 578E-02 14 On A/lnt, Off I
P29323 D10ef5 EphB2 269 1596 232 7435016 191 9946 -1 86E+00 -2 11E-01 14 On A lnt, Off I
Q9UKF9 H10cd7 ets homologous factor 6030262 587 1020333 4306372 -2 56E+00 -392E-02 14 On A/lnt, Off I
Q9NPD3 P22gh2 exosome component Rrp41 273 527 300 4972784 2079117 -246E+00 1 36E-01 14 On A/lπt, Off I
043524 G12ab4 forkhead box 03A 262 2734 169 1026435 177 9385 -1 35E+00 -635E-01 14 On A/lnt, Off I
P21217 M16ab3 fucosyltransferase 3 (galactoslde 1893354 257 6024803 1688097 -1 65E+00 440E-01 14 On A/lnt, Off I
075205 D24ef2 G protein-coupled receptor, famil 621 7284 382 90 93956 364 8596 -2 77E+00 -703E-01 14 On A/lnt, Off I
075712 A03ef1 gap junction protein, beta 3, 31kt 2353139 402 145 5466 260 8655 -693E-01 7 72E-01 14 On A/lnt, Off I
Q92908 D12ab4 GATA binding protein 6 293 117 199 9359788 1953976 -1 65E+00 -5 55E-01 14 On A/lnt, Off I
095210 P05cd4 genethonln 1 331 9855 241 112 69 2286851 -1 56E+00 -4 60E-01 14 On A/lnt, Off I
095395 K21cd5 glucosaminyl (N-acetyl) transfera 2974236 274 4582301 205 5863 -270E+00 -1 21E-01 14 On A/lnt, Off I
P48506 F22ab5 glutamate-cysteme ligase, cataly 299 1944 243 1349982 225 879 -1 15E+00 -297E-01 14 On A/lnt, Off I
Q9UI98 FOβefβ hqp0256 protein 357587 336 106803 2668154 -1 74E+00 -8 96E-02 14 On A/lnt, Off I
Q9H6D8 D18gh5 hypothetical protein FLJ22362 5426184 595 1274299 421 5312 -2 09E+00 1 32E-01 14 On A/lnt, Off I
P05362 I02ab6 intercellular adhesion molecule 1 411 0131 424 67 80016 301 0074 -2 60E+00 4 56E-02 14 On A/lnt, Off 1
Q07627 J20gh7 keratin associated protein 1 1 288 3566 303 40 28571 2103957 -284E+00 6 93E-02 14 On A/lnt, Off 1
Q9BYQ7 D10gh8 keratin associated protein 4 10 4934934 605 9651137 3982261 -235E+00 2 93E-01 14 On A lnt, Off I
075071 F15gh1 KIAA0494 gene product 2402512 167 91 77931 1663595 -1 39E+00 -524E-01 14 On A/lnt, Off I
Q9UPQ2 G22ef8 KIAA1100 protein 2247248 349 1356811 2364102 -7 28E-01 634E-01 14 On A/lnt, Off I
043896 H10cd6 kinesiπ family member 1C 1596982 170 7344924 134 4385 -1 12E+00 9 16E-02 14 On A/lnt, Off I
Q13887 L05ab5 Kruppel-like factor 5 (intestinal) 494 1259 376 9743054 3226178 -2 34E+00 -393E-01 14 On A/lnt, Off I
000312 D22cd3 MAP kinase-interactiπg senne/thi 1479629 150 8660695 1282701 -7 73E-01 220E-02 14 On A/lnt, Off I
015264 H07ab8 mitogen-activated protein kinase 2137425 160 7632069 1500667 -1 49E+00 -4 17E-01 14 On A/lnt Off I
Q9UHA4 P10gh1 mitogen-activated protein kinase 268 8101 244 7250042 1950133 -1 89E+00 -1 41E-01 14 On A/lπt, Off I
P21397 F23ef6 monoamme oxidase A 427 3495 480 3042645 312 5207 -3 81E+00 1 67E-01 14 On A/lnt, Off I
P55196 N07ab7 myeloid/lymphoid or mixed-lineat 164 9238 168 7862952 137 1449 -1 07E+00 256E-02 14 On A lπt, Off I
Q12965 I24ab7 myosin IE 2124935 276 1220015 2033655 -801E-01 375E-01 14 On A/lπt, Off I
Q9HBW1 O10gh7 NAG14 protein 417 9837 396 8684398 3002834 -227E+00 -779E-02 14 On A/lnt, Off I
Q9H2W4 D20gh6 neural precursor cell expressed, 361 6431 463 7541197 299 9778 -226E+00 3 56E-01 14 On A/lnt, Off I
Q9NRR3 O06gh4 non-kmase Cdc42 effector protei 194 8075 327 117 0936 213 1256 -7 34E-01 7 49E-01 14 On A/lnt, Off I
P23511 M19ab8 nuclear traπscπption factor Y, alp 2392485 226 1323351 199 2783 -8 54E-01 -806E-02 14 On A/lπt, Off I
Q99650 D14cd4 oncostatin M receptor 337 1614 233 141 0848 237 114 -1 26E+00 -533E-01 14 On A/lnt, Off I
P04085 016ef7 platelet-deπved growth factor alp 441 7554 463 1244793 3432015 -1 83E+00 6 89E-02 14 On A/lnt, Off I
Q13048 N06cd2 pregnancy specific beta-1-glycop 1497737 203 84 53571 145 8869 -825E-01 441E-01 14 On A/lnt, Off I
P10586 E11ef6 protein tyrosiπe phosphatase, rei 4662876 405 1366718 335 8682 -1 77E+00 -2 05E-01 14 On A/lnt, Off I
095200 N22ab8 retinoic acid receptor responder ι 437 2899 315 7262859 2750752 -2 59E+00 -472E-01 14 On A/lnt, Off I
Q9NVX8 P17ef3 Rho GTPase activating protein 8 4252848 479 1092541 337 8544 -1 96E+00 1 72E-01 14 On A/lnt Off I
Q15418 N14ef5 πbosomal protein S6 kinase, 90k 299 528 361 7838666 2462347 -1 93E+00 2 68E-01 14 On A/lnt, Off I
Q15434 F10ab8 RNA binding motif, single straπdi 454 6438 328 1452438 3093377 -1 65E+00 -4 70E-01 14 On A/lπt, Off I
Q15437 O10cd6 Sec23 homolog B (S cerevisiae) 281 2005 235 126 9582 2144633 -1 15E+00 -258E-01 14 On A/lnt, Off I
060679 D15ef5 serum-inducible kinase 202 0368 194 6220916 152 8498 -1 70E+00 -563E-02 14 On A/lnt, Off I
Q12890 N06ef5 SFRS protein kinase 1 3504057 278 1130428 247 1823 -1 63E+00 -3 33E-01 14 On A/lnt, Off I
Q12971 L03cd6 sialyltransferase 247 3141 329 9691002 224 3379 -1 35E+00 4 11E-01 14 On A/lnt, Off I
P78556 M02cd2 small inducible cytokme subfamil 3080437 382 5931325 2497105 -2 38E+00 3 10E-01 14 On A/lnt Off I
075751 F14ef4 solute earner family 22 (extraneu 1646419 238 66 83593 1564431 -1 30E+00 531E-01 14 On A lnt, Off I
Q9UM01 D08cd4 solute earner family 7 (cationic ai 201 657 260 55 89528 1724611 -1 85E+00 366E-01 14 On A lnt, Off I
Q9Y5X1 D10ef2 sorting nexin 9 219 1839 240 108 9101 1892981 -1 01 E+00 1 30E-01 14 On A lnt, Off I
P08842 D19ab3 steroid sulfatase (microsomal), a 436 4255 414 1362997 328904 -1 68E+00 -7 62E-02 14 On A/lnt Off 1
043760 G09cd5 synaptogyπn 2 391 0545 238 118 1167 249 1866 -1 73E+00 -7 14E-01 14 On A/lπt, Off 1
075674 N15cd5 target of mybl -like 1 (chicken) 2765234 285 5432353 2052456 -2 35E+00 4 30E-02 14 On A/lπt, Off I
P01135 K04ef7 transforming growth factor, alpha 2159023 160 5963082 1453108 -1 86E+00 -4 29E-01 14 On A/lnt, Off I
Q9NT70 K13gh3 transmembrane protein vezatm 3659385 401 1292607 2987991 -1 50E+00 1 33E-01 14 On A/lnt, Off I
060656 G13gh3 UDP glycosyltransferase 1 family 5463937 438 27 51254 337 3961 -4 31E+00 -3 18E-01 14 On A/lnt, Off I
Q9NZ42 N18gh4 uπcharacteπzed hematopoietic si 196 9377 213 1152737 175 1842 -7 73E-01 1 15E-01 14 On A/lnt, Off I
076080 E14cd4 zinc finger protein 216 314 9706 211 74 56541 2000768 -208E+00 -580E-01 14 On A/lπt, Off 1
Q13015 H11ab2 ALU-fused gene from chromoso 3296061 1730 1752 9 1272 138 241E+00 240E+00 6 On Acinar, Up lnt=l
P04083 I06ab2 annexm A1 1114486 8240 8292 245 5883787 2 90E+00 2 89E+00 6 On Acinar, Up lnt=l
060592 B14ab2 Arg/Abl-interacting protein ArgBF 1576 114 3320 2017836 2304427 356E-01 1 07E+00 6 On Acinar, Up lnt=l
Q07814 E04ef6 BCL2-assocιated X protein 430 8903 862 101 457 797 9572 1 35E+00 1 OOE+00 6 On Acinar, Up lnt=l
Q14201 E17cd7 BTG family, member 3 197 8608 451 4194378 355 9496 1 08E+00 1 19E+00 6 On Acinar, Up lnt=l
Q9NR0O J21gh4 chromosome 8 open reading frar 2766 931 7310 3283 111 4453955 247E-01 1 40E+00 6 On Acinar, Up lnt=l
Q9BUW7 K19gh6 chromosome 9 open reading frar 228 4878 650 551 4272 4765934 1 27E+00 1 51E+00 6 On Acinar, Up lnt=l
095401 N04cd4 cofactor required for Sp1 transcn 1863494 395 5886133 390 063 1 66E+00 1 08E+00 6 On Acinar, Up lnt=l
Q00535 B09ef5 cyclin-dependent kinase 5 2697495 476 432 1176 392 629 680E-01 8 19E-01 6 On Acinar, Up lnt=l
P21741 E17ab7 midkiπe (neunte growth-promotln 2991 463 15400 9802 656 9388 855 1 71E+00 236E+00 6 On Acinaπ Up lnt=l
Q9Y291 J15ef2 mitochondπal πbosomal protein ϊ 1774689 330 3654484 290 8529 1 04E+00 8 93E-01 6 On Acinar, Up lπt=l
075376 E17cd6 nuclear receptor co-repressor 1 375 3679 1270 7273836 791 9381 9 54E-01 1 76E+00 6 On Acinar, Up lnt=l
P03973 N10cd1 secretory leukocyte protease inhi 592855 2070 415351 2270 718 2 81E+00 1 80E+00 6 On Acinar, Up lnt=l
015427 F06cd4 solute earner family 16 (monocar 228 58 753 7858975 589 0175 1 78E+00 1 72E+00 6 On Acinar, Up lnt=l
P16949 D11ab7 stathmin 1/oncoproteιn 18 7282643 2630 1984807 1781 654 1 45E+00 1 85E+00 6 On Acinar, Up lnt=l
Q9NZ86 J08gh3 uncharacteπzed bone marrow pπ 311 3754 945 536938 597 7198 786E-01 1 60E+00 6 On Acinar, Up lnt=l P50440 A09ab5 glycine amidinotr ansferase (L-ar| 1737 906 395 261 2318 798 1958 -273E+00 -2 14E+00 20 Other
P29622 A06cd1 serine (or cysteine) protemase In 461 3518 189 264 9574 304 9848 -8 00E-01 -1 29E+00 20 Other
014646 C17ab4 chromodomaln helicase DNA bin 867 7631 180 273 1703 4403418 -1 67E+00 -227E+00 20 Other
P48307 I10cd4 tissue factor pathway inhibitor 2 920 3007 366 277 6619 521 385 -1 73E+00 -1 33E+00 20 Other
Q15125 D08cd6 emopamll binding protein (sterol 897 4306 230 2824317 470 0852 -1 67E+00 -1 96E+00 20 Other
P19387 B13abβ polymerase (RNA) II (DNA direct 1964282 155 2828549 211 5128 526E-01 -339E-01 20 Other
Q9P0K7 H08gh6 retinoic acid induced 14 177983 275 283 8007 2454643 673E-01 6 26E-01 20 Other
P30086 E04ab8 prostatic binding protein 634 2686 462 300 6211 465627 -1 08E+00 -4 57E-01 20 Other
Q13045 C06ab5 flightless I homolog (Drosophila) 622 7072 501 3060777 476 5407 -1 02E+00 -3 14E-01 20 Other
O95084 G10cd7 protease, serine, 23 1096756 246 314746 552 6166 -1 80E+00 -2 15E+00 20 Other
P49770 L11ef4 eukaryotic translation initiation fa 731 6826 547 3297361 5362071 • -1 15E+00 -4 19E-01 20 Other
Q13948 J02ef6 cut-like 1 , CCAAT displacement i 2222758 349 330 5149 300 5112 572E-01 6 50E-01 20 Other
Q30201 H05ab3 hemochromatosis 205 1607 291 3394607 278446 7 26E-01 503E-01 20 Other
P52895 I16gh6 aldo-keto reductase family 1 , mei 4001 572 263 3397988 1534 634 -356E+00 -393E+00 20 Other
Q9Y5N1 M24cd7 histamme receptor H3 5265133 203 341 1301 3567517 -626E-01 -1 38E+00 20 Other
P43378 N23ab8 protein tyrosiπe phosphatase, no 1360729 445 3684734 7248175 -1 88E+00 -1 61E+00 20 Other
P35414 011ab2 angiotensin receptor-like 1 620 7039 406 3958948 474 2345 -649E-01 -6 12E-01 20 Other
Q14802 K03cd1 FXYD domain-containing Ion trar 2174215 711 402 87 1096 127 -243E+00 -1 61E+00 20 Other
Q9Y266 F16cd6 nuclear distnbution gene C home 745 3985 447 4083037 5336949 -868E 01 -7 37E-01 20 Other
P30043 021 ab3 biliverdm reductase B (flavin redi 877 8813 565 417 1383 620 0433 -1 07E+00 -6 35E-01 20 Other
Q9NP73 L06gh3 uπcharacterized hematopoietic si 8042103 446 421 5183 557 2055 -932E-01 -8 51E-01 20 Other
Q12972 D17ab8 protein phosphatase 1 , regulator 251 1796 358 425 52 3450523 7 61E-01 5 13E-01 20 Other
Q9Y296 N21ef2 PTD009 protein 738 5086 424 4366114 532 9995 -758E-01 -801E-01 20 Other
Q02750 K02ef7 mitogen-activated protein kinase 810206 508 441 4249 5866635 -876E-01 -672E-01 20 Other
P42226 G23cd2 signal transducer and activator o 892 6025 516 4504229 6195568 -987E-01 -7 92E-01 20 Other
P31947 M07ef6 stratifiπ 2941 197 741 452 267 1378 205 -270E+00 -1 99E+00 20 Other
P46597 J12ab2 acetylserotoπin 0 methyltransfer 2225944 437 4669229 1043272 -2 25E+00 -235E+00 20 Other
014745 J24cd4 solute carrier family 9 (sodium/h- 1844719 642 5044269 997 106 -1 87E+00 -1 52E+00 20 Other
Q9NS67 D24gh1 G protein-coupled receptor 27 1464475 381 5950192 8134043 -1 30E+00 -1 94E+00 20 Other
Q9UKL5 J07cd8 programmed cell death 6 interact 9956375 886 6059272 829 3129 -7 16E-01 -1 68E-01 20 Other
Q9UQL.3 B11ef2 liver-specific bHLH-Zip transcript 8257324 1150 6067901 860 8974 -444E-01 478E-01 20 Other
Q9NZZ1 P18ef2 hypothetical protein HSPC138 397 5554 450 6184035 488 5944 637E-01 1 78E-01 20 Other
Q9Y3Q3 H03cd7 integral type I protein 5262023 355 631 4284 504 2124 263E-01 -568E-01 20 Other
Q9NSN3 C10gh4 similar to aspartate beta hydroxy 355 1305 273 667 4052 431 8528 9 10E-01 -379E-01 20 Other
Q9Y5Z0 B12cd7 beta-site APP-cleavmg enzyme 2 1469687 960 6803343 1036811 -1 11E+00 -6 14E-01 20 Other
C21gh7 H2B histone family member B 511 589 855 7334035 699 9713 5 20E-01 741E-01 20 Other
014713 M11cd5 Integπn cytoplasmic domam-assc 446 3806 746 737 9643 643 5596 7 25E-01 742E-01 20 Other
P46095 P11ab4 G protein-coupled receptor 6 2336841 460 7604217 1185918 -1 62E+00 234E+00 20 Other
Q9BV10 K07gh6 hypothetical protein MGC3136 1761 627 653 7797338 1064 815 -1 18E+00 -1 43E+00 20 Other
Q99653 O08cd7 calcium binding protein P22 1713 549 1430 7932383 1313 03 -1 11E+00 -259E-01 20 Other
P41584 P16gh1 polymerase (RNA) II (DNA direct 560 1066 892 821 9856 758 0427 553E-01 671E 01 20 Other
P11940 E06ab8 poly(A) binding protein, eytoplasi 1738585 669 827 8343 1078525 -1 07E+00 -1 38E+00 20 Other
Q00341 G21ab6 high density lipoprotein binding p 545 5844 444 866 5328 618 5713 667E-01 -299E-01 20 Other
Q16795 K08ab7 NADH dehydrogenase (ubiqumoi 1582872 1190 8730478 1214409 -858E-01 -4 15E-01 20 Other
Q13082 E05ab7 microtubule-assoclated protein 4 1217 396 472 8738683 854 4272 -478E-01 -1 37E+00 20 Other
P36405 D16ab2 ADP-πbosylation factor-like 3 5083031 547 9397284 665 109g 8 87E-01 1 07E-01 20 Other
Q9NXH2 C04gh2 hypothetical protein FLJ20254 5156731 467 9599781 6474269 897E-01 -1 44E-01 20 Other
Q9Y323 D21ef2 hypothetical protein HSPC177 838 9663 1630 9762242 1148 545 2 19E-01 959E-01 20 Other
P48059 I12ab7 LIM and senescent cell antigen-Ii 560 9674 918 1003945 827 7691 840E-01 7 11E-01 20 Other
Q9POM9 M02ef2 mitochondnal nbosomal protein t 5790083 936 1024359 846 5801 823E-01 6 93E-01 20 Other
Q13813 E07cd2 spectrin, alpha, non-erythrocytic 2261 592 886 1070984 1406 107 -1 08E+00 -1 35E+00 20 Other
Q9Y379 H07ef2 CGI-69 protein 2556713 1900 1174 107 1877939 -1 12E+00 -426E-01 20 Other
Q13247 013gh1 splicing factor, arglnlne/seπne-ric 718 1614 1210 1194951 1041 827 735E-01 755E 01 20 Other
P14416 D03ef6 dopamine receptor D2 814 5351 745 1299 03 952 9439 673E 01 -1 28E-01 20 Other
Q06323 A15ef7 proteasome (prosome, macrapan 1491 803 2350 1386 719 1742 377 -1 05E-01 655E-01 20 Other
Q9NR31 H17gh4 SAR1 protein 752 6343 886 1386 849 1008 646 882E-01 236E 01 20 Other
P05451 C07cd3 regenerating islet-denved 1 alph 75644 12 1690 1394 425 2624372 -576E+00 -548E+00 20 Other
P04075 C12ab2 aldolase A, fructose-bisphosphat 4534 199 1590 1470 967 2532 66 -1 62E+00 -1 51E+00 20 Other
Q15904 A19ab3 ATPase, H+ transporting, lysosoi 8330193 1380 1471 799 1228765 821E-01 7 30E-01 20 Other
P15559 G24ef7 NAD(P)H dehydrogenase, qumoi 537 0892 303 148645 775 5735 1 47E+00 -825E-01 20 Other
000303 L20cd3 eukaryotic translation initiation fa 1243805 636 1556448 1145377 323E-01 -968E-01 20 Other
P56705 M01gh7 wingless-type MMTV integration 3589 752 1590 1635 805 2271 364 -1 13E+00 -1 18E+00 20 Other
P39210 I04ef7 MpV17 transgene murine homol 990 336 894 172306 1202587 7 ggε-01 -1 47E-01 20 Other
Q9UKL9 N03ef4 aldo-keto reductase family 1 , mei 16311 31 2840 1896 102 7016796 -3 10E+00 -252E+00 20 Other
043516 E12cd3 Wiskott-Aldπch syndrome proteir 1162 511 1190 1979 246 1444 29 768E-01 351E-02 20 Other
Q9Y470 D01ef7 stem cell growth factor, lymphocs 1346 693 1110 2049542 1503 556 606E-01 -273E-01 20 Other
P29312 H12cd4 tyrosme 3-monooxygenase/tryptc 5187766 4710 2331 854 4076 247 -1 15E+00 -1 40E-01 20 Other
Q9Y5R8 P24gh4 MUM2 protein 1596032 1750 2568 113 1971 095 686E-01 1 32E-01 20 Other
P17676 D01ab5 CCAAT/enhancer binding proteir 6064 068 2880 2723 688 3890 676 -1 15E+00 -1 07E+00 20 Other
095362 F11gh6 differentially expressed in hemati 1040752 2680 2912 158 5333 102 -1 84E+00 -1 96E+00 20 Other
060417 C11gh7 S100 calcium binding protein A1> 6955 642 5690 3097 579 5248939 -1 17E+00 -2 89E-01 20 Other
P19623 E17cd2 spermidine synthase 1644 266 1020 3417 978 2027 643 1 06E+00 -688E-01 20 Other
Q9P039 P02ef7 FXYD domain-containing ion trar 241008 2120 4486029 3004627 896E-01 -1 87E-01 20 Other
Q9BUF5 F05gh8 tubulin beta-5 2252 623 1580 4730 755 2855744 1 07E+00 -508E-01 20 Other
P00995 C23cd2 serine protease inhibitor, Kazal t1 6798921 11300 5416 175 2822658 -365E+00 -259E+00 20 Other
PI 1142 E22ef7 heat shock 70kD protein 8 11154 99 7840 5433 843 8144601 -1 04E+00 -508E-01 20 Other
P10620 E16ef7 microsomal glutathione S-traπsfe 6706736 2430 5571 411 4901 595 -268E-01 -1 47E+00 20 Other
Q13347 N02cd3 eukaryotic translation initiation fa 19633 03 5210 5660757 1016891 -1 79E+00 -1 91E+00 20 Other
P15880 B16cd1 nbosomal protein S2 4356 01 2060 5964 993 4127 437 4 54E-01 -1 08E+00 20 Other
Q9HCU0 E24gh4 tumor endothelial marker 1 preα. 3130 145 2600 7148075 4295784 1 19E+00 -272E-01 20 Other
Q04941 016ab8 proteolipid protein 2 (coloπic epit 17g51 73 11800 8567736 1277593 -1 07E+00 -604E-01 20 Other
Q9UPI1 M14cd2 small nuclear πbonucleoproteiπ [ 4625 515 8280 8998 787 7300 387 960E-01 839E-01 20 Other
P13987 B18ef7 CD59 antigen p18-20 (antigen id 17383 17 19200 1045343 15673 38 -7 34E-01 1 42E-01 20 Other Q9UI09 L02gh4 13kDa differentiation-associated 1754698 1990 2889 148 2210 196 19E-01 1 79E-01 3 Unchanged High
Q9Y6H1 E23ef2 167Kd protein 5687333 4050 5837 94 5191 628 377E-02 -4 90E-01 3 Unchanged High
Q9P0U1 C07gh3 62 kd protein 2323402 1990 3847 586 2721 439 728E-01 -221E-01 3 Unchanged High
P80095 N10ab7 6-pyruvoyl-tetrahydropterιn syπt 3223922 2620 156969 2471 592 -1 04E+00 -2 g9E-01 3 Unchanged High
Q92747 F04ab2 actin related protein 2/3 complex 4894401 3990 3030 018 397289 -692E-01 -293E-01 3 Unchanged High
015144 F08ab2 actin related protein 2/3 complex 1397676 21400 1720631 1753809 300E-01 6 17E-01 3 Unchanged High
015145 F10ab2 actin related protein 2/3 complex 3065881 3190 1793 813 2683 638 -773E-01 578E-02 3 Unchanged High P02570 A01cd7 actin, beta 66304 81 45400 38777 92 50171 41 -774E-01 -545E-01 3 Unchanged High P02570 H12cd7 actin; beta 6494974 42400 4459866 5064344 -542E-01 -6 16E-01 3 Unchanged High P02570 P12cd7 actin; beta 2134736 12200 1540861 16331 85 -470E-01 -803E-01 3 Unchanged High P02571 A06ab6 actin, gamma 1 69165 16 59100 65677 15 6464345 -747E-02 -227E-01 3 Unchanged High P12814 E23ab2 actinin, alpha 1 2400607 2160 2638011 2400 844 1 36E-01 -1 50E-01 3 Unchanged High 043707 G05ab2 actinin, alpha 4 6999 138 3810 3499 234 4769 196 -1 OOE+00 -878E-01 3 Unchanged High P53999 C05cd7 activated RNA polymerase II traπ 4478986 4320 6009318 4936 98 4 24E-01 -5 13E-02 3 Unchanged High P18848 I03ef5 activating transcπption factor 4 (t 7160 888 5420 7668 286 6749 873 9 88E-02 -402E-01 3 Unchanged High P53680 A07ef1 adaptor-related protein complex 2255235 2530 4102 633 2963423 863E-01 1 67E-01 3 Unchanged High P29274 A18ef5 adenos e A2a receptor 1990 124 2960 2004596 2318367 1 05E-02 573E-01 3 Unchanged High P54819 A04ab2 adenylate kinase 2 2997607 2520 2851 739 2788 3 -720E-02 -253E-01 3 Unchanged High Q01518 018cd6 adenylyl cyclase-associated prot 6946 788 11000 7171 205 8362 375 4 59E-02 6 59E-01 3 Unchanged High P32889 C03ef6 ADP-πbosylation factor 1 6040796 7220 7907 02 7056 851 3 88E-01 258E-01 3 Unchanged High P18085 P21ab2 ADP-πbosylatlon factor 4 4777 904 8880 8342 165 7331 81 804E-01 8 93E-01 3 Unchanged High P26437 B02ab2 ADP-nbosylation factor 5 3739477 4430 3984 845 4052 262 9 17E-02 245E-01 3 Unchanged High Q9BZX4 L08gh6 AKAP-bmding sperm protein ropi 2345455 2780 2500 118 2541 066 921E-02 244E-01 3 Unchanged High P11766 K01ab2 alcohol dehydrogenase 5 (class I 2220 156 1990 2854 318 2354 247 362E-01 -1 59E-01 3 Unchanged High P05067 N03ef6 amyloid beta (A4) precursor prod 284685 4180 3918 595 3649558 4 61E-01 555E-01 3 Unchanged High Q06481 K22ab2 amyloid beta (A4) precursor-like 2117 652 3230 2290 191 2546 598 1 13E-01 6 10E-01 3 Unchanged High P07355 I12ab2 aπnexιπ A2 7476739 112000 97217 17 94734 13 3 79E-01 586E-01 3 Unchanged High P08758 I18ab2 anπexin Aδ 4487 905 4270 7134202 5295 976 6 69E-01 -732E-02 3 Unchanged High P55064 O08ab2 aquapoπn 5 10851 57 14200 11650 24 12248 87 1 02E-01 393E-01 3 Unchanged High Q13520 O10ab2 aquapoπn 6, kidney specific 2404748 2350 2457278 2404397 3 12E-02 -325E-02 3 Unchanged High P32391 D19ab2 ARP3 actln-related protein 3 hoπ 4291 823 4280 3941 05 4171 013 -1 23E-01 -392E-03 3 Unchanged High 043776 E18ab7 asparagmyl-tRNA synthetase 2570968 3010 2854989 2811 634 1 51E-01 227E-01 3 Unchanged High P24539 N22ab2 ATP synthase, H+ transporting, r 2908 697 3800 3228203 3312717 1 50E-01 3 86E-01 3 Unchanged High P48201 P04ab2 ATP synthase, H+ transporting, r 5694 182 4370 4857 955 4974 135 -229E-01 -382E-01 3 Unchanged High P05496 N24ab2 ATP synthase, H+ transporting, r 217S 378 1760 2400575 2112628 1 41E-01 -306E-01 3 Unchanged High Q06055 P02ab2 ATP synthase, H+ transporting, r 5784579 3530 7732 552 5682609 4 19E-01 -7 12E-01 3 Unchanged High 075947 P14ab2 ATP synthase H+ transporting, r 2668028 2520 1881 974 2355858 -5 04E-01 -837E-02 3 Unchanged High P56385 P06ab2 ATP synthase, H+ transporting, r 2682798 2090 2616726 2462524 -360E-02 -362E-01 3 Unchanged High P56134 P10ab2 ATP synthase, H+ transporting, r 1158791 17200 14181 18 14327 12 291E-01 571E-01 3 Unchanged High P18859 P08ab2 ATP synthase, H+ transporting, r 3879939 4840 5176585 4633 559 4 16E-01 320E-01 3 Unchanged High 075964 P16ab2 ATP synthase, H+ transporting, r 2021 591 2630 2009026 2219 11 -899E-03 378E-01 3 Unchanged High P25705 N14ab2 ATP synthase, H+ transporting, r 3657 512 2410 2967207 3009915 -302E-01 -605E-01 3 Unchanged High P06576 N16ab2 ATP synthase, H+ transporting, r 4072978 3280 2557 962 3305047 -671 E-01 -3 1E-01 3 Unchanged High P36542 N18ab2 ATP synthase, H+ transporting, r 2479 5 2030 2436284 2313989 -2 54E-02 -291E-01 3 Unchanged High P48047 P18ab2 ATP synthase, H+ transporting, r 4222314 4100 3541 047 3955 838 -254E-01 -409E-02 3 Unchanged High Q01814 P01ef5 ATPase, Ca++ transporting, plas 3157447 3180 3242707 3193 535 384E-02 1 05E-02 3 Unchanged High Q99437 A11ab3 ATPase, H+ transporting, lysosoi 2495618 3870 2087291 2817 803 -258E-01 633E-01 3 Unchanged High P36543 A09ab3 ATPase, H+ transporting, lysosoi 1854 198 2920 1659749 2145 908 -1 60E-01 657E-01 3 Unchanged High 075348 A15ab3 ATPase, H+ transporting lysosoi 2734484 5660 2721 878 370442 -667E-03 1 05E+00 3 Unchanged High Q16864 A21ab3 ATPase, H+ transporting, lysosoi 645229 15900 7960234 10101 59 303E-01 1 30E+00 3 Unchanged High P27449 A05ab3 ATPase, H+ transporting, lysosoi 17134 14 24300 13120 57 1818504 -385E-01 504E-01 3 Unchanged High 000244 L14ab2 ATX1 antioxidant protein 1 homo 2833957 3500 3977 547 3435 675 489E-01 303E-01 3 Unchanged High 014503 19ab3 basic helix-loop-helix domain cor 4978916 4280 3254 631 4169 761 -6 13E-01 -220E-01 3 Unchanged High 060238 L11ab5 BCL2/adenovirus E1B 19kD ιnteι 1473428 2420 3224 141 2371 407 1 13E+00 7 14E-01 3 Unchanged High P30536 L21ab3 benzodiazapine receptor (peπph. 1997 929 2890 2326211 2405 625 2 19E-01 534E-01 3 Unchanged High P01884 C23ab3 beta-2-mιcroglobulιn 64872 105000 3605595 6847891 -847E-01 688E-01 3 Unchanged High P22004 I13ab5 bone morphogenetic protein 6 5036985 4710 3780005 4509 317 -4 14E-01 -965E-02 3 Unchanged High 095415 B02ef3 brain protein 13 7498 734 11200 5348 84 8032295 -4 87E-01 5 85E-01 3 Unchanged High 075531 K11ab3 Breakpoint cluster region protein 2541 789 2740 2924 826 2736 992 203E-01 1 11 E-01 3 Unchanged High P02593 A10ab6 calmodulin 2 (phosphorylase kin, 157377 4130 4742485 3482215 1 59E+00 1 39E+00 3 Unchanged High P07384 024ef1 calpam 1, (mu/l) large subunit 3429 132 3420 2390011 3078324 -521E-01 -561 E-03 3 Unchanged High P27797 P05ab5 calreticulin 1025942 9700 15437 35 1179733 589E-01 -8 16E-02 3 Unchanged High
N06gh8 CaM-KII inhibitory protein 2029871 28200 21760 79 23425 99 1 OOE-01 475E-01 3 Unchanged High
P47756 N14ab4 capping protein (actin filament) n 4348079 4450 5015377 4604 9 206E-01 338E-02 3 Unchanged High
P15086 H13abS carboxypeptidase B1 (tissue) 9766062 27 1 26 97129 3273378 -850E+00 -849E+00 3 Unchanged High
P52952 D22ab5 cardiac-specific homeo box 2859 197 1740 2282 546 229294 -325E-01 -7 19E-01 3 Unchanged High
P13862 M21ef1 casein kinase 2, beta polypeptidi 3674921 3840 3873228 3795282 7 58E 02 625E-02 3 Unchanged High
014675 I02ef6 CASP8 and FADD-like apoptosis 2622586 2500 1151 661 2092 229 -1 19E+00 -6 77E-02 3 Unchanged High
P35221 C17ef7 catenin (cadheππ-associated pro 3813516 4230 3300738 3782772 -208E 01 1 51E-01 3 Unchanged High
P07858 E01ab5 cathepsin B 2480797 3860 4485422 3607 853 854E-01 637E-01 3 Unchanged High
P48509 K16ab4 CD151 antigen 7267 56 13700 8768731 9g01 71 271E-01 9 11E-01 3 Unchanged High
P25063 G22cd8 CD24 antigen (small cell lung cai 21319 27 18200 8278973 1593279 -1 36E+00 -228E-01 3 Unchanged High
P16070 021ef1 CD44 antigen (homing function a 1617896 9640 5778 642 1053343 -1 49E+00 -7 47E-01 3 Unchanged High
P08962 018ab4 CD63 antigen (melanoma 1 antiς 9354 914 11600 1001629 10307 1 9 86E-02 304E-01 3 Unchanged High
014519 K04ef5 CDK2-assocιated protein 1 4231 191 4180 4763013 4389995 1 71 E-01 -1 90E-02 3 Unchanged High
P25763 A12ab6 Cell division cycle 42 (GTP bindir 4588819 2840 2852 186 3426736 -6 86E-01 -693E-01 3 Unchanged High
P49368 N17cd2 chaperonm containing TCP1, sut 2356627 2880 2222361 2484 939 -846E-02 287E-01 3 Unchanged High
P48643 H10ef4 chaperonm containing TCP1 , sut 2238933 2330 1561 625 2042 12 -520E-01 549E-02 3 Unchanged High
000299 M19abβ chlonde intracellular channel 1 6811 55 7240 5727 121 6591 299 -2 50E-01 871E-02 3 Unchanged High
Q9Y2Q7 N02cd8 chromosome 11 open reading frε 4087 361 3800 5946259 4610 942 541E-01 -1 05E-01 3 Unchanged High
P09496 F15ab5 clathπn, light polypeptide (Lea) 5758632 9260 5849641 6957 341 2 26E-02 6 86E-01 3 Unchanged High
095832 L04gh1 claudin 1 3046376 2450 9180838 2138 383 -1 3E+00 -3 14E-01 3 Unchanged High
095471 A13ef1 claudin 7 2888819 3350 1520977 2587 177 -925E-01 2 14E-01 3 Unchanged High Q9UII4 B14ef1 eyclln-E binding protein 1 26180 8 29800 39655 02 318774 5 99E-01 1 87E-01 3 Unchanged High
P04080 G16ab3 cystatiπ B (stefin B) 4312 168 5420 2370 13 4034 272 -8 63E-01 330E-01 3 Unchanged High
P21291 JOIabδ cysteine and glyciπe-rich protein 2478366 1710 213586 2109096 -2 15E-01 -533E-01 3 Unchanged High
000622 J15ef7 cysteine-nch, angiogeπlc inducei 2070203 1620 2978542 2224 339 525E-01 -3 50E-01 3 Unchanged High
P13073 L19ab5 cytochrome c oxidase subunit IV 6219628 8550 6571 848 7115048 7 95E-02 4 60E-01 3 Unchanged High
P12074 13gh1 cytochrαme e oxidase subunit Vii 325324 5800 4244 557 4434 13 3 84E-01 835E-01 3 Unchanged High
Q02221 E17ab6 cytochrome c oxidase subunit Vii 296824 2820 4604241 3464 904 6 33E-01 -728E-02 3 Unchanged High
P14854 A20ab6 cytochrome c oxidase subunit VII 1991 91 2660 2380795 2344 331 2 57E-01 4 17E-01 3 Unchanged High
P09669 E12ab6 cytochrome e oxidase subunit Vii 2580598 2090 1927002 219758 -4 21E-01 -308E-01 3 Unchanged High
P14406 G02ab5 cytochrome c oxidase subunit VII 4846713 4500 4245478 4530 346 -1 91 E-01 -1 07E-01 3 Unchanged High
014548 G23cd5 cytochrome c oxidase subunit VII 2182 954 2450 3040 586 2556481 478E-01 1 64E-01 3 Unchanged High
P24311 K17ab5 cytochrome c oxidase subunit VII 3224 558 5150 3801 752 4057995 2 38E-01 6 75E-01 3 Unchanged High
P15954 P04ab5 cytochrome c oxidase subunit VII 1233574 12200 9883688 1148248 -3 20E-01 -1 27E-02 3 Unchanged High
P10176 B10ab5 cytochrome c oxidase subunit VII 3019 162 1900 3329281 2750 974 1 41 E-01 -6 65E-01 3 Unchanged High
043293 19ab4 death-associated protein kinase 2535403 1850 2088 808 2157 783 -2 80E-01 -4 55E-01 3 Unchanged High
P46966 G14ef6 defender against cell death 1 7921 682 11200 9546896 9563 241 269E-01 502E-01 3 Unchanged High
Q09753 G01ab6 defensin, beta 1 4071 982 7630 2153 638 46ig 611 -9 19E-01 907E-01 3 Unchanged High
P18282 F23ab2 deslπn (actin depolymeπzlng fad 7729 126 7570 6083408 712601 -345E-01 -3 09E-02 3 Unchanged High
P07108 H04gh1 diazepam binding Inhibitor (GAB, 2541 011 1730 2995768 2422 578 2 38E-01 -554E-01 3 Unchanged High
P31689 D18ab7 DnaJ (Hsp40) homolog, subfamil 2491 051 2930 1789662 2402398 -477E-01 232E-01 3 Unchanged High
Q9Y5T4 HOcdB DNAJ domain-containing 2324933 2520 2397896 2414 457 4 46E-02 1 17E-01 3 Unchanged High
Q9Y463 G15cd5 dual-specιficιty tyrosιne-(Y)-phos 8211 965 6870 5987 39 7023 599 -4 56E-01 -257E-01 3 Unchanged High
Q9NP97 C02ef8 dynein light chain 2A 4080949 4160 5365928 4534 283 3 95E-01 2 63E-02 3 Unchanged High
Q15701 L08cd3 dynein, cytoplasmic, light polypei 4492 679 5800 4332 161 4875 685 -5 25E-02 3 69E-01 3 Unchanged High
P78545 016ab4 E74-lιke factor 3 (ets domain trar 3781 196 2780 1455944 2673744 •1 38E+00 -4 42E-01 3 Unchanged High
060869 A03cd4 endothelial differentiation-related 5515692 5680 4090 527 5094 856 -4 31 E-01 4 19E-02 3 Unchanged High
Q14259 L06ab4 enhancer of rudimentary homotoi 3593 608 3950 5175 131 4241 036 526E 01 1 38E-01 3 Unchanged High
P06733 C16ab4 enolase 1, (alpha) 1253997 7460 9955024 9983774 -333E-01 -7 50E 01 3 Unchanged High
P22712 D11gh6 enolase , (alpha) 6900 857 4290 5016695 5403 444 -4 60E-01 -685E-01 3 Unchanged High
P04720 O07ab6 eukaryotic translation elongation 3622234 23200 23485 94 2764874 -625E-01 -640E-01 3 Unchanged High
P26641 A10ab4 eukaryotic translation elongation 6863565 6540 11607 61 8337 901 7 58E-01 -691E-02 3 Unchanged High
P13639 I15ab5 eukaryotic translation elongation 4023 855 2310 3360 073 3231 325 -2 60E-01 -801 E-01 3 Unchanged High
015372 L24cd3 eukaryotic translation initiation fa 2870 027 1930 2391 869 2398 394 -2 63E-01 -570E-01 3 Unchanged High
075821 L22cd3 eukaryotic translation initiation fa 3009075 2670 3333728 3005 577 1 48E-01 -1 70E-01 3 Unchanged High
Q64252 L11ab6 eukaryotic translation Initiation fa 2755438 1540 2127 874 2141 68 -373E-01 -838E-01 3 Unchanged High
015371 L18cd3 eukaryotic translation initiation fa 4273919 4030 3558 838 3954 374 -2 64E-01 -846E-02 3 Unchanged High
P04765 A22ab4 eukaryotic translation Initiation fa 7716222 7170 6363 169 7083 99 -278E-01 -1 05E-01 3 Unchanged High
Q14240 H13ab4 eukaryotic translation initiation fa 2091 816 2190 2519322 2267 015 2 68E-01 661E-02 3 Unchanged High
P10159 A18ab5 eukaryotic translation initiation fa 9023244 5240 5651 752 663865 -675E-01 -7 84E-01 3 Unchanged High
Q9NQT4 H05gh4 exosome component Rrp46 2098514 2590 2304 48 2331 056 1 35E-01 3 04E-01 3 Unchanged High
P02794 C12ab6 ferπtin, heavy polypeptide 1 35912 81 48700 4207522 4224359 228E-01 441 E-01 3 Unchanged High
P02792 M10ab3 ferntin light polypeptide 4422586 29600 178492 30568 13 -1 31E+00 -578E-01 3 Unchanged High
Q05472 B02ab4 Finkel-Biskis-Reilly muπne sarco 1032294 10400 9704 642 1014546 -891 E 02 1 19E-02 3 Unchanged High
P20071 F08ab3 FK506 binding protein 1A (12kD) 2741 389 1870 1414969 2009 291 -9 54E-01 -551 E-01 3 Unchanged High
P50395 J02ab4 GDP dissociation inhibitor 2 2287713 1580 2291 27 2051 41 2 24E 03 -538E 01 3 Unchanged High
P48507 E12ab5 glutamate-cysteine ligase, modifi 154 1773 762 5937 375 2055 914 527E+00 -1 02E+00 3 Unchanged High
P36969 D14ab5 glutathione peroxidase 4 (phospt 33972 4860 3108036 3787 13 -1 28E-01 5 15E 01 3 Unchanged High
P09211 L10ab3 glutathione S-transferase pi 6392 334 8670 4067789 6378 198 -6 52E-01 440E-01 3 Unchanged High
P04406 A01cd8 glyceraldehyde-3-phosphate deh 2880937 38300 4465567 37260 67 632E-01 4 11E-01 3 Unchanged High
P04406 H12cd8 glyceraldehyde-3-phosphate deh 3756225 60200 5713541 51621 55 605E-01 6 B0E-01 3 Unchanged High
P04406 P12cd8 glyceraldehyde-3-phosphate deh 120535 14900 19061 62 15342 7 6 61 E-01 307E 01 3 Unchanged High
P43304 H01ab3 glycerol-3-phosphate dehydrogei 3450 634 2340 3276264 3023 392 -7 48E-02 -5 58E-01 3 Unchanged High
P41250 F02ef7 glycyl-tRNA synthetase 4333439 3630 6248 604 4736 632 528E 01 -2 56E 01 3 Unchanged High
P048g5 K17ef5 GNAS complex locus 7755 858 9290 9107 558 8718 93 2 32E-01 261 E-01 3 Unchanged High
P24522 B03ef6 growth arrest and DNA-damage I 2792429 6130 3395736 4105 138 283E-01 1 13E+00 3 Unchanged High
Qg2847 M24ab5 growth hormone secretagogue re 2827902 2100 2597 123 2508414 -1 23E-01 -4 29E-01 3 Unchanged High
P04901 B01ef1 guanlne nucleotide binding prate 5734 337 7610 5853 112 6398 85 296E-02 4 08E-01 3 Unchanged High
P25388 E20cd6 guanine nucleotide binding prate 2243028 15300 190557 1893985 -235E-01 -549E-01 3 Unchanged High
P06351 G08ab6 H3 histone, family 3B (H33B) 2448264 2770 2042 864 2421 658 -261 E-01 1 80E 01 3 Unchanged High
P04792 A16ef5 heat shock 27kD protein 1 41952 14 34500 31970 86 36135 19 -392E-01 -2 83E 01 3 Unchanged High
P11021 H01ef1 heat shock 70kD protein 5 (glucc 3226 183 1600 4101 742 2976 537 346E-01 -1 01E+00 3 Unchanged High
P38646 019ab7 heat shock 70kD protein 9B (mor 2851 743 2180 2220 509 2417 791 -3 61 E-01 -387E-01 3 Unchanged High
Q9UK76 J14ef1 hematological and neurological ε 26342 33 35400 4109958 3428674 642E-01 4 27E-01 3 Unchanged High
P09651 F12ab7 heterogeneous nuclear nboπucle 2522253 1650 2524082 2231 413 1 05E-03 -6 14E-01 3 Unchanged High
Q9Y4J5 I23ef1 heterogeneous nuclear nbonucle 3825 912 2370 3770 457 3320 487 -2 11E-02 -6 94E-01 3 Unchanged High
P09429 F10ab7 high-mobility group (nonhistone ( 2534273 1660 3502047 2567093 4 67E-01 -606E-01 3 Unchanged High
P49773 M03ef6 histidine tπad nucleotide binding 6025078 7790 7379 267 7064 436 292E-01 370E-01 3 Unchanged High
Q92769 N05ab4 histone deacetylase 2 2454 324 2220 1789508 2155575 -4 56E-01 -1 43E-01 3 Unchanged High
P17693 F08ab7 HLA-G histocompatibility antigen 2048009 2780 1844 177 2225 106 -1 51 E-01 4 42E-01 3 Unchanged High
P17483 C15gh2 homeo box B4 2892488 3490 290269 3095 004 508E 03 271 E-01 3 Unchanged High
Q9UL99 C01cd8 hyalυronoglucosammidase 4 3623461 2050 2189656 2621 286 -7 27E-01 -821 E-01 3 Unchanged High
Q9GZT3 L18gh7 hypothetical protein DC50 3343 922 3750 4298 676 3797 943 362E-01 1 66E-01 3 Unchanged High
QgNWY5 012gh2 hypothetical protein FLJ20533 3104 471 5460 6184 227 4915 419 994E-01 8 14E-01 3 Unchanged High
Q9UI30 P08ef2 hypothetical protein HSPC152 3000217 4060 4396862 3819313 551 E-01 437E-01 3 Unchanged High
Q9BQB6 P08gh5 hypothetical protein 1MAGE3455 3599 509 5410 8687 307 5897 337 1 27E+00 587E-01 3 Unchanged High
Q9BWJ5 P18gh7 hypothetical protein MGC3133 2074 073 2520 2719671 2436767 391E 01 279E-01 3 Unchanged High
Q9Y683 N11ef2 hypothetical protein MGC8721 2425475 2730 2939253 26g9 545 277E-01 1 73E-01 3 Unchanged High
Q16665 P01ef6 hypoxia-lnducible factor 1, alpha 3544753 2960 1526 935 2675668 -1 22E+00 -262E-01 3 Unchanged High
075353 G04ef6 immediate early response 3 4564 408 4690 3129721 4129098 -544E-01 401E-02 3 Unchanged High
Q16270 J15ab6 insulin-like growth factor binding 5185 622 21800 18047 34 15334 47 1 54E+00 1 82E+00 3 Unchanged High
Q9Y287 A03gh2 integral membrane protein 2B 6908997 10500 1001447 9139933 5 36E-01 603E-01 3 Unchanged High
P56537 D16ab6 integnn beta 4 binding protein 2594316 3270 1568747 2476062 -7 26E-01 3 32E 01 3 Unchanged High
P26006 DOSabβ Integπn, alpha 3 (antigen CD49C 2669777 2740 1339 712 2249026 -9 95E-01 362E-02 3 Unchanged High Q13907 A24ab7 Isopentenyl-dlphosphate delta 2958 139 1660 2475365 2362933 -2 57E-01 -838E-01 3 Unchanged High
P33947 K03cd7 KDEL (Lys-Asp-Glu-Leu) endopl, 1667 246 1250 3924993 2281 692 1 24E+00 -4 12E-01 3 Unchanged High
P00338 D15ab7 lactate dehydrogenase A 44081 29 34500 4215003 40260 24 -646E-02 -3 52E-01 3 Unchanged High
P08865 G21ef7 laminin receptor 1 (67kD, ribosor 8548245 6070 9921 409 8180 607 2 15E-01 -4 93E-01 3 Unchanged High
Q08380 D17ab7 lectin, galactoside-binding, solub 2294491 2850 301402 2719794 394E-01 3 13E-01 3 Unchanged High
014949 F17ef3 low molecular mass ublquinoπe-t 2942 579 3550 3637463 3377 305 306E-01 271 E-01 3 Unchanged High
Q15012 F20ef4 lysosomal-associated protein trai 2815002 4690 5453634 4319 567 9 54E-01 736E-01 3 Unchanged High
P14174 J05ef7 macrophage migration inhibitory 5544722 6700 6763718 6337062 287E-01 274E-01 3 Unchanged High
P49006 M05ef6 macrophage myπstoylated alanir 5857382 10400 8986315 8400 725 6 17E-01 8 22E-01 3 Unchanged High
P30463 G10ab6 major histαcompatibi ty complex, 2701 757 4890 2255 929 3281 592 -260E-01 8 55E-01 3 Unchanged High
P10321 A01cd2 major histocompatibility complex, 8949086 17000 10196 88 12044 89 1 88E-01 g 25E-01 3 Unchanged High
P10321 H12cd2 major histocompatibility complex, 7187 905 21600 11111 54 13298 19 628E-01 1 59E+00 3 Unchanged High
P10321 P12cd2 major histocompatibility complex, 13121 35 16800 1172568 13868 02 -1 62E-01 353E-01 3 Unchanged High
P13747 M24ab7 major histocompatibility complex, 2540911 2790 2053351 2460 503 -307E-01 1 33E-01 3 Unchanged High
Q95HC0 P02gh6 major histocompatibility complex, 5067 294 4140 3295 115 4168 835 -621 E-01 -290E-01 3 Unchanged High
P13640 D13gh6 metallothionein 1G 6180376 4750 2940 683 4624 849 • •1 07E+00 -379E-01 3 Unchanged High
P80297 D17gh6 metallothionein 1X 4881 982 5310 5233749 5142996 1 00E-01 1 22E-01 3 Unchanged High
P02795 L04ab7 metallothionein 2A 6620235 7330 8067 274 7340215 285E-01 1 48E-01 3 Unchanged High
014880 E04ab7 microsomal glutathione S-transfe 5023542 7940 4177 165 5712 043 -266E-01 660E-01 3 Unchanged High
Q9NYZ2 M22ef2 mitochondπal solute carrier 248807 2850 2240 824 2527 436 -1 51 E-01 1 98E-01 3 Unchanged High
P26038 K05ab7 moesin 426051 4580 3801 298 4212 427 -1 65E-01 1 03E-01 3 Unchanged High
015329 012ef1 mucln 6, gastric 5574093 5950 6685047 6068269 262E-01 931E-02 3 Unchanged High
P16475 J02gh1 myosin, light polypeptide 6 alkal 48122 62 45200 48882 54 47407 02 226E-02 -899E-02 3 Unchanged High
P19105 N03cd6 myosin, light polypeptide, regulal 7920 873 8150 7228401 7764 994 -1 32E-01 404E-02 3 Unchanged High
Q9UK23 D06ef1 N-acetylglucosamιne-1 -phosphoi 1884 596 2680 2511 293 2357 087 4 14E-01 505E-01 3 Unchanged High
015239 E22ab7 NADH dehydrogenase (ubiqumoi 2859738 5440 3719 503 4005 894 379E-01 927E-01 3 Unchanged High
000483 J02ab7 NADH dehydrogenase (ubiqumoi 5214222 5540 9086615 6613046 801 E-01 870E-02 3 Unchanged High
075438 J04ab8 NADH dehydrogenase (ubiqumoi 1628024 2170 2842 647 2212932 804E-01 4 13E-01 3 Unchanged High
095168 J08ab8 NADH dehydrogenase (ublqulnoi 2297787 3270 2253 854 2607 423 -279E-02 509E-01 3 Unchanged High
095298 J12ab8 NADH dehydrogenase (ubiqumoi 1909371 2840 2888281 2544 679 597E-01 571 E-01 3 Unchanged High
043920 J18abβ NADH dehydrogenase (ubiqumoi 6241 135 11500 8014 187 8594 08 361 E-01 885E-01 3 Unchanged High
Q13765 H09ab7 πascent-polypeptide-associated ι 2800 535 3390 3897 956 3363 371 477E-01 276E-01 3 Unchanged High
Q15843 K13cd1 neural precursor cell expressed, 3449484 4710 413956 4098747 263E-01 448E-01 3 Unchanged High
Q9NX14 C01gh3 neuronal protein 173 3476812 3150 5077 834 3902 8 546E-01 -1 41 E-01 3 Unchanged High
Q9Y2R6 F18gh6 NICE-3 protein 1763974 2250 2329 521 2113511 401 E-01 349E-01 3 Unchanged High
Q15668 H13cd6 Niemann-Pick disease, type C2 1516 592 3640 2828255 2662 845 8 99E-01 1 26E+00 3 Unchanged High
014597 J21ef4 non-functional folate binding prol 2917293 2170 3004012 2697 108 423E-02 -4 27E-01 3 Unchanged High
P15531 E02ef5 πon-metastatic cells 1 , protein (N 6653 515 6940 7836897 7143 349 236E-01 607E-02 3 Unchanged High
P22392 L12cd2 non-metastatic cells 2, protein (N 4827494 5680 4836596 5114664 272E-03 235E-01 3 Unchanged High
000746 D04ef7 non-metastatic cells 4, protein ex 2211 058 2270 4300 604 2927 223 960E-01 3 80E-02 3 Unchanged High
075534 B01cd4 NRAS-related gene 3478657 3510 2737 425 3241 269 -346E-01 1 20E-02 3 Unchanged High
Q9H9A1 C24gh6 nuclear receptor co-repressor/HC 5951 715 3290 29gθ 083 4076544 -993E-01 -856E-01 3 Unchanged High
Q9NPE3 K15ef4 nucleolar protein family A, memb 3543239 7130 3639205 4771 656 386E-02 1 01E+00 3 Unchanged High
P54368 G10ef1 ornithine decarboxylase antizyrre 7212068 6880 7782 339 7292 818 1 10E-01 -672E-02 3 Unchanged High
Q9UH52 L23cd8 over-expressed breast tumor pro 2335527 2320 1884264 2181 482 -3 10E-01 -673E-03 3 Unchanged High
Q15070 A09cd1 oxidase (cytochrome c) assembly 2161 529 2500 1435463 2031 796 -590E-01 208E-01 3 Unchanged High
Q9H230 G14gh5 p53-induced protein PIGPC1 1823554 3330 1443914 2199 367 -337E-01 8 69E-01 3 Unchanged High
060356 M03cd8 p8 protein (candidate of metasta' 1774 942 1940 2740792 2150 631 627E-01 1 25E-01 3 Unchanged High
P78337 M22ab8 paired-like homeodomain transcr 15428 96 13300 1449063 14411 94 -905E-02 -2 12E-01 3 Unchanged High
Q9C086 P20gh7 PAP-1 binding protein 29g22 3610 5014 215 3872 969 745E-01 272E-01 3 Unchanged High
Q15165 D06ef6 paraoxonase 2 1325972 3740 2122 119 2394.717 678E 01 1 49E+00 3 Unchanged High
P20962 N13ab8 parathymosin 2345 869 2330 3489616 2722 317 573E-01 -8 88E-03 3 Unchanged High
P23284 I17ab8 peptidylpralyl isomerase B (cyclo 5298 839 5860 889043 6683 166 747E-01 1 45E-01 3 Unchanged High
Q06830 E18ab8 peroxiredoxm 1 2973 862 2450 2056 112 249375 -532E-01 -2 79E-01 3 Unchanged High
P32119 G04ef7 peroxiredoxin 2 3141 718 3330 2921 471 3130 835 -1 05E-01 837E-02 3 Unchanged High
P30048 N09ab2 peroxiredoxm 3 2420 936 2010 1671 796 2035218 -534E-01 -266E-01 3 Unchanged High
Q13162 N07ab2 peroxiredoxin 4 2744 707 2080 3645718 2822 139 4 10E-01 -403E-01 3 Unchanged High
P30044 P15cd7 peroxiredoxm 5 2205 14 3820 1714041 2581 24 -363E-01 7 94E-01 3 Unchanged High
Q13492 B13cd4 phosphatidylinositol binding clat. 2688 917 2690 1861 508 2414 998 -531 E-01 3 03E-03 3 Unchanged High
P08237 P02ab7 phosphofructokiπase, muscle 2790708 1980 2829743 2533 875 200E-02 -494E-01 3 Unchanged High
P00558 P06ab7 phosphoglycerate kinase 1 5186346 5130 6341 68 5552 736 290E-01 -1 57E-02 3 Unchanged High
P18669 K14ab8 phosphoglycerate mutase 1 (brai 1847 463 2730 2859446 247775 630E-01 561 E-01 3 Unchanged High
Q14801 B01cd8 phosphoproteln enπched in astrc 23286 56 17400 1972936 20128 93 -239E-01 -423E-01 3 Unchanged High
014832 A04cd1 phytaπoyl-CoA hydroxylase (Ref" 7333 104 7780 8341 917 7819036 1 86E-01 8 57E-02 3 Unchanged High
P53801 L01ef1 pituitary tumor-transforming 1 int 4385 308 5330 4172 137 4627 881 -7 19E-02 2 80E-01 3 Unchanged High
Q9HB21 E19gh5 pleckstπn homology domain-conl 231808 3070 2907 381 2766359 327E-01 4 07E-01 3 Unchanged High
Q15365 O09cd1 poly(rC) binding protein 1 4617 635 3130 3156644 3635431 -549E-01 -560E-01 3 Unchanged High
P52433 B17ab8 polymerase (RNA) II (DNA direct 2157 353 3780 3657 763 3198285 762E-01 809E-01 3 Unchanged High
P52436 L16gh1 polymerase (RNA) II (DNA direct 2161 398 2600 2709495 2489 343 326E-01 265E-01 3 Unchanged High
Q03052 B19ab8 POU domain, class 3, transcnptK 3321 206 2650 2251 677 2740 913 -561 E-01 -326E-01 3 Unchanged High
K20gh5 PP1201 protein 7127293 6650 2688 636 5487 085 -1 41E+00 - 01 E-01 3 Unchanged High
P40425 G08ab8 pre-B-cell leukemia transcription 2817 191 2650 3413 81 2958976 277E-01 -9 05E-02 3 Unchanged High
Q99471 K06ab8 prefoldin 5 1827 777 2160 2837 334 2275038 634E-01 241 E-01 3 Unchanged High
Q9UHZ2 E21ef8 PR01073 protein 1872208 3140 1690 101 2234 209 -1 48E-01 7 46E-01 3 Unchanged High
P07737 A21cd1 profilm 1 29650 38 48900 35394 8 3797006 255E-01 7 21 E-01 3 Unchanged High
Q92740 E03gh1 prosaposin (variant Gaucher dise 4235232 5370 4268459 4622 898 1 13E 02 341 E-01 3 Unchanged High
P07478 N02cd2 protease, serine, 2 (trypsin 2) 7735927 42600 51746 68 57240 67 -580E-01 -8 60E-01 3 Unchanged High
Q9UL46 N09ab8 proteasome (prosome, macropaii 3682 153 4550 2712 172 3648995 -441 E-01 306E-01 3 Unchanged High
P25786 L09ef7 proteasome (prosome, macropaii 2270 079 2570 2265763 2369437 -275E-03 1 80E-01 3 Unchanged High
P20618 J17ab8 proteasome (prosome, macropaii 2835653 3590 2820 916 3082 003 -752E 03 340E-01 3 Unchanged High
P49720 J21ab8 proteasome (prosome, macropaii 1714767 2100 2435426 2081 991 506E-01 2 89E-01 3 Unchanged High
P28070 J23ab8 proteasome (prosome, macropaii 2193 138 1760 2224325 2058212 204E-02 -320E-01 3 Unchanged High
Q99436 L03abβ proteasome (prosome, macropaii 4179694 3450 3072098 3566368 -444E-01 -278E-01 3 Unchanged High Q15249 H13ef5 prothymosin, alpha (gene sequel 1138244 14500 9974 587 1195468 -1 90E-01 350E-01 3 Unchanged High
Q9NQ11 G03gh7 putative ATPase 2774724 2460 2271 593 2501 162 -289E-01 -1 75E-01 3 Unchanged High
P41567 N06cd5 putative translation Initiation facti 7487 872 6600 8909 545 7666779 2 51 E-01 -1 81 E-01 3 Unchanged High
Q15181 L18gh1 pyrophosphatase (inorganic) 4914 897 4350 2667 605 3978 537 -8 82E-01 -1.75E-01 3 Unchanged High
P14786 M24ab8 pyruvate kinase, muscle 6305222 8060 9000504 7787 922 5 13E-01 354E-01 3 Unchanged High
P57735 G12gh4 F-AB25, member RAS oncogene 3343628 4890 1366 379 3198 69g 1 29E+00 547E-01 3 Unchanged High
P54725 E21cd1 RAD23 homolog A (S cerevisiae 253336 1790 1753 113 2026 126 -531 E-01 -500E-01 3 Unchanged High
P54727 M10ef6 RAD23 homolog B (S cerevisiae 4038864 5410 498321 4809 132 303E-01 420E-01 3 Unchanged High
000538 P16cd5 RAS guanyl releasing protein 2 ( 2418688 2310 1906 199 2210 191 -344E-01 -690E-02 3 Unchanged High
P06749 C21gh1 ras homolog gene family, memb- 2136708 1940 3003 841 2358 668 4 91 E-01 -1 43E-01 3 Unchanged High
P08134 B16ab2 ras homolog gene family, membe 4404567 4490 2930236 3943029 -588E-01 291E-02 3 Unchanged High
P06gh8 ras-like protein VTS58635 5451 542 6580 9066 798 7033479 734E-01 2 72E-01 3 Unchanged High
P15154 C01ef6 ras-related C3 botulmum toxin 10849 13 9720 10044 19 10202 94 -1 11 E-01 -1 59E-01 3 Unchanged High
Q15347 B20cd6 Ras-related GTP-biπding protein 1728963 2380 2623418 2244978 602E-01 4 63E-01 3 Unchanged High
095197 A06cd6 reticulon 3 3712756 3420 3833411 3654 06 461E-02 -1 20E-01 3 Unchanged High
P09455 F12ab8 retlπol binding protein 1 , cellular 2211 12 4480 2383274 3023 27 1 08E-01 1 02E+00 3 Unchanged High
P52565 K13ef6 Rho GDP dissociation inhibitor (< 316604 3200 3141 434 3169009 -1 13E-02 1 52E-02 3 Unchanged High
P27635 N19cd2 πbosomal protein L10 1340629 7100 1110369 1053625 -272E-01 -9.17E-01 3 Unchanged High
P53025 G22cd1 ribosomal protein L10a 1937473 15100 1993926 1812491 4 14E-02 -363E-01 3 Unchanged High
P39026 D07cd1 nbosomal protein L11 1417229 6760 1034692 10427 07 -454E-01 -1 07E+00 3 Unchanged High
P30050 D09cd1 nbosomal protein L1 3837669 24500 3866934 33860 13 1 10E-02 -645E-01 3 Unchanged High
P40429 A01ef1 nbosomal protein L13a 23800 5 22200 28159 37 24735 85 243E-01 -973E-02 3 Unchanged High
P50914 B18cd4 πbosomal protein L14 1850736 14600 16108 18 16402 14 -200E-01 -343E-01 3 Unchanged High
P39030 C13cd3 πbosomal protein L15 8407 532 8100 10809 2 9104 589 3 62E-01 -543E-02 3 Unchanged High
P18621 D19cd1 nbosomal protein L17 8779 141 8440 10004 78 9074 168 1 89E-01 -571E-02 3 Unchanged High
Q07020 D13cd1 πbosomal protein L18 1216843 10200 15619 17 1265845 360E-01 -256E-01 3 Unchanged High
Q02543 C15gh1 nbosomal protein L18a 24976 59 27200 28170 19 2679674 1 74E-01 1 25E-01 3 Unchanged High
P14118 D15cd1 nbosomal protein LI 9 6226 589 5530 5535 643 5762718 -1 70E-01 -1 72E-01 3 Unchanged High
P46778 A13cd3 πbosomal protein L21 1115659 11800 1674221 1322279 5 86E-01 7 2E-02 3 Unchanged High
P35268 D17cd1 nbosomal protein L22 1628945 16200 18991 35 1716894 221 E-01 -563E-03 3 Unchanged High
P23131 F11cd4 nbosomal protein L23 2097293 20400 25729 93 2235623 295E-01 -424E-02 3 Unchanged High
P2g316 G09cd3 nbosomal protein L23a 6385 675 4840 5446 963 5556302 -2 29E-01 -401 E-01 3 Unchanged High
P38663 D21cd1 πbosomal protein L24 7805803 6180 5479 195 6488 503 -5 11 E-01 -337E-01 3 Unchanged High
P08526 F01cd1 nbosomal protein L27 1287422 5280 1025669 9469252 -328E-01 -1 29E+00 3 Unchanged High
P46776 F05cd1 ribosomal protein L27a 1604637 17000 20949 85 1800807 385E-01 857E-02 3 Unchanged High
P46779 F07cd1 nbosomal protein L28 40540 59 32400 45810 52 39577 25 1 76E-01 -324E-01 3 Unchanged High
P47914 E23cd3 πbosomal protein L29 3346473 1960 1947 028 2417 223 -7 81 E-01 -773E-01 3 Unchanged High
P39023 B21cd1 nbosomal protein L3 13192 5 10500 13962 55 12535 38 8 18E-02 -3 36E-01 3 Unchanged High
P04645 F03cd1 πbosomal protein L30 17693 61 12300 21530 83 1718803 283E-01 -520E-01 3 Unchanged High
P12947 F09cd1 πbosomal protein L31 9749 468 8980 12591 65 10441 63 369E-01 -1 18E-01 3 Unchanged High
P02433 A15cd3 nbosomal protein L32 2277444 24400 30742 77 2598245 4 33E-01 1 01 E-01 3 Unchanged High
P49207 F11cd1 nbosomal protein L34 13251 1 11500 1319366 12661 96 -627E-03 -1 99E-01 3 Unchanged High
P42766 K16cd7 ribosomal protein L35 1045427 10500 10655 65 10527 37 275E-02 247E-03 3 Unchanged High
P18077 F13cd1 nbosomal protein L35a 14583 91 10700 8811 726 11356 13 -7 27E-01 -4 50E-01 3 Unchanged High
P09896 J06gh1 nbosomal protein L36a 8395 644 8780 12052 18 9742 196 522E-01 644E-02 3 Unchanged High
P09896 A19cd3 πbosomal protein L36a-lιke 5167 775 5750 4693401 5203379 -1 39E-01 1 54E-01 3 Unchanged High
P02403 F15cd1 nbosomal protein L37 318954 45000 41301 54 3938647 373E-01 4 95E-01 3 Unchanged High
P12751 F17cd1 πbosomal protein L37a 1865248 17300 19955 82 18651 98 974E-02 -1 05E-01 3 Unchanged High
P23411 F19cd1 πbosomal protein L38 5149 82 5570 7560 21 6091 715 554E-01 1 12E-01 3 Unchanged High
P02404 A17cd3 ribosomal protein L39 14114 05 21300 22827 16 19427 01 694E-01 596E-01 3 Unchanged High
P36578 B23cd1 πbosomal protein L4 1436747 10400 10448 85 1172395 -459E-01 -472E-01 3 Unchanged High
P28751 L06gh1 nbosomal protein L41 3513575 34300 40372 62 36514 61 200E-01 -332E-02 3 Unchanged High
P46777 E21cd3 πbosomal protein L5 1200266 8880 10351 69 10411 06 -2 13E-01 -435E-01 3 Unchanged High
Q02878 D01cd1 nbosomal protein L6 15861 7 7300 1011901 11094 61 -648E-01 -1 12E+00 3 Unchanged High
P18124 D03cd1 πbosomal protein L7 21230 67 15900 1953832 1888503 -1 20E-01 -4 18E-01 3 Unchanged High
P11518 G11cd3 nbosomal protein L7a 133855 8240 1058653 1073639 -338E-01 -700E-01 3 Unchanged High
P25120 D05cd1 nbosomal protein L8 2358043 18300 24766 14 22208 81 708E-02 -367E-01 3 Unchanged High
P32969 B19cd1 nbosomal protein L9 2885342 32200 3728841 32766 75 370E-01 1 56E-01 3 Unchanged High
P46783 H13cd1 πbosomal protein S10 7453342 7660 7511 766 7540 695 1 13E-02 380E-02 3 Unchanged High
P04643 H15cd1 nbosomal protein S11 1342985 15600 1362352 14209 6 207E-02 2 14E-01 3 Unchanged High
P25398 H17cd1 πbosomal protein S12 1617073 10600 12294 27 1301869 -395E-01 -6 11 E-01 3 Unchanged High
Q02S46 H19cd1 πbosomal protein S13 1395688 12600 1528 54 1394674 1 32E-01 -1 48E-01 3 Unchanged High
P11174 H21cd1 πbosomal protein S15 2132273 19600 233346 21408 92 1 30E-01 -1 24E-01 3 Unchanged High
P39027 H23cd1 πbosomal protein S15a 16787 1 15100 21854 01 1791292 381 E-01 -1 53E-01 3 Unchanged High
P17008 J01cd1 ribosomal protein S16 26604 5 15700 24481 55 22257 3 -1 20E-01 -7 62E-01 3 Unchanged High
P08708 J03cd1 nbosomal protein S17 1397925 7990 15360 88 12443 09 1 36E-01 -807E-01 3 Unchanged High
P25232 A17gh2 nbosomal protein S18 12558 18 12800 2009307 150897 678E-01 684E-03 3 Unchanged High
P17075 J07cd1 nbosomal protein S20 21944 13 19g00 31381 43 2440098 5 16E-01 -1 43E-01 3 Unchanged High
P35265 D24ef7 nbosomal protein S21 140467 9470 9023 678 10847 43 -6 38E-01 -569E-01 3 Unchanged High
P3g028 J09cd1 πbosomal protein S23 1222896 10900 14550 17 125456 251 E-01 -1 72E-01 3 Unchanged High
P16632 J11cd1 πbosomal protein S24 1291337 13100 1213549 1269984 -896E-02 1 53E-02 3 Unchanged High
P25111 J13cd1 πbosomal protein S25 6274 159 5630 5123747 5677 337 -292E-01 -1 55E-01 3 Unchanged High
P02383 C01cd3 nbosomal protein S26 2613826 30900 194402 2549992 -427E-01 242E-01 3 Unchanged High
P42677 G01cd3 nbosomal protein S27 (metallop- 17556 94 12800 20383 13 169274 2 15E-01 -4 51 E-01 3 Unchanged High
P14798 B18cd1 nbosomal protein S27a 3284 551 3180 2757 252 3073 17 -252E-01 -477E-02 3 Unchanged High
P25112 J15cd1 πbosomal protein S28 3038424 32000 28529 21 3031847 -909E-02 766E-02 3 Unchanged High
P30054 J17cd1 nbosomal protein S29 18454 55 20900 2553927 21630 2 4 69E-01 1 79E-01 3 Unchanged High
P23396 H03cd1 πbosomal protein S3 5913 682 2830 5523 561 4754218 -985E-02 -1 07E+00 3 Unchanged High
P49241 016ef5 nbosomal protein S3A 7154 088 6200 8592248 7316 667 264E-01 -206E-01 3 Unchanged High
P12750 A21cd3 πbosomal protein S4, X-lmked 19821 56 16200 21778 05 192825 1 36E-01 -287E-01 3 Unchanged High
P22090 A23cd3 πbosomal protein S4, Y-linked 2629 697 2330 2779 184 2680 924 798E-02 -1 72E-01 3 Unchanged High
P46782 H05cd1 nbosomal protein S5 15421 08 11000 17355 54 1459896 1 70E-01 -4 85E-01 3 Unchanged High pιnκso H07rri1 46408 18 26100 40579 46 3769524 -1 94E-01 -830E-01 3 Unchanαed Hiαh P46781 H12cd5 nbosomal protein S9 8827416 9710 1529598 1127836 7 93E-01 1.38E-01 3 Unchanged High
P46781 P12cd5 πbosomal protein S9 9059 523 1790 5725082 5525883 -6 62E-01 -234E+00 3 Unchanged High
P05387 H01cd1 πbosomal protein, large P2 16611 14 12700 1777572 15695 14 978E-02 -387E-01 3 Unchanged High
P05388 F21cd1 πbosomal protein, large; PO 1712741 12400 19746 88 16430 54 205E-01 -4 64E-01 3 Unchanged High
P05386 F23cd1 πbosomal protein, large, P1 2228298 1880 3134529 241378 4 92E-01 -246E-01 3 Unchanged High
Q9Y254 C08ef3 ring-box 1 2597578 4260 3365 165 3408 892 374E-01 7.15E-01 3 Unchanged High
Q9NWJ8 A23gh3 roundabout homolog 4, magic roi 1969602 3940 2093279 266666 879E-02 9 99E-01 3 Unchanged High
P08206 D06cd1 S100 calcium binding protein AH 3848573 49800 3174547 4001788 -2 78E-01 372E-01 3 Unchanged High
P31949 E09cd3 S100 calcium binding protein A1 8890 594 11100 5408269 8466714 -7 17E-01 320E-01 3 Unchanged High
P06703 P17gh6 S100 calcium binding protein A6 3403146 4070 2088478 3188753 -704E-01 260E-01 3 Unchanged High
P55735 J04ef4 SEC13-lιke 1 (S cerevisiae) 1695 152 iggo 2362541 2016 062 479E-01 232E-01 3 Unchanged High
P38384 I06ef3 Sec61 gamma 5653 955 7820 7254423 6908 432 3 60E-01 467E-01 3 Unchanged High
Q9NZJ3 H06ef2 selenoprotein T 2923813 2440 1325491 2230 091 • ■1 14E+00 -2 60E-01 3 Unchanged High
015532 H16cd1 seleπoprotem W, 1 2678843 2970 391844 3189 642 549E-01 1 50E-01 3 Unchanged High
Q13501 J23cd4 sequestosome 1 3214395 3170 1164 17 2517 543 - -1 47E+00 -1 82E-02 3 Unchanged High
P35237 L18ab8 seππe (or cysteine) protemase in 4203 074 8180 293672 5105477 -5 17E-01 9 60E-01 3 Unchanged High
P05121 P05ef7 seπne (or cysteine) protemase In 445456 7280 9179863 6972284 1 04E+00 709E-01 3 Unchanged High
Q00587 C14cd7 serum constituent protein 2480698 2660 2044608 239346 -279E-01 980E-02 3 Unchanged High
Q9H299 P16gh7 SH3 domain binding glutamic aci 144736 17100 1379802 1513474 -6 90E-02 243E-01 3 Unchanged High
P37108 E21cd2 signal recognition particle 14kD ( 2432627 35600 2431959 2808256 -3 96E-04 549E-01 3 Unchanged High
P49458 E19cd2 signal recognition particle 9kD 1874 67 2640 3141 422 2551 928 7 45E-01 4 93E-01 3 Unchanged High
P43308 G15cd2 signal sequence receptor, beta (t 4209 147 4610 5876451 4898 581 481 E-01 1 31 E-01 3 Unchanged High
P51571 015gh1 signal sequence receptor, delta ( 2062 113 2330 2654968 234929 365E-01 1 77E-01 3 Unchanged High
000422 M17cd6 sln3-assocιaled polypeptide, 18k 250279 2610 2079295 2396002 -267E-01 583E-02 3 Unchanged High
075918 J10cd5 small EDRK-nch factor 2 5927 595 7010 7926059 6955245 4 19E-01 2 42E-01 3 Unchanged High
P13500 C15cd3 small Inducible cytokme A2 (mon 1707797 38100 8786323 2133026 -959E-01 1 16E+00 3 Unchanged High
Q15356 A09cd2 small nuclear πbonucleoproteln f 2743428 2150 2819855 2570 901 396E-02 -3 52E-01 3 Unchanged High
P14648 A13cd2 small nuclear πbonucleoprotein p 8996242 2800 2362597 2021 429 1 39E+00 1 64E+00 3 Unchanged High
P12236 G01ef1 solute earner family 25 (mitochor 7384066 4760 6176034 6107 995 -2 58E-01 -6 32E-01 3 Unchanged High
Q00325 K22ab8 solute earner family 25 (mitochor 5074308 3750 3770577 4200626 -4 25E-01 -4 37E-01 3 Unchanged High
P32745 N01cd1 sorπatostatiπ receptor 3 4102668 4170 4748989 4340 964 2 11E-01 239E-02 3 Unchanged High
P30626 E13cd2 sorcm 1895592 2790 2280297 2323 149 267E-01 559E-01 3 Unchanged High
Q01826 F18ef6 special AT-πch sequence bindiπj 2644932 41300 2422561 3064509 -1 27E-01 642E-01 3 Unchanged High
P21673 D12cd1 spermldine/spermine N1-acetyltπ 8349882 16500 6013659 1027593 -474E-01 980E-01 3 Unchanged High
P34g91 G05cd3 S-phase kinase-associated prote 3072601 2990 23g6506 2820643 -359E-01 -380E-02 3 Unchanged High
P23246 B09cd2 splicing factor prol e/glutamine I 2694629 2460 3348423 2834 056 3 13E-01 -1 32E-01 3 Unchanged High
P35716 C07cd2 SRY (sex determining region Y)-l 5019 988 4860 2125089 4001 241 -1 24E+00 -471E-02 3 Unchanged High
P35713 E10ef4 SRY (sex determining region Y)-l 2575791 3100 2024386 2565998 -348E-01 2 66E-01 3 Unchanged High
Q06945 C05cd2 SRY (sex determining region Y)-l 2299474 2210 1636067 2049214 -4 91 E-01 -559E-02 3 Unchanged High
P00441 G20ef7 superoxide dtsmutase 1 , soluble 4439342 4930 3239 195 4202 954 -4 55E-01 1 51 E-01 3 Unchanged High
P50502 I18cd2 suppression of tumongenicity 13 2307599 2530 2358 117 2400 085 3 12E-02 1 35E-01 3 Unchanged High
Q9Y5Y6 P20gh1 suppression of tumongenicity 14 235828 2700 1494856 2183 041 -658E-01 1 93E-01 3 Unchanged High
P17600 J06cd2 synapsin I 1969 157 2220 2010908 2067 417 303E-02 1 74E-01 3 Unchanged High
043759 G11cd5 synaptogyπn 1 145166 10700 10060 61 11775 53 -52gE-01 -4 33E-01 3 Unchanged High
Q12962 P19cd2 TAF10 RNA polymerase II, ΥAJA 5937 255 5080 3962323 4992 528 -583E-01 -226E-01 3 Unchanged High
Q15763 B20cd2 t-complex-associated-testis-expn 2022997 2890 2885017 2600459 512E-01 5 16E-01 3 Unchanged High
P10599 B23cd4 thioredoxm 11525 16 11900 6440 37 9965777 -840E-01 5 00E-02 3 Unchanged High
P13472 O02ef7 thymosin, beta 10 46982 91 74300 5426348 58508 68 2 08E-01 661 E-01 3 Unchanged High
P01253 L12gh1 thymosin, beta 4, X chromosome 2314554 26000 16231 51 2178342 -5 12E-01 1 66E-01 3 Unchanged High
Q01085 C02cd2 TIA1 cytotoxic granule-associate 2250456 1770 2917342 2312331 374E-01 -347E-01 3 Unchanged High
Q15370 J12cd2 transcnptioπ elongation factor B < 2616595 3980 3919327 3505 384 583E-01 605E-01 3 Unchanged High
043680 011cd2 transcnption factor 21 1789295 1790 3044 118 2209 014 7 67E-01 349E-03 3 Unchanged High
P2ig80 016cd2 transglutaminase 2 (C polypeptid 3131 079 3490 1857596 2827774 -753E-01 1 58E-01 3 Unchanged High
P2g401 N15cd1 transketolase (Wernicke-Korsakc 3258575 2040 2715206 2671 504 -263E-01 -675E-01 3 Unchanged High
O6073g O01cd6 translation factor suι1 homolog 2671 935 3400 3868727 3315099 534E-01 350E-01 3 Unchanged High
Q9NS69 102gh7 translocase of outer mitochondπ- 2988423 2450 3754 914 3062 809 329E-01 -2 89E-01 3 Unchanged High
P00938 M24cd1 tπosephosphate isomerase 1 5701 29 5820 8345738 6622 243 550E-01 2 97E-02 3 Unchanged High
P07226 G10cd2 tropomyosin 4 2636256 2300 3755882 2897 509 5 11E-01 -1 97E-01 3 Unchanged High
P04687 F09cd4 tubulin, alpha 3 2022003 14500 22303 88 1899231 1 42E-01 -4 84E-01 3 Unchanged High
P04687 A01cd1 tubulin, alpha, ubiquitous 1525881 7840 2247865 1519376 559E-01 -960E-01 3 Unchanged High
Q13509 E04cd6 tubulin, beta, 4 2338877 2990 1853273 2394 89 -336E-01 3 56E-01 3 Unchanged High
P04350 F01gh6 tubulin, beta, 5 7573765 4430 3448455 5149498 -1 14E+00 -7 75E-01 3 Unchanged High
075347 O08cd2 tubulm-specific chaperane a 3000065 3900 3275629 33go 7i 1 27E-01 3 77E-01 3 Unchanged High
075509 L10ef3 tumor necrosis factor receptor su 2245338 4890 1881 231 3007 078 -255E-01 1 12E+00 3 Unchanged High
P13693 G16cd2 tumor protein, traπεlationally-con 39878 18 60800 48468 25 49731 11 281 E-01 6 10E-01 3 Unchanged High
P14625 G24cd2 tumor rejection antigen (gp96) 1 2185 187 2060 4905342 3049 346 1 17E+00 -8 69E-02 3 Unchanged High
P42655 K04cd4 tyrosine 3-monooxygenase/tryptc 6584565 5730 5558974 5956713 -244E-01 -201 E-01 3 Unchanged High
Q04917 G06cd3 tyrosiπe 3-monooxygenase/tryptc 8621 322 8150 4562 366 7111 932 -g 18E-01 -8 07E-02 3 Unchanged High
P29312 A01cd4 tyrosine 3-monooxygenase/tryptc 5873282 4670 2279 148 4275 506 -1 37E+00 -329E-01 3 Unchanged High
P29312 P12cd4 tyrosine 3-monooxygenase/tryptc 4562964 1140 15202 2406 497 -1 59E+00 -201E+00 3 Unchanged High
014957 G17cd7 ublquiπol-cytochrome c reductasi 2728765 3990 3332422 3351 45 2 88E-01 5 49E-01 3 Unchanged High
P14793 D01cd4 ubiquitin A-52 residue πbosomal 3536225 1730 3258439 2840732 -1 18E-01 -1 03E+00 3 Unchanged High
P02248 D22gh1 ubiquitin B 2753 942 4430 4152235 3779 352 592E-01 6 86E-01 3 Unchanged High
076069 B12cd4 ubiquitin-conjugating enzyme E2 2001 262 1980 2223574 2068 646 1 52E-01 -1 46E-02 3 Unchanged High
Q9BZL1 B17gh7 ubiquitm-like 5 4339474 9100 5279835 6239513 2 83E-01 1 07E+00 3 Unchanged High
P08670 C24cd3 vimentin 5940 876 8720 177834 10813 94 1 58E+00 5 53E-01 3 Unchanged High
P45880 C18cd3 voltage-dependent anion channe 7005537 7280 4758 179 6347 014 -558E-01 549E-02 3 Unchanged High
Q9Y277 C04cd4 voltage-dependent anion channe 1863424 2210 2573885 221675 466E-01 248E-01 3 Unchanged High
P17861 015cd4 X-box binding protein 1 3398455 1600 2040224 2347 333 -736E-01 -1 08E+00 3 Unchanged High
043670 M04cd3 zinc finger protein 207 3338 117 3170 317S 631 3226 643 -7 15E-02 -7 67E-02 3 Unchanged High
Q07352 N21ef6 zinc finger protein 36, C3H type-l 6097384 5750 4958224 5601 518 -298E-01 -849E-02 3 Unchanged High
Q15942 M10cd3 zyxin 257021 2070 2519748 2387 987 -2 86E-02 -3 09E-01 3 Unchanged High
Q16659 B17ef5 mitogen-activated protein kinase 144 6425 141 1000111 1286073 -532E-01 -351E-02 1 Unchanged Low
075324 B05cd3 stannin 131 7242 172 1000655 1347009 -397E-01 3 88E-01 1 Unchanged Low
Q9BYP8 E16gh8 keratin associated protein 17 1 1764958 174 100 1011 150 0893 -8 18E-01 -2 33E-02 1 Unchanged Low
P55291 J01ab4 cadheπn 15, M-cadheπn (myotub 158 7215 128 1003297 128 8583 -662E-01 -3 16E-01 1 Unchanged Low P49768 L14ab7 presenlllπ 1 (Alzheimer disease : 1279653 124 1003504 117 5823 -3 51 E-01 -4 04E-02 Unchanged Low
P55107 G10ab5 growth differentiation factor 10 1147206 168 1006326 127 9343 -1 89E-01 5 54E-01 Unchanged Low
P17082 P18cd7 related RAS viral (r-ras) oncoger 433219 176 1008465 2367776 -2 10E+00 -1 30E+00 Unchanged Low
P23634 N08ab2 ATPase, Ca++ transporting, plas 1793836 276 1009041 1854081 -830E-01 621 E-01 Unchanged Low
P78347 J20ab5 general transcription factor II, I 151 6834 103 1009514 1186963 -5 87E-01 -552E-01 Unchanged Low
P09912 F08ef7 Interferon, alpha-lnducible proteu 1836419 1050 101 0749 444 3716 -8 61 E-01 251E+00 Unchanged Low
Q9H2F5 F13gh7 enhancer of polycomb 1 127 3938 115 101 3763 114 5773 -330E-01 -1 48E-01 Unchanged Low
014811 M06cd7 programmed cell death 10 1523457 132 101 596 128 8019 -5 85E-01 -202E-01 Unchanged Low
060942 A17cd4 RNA guanylyltransferase and 5'-| 1767836 97 1 101 6765 125 1735 -7 98E-01 -8 65E-01 Unchanged Low
Q9Y5Y3 M18cd7 G protein-coupled receptor 45 1743335 161 101 8478 145 8365 -7 75E-01 -1 12E-01 Unchanged Low
P11908 H15ab8 phosphonbosyl pyrophosphate s 166 1373 174 101 9334 1472722 -7 05E-01 646E-02 Unchanged Low
Q92851 P18ab3 caspase 10, apoptosis-related cy 135919 107 101 9435 1150308 -4 15E-01 -342E-01 Unchanged Low
Q9BQE5 M03gh7 apolipoprotem L, 2 109 8196 148 1020533 119 8218 -1 06E-01 4 26E-01 Unchanged Low
P55327 D05cd2 tumor protein D52 1362596 112 102 1111 1169522 -4 16E-01 -277E-01 Unchanged Low
P28332 K03ab2 alcohol dehydrogenase 6 (class ' 1424055 97 7 102 1575 1140924 -479E-01 -543E-01 Unchanged Low
095861 E02cd6 3'(2'), 5'-blsphosphate nucleotids 128 1251 116 102 1715 1154153 -327E-01 -1 44E-01 Unchanged Low
Q9NXJ5 A10gh2 hypothetical protein FLJ20208 1224219 151 1023038 125322 -259E-01 3 05E 01 Unchanged Low
Q15642 K09gh1 thyroid hormone receptor Interac 120 9158 142 1023082 121 6641 -241 E-01 230E-01 Unchanged Low
094997 O09cd7 decidual protein induced by prog 1743087 140 1023137 1388592 -7 69E-01 -3 17E-01 Unchanged Low
095453 G02ab8 poly(A)-specιfio πboπuclease (de 1399344 105 1023217 1157147 -4 52E-01 4 16E-01 Unchanged Low
Q9H9C5 F01gh7 KIAA1453 protein 1358299 126 1024347 121 5247 -4 07E-01 -1 05E-01 Unchanged Low
P10451 B13cd1 secreted phosphoprotem 1 (ostei 1904604 767 1025193 1232388 -8 94E-01 -1 31E+00 Unchanged Low
P53992 B03cd5 SEC24 related gene family, mem 134 307 105 1025437 113 9998 -3 89E-01 -353E-01 Unchanged Low
Q9NQW1 F22gh6 secretory pathway component Se 111 3643 158 102 6234 1238833 -1 18E-01 5 02E-01 Unchanged Low
Q01449 A17gh5 myosin light chain 2a 179 1031 170 1030725 150 5611 -7 97E-01 -7 94E-02 Unchanged Low
Q9NX46 K12gh2 hypothetical protein FLJ20446 1095374 159 103 1083 1238664 -873E-02 5 37E-01 Unchanged Low
P53609 A23cd1 protein geranylgeraπyltransferas 140 0296 128 103 1248 123 8135 -441 E-01 -1 26E-01 Unchanged Low
Q15029 J16cd4 U5 snRNP-speαfic protein, 116 i 1193284 126 103 1503 1159932 -2 10E 01 7 28E-02 Unchanged Low
P50458 023cd5 LIM homeobox protein 2 145 905 120 103 1971 1229669 -5 OOE-01 -2 84E-01 Unchanged Low
P33764 B24cd1 S100 calcium binding protein A3 1505991 204 1033783 1525858 -543E-01 436E 01 Unchanged Low
Qgp2βg G03ef3 Mst3 and SOK1-related kinase 133 5225 116 1034345 1177841 -3 68E 01 -1 98E-01 Unchanged Low
P52429 P17cd3 diacylglycerol kinase, epsilon (64 1287238 123 1035015 118 2956 -3 15E-01 -696E-02 Unchanged Low
P54578 H17cd5 ubiquitin specific protease 14 (tR 1607495 108 103 6864 1242132 -633E-01 -571E 01 Unchanged Low
Q13219 E24ab8 pregnancy-associated plasma pr 1129052 154 1037948 1234254 -1 21 E-01 444E-01 Unchanged Low
060547 M12ab5 GDP-mannose 4,6-dehydratase 1472805 108 103 8004 1198044 -505E-01 -443E 01 Unchanged Low
P23207 I17ef6 S100 calcium binding protein A1 1452558 126 1039033 124 9008 -4 83E-01 -2 10E 01 Unchanged Low
Q9H5J8 M01gh6 hypothetical protein MGC5306 216091 91 7 1040432 137 2762 -1 05E+00 -1 24E+00 Unchanged Low
Q14493 I08cd4 stem-loop (histone) binding prate 1267755 155 104 1318 1284702 -2 84E-01 2 85E-01 Unchanged Low
Q9NZU0 016cd8 fibronectin leuclne πch transmerr 2849107 268 1043033 219 1816 -1 45E+00 -865E-02 Unchanged Low
P80370 B01ef7 delta-like 1 homolog (Drosophila 160 1421 80 104328 114 8185 -6 18E-01 -1 OOE+00 Unchanged Low
Q9NYV4 C23ef3 CDC2-related protein kinase 7 1285947 107 104 3521 1134542 -301 E-01 -260E-01 Unchanged Low
P09016 C23ef5 homeo box D4 1732254 192 104 3556 156 5829 -731 E-01 1 50E-01 Unchanged Low
Q13873 A16ab3 bone morphogenetic protein rece 1558113 868 1044206 1156624 -577E-01 -845E-01 Unchanged Low
014878 B22ef4 inosme tnphosphatase (nucleosli 124 8814 120 1044238 116 398 -2 58E-01 -5 89E-02 Unchanged Low
P52848 J01ab6 N-deacetylase/N-sulfotransferasi 1662411 844 1044555 118 3793 -670E-01 -977E-01 Unchanged Low
Q14848 A05cd5 TNF receptor-associated factor 4 1242461 136 1044604 121 4689 -250E-01 1 27E-01 Unchanged Low
000204 O04cd2 sulfotransferase family, cytosolio 1858106 117 1044824 135 653 -8 31 E-01 -6 71 E-01 Unchanged Low
P35610 E13gh1 sterol O-acyltransferase (acyl-Cc 143 8417 88 1045518 112 1404 -460E-01 -7 08E-01 Unchanged Low
Q04760 L03ab5 glyoxalase I 132 6871 107 104 5782 114 7132 -343E-01 -3 12E-01 Unchanged Low
P51690 H06ab2 arylsulfatase E (chondrodysplasi 177023 762 1045865 119 2772 -7 59E-01 -1 22E+00 Unchanged Low
P26012 C11ef7 Integπn beta 8 1107396 170 104 6296 1284899 -8 19E-02 6 19E 01 Unchanged Low
Q14978 K11cd5 nucleolar and coiled-body phosp 117 0048 131 104 685 1174911 -1 61 E-01 1 61 E-01 Unchanged Low
000764 D16cd3 pyπdoxal (pyndoxme, vitamin B6 1602678 140 104 6915 135073 -6 14E-01 -1 92E-01 Unchanged Low
Q9Y6Q5 P13cd5 adaptor-related protein complex 1493929 107 104 7705 120 3004 -5 12E-01 -4 85E-01 Unchanged Low
095350 G04cd5 Homer, neuronal immediate earl) 1372833 126 1047829 1226314 -390E-01 -1 26E 01 Unchanged Low
P49748 C13ab2 acyl-Coenzyme A dehydrogenasi 121 151 141 1047897 1224441 -209E-01 223E-01 Unchanged Low
P08100 024cd1 rhodopsin (opsm 2, rod pigment) 1253282 116 1048101 115 4338 -258E-01 -1 10E-01 Unchanged Low
Q15477 F24cd2 super killer viralicidic activity 2-lιk 1025551 186 104 8138 131 0636 3 14E-02 8 58E-01 Unchanged Low
043520 I17cd1 ATPase, Class I, type 8B, membi 199 1157 91 5 1048252 131 8072 -926E-01 -1 12E+00 Unchanged Low
Q13039 P02ef4 ATP-bind g cassette, sub-family 1757841 80 5 104 8585 120 383 -7 45E 01 -1 13E+00 Unchanged Low
015291 L12cd1 solute carrier family 7 (cationic ai 2763689 176 104904 1857368 -1 40E+00 -5 52E-01 Unchanged Low
Q9NR71 L23gh4 mitochondnal ceramidase 108 9644 152 1049361 122091 -543E-02 4 84E-01 Unchanged Low
060884 H10cd4 DnaJ (Hsp40) homolog subfamil 221 9835 239 104 9441 1885763 -1 08E+00 1 05E-01 Unchanged Low
Q9BYE0 J17gh8 hairy and enhancer of split 7 (Drc 128 0255 108 1049542 113 8134 -2 87E 01 -2 39E-01 Unchanged Low
Q9Y272 L01ef2 RAS, dexamethasone-induced 1 101 2051 166 1049825 1240354 529E 02 7 13E-01 Unchanged Low
Q9BUR5 M13gh6 hypothetical protein MGC4825 78 2636 239 1050137 140 65 4 24E-01 1 61 E+00 Unchanged Low
060859 A13cd7 neuropathy target esterase 123 9707 117 105029 1153513 -239E-01 -828E-02 Unchanged Low
Q9GZU1 A20gh4 mucolip 1 85 32301 243 105 1039 144 4516 3 01 E-01 1 51 E+00 Unchanged Low
P19878 B15ab6 neutrophil cytosollc factor 2 (65kl 310 5103 515 105 1041 3103051 -1 56E+00 731 E-01 Unchanged Low
Q13277 K12cd2 syπtaxm 3A 1185375 185 1052511 136 1937 -1 72E-01 641 E-01 Unchanged Low
B04gh8 reserved 130 849 124 1052594 120 0361 -3 14E-01 -7 76E-02 Unchanged Low
P32456 N18ab4 guanylate binding protein 2, Intel 1093786 142 1052611 118 8515 -5 54E-02 376E-01 Unchanged Low
Q9H4M9 E01cd7 EH-domain containing 1 1490051 151 1053893 134 9992 -500E-01 1 54E-02 Unchanged Low
Q9BTX7 019gh6 chromosome 20 open reading frs 1159099 157 1054128 126203 -1 37E-01 440E-01 Unchanged Low
Q9NVN2 M02gh3 solute carrier family 4 (anion excl 123 8178 114 105466 114476 -231 E-01 -1 17E-01 Unchanged Low
Q99758 A17ab2 ATP-bindmg cassette, sub-family 238456 145 1055504 163 1362 -1 18E+00 -7 14E-01 Unchanged Low
P43694 B06ef6 GATA binding protein 4 107 7539 161 1055891 124 6996 -2 93E-02 577E-01 Unchanged Low
Q13825 C07ab3 AU RNA binding proteiπ/enoyl-Ci 1234494 140 1056272 123 0884 -225E-01 1 83E 01 Unchanged Low
Q92550 L23ef3 πng finger protein 10 1974603 112 1057052 138 2365 -9 02E-01 -824E-01 Unchanged Low
Q9UJS0 C12ef3 solute earner family 25, member 119 1806 139 1058216 121 1782 -1 72E-01 2 17E-01 Unchanged Low
Q99611 O05ef3 seleπophosphate synthetase 2 168 8742 128 1058955 134292 -673E-01 -399E-01 Unchanged Low
P17275 F08ab6 jun B proto-oncogene 1359478 949 1059141 1122701 -360E-01 -518E-01 Unchanged Low rm 77 Rn9rri4 mucosal vascular addressin cell 127 8352 110 1059239 114 7415 -271 E-01 -2 11 E-01 Unchanged Low P50991 H09cd6 chaperonln containing TCP1 , sut 161 4396 148 1060337 138 5613 -606E-01 -1 23E-01 1 Unchanged Low
P35548 K11ab7 msh homeo box homolog 2 (Dros 1824309 124 106057 137 5011 -7 83E-01 -5 57E-01 1 Unchanged Low
P11309 M14ab8 plm-1 oncogene 1363951 99 106 0757 1138227 -363E-01 -4 62E-01 1 Unchanged Low
075570 A03cd5 mitochondπal translational relea. 1289238 118 106 1208 117597 -281 E-01 -1 31 E-01 1 Unchanged Low
Q9NY61 O01ef3 apoptosis antagonizing transcπpl 120 3605 124 106 1404 116 8527 -1 81 E-01 436E-02 1 Unchanged Low
Q9BTY8 D01gh7 hypothetical protein MGC4342 1395304 92 9 106 2168 112876 -394E-01 -5 87E-01 1 Unchanged Low
Q9NWS2 F09gh2 hypothetical protein FLJ20640 1830823 140 106 2384 1430354 -7 85E-01 -3 89E-01 1 Unchanged Low
000180 H06ab6 potassium channel, subfamily K, 1294915 122 1062703 1193824 -285E-01 -8 14E-02 1 Unchanged Low
015382 I05ab3 branched chain amtnotransferasi 1368391 955 1063058 1128868 -364E-01 -5 19E-01 1 Unchanged Low
Q0Y2Z1 D05ef2 CGI-01 protein 1564563 196 106 3369 153067 -5 57E-01 328E-01 1 Unchanged Low
QgY315 E18ef2 CGI-26 protein 1357793 111 1066662 1178557 -348E-01 -2 89E-01 1 Unchanged Low
Q9Y592 P20ef1 NY-REN-58 antigen 1186541 121 1067049 1153792 -1 53E-01 2 S6E-02 1 Unchanged Low
Q9NYT0 D20ef3 pleckstnn 2 (mouse) homolog 114 99g 153 1067508 124 8364 -1 07E-01 4 10E-01 1 Unchanged Low
Q9Y343 M10ef4 SBBI31 protein 1230625 120 106 8362 1166438 -204E-01 -3 60E-02 1 Unchanged Low
Qgβvw G09gh6 hypothetical protein MGC3162 140 5988 123 106 8523 1236298 -396E-01 -1 88E-01 1 Unchanged Low
P30622 B20cd1 restin (Reed-Steinberg cell-expre 1168074 136 107 0013 1197985 -1 27E-01 2.15E-01 1 Unchanged Low
Q08345 F08ef5 discoidin domain receptor family, 2666468 264 107 136 2126497 1 32E+00 -1 35E-02 1 Unchanged Low
P33176 C16ab7 kinesm family member 5B 1235679 113 1072314 114 5075 -205E-01 -1 33E-01 1 Unchanged Low
PS5273 D14ab4 cyclin-dependent kinase inhibitor 9964375 174 107 4234 1268971 1 08E-01 801 E-01 1 Unchanged Low
Q9NW92 E10gh3 hypothetical protein FLJ10209 177 1237 166 107454 1503287 -721 E-01 -900E-02 1 Unchanged Low
Q9NZC3 K03ef3 membrane interacting protein of l 1058303 152 107465 121 8015 221E-02 523E-01 1 Unchanged Low
P15172 M19ab7 myogenic factor 3 1327839 110 1074694 167347 -305E-01 -272E-01 1 Unchanged Low
P27144 A06ab2 adenylate kinase 3 118 5733 124 107 5998 1167128 -1 40E-01 642E-02 1 Unchanged Low
060508 A06ef2 pre-mRNA splicing factor 17 150 1968 130 107 6187 129259 -4 81 E-01 -209E-01 1 Unchanged Low
Q14012 B08cd3 calcium/calmodulin-dependent pi 1139231 135 1076204 1188965 -821E-02 246E-01 1 Unchanged Low
Pg8179 G12cd1 RNA binding motif protein 3 140 1356 932 107 7553 1136891 -379E-01 -589E-01 1 Unchanged Low
Q13223 E10ab5 BRF1 homolog, subunit of RNA p 150 0469 115 1077567 124 3969 -478E-01 -379E-01 1 Unchanged Low
P55198 N09ab7 myeloid/lymphoid or mixed-linea. 1807113 122 1077762 1367788 -746E-01 -5 69E-01 1 Unchanged Low
P46459 G02ef1 N-ethylmaleimide-sensitlve factoi 138 9363 957 107 8044 114 1635 -366E-01 -537E-01 1 Unchanged Low
P34969 121 ef1 5-hydroxytryptamιne (serotonin) I 2187666 181 107 8181 169 3507 -1 02E+00 -270E-01 1 Unchanged Low
Q14667 K02gh1 KIAA0100 gene product 1059471 222 107 8612 145 1883 258E-02 1 07E+00 1 Unchanged Low
Q92830 J14cd8 GCN5 general control of ammo-s 1294527 106 107 863 1145758 -263E-01 -283E-01 1 Unchanged Low
P14cd2 RNA binding motif protein, Y chrt 1123917 153 1079125 1244395 -5 87E-02 445E-01 1 Unchanged Low
043252 J01cd5 3'-phosphoadenosιne 5'-phosphc 194 4946 188 107 9154 1634169 -850E-01 -5 02E-02 1 Unchanged Low
Q9NS93 G09ef3 seven transmembrane protein Tft 1380932 237 107 9483 1608518 -355E-01 7 76E-01 1 Unchanged Low
060616 E20ab6 core-binding factor, runt domain, 4890924 481 1079969 2150608 -2 18E+00 -335E+00 1 Unchanged Low
P02261 D19cd4 H2A histone family, member C 1450821 84 1 108023 1124051 -4 26E-01 -7 87E-01 1 Unchanged Low
Q14701 F18ef7 DNA cross-link repair 1 A (PS02 1192486 307 108208 1782467 -1 40E-01 1 37E+00 1 Unchanged Low
Q9P025 A04ef8 HSPC135 protein 160 3109 135 1082493 1346437 -567E-01 -244E-01 1 Unchanged Low
P06702 012ef7 S100 calcium binding protein A9 144 7319 163 1082576 138 5985 - 19E-01 1 70E-01 1 Unchanged Low
Q9Y5Q9 P05cd7 general transcπption factor MIC, | 138644 220 1083524 1557377 -356E-01 668E-01 1 Unchanged Low
P19075 O20cd2 transmembrane 4 superfamily me 129 5468 103 1086355 1137491 -254E-01 -330E-01 1 Unchanged Low
060905 B16cd4 sperm associated antigen 9 1107683 139 1086913 1194574 -273E-02 327E-01 1 Unchanged Low
Q13322 F24ef5 growth factor receptor-bound pro 120 8593 115 1087182 1147351 -1 53E-01 -7 64E-02 1 Unchanged Low
Q9UQ09 L01gh1 KIAA0470 gene product 1903667 103 108 9005 1340152 -806E-01 -8 89E-01 1 Unchanged Low
P57053 J20gh6 H2B histone family, member S 1136057 199 1089238 140 5964 -607E-02 8 11E-01 1 Unchanged Low
Q92876 J03ab8 kallikrem 6 (neurosm, zyme) 197 2979 130 1089308 1455667 -857E-01 -597E-01 1 Unchanged Low
P09960 F21ab6 leukotnene A4 hydrolase 9636818 185 1090526 1302822 1 78E-01 944E 01 1 Unchanged Low
Q9HBH1 O02ghS peptide deformylase-ltke protein 1380653 91 1090612 1127249 -340E-01 -6 01 E-01 1 Unchanged Low
P55082 L15ab7 microfibπllar-associated protein ; 121 4467 124 109 134 118 1545 -1 54E-01 2 87E-02 1 Unchanged Low
Q9NVH6 B01gh3 tπmethyllysme hydroxylase, epsil 1747559 81 6 109 1442 121 828 -670E-01 -1 10E+00 1 Unchanged Low
095249 K10cd5 golgi SNAP receptor complex me 1075878 143 109 1657 119983 210E-02 4 12E-01 1 Unchanged Low
Q13891 M15ab6 basic transcnption factor 3, like 2 1266543 120 109 1942 1185076 -2 14E-01 -8 18E-02 1 Unchanged Low
Q9BZM5 H05gh7 UL16 binding protein 2 1336731 245 1092193 162 5485 -291E-01 873E-01 1 Unchanged Low
094913 O20ef2 PCF11p homolog 205 6752 80 3 1092409 131 7517 -9 13E-01 -1 36E+00 1 Unchanged Low
Q12987 E03ef4 acidic 82 kDa protein mRNA 132 1136 117 1094318 1193623 -272E-01 -1 81 E-01 1 Unchanged Low
Q92499 D05ab5 DEAD/H (Asp-Glu-Ala-Asp/His) t 1766983 124 1094356 136 6656 -691 E-01 -5 13E-01 1 Unchanged Low
Q13686 B19ab2 alkylation repair, alkB homolog 1055169 143 1094797 1194385 532E-02 4 42E-01 1 Unchanged Low
P43250 I08ab4 G protein-coupled receptor kinas 120 3579 113 1094844 1142814 -1 37E-01 -9 10E-02 1 Unchanged Low
Q9UMX0 L03ef4 ubiquitin 1 1220111 141 1095522 1240398 -1 55E-01 2 04E-01 1 Unchanged Low
094905 G12cd7 chromosome 8 open reading frar 127 8659 107 1096202 114 8261 -222E-01 -257E-01 1 Unchanged Low
Q9UHK0 K01cd8 nuclear fragile X mental retardati 157 4757 876 1096296 1182396 -522E-01 -846E-01 1 Unchanged Low
P25189 D01ab6 myelin protein zero (Charcot-Mai 1105502 132 1096859 1173068 -1 13E-02 252E-01 1 Unchanged Low
Q10567 M11ab2 adaptor-related protein complex 208 9283 187 109 8204 1684738 -928E-01 -1 62E-01 1 Unchanged Low
015230 D18cd8 laminin, alpha 5 111 864 141 109 8469 120 9363 -263E-02 335E-01 1 Unchanged Low
P52294 J10ab6 karyopheπn alpha 1 (importin alp 1787513 169 1099831 1527331 -701 E-01 -770E-02 1 Unchanged Low
060668 M03cd2 TAF2 RNA polymerase II, TATA 1236244 111 1100571 114 8794 -1 68E-01 -1 56E-01 1 Unchanged Low
P11686 J02cd1 surfactant, pulmonary-associatec 1360267 117 1100847 121 0017 -305E-01 -2 19E-01 1 Unchanged Low
Q9NWB6 P03gh2 hypothetical protein FLJ10154 1747789 75 110 1306 1199579 -666E-01 -1 22E+00 1 Unchanged Low
Q9H028 E22gh8 histone deacetylase 10 107 5034 138 110 1585 1184626 352E-02 3 57E-01 1 Unchanged Low
Q9UMZ2 022cd7 AP1 gamma subunit binding prot 1202821 119 110 2219 1165628 -1 26E-01 -1 32E-02 1 Unchanged Low
P24752 C15ab2 acetyl-Coenzyme A acetyltransfe 216 1409 114 1102562 1468035 -971E-01 -923E-01 1 Unchanged Low
P11230 B06ab3 cholmergic receptor, πicotmic, be 106 1774 151 1102999 122 607 550E-02 5 11E-01 1 Unchanged Low
014977 018ef2 ornithine decarboxylase aπtizyrro 119 9172 129 110 3 1197626 -1 21 E-01 1 06E-01 1 Unchanged Low
E15ef5 T cell receptor beta locus 139 7091 844 110 3287 3646946 -341 E-01 259E+00 1 Unchanged Low
P56937 N06ef2 hydroxysteroid (17-beta) dehydrc 227 1137 74 5 1103428 1373284 -1 04E+00 -1 61 E+00 1 Unchanged Low
075299 B21ab7 kines family member C3 113 15 128 110 3535 117 1803 -361E-02 1 78E-01 1 Unchanged Low
P16219 C09ab2 acyl-Coenzyme A dehydrogenas 1094688 136 1103636 11869 1 17E-02 3 16E-01 1 Unchanged Low
Q9NZ48 J20gh3 uncharactenzed hematopoietic s 1125665 189 1103995 1372614 -280E-02 746E-01 1 Unchanged Low
Q9P163 L10gh4 hypothetical protein PR02521 101 1317 159 1104184 1234514 1 27E-01 651 E-01 1 Unchanged Low
Q9BVT8 I07gh8 hypothetical protein MGC5442 1355302 137 110 5044 1277419 -295E-01 1 76E-02 1 Unchanged Low
Q99933 E02ef6 BCL2-assocιated athanogeπe 1197332 115 110533 115 0469 -1 15E-01 -5 98E-02 1 Unchanged Low
014645 M12cd3 dynein, axoπemal, light Intermed 164 1806 207 1105493 160 4204 -571E-01 331 E-01 1 Unchanged Low
Q9BRR9 E01gh8 Rho GTPase activating protein 9 1203646 115 1105606 115 1711 -1 23E-01 -7 10E-02 1 Unchanged Low
Q9Y3E7 Jigef2 CGI-149 protein 1584397 202 1106074 157 1807 -5 18E-01 354E-01 1 Unchanged Low
P46976 C09ab6 glycogenin 127 6502 117 110 6815 118 5706 -206E-01 -1 21 E-01 1 Unchanged Low 075928 C01cd5 Protein inhibitor of activated STA 9884393 173 110 7286 1274786 1 64E-01 806E-01 1 Unchanged Low
Q9NX63 I18gh2 hypothetical protein FLJ20420 1233725 159 110 8068 131 146 -1 55E-01 368E-01 1 Unchanged Low
Q9UBS0 I20cd2 nbosomal protein S6 kinase, 70k 186953 155 110 8188 150 9199 -7 54E-01 -271 E-01 1 Unchanged Low
Q15185 F18cd6 uπactive progesterone receptor, 1694269 723 110 8534 11754 -6 12E-01 -1 23E+00 1 Unchanged Low
060516 J18cd3 eukaryotic translation initiation fa 1043739 147 110 9085 120 8526 876E-02 4 97E-01 1 Unchanged Low
Q16651 J01ab8 protease; serine, 8 (prostasin) 3340498 125 110.9253 190 1399 -1 59E+00 -1 41 E+00 1 Unchanged Low
P48788 E22cd2 troponin I; skeletal; fast 121 3602 110 110 9357 114 1376 -1 30E-01 -1 40E-01 1 Unchanged Low
Q01968 N06ab7 oculocerebroreπal syndrome of L 1690079 959 110 9507 125 3025 -607E-01 -8 17E-01 1 Unchanged Low
Q9H6Z6 L11gh7 hypothetical protein FLJ21628 115 1548 126 111 0337 117 2667 -526E-02 1 25E-01 1 Unchanged Low
Q9NQ55 B01gh4 peter pan homolog (Drosophila) 122449 120 111 0627 117.676 -1 41 E-01 -3 50E-02 1 Unchanged Low
095359 A24gh1 transforming, acidic coiled-coil cc 1082194 139 111 0999 1194624 379E-02 362E-01 1 Unchanged Low
P01189 I15ab8 proopiomelanocortin (adrenocort 1450634 904 111 1389 115 5442 -3 84E-01 -682E-01 1 Unchanged Low
Q9Y525 G13cd8 v-maf musculoapoπeurotic fibros 119023 141 111 1934 123 6546 -982E-02 242E-01 1 Unchanged Low
Q9UHC9 L09cd8 NPC1 (Niemann-Pick disease, ty 1077403 138 111 3741 118 9021 479E-02 3 53E-01 1 Unchanged Low
Q9HBT2 P14gh7 hypothetical protein PP1057 1475097 98 111 4385 1189743 -405E-01 -5 gOE-01 1 Unchanged Low
000219 M22ef1 hyaluronan synthase 3 2245087 89 111 4539 141 641 -1 01 E+00 -1 34E+00 1 Unchanged Low
P22735 M16cd1 transglutam ase 1 (K polypeptid 1368808 91 111 5589 113 1407 -295E-01 -580E-01 1 Unchanged Low
015388 A11ab4 sia c acid binding Ig-like lectm 6 1052847 147 111 6016 121 3043 841E-02 4 82E-01 1 Unchanged Low
095389 J01cd4 WNT1 inducible signaling pathw, 1348825 94 111 6123 1134959 -273E-01 -521E-01 1 Unchanged Low
Q06190 D21ab8 protein phosphatase 2 (formerly 1346973 102 111 8192 1162494 -269E-01 -398E-01 1 Unchanged Low
P50226 C03cd3 sulfotransferase family, cytosolic 147 6874 101 111 8328 1200792 -401 E-01 -552E-01 1 Unchanged Low
Q16632 N10ab5 general transcπption factor IIIC, | 1207982 116 111 85 116 1383 -1 1 E-01 -6 14E-02 1 Unchanged Low
P54762 A24ef7 EphB1 1073397 168 111 8669 1291191 596E-02 648E-01 Unchanged Low
Q15269 E15cd1 PWP2 periodic tryptophan protei 1250688 107 111 8713 114 654 -1 61 E-01 -225E-01 1 Unchanged Low
014495 H10cd3 phosphatidic acid phosphatase t< 120761 109 111 9087 1139808 -1 10E-01 -1 44E-01 1 Unchanged Low
Q9P0U0 N24ef3 PC326 protein 1525639 101 111 9543 121 9267 -447E-01 -591 E-01 1 Unchanged Low
P50120 J02abβ retinol binding protein 2, cellular 231 806 217 111 9639 187 0028 -1 05E+00 -936E-02 1 Unchanged Low
Q9UHR0 D08gh1 G protein-coupled receptor klnas 111 83 151 111 9778 124 9147 1 91E-03 433E-01 1 Unchanged Low
Q13977 A12ef1 cerebellar degeneration-related | 1052052 180 1120477 1324319 909E-02 775E-01 Unchanged Low
P51692 C18cd8 signal transducer and activator o 1267779 100 1120645 112 9412 -1 78E-01 -343E-01 1 Unchanged Low
P51164 N12ab2 ATPase, H+/K+ exchanging, bete 1364695 112 112 2007 120 3347 -2 82E-01 -281 E-01 1 Unchanged Low
Q9NXH3 C02gh2 protein phosphatase 1, regulator 1133081 127 1122521 117 6836 -1 35E-02 1 70E-01 1 Unchanged Low
C04gh7 ER to nucleus signalling 2 1129203 125 1122701 116 8658 -833E-03 1 51 E-01 Unchanged Low
P16435 G16ef6 P450 (cytochrome) oxidoreducta 1102003 132 112 2899 118 227 271E-02 2 62E-01 Unchanged Low
E05gh6 hypothetical protein MGC5338 1161511 137 1123522 121 7814 -480E-02 236E-01 Unchanged Low
Q02080 L03ab7 MADS box transcπption enhance 1386124 100 1123745 117 0502 -303E-01 -4 69E-01 1 Unchanged Low
Q15334 J06ab7 lethal giant larvae homolog 1 (Dr 1233076 110 1123893 1153049 -1 34E-01 -1 62E-01 1 Unchanged Low
P10636 J13ab7 microtubule-associated protein tj 1158818 142 1124092 12346 -43gE-02 2 94E-01 Unchanged Low
Q9Y4J6 A01gh2 zinc finger protein 6 (CMPX1) 1388767 102 1124376 117 8247 -305E-01 -443E-01 Unchanged Low
Q9UHY7 P18gh4 E-1 enzyme 1089217 134 1125485 1185336 473E-02 300E-01 Unchanged Low
Q14147 K04gh1 DEAD/H (Asp-Glu-Ala-Asp/His) t 1175358 119 1127866 1164348 -595E-02 1 76E-02 Unchanged Low
095880 N06gh4 KIAA1513 protein 1682097 104 112 9115 128 5046 -575E-01 -6 88E-01 Unchanged Low
Q15013 J23ef3 gene predicted from cDNA with a 104 556 198 1130807 138 5918 1 13E-01 9 22E-01 Unchanged Low
Q9P1E2 E01gh4 hypothetical protein PR02219 1386039 107 113 1066 1196869 -2 93E-01 -369E-01 Unchanged Low
P07203 H23ef1 glutathione peroxidase 1 1205127 114 113 1788 1158519 -906E-02 -8 ι ε-02 Unchanged Low
Q13206 M07ab5 DEAD/H (Asp-Glu-Ala-Asp/His) t 140 5274 92 5 113 1804 1154153 -3 12E-01 -603E-01 Unchanged Low
015085 L15ef3 Rho guanine nucleotide exchaπg 121 8405 111 1132492 115 3055 -1 05E-01 -1 37E-01 Unchanged Low
P43426 C07cd1 phosphatιdylιπosιtol-4-phosphate 2329191 163 1132533 1696778 -1 04E+00 -5 16E-01 Unchanged Low
Q9NRQ2 K20gh4 phospholipid scramblase 4 1262397 116 1132849 1184782 -1 56E-01 -1 23E-01 Unchanged Low
043171 B24cd3 CDC14 cell division cycle 14 hon 126784 113 113382 117 8862 -1 61 E-01 -1 60E-01 Unchanged Low
Q9HB90 M02gh5 Rag C protein 1329037 136 1134299 127 5658 -229E-01 371E-02 Unchanged Low
Q9H733 I21gh5 single lg IL-1R-related molecule 1135449 137 1134753 121 334 -8 84E-04 2 71 E-01 Unchanged Low
P43353 C06ab2 aldehyde dehydrogenase 3 famil 141 7651 101 113 5244 118734 -321 E-01 -4 90E-01 Unchanged Low
Q15053 G14gh1 KIAA0040 gene product 111 1705 146 1135775 123 496 309E-02 391 E-01 Unchanged Low
P22301 H01ef7 interleukin 10 174 8595 108 1135877 132021 -622E-01 -700E-01 Unchanged Low
Q9BW47 N12gh5 chromosome 20 open reading frs 1258289 154 1136231 131 1841 -1 47E-01 2 92E-01 Unchanged Low
P21917 M03ab6 dopamine receptor D4 1586974 151 1137899 141 2355 -4 80E-01 -6 96E-02 Unchanged Low
Q9Y6K5 M19cd1 2'-5'-olιgoadenylate synthetase 3 1272648 142 1139993 1276931 -1 59E-01 1 56E-01 Unchanged Low
Q9Y2A4 N22cd5 Kruppel-type zinc finger (C2H2) 1360849 133 114 1396 127 5854 -254E-01 -3 82E-02 Unchanged Low
Q16880 A16cd3 UDP glycosyltransferase 8 (UDP 112 9309 133 114 1612 1 i 407 1 56E-02 2 33E-01 Unchanged Low
095747 D09cd5 oxidative-stress responsive 1 11339 123 1142384 1167318 1 08E-02 1 12E-01 Unchanged Low
P25106 L12ef4 G protein-coupled receptor 1007123 147 1142482 120 5368 1 82E-01 542E-01 Unchanged Low
H23ab6 immunoglobuliπ superfamily, mei 1026971 145 114 3219 1206924 1 55E-01 4 98E-01 Unchanged Low
P45984 L18ef5 mitogen-activated protein kinase 1394168 88 1143405 113 914 -286E-01 -664E-01 Unchanged Low
Q9NPF7 I03ef3 interleukin 23, alpha subunit p19 9883593 182 114 4153 131 5891 2 11E-01 877E-01 Unchanged Low
Q9UH94 L07cd8 prolactin regulatory element bind 1404102 106 1144158 120 3231 -295E-01 -4 04E-01 Unchanged Low
Q16559 F05cd2 T-cell acute lymphocytio leukemi, 131 4974 111 114 5482 1189991 -1 99E-01 -2 45E-01 Unchanged Low
Q9UGH0 C02cd8 solute carrier family 17 (anion/su 9873308 158 114 6616 123 6748 2 16E-01 675E-01 Unchanged Low
Q15544 J13cd2 TAF11 RNA polymerase II, TAT/ι 1174634 123 1146792 118 4317 -346E-02 6 82E-02 Unchanged Low
000628 N24ab7 peroxisomal biogenesis factor 7 15616 969 1147281 122588 -445E-01 -689E-01 Unchanged Low
043241 F07ab5 golgi autoantigen, golgin subfam 1239421 104 114 8381 114 422 -1 10E-01 -2 46E-01 Unchanged Low
Q9Y6N1 M14ab4 COX11 homolog, cytochrome o c 127 1203 100 1148993 114 0678 -1 46E-01 -344E-01 Unchanged Low
Q9UHX5 O01ef4 HT002 protein, hypertension-relε 9826523 155 1149242 122 8348 226E-01 6 60E-01 Unchanged Low
Q01664 A02cd2 transcπption factor AP-4 (activati 268 3453 667 1150377 150 0321 -1 22E+00 -201 E+00 Unchanged Low
Q9BUI1 O03gh6 leukocyte receptor cluster (LRC) 1122417 125 115039 1173611 355E-02 1 53E-01 1 Unchanged Low
Q9HBL5 M17gh4 AD023 protein 1039999 137 1150443 1185457 1 46E-01 393E-01 Unchanged Low
Q9NXV2 N08gh2 hypothetical protein FLJ20040 126 6647 147 115 1386 1296462 -1 38E-01 2 16E-01 Unchanged Low
Q15424 D08cd1 scaffold attachment factor B 1349613 927 115 1845 1142781 -229E-01 -5 42E-01 Unchanged Low
P26440 F06ab6 isovaleryl Coenzyme A dehydrog 1787093 115 1152412 136 2534 -633E-01 -638E-01 1 Unchanged Low
060264 J11cd3 S I/SNF related, matrix associa 1057775 132 1152498 1177402 1 24E-01 3 22E-01 1 Unchanged Low
Q15286 K07cd7 RAB35 member RAS oncogene 1382766 183 1153443 145 6 -262E-01 4 06E-01 1 Unchanged Low
Q9UGK0 I10ef4 DIPB protein 3032745 172 1154096 ig67868 -1 39E+00 -821 E-01 Unchanged Low
Q92980 J06cd5 putative protein similar to nessy I 142039 181 1154166 146 2003 -300E-01 3 50E-01 1 Unchanged Low
Q99726 M06cd3 solute earner family 30 (zinc tran 112 8008 121 1154854 1163247 339E-02 975E-02 1 Unchanged Low
P01111 017ab8 neur oblastoma RAS viral (v-ras) 1236283 108 115 5932 115 8629 -970E-02 -1 90E-01 1 Unchanged Low
Q92574 G13cd3 tuberous sclerosis 1 109 8519 128 1157107 117 8303 7 50E-02 220E-01 1 Unchanged Low P16106 C01gh7 H3 histone family, member I 134 9364 118 115 868 122 8016 -220E-01 -1 98E-01 1 Unchanged Low
Q9N X5 024gh2 hypothetical protein FLJ20548 118 1581 112 1159919 115 5043 -267E-02 -7 26E-02 1 Unchanged Low
Q9Y6B7 M05ab3 adaptor-related protein complex 217 8572 170 1160173 168 0108 -9 09E-01 -3 57E-01 1 Unchanged Low
Q9Y4F1 J04cd5 FERM, RhoGEF (ARHGEF) and 108 6215 130 1160342 1180819 952E-02 255E-01 1 Unchanged Low
Q06710 M14cd3 paired box gene 8 120 1357 129 116 1006 121 7641 -493E-02 1 03E-01 1 Unchanged Low
Q9H6N1 J17gh5 hypothetical protein FLJ22056 214 4909 242 1162509 190 8582 -8 84E-01 1 73E-01 1 Unchanged Low
Q9NSY1 K09gh3 homolog of mouse BMP-2 Inducil 111 9034 123 1162514 117 0914 5 50E-02 1 38E-01 1 Unchanged Low
Q14106 H20cd6 transducer of ERBB2, 2 117 9634 134 1162536 1228358 -2 11E-02 1 87E-01 1 Unchanged Low
Q9UK11 B02ef4 zinc finger protein 223 119 1221 133 1162873 1228322 -347E-02 1 60E-01 1 Unchanged Low
P08069 017ef6 insulin -like growth factor 1 recepl 1063434 178 1163103 1334883 1 29E 01 742E-01 1 Unchanged Low
Q9H6F5 I21gh6 hypothetical protein MGC2574 120 5097 112 1163129 116 1638 -5 11E-02 -1 10E-01 1 Unchanged Low
Q14373 O04ab3 galactose-1 -phosphate uπdylyltre 157 7476 231 1163555 1683955 -439E-01 551 E-01 1 Unchanged Low
P20393 G04ef5 nuclear receptor subfamily 1 , gro 107 1138 138 1164228 120 571 1 20E-01 367E-01 1 Unchanged Low
P36915 O01ab5 guanine nucleotide binding prate 1209306 111 1164819 1162706 -541E-02 -1 18E-01 1 Unchanged Low
095109 G02cd8 chromosome 20 open reading frs 143 5728 103 1165321 121 0452 -301 E-01 -479E-01 1 Unchanged Low
Q9NVS2 I24gh3 mitochondnal nbosomal protein 5 117 9573 124 116 6011 1195497 -1 67E-02 7 31E-02 1 Unchanged Low
Q92950 B08cd6 CUG tπplet repeat, RNA binding 109 8876 129 1167366 118 6125 8 72E-02 2 34E 01 1 Unchanged Low
Q14977 C04ab7 SP110 nuclear body protein 1070969 158 1168973 127 3783 1 26E-01 562E-01 1 Unchanged Low
P16106 O04gh6 H3 histone family member A 9476745 159 116 9796 123 5385 304E-01 745E-01 1 Unchanged Low
Q9Y3C1 N18ef2 hypothetical protein HSPC111 145 1935 164 117 0185 141 934 -3 11 E-01 1 72E-01 1 Unchanged Low
P37287 C11ef1 phosphatidylmositol glycan, clas1 132 5354 109 1172467 1194716 -1 77E-01 -2 B7E-01 1 Unchanged Low
Q9UIG5 G05ef4 SEEK1 protein 102 5149 148 117279 122443 1 94E-01 525E-01 1 Unchanged Low
Q9UNE2 G15cd6 rabphl n 3A like (without C2 dorr 110 3023 123 117 2874 117 0111 8 86E-02 1 62E-01 1 Unchanged Low
Q14123 A17cd1 phosphodiesterase 1C, calmodul 121 3078 132 1173754 1235304 -4 75E-02 1 21 E-01 1 Unchanged Low
Q16206 P03ab2 cytosolic ovaπan carcinoma antic 1165183 157 1174492 130 1671 1 15E-02 426E-01 1 Unchanged Low
Q9NWT1 D21gh2 hypothetical protein FLJ20624 1160517 116 1174816 1164708 1 77E-02 -2 15E-03 1 Unchanged Low
Q12756 C05ab3 axonal transport of synaptic veslc 1384398 232 1175489 162 7767 -236E-01 747E-01 1 Unchanged Low
P28288 B10ab8 ATP-bindmg cassette sub-family 1404464 959 1175959 117 9674 -2 56E-01 -551 E-01 1 Unchanged Low
P05198 G08ab5 eukaryotic translation initiation fa 115 5074 119 1176033 1172266 2 59E-02 377E-02 1 Unchanged Low
Q9H0V9 D08gh7 hypothetical protein DKFZp564L 128832 101 117 6689 115 9248 -1 31 E-01 -347E-01 1 Unchanged Low
Q92984 M10ef1 mterferon-induced protein 35 2580737 221 117 8182 198 97gg -1 13E+00 -223E-01 1 Unchanged Low
095498 A13cd5 vaπin 2 1097731 123 117 8273 1168572 1 02E-01 1 64E-01 1 Unchanged Low
Q9H1E1 J01gh8 nbonuclease 7 109332 131 117 8377 1194295 1 08E-01 262E-01 1 Unchanged Low
Q9NV88 H01gh3 hypothetical protein FLJ10871 1085849 125 117 8411 117 172 1 18E-01 204E-01 1 Unchanged Low
Q9Y310 F06cd6 SπRNP assembly defective 1 hoi 1ig g305 113 1178563 117 0556 -2 52E-02 -8 10E-02 1 Unchanged Low
P48382 O06cd1 regulatory factor X, 5 (influences 191 5142 122 1180773 1439771 -6 98E-01 -647E-01 1 Unchanged Low
P52738 K04cd3 zinc finger protein 140 (clone pH 136 6586 154 118 1501 1362205 -2 10E-01 1 71 E-01 1 Unchanged Low
Q9NRW1 G23ef3 RAB6B, member RAS oncogene 100 578 179 118 1659 132 4668 232E-01 829E-01 1 Unchanged Low
015298 A02ab3 basic leucme zipper nuclear facti 2669887 110 1182062 165 1797 -1 18E+00 -1 27E+00 1 Unchanged Low
Q9NUN5 D14gh3 hypothetical protein FLJ11240 114 5392 116 1182691 116 1573 4 62E-02 1 41E-02 1 Unchanged Low
Q07699 L03cd1 sodium channel, voltage-gated, t 1165431 113 1183239 1158757 2 19E-02 -476E-02 1 Unchanged Low
P27701 F10ab6 kangal 1 (suppression of tumoπg 1162761 108 1183881 114 2624 2 60E-02 -1 05E-01 1 Unchanged Low
Q9UER5 O02ef3 TNF- duced protein 104 9755 131 1184653 1182694 1 74E-01 324E-01 1 Unchanged Low
Q8TAC6 124gh7 chromosome 11 open reading frs 1174257 138 1185887 124 5089 1 42E-02 228E-01 1 Unchanged Low
Q9NRW9 K16gh4 angiotensin II, type I receptor-as' 1366357 105 1186777 120 1901 -203E 01 -376E-01 1 Unchanged Low
Og5147 015cd7 dual specificity phosphatase 14 181 9968 200 1187007 166 9415 -6 17E-01 1 37E-01 1 Unchanged Low
Q13895 Aigef7 bystin-like 1080232 124 1187967 1169004 1 37E-01 1 98E-01 1 Unchanged Low
P31645 N03ef5 solute earner family 6 (neurotran 114 6464 189 1188487 1407231 5 19E-02 7 19E-01 1 Unchanged Low
P51511 N17ef7 matrix metalloproteinase 15 ( er 122 9018 125 118 8609 122 1739 -482E-02 2 16E-02 1 Unchanged Low
Q15154 011cd1 peπcentπolar mateπal 1 1278378 139 118 8759 1287076 -1 05E-01 1 25E-01 1 Unchanged Low
Q00007 E17ef6 protein phosphatase 2 (formerly 108364 123 1189838 1167703 1 35E-01 1 82E-01 1 Unchanged Low
P55822 L08cd2 SH3 domain binding glutamic ad 131 7189 133 1190263 1280275 -1 46E-01 1 76E-02 1 Unchanged Low
Q14442 L20ab8 phosphatidylmositol glycan das' 121 0635 114 1190306 1180476 -244E-02 -861E-02 1 Unchanged Low
P54792 L04ab4 dishevelled, dsh homolog 1 (Dro' 126677 113 119067 1194338 -894E-02 -1 70E-01 1 Unchanged Low
P42336 A03ef6 phosphoιnosιtιde-3 kinase, catal' 101 0905 143 119 1581 121 01 237E-01 4 gβE-01 1 Unchanged Low
Q9UMQ3 G15ab3 BarH-like homeobox 2 995713 179 119 1741 1326879 259E-01 849E-01 1 Unchanged Low
Q9UPY5 M04ef3 solute carrier family 7, (cationic ε 1739407 695 1193079 1209226 -544E-01 -1 32E+00 1 Unchanged Low
P19113 H01ef6 histidine decarboxylase 111 9277 119 1193155 1166743 922E-02 8 57E-02 1 Unchanged Low
095394 B16ef3 N-acetylglucosamine-phosphate 124 8164 112 1193184 1188198 -6 50E-02 -1 52E 01 1 Unchanged Low
P22557 A14ab2 aminolevulinate delta-, synthase 202 1170 129 1193857 1502281 -7 60E-01 -646E-01 1 Unchanged Low
Q9Y3A2 G10ef2 CGI-94 protein 1087497 167 1194751 131 6512 1 36E-01 6 16E 01 1 Unchanged Low
Q9H5J4 I05gh6 long-chain fatty-acyl elongase 1350119 87 119 5181 1138461 -1 76E-01 634E-01 1 Unchanged Low
P16083 E15ab8 NAD(P)H dehydrogenase, quinoi 1547986 98 6 195724 1243296 -373E-01 -650E-01 1 Unchanged Low
Q99819 D02ab2 Rho GDP dissociation inhibitor (( 1257962 106 1195853 1172457 -7 30E-02 -242E-01 1 Unchanged Low
075569 F06cd3 protein kinase, interferan-lnducib 1003086 137 1196257 118 9057 254E-01 447E-01 1 Unchanged Low
015038 F12ef7 seππe/ar ginine repetitive matrix ; 125 19 966 119719 1138294 -645E-02 -374E-01 1 Unchanged Low
Q9HBH5 K09gh4 PAN2 protein 102 0601 139 1197321 1203437 230E-01 448E-01 1 Unchanged Low
P41231 C22ab8 punnergic receptor P2Y, G-prote 131 9219 130 1198105 1273275 -1 39E-01 -1 84E-02 1 Unchanged Low
015397 D01cd6 RAN binding protein 8 1146925 118 119 9197 117 4304 643E-02 371E-02 1 Unchanged Low
Q9UDY8 C17cd7 mucosa associated lymphoid tiss 1144769 120 1199403 118 129 673E-02 676E-02 1 Unchanged Low
095819 E22cd5 mitogen-activated protein kinase 9242403 156 119956 122 7769 376E-01 755E 01 1 Unchanged Low
Q12999 J01ef5 sarcoma amplified sequence 1149397 110 119 9579 114 8641 6 17E-02 -674E-02 1 Unchanged Low
P25440 D07cd2 bromodomain containing 2 1166707 108 120 0152 1147701 408E-02 -1 16E-01 1 Unchanged Low
P20827 H21ef7 ephπn-A1 2980458 760 120 3333 392 8203 -1 31 E+00 1 35E+00 1 Unchanged Low
Q9H652 P20gh8 hypothetical protein MGC4171 1295733 107 1204428 118 9065 -1 05E-01 -2 80E-01 1 Unchanged Low
P31483 L20ef4 TIA1 cytotoxic granule-associate 1054425 129 120 5386 1182227 1 93E-01 287E-01 1 Unchanged Low
Q9BSM8 G15gh8 hypothetical protein MGC10812 1482279 273 120 573 180 6391 -2 g8E-01 882E-01 1 Unchanged Low
P36897 F04ef5 transforming growth factor, beta i 1157567 108 1206724 114 8546 600E-02 -9 83E-02 1 Unchanged Low
Q9UMR9 E08ef3 YMEMike 1 (S cerevisiae) 2560314 197 1207227 191 0958 -1 08E+00 -382E-01 1 Unchanged Low
Q92560 G11ab3 BRCA1 associated proteιn-1 (ubi 101 36 161 1207575 127 8687 253E-01 672E-01 1 Unchanged Low
Q9NWU1 D05gh2 hypothetical protein FLJ20604 9976081 154 1207609 124 8325 276E-01 626E-01 1 Unchanged Low
Q92696 N14ab8 Rab geraπylgeranyltransferase e 2227157 272 120 7706 205 3234 -883E-01 291 E-01 1 Unchanged Low
095236 M24ef3 apolipoprotem L, 3 106592 130 120 798 119 1528 1 80E-01 2 87E-01 1 Unchanged Low
Q13202 E21ab5 dual specificity phosphatase 8 1463963 129 1207987 131 9045 -277E-01 -1 88E-01 1 Unchanged Low
P11277 M02cd1 spectπn, beta, erythrocytic (iπclu 11272 114 1208055 1160084 999E-02 226E-02 1 Unchanged Low
095397 P18ef1 putative glycolipid transfer protei 9978536 143 120 8708 121 1071 277E-01 5 16E-01 1 Unchanged Low P05423 A20ab3 BN51 (BHK21) temperature sens 1318122 955 1200201 1160734 -1 24E-01 -465E-01 1 Unchanged Low
Q14338 I17ab6 fucosyltraπsferase 2 (secretor st< 9971915 181 120 g483 133 9938 278E-01 863E-01 1 Unchanged Low
Q9BYI8 A22gh8 AIE-75 binding protein protein 9011911 164 1210200 125 1864 4 25E-01 867E-01 1 Unchanged Low
Q06203 D01ab8 phosphonbosyl pyrophosphate a 2163154 105 121029 147 3953 -838E-01 ■1 04E+00 1 Unchanged Low
Q9NZ33 P10gh4 brain expressed, X-llnked 1 1138613 162 1210508 1324428 8 83E-02 5 12E-01 1 Unchanged Low
P04196 O10ab6 hlstldiπe-nch glycoproteln 1161305 116 1211163 117 5882 606E-02 -763E-03 1 Unchanged Low
096029 F03cd7 oplold growth factor receptor 2013579 935 1212888 1387174 -7 31 E-01 •1 11 E+00 1 Unchanged Low
Q01196 H6ab5 runt-related transcπption factor 1 4411217 136 1213316 2329078 -1 86E+00 •1 69E+00 1 Unchanged Low
Q9UHL4 J17cd8 dipeptidylpeptidase 7 1803445 191 121351 164207 -572E-01 823E-02 1 Unchanged Low
P55211 P16ab3 caspase 9, apoptosls-related cys 1135416 111 1213742 1153899 962E-02 -294E-02 1 Unchanged Low
P21283 A07ab3 ATPase, H+ transporting, lysosoi 2886034 288 1213828 232 7446 -1 25E+00 -1 78E-03 1 Unchanged Low
043422 P02ab8 proteiπ-kinase, iπterferoπ-iπduαb 1318635 100 121394 117 7416 -1 19E-01 -4 00E-01 1 Unchanged Low
P78406 L01cd3 RAE1 RNA export 1 homolog (S 1471192 971 1214625 121 9098 -2 76E-01 -599E-01 1 Unchanged Low
P43362 J18ab7 melanoma antigen, family A, 9 9905783 139 1215326 11997 295E-01 4 92E-01 1 Unchanged Low
Q9H693 E12gh6 hypothetical protein FLJ22477 1717699 964 1216097 1299396 -4 98E-01 -833E-01 1 Unchanged Low
QgUJ83 A11cd8 2-hydroxyphytanoyl-CoA lyase 9945467 141 1216399 120 5495 291E-01 4 99E-01 1 Unchanged Low
Q05048 H5ab4 cleavage stimulation factor, 3' pn 124.1609 105 1216764 117 088 -2 92E-02 -236E-01 1 Unchanged Low
Pig784 D11ab4 casein kinase 2, alpha prime pol' 9468573 152 1217819 1226579 363E-01 678E-01 1 Unchanged Low
Q9BUX8 D06gh6 homolog of yeast πbosome bioge 1674752 178 1218214 1556701 -459E-01 856E-02 1 Unchanged Low
Q9Y5P6 D23cd8 GDP-maππose pyrophosphorylas 1664572 894 1218219 1258828 -4 50E-01 -897E-01 1 Unchanged Low
Q9Y3E1 F16ef1 hepatoma-derived growth factor 9700713 148 1219163 122 172 330E-01 605E-01 1 Unchanged Low
P40426 O07cd1 pre-B-cell leukemia transcnption 1226888 948 1219253 113 1427 -901E-03 -372E-01 1 Unchanged Low
P11217 K01cd1 phosphorylase, glycogen, muscle 3148041 110 122008 182286 -1 37E+00 -1 52E+00 1 Unchanged Low
Q16563 D18cd2 synaptophysm-like protein 9762823 144 1220944 121 3173 323E-01 563E-01 1 Unchanged Low
095698 L07ab6 inhibitor of growth family, membe 1022388 135 1221358 1196732 2 57E-01 397E-01 1 Unchanged Low
P19447 K24ef6 excision repair cross-complemen 95411eg 148 1221425 121 7269 356E-01 6 30E-01 1 Unchanged Low
Q9UK39 D08cd7 CCR4 carbon catabolite repressi 1738761 262 1221589 1858825 -509E-01 589E-01 1 Unchanged Low
Q15785 E23cd7 translocase of outer mitochondπ. 2968521 144 1221776 1876861 -1 28E+00 -1 04E+00 1 Unchanged Low
Q9g571 C14ab8 puππergic receptor P2X, ligand-c 4181812 410 1223053 3167241 -1 77E+00 -2 96E-02 1 Unchanged Low
Q9BTY2 E24gh8 hypothetical protein MGC1314 si 1319449 915 1223524 115 258 -1 09E-01 -528E-01 1 Unchanged Low
Q9P0P1 D12ef1 hypothetical protein FLJ10769 1479172 191 1224861 153 8845 -2 72E-01 371 E-01 1 Unchanged Low
Q9Y324 P01ef1 CGI-35 protein 1291118 97 1225531 11620g3 -7 52E-02 -4 13E-01 1 Unchanged Low
P37286 017cd3 ubiquitin-conjugatmg enzyme E2 9888763 165 1225669 1287921 3 10E-01 738E-01 1 Unchanged Low
Q00577 O07ef5 puπne-πch element binding prate 1160341 123 1225705 120 658 iE-02 8 84E-02 1 Unchanged Low
075152 L21gh1 KIAA0663 gene product 1014464 140 1225789 12 2139 273E-01 4 61 E-01 1 Unchanged Low
P23610 H06cd7 coagulation factor Vlll-associatei 164911 103 1225902 1303149 -428E-01 -673E-01 1 Unchanged Low
075436 M20cd5 vacuolar protein sorting 26 (yeas 1181135 108 1226522 1162363 544E-02 -1 30E-01 1 Unchanged Low
QgHA40 B23gh5 hypothetical protein FLJ12287 si 1046286 126 122666 1178494 229E-01 271 E-01 1 Unchanged Low
Q9NX62 I20gh2 hypothetical protein FLJ20421 1037764 136 122701 1207522 242E-01 3 88E-01 1 Unchanged Low
076062 E04cd2 transmembrane 7 superfamily me 3011903 215 1227645 2128749 -129E+00 -4 B9E-01 1 Unchanged Low
Q16445 H02ab3 gamma-a iπobutyπc acid (GAB i 150641 875 1227829 1203177 -295E-01 -7 83E-01 1 Unchanged Low
Q08462 G11ef6 adenylate cyclase 2 (brain) 107541 146 1228502 1253933 192E-01 439E-01 1 Unchanged Low
P78560 A22ef6 CASP2 and RIPK1 domain conta 1084508 153 1228627 1281152 180E-01 4 g7E-01 1 Unchanged Low
P19634 N17ef5 solute earner family 9 (sodium/hy 1189969 99 122898 1136214 465E-02 -266E-01 1 Unchanged Low
P28370 N12cd1 S I/SNF related, matrix associa 115471 106 1229184 1149572 902E-02 -1 17E-01 1 Unchanged Low
Q92503 H06cd1 SEC14-lιke 1 (S cerevisiae) 1515939 151 1229424 1419225 -302E-01 -346E-03 1 Unchanged Low
Q9UL02 H24ef1 L-kynurenine/alpha-ammoadipati 1056951 124 1230487 1174294 219E-01 225E-01 1 Unchanged Low
Q9Y5T5 J13cd6 ubiquitin specific protease 16 1171056 120 1230646 1200007 716E-02 332E-02 1 Unchanged Low
G03gh8 protocadheπn 15 1530978 126 1231548 1341729 -314E-01 -278E-01 1 Unchanged Low
P15848 H02ab2 arylsulfatase B 1494791 956 1231651 1227499 -279E-01 -645E-01 1 Unchanged Low
Q9UP66 P24ab6 low density lipoprotein receptor-r 1142435 124 1232083 1204437 109E-01 1 17E-01 1 Unchanged Low
075160 P07gh1 KIAA0672 gene product 1219398 117 1232554 1208501 155E-02 -553E-02 1 Unchanged Low
P78385 L14ab6 keratin, hair, basic, 3 100703 135 1232569 1196793 292E-01 424E-01 1 Unchanged Low
094967 B21ef8 KIAA0893 protein 9215324 158 1232707 1246247 420E-01 7 82E-01 1 Unchanged Low
0957i K01cd5 xenotropio and polytropic retrovir 1080877 122 1233497 1177043 191E-01 1 71 E-01 1 Unchanged Low
P48147 F09ab8 pralyl endopeptidase 1300641 129 1233564 1276048 -764E-02 -745E-03 1 Unchanged Low
P20231 B15gh7 tryptase beta 2 1066865 130 1234905 119g323 211E-01 281 E-01 1 Unchanged Low
095299 G02ab7 NADH dehydrogenase (ubiqumoi 107385 129 1235991 1198634 203E-01 260E-01 1 Unchanged Low
075033 I18gh1 KIAA0445 gene product 1215196 122 123624 1224835 248E-02 032E-03 1 Unchanged Low
P51668 D03cd4 ubiquitin-conjugatmg enzyme E2 9984401 137 123637 1203 308E-01 461 E-01 1 Unchanged Low
P28289 E08cd2 tropomodulin 303877 272 1236484 2330271 -130E+00 -1 62E-01 1 Unchanged Low
Q15631 012ef6 translin 173134 152 1236887 1495989 -485E-01 -1 88E-01 1 Unchanged Low
P49888 F03cd2 sulfotransferase, estrogen-prefer 1222586 951 1237564 1136937 1 76E-02 -363E-01 1 Unchanged Low
P51959 012ef5 cyclin G1 1166841 102 1237661 114 0387 8 50E-02 -1 99E-01 1 Unchanged Low
Q9Y5V0 J16ef1 HSPC038 protein 1140123 179 1237928 1390584 1 19E-01 654E-01 1 Unchanged Low
P56270 H2ef1 MYC-associated zinc finger prate 2483395 140 1238618 1707774 -1 OOE+00 -826E-01 1 Unchanged Low
Q9HD23 011gh4 MRS2-lιke, magnesium homeost, 1408864 117 1238621 127 1502 -1 86E-01 -272E-01 1 Unchanged Low
P78358 O03ab6 cancer/testis antigen 1 2179167 137 1239307 159681 -8 14E-01 -668E-01 1 Unchanged Low
000327 D24ab2 aryl hydrocarbon receptor nudes 1182008 185 12396 8 142 5298 6 87E-02 6 50E-01 1 Unchanged Low
Q9H969 F08gh5 hypothetical protein FLJ12969 8923821 177 1240248 130 1172 475E-01 989E-01 1 Unchanged Low
015504 F01cd7 nucleoponn-like protein 1 2004449 124 1242046 149 5876 -690E-01 -6 92E-01 1 Unchanged Low
P35250 I24ef6 replication factor C (activator 1 ) . 1113418 112 1243534 1159922 1 59E-01 1 21E-02 1 Unchanged Low
Q9BXC0 F17gh8 G protein-coupled receptor 81 1044833 128 1243568 118786 251 E-01 287E-01 1 Unchanged Low
015232 A19ef1 matπlin 3 1131634 110 1244317 1158185 1 37E-01 -427E-02 1 Unchanged Low
076049 L19cd5 spectπn SH3 domain binding pro 1719625 299 1245037 ig86303 -4 66E-01 800E-01 1 Unchanged Low
Q14145 C21cd8 Kelch-like ECH-associated protei 1939671 120 1245928 146 2645 -6 30E-01 -6 90E-01 1 Unchanged Low
P20848 A10cd1 senne (or cysteine) protemase in 9777909 161 1246004 127 9292 350E-01 7 23E-01 1 Unchanged Low
Q9P0N6 C19ef3 hypothetical protein HSPC242 1120065 109 1246034 115304 1 54E-01 -353E-02 1 Unchanged Low
P05188 E12ab2 alkaline phosphatase, placental ( 8850098 164 1246125 125869 494E-01 894E-01 1 Unchanged Low
Q9UBJ4 A01gh5 transposon-denved Busterl tran' 1310923 973 1247023 117 605 -721E-02 -430E-01 1 Unchanged Low
Q13876 I24ef7 quiescln Q6 1443305 109 1247205 1259829 -2 11 E-01 -4 06E-01 1 Unchanged Low
QgUBF2 F12cd7 coatomer protein complex, subur 1101673 115 1249117 116 849 1 81 E-01 678E-02 1 Unchanged Low
P43026 I23cd3 growth differentiation factor 5 (ca 1019864 152 1249218 1263658 293E-01 577E-01 1 Unchanged Low
Q9HD20 E14gh4 CGI-152 protein 1116731 134 1249301 1236472 1 62E-01 267E-01 1 Unchanged Low
Qg6KK6 P04ab8 RAB2, member RAS oncogene ft 1198171 106 1249467 1168445 6 05E-02 -1 80E-01 1 Unchanged Low
P40617 D18ab2 ADP-πbosylation factor-like 4 1241402 143 1250573 1307449 1 06E-02 204E-01 1 Unchanged Low 075651 L12gh2 unc-93 homolog A (C elegans) 131 989 128 1250667 128 2583 -777E-02 -474E-02 1 Unchanged Low
Q9Y2S1 L04ef1 galanin-related peptide 1356724 134 125067 131 4839 -1 17E-01 -2 10E-02 1 Unchanged Low
Q13330 M20ef5 metastasis associated 1 104 9962 118 125 1131 1160949 2 53E-01 1 71 E-01 1 Unchanged Low
Q9Y389 L22gh4 aminoadipate-semialdehyde deh 115 3352 104 125222 1147055 1 19E-01 -1 55E-01 1 Unchanged Low
060513 I03gh1 UDP-Gal betaGlcNAc beta 1 ,4- c 113705 106 1252504 1150129 1 40E-01 -1 00E-01 1 Unchanged Low
000212 C15ef6 ras homolog gene family, membe 407 7018 492 125 2682 341 5178 - -1 70E+00 2 70E-01 1 Unchanged Low
Q9NXE1 J04gh2 membrane-associated nucleic ac 9625484 146 125 3861 1224125 3 81 E-01 597E-01 1 Unchanged Low
095405 A16cd5 MAD, mothers against decapente 113 9303 223 1253908 154 2554 1 38E-01 972E-01 1 Unchanged Low
P01112 K12ab7 v-Ha-ras Harvey rat sarcoma virs 1297326 104 125 3947 1196125 -4 91 E 02 -323E-01 1 Unchanged Low
015120 F11cd6 1-acylglycerol-3-phosphate O-ac 264 2959 238 1254039 2093705 ■ •1 08E+00 -1 49E-01 1 Unchanged Low
P12645 N10ab3 bone morphogenetic protein 3 (o 107 6548 117 1254244 1166372 220E-01 1 18E-01 1 Unchanged Low
P50579 I01cd7 methioπyl ammopeptidase 2 144 5853 95 1 1254613 121 7158 -2 05E-01 -604E 01 1 Unchanged Low
014908 K01cd6 regulator of G-protein signalling 204527 200 125 5241 1766683 -7 04E 01 -3 26E-02 1 Unchanged Low
Q9HCC6 I17gh4 bHLH factor Hes4 8207855 213 125 5621 140 2118 6 13E-01 1 38E+00 1 Unchanged Low
Q15737 E23gh1 suppressor of Ty 6 homolog (S c 112 2771 140 1255917 125 8246 1 62E-01 3 14E-01 1 Unchanged Low
Q9Y519 A17cd8 chromosome 22 open reading frs 100 4037 131 1256586 119 1056 324E-01 3 87E-01 1 Unchanged Low
Q9Y5J0 J01ef2 mitochondπal nbosomal protein t 1174353 107 1258555 1167g86 999E-02 -1 33E-01 1 Unchanged Low
PS1687 016cd1 sulflte oxidase 1052314 128 125 g497 1195637 2 59E-01 277E-01 1 Unchanged Low
P51178 A13ef6 phospholipase C, delta 1 126 4221 162 1260345 138 0904 -4 43E-03 3 56E-01 1 Unchanged Low
Q9H8J6 H23gh5 NDRG family member 3 121 7115 198 126048 1484765 505E-02 7 00E-01 1 Unchanged Low
095900 B20ef8 hypothetical protein CLONE2492 165 6404 257 1260637 182738 -3 94E-01 631 E-01 1 Unchanged Low
Q9Y6N3 B01cd5 chloride channel, calcium activat 99 89597 135 126 1695 120 3564 3 37E-01 4 35E-01 1 Unchanged Low
007860 C21cd1 peroxisome proliferative activatei 120 1031 112 1262127 1194872 716E-02 -989E-02 1 Unchanged Low
Q9Y333 I07gh4 chromosome 6 open reading frar 109 0761 114 1262563 1164501 2 11E-01 639E-02 1 Unchanged Low
Q9NPD1 L06gh2 G protein-coupled receptor 85 206 0578 285 1262683 2057432 -707E-01 4 67E-01 1 Unchanged Low
Q15928 K06cd3 zinc finger protein 141 (clone pH 101 1559 188 1262732 138 6304 320E 01 8 98E-01 1 Unchanged Low
043826 I04ab4 glucose-6-phosphatase, transpoi 2297084 111 126 3113 1555451 -863E-01 •1 05E+00 1 Unchanged Low
Q9NWL0 J05gh2 hypothetical protein FLJ20758 114 0453 120 1263891 120 1186 1 48E-01 725E-02 1 Unchanged Low
P31629 B04ef6 human immunodeficiency virus tj 1160174 211 1264284 151 1911 1 24E-01 864E 01 1 Unchanged Low
015530 I10ab8 3-phosphoιnosιtιde dependent pi 186 1234 193 12645 168488 -558E 01 5 15E-02 1 Unchanged Low
Q9Y2R5 L21ef4 mitochoπdnal nbosomal protein J 106 3741 136 1264713 122 8701 2 50E 01 352E-01 1 Unchanged Low
Q15208 D01cd7 senne/threonme kinase 38 158 8765 204 126 5253 1632891 -328E-01 3 64E-01 1 Unchanged Low
Q9UET6 J19gh6 FtsJ homolog 1 (E coli) 1025266 120 126 5378 1164386 304E 01 2 30E-01 1 Unchanged Low
Q9H5N0 F15gh5 chromosome 7 open reading frar 102 3349 129 126 5687 119 1911 307E-01 330E-01 1 Unchanged Low
Q9H019 B22gh4 hypothetical protein RP1-317E2C 102 5329 150 1265974 1265367 304E-01 553E-01 1 Unchanged Low
Q9Y673 F05cd8 Alg5, S cerevisiae homolog of 100 2543 131 126 6884 119 1797 338E-01 3 81 E-01 1 Unchanged Low
075690 M08gh7 UHS KerB 121 3598 150 126 7819 132 5659 631E-02 301 E-01 1 Unchanged Low
Q9NUP6 H22gh2 hypothetical protein FLJ11220 95908 144 1268164 122 1684 403E 01 5 84E-01 1 Unchanged Low
Q14296 C03cd7 FAST kinase 122 4924 92 9 126 9021 114 1093 5 10E 02 -3 98E-01 1 Unchanged Low
Q9NW55 B20gh2 hypothetical protein FLJ10307 9473914 141 126 9877 120 8058 423E-01 570E-01 1 Unchanged Low
043639 H01cd3 NCK adaptor protein 2 139 9609 796 127 0293 1155457 -1 40E-01 -8 13E-01 1 Unchanged Low
P17544 L08ab2 activating transcnption factor 7 108 5839 112 127 0848 115 9726 227E-01 479E-02 1 Unchanged Low
075911 M01cd5 short-chain dehydrogenase/redu 1563658 173 127 1125 152 0313 -299E-01 1 43E-01 1 Unchanged Low
Q06430 K15ef3 glucosaminyl (N-acetyl) transfers 9456995 139 127 1541 120315 427E 01 558E-01 1 Unchanged Low
Q13769 D10cd3 chromosome 22 open reading frs 1227812 121 127 1547 1235081 505E-02 -260E-02 1 Unchanged Low
Q9H864 J14gh5 hypothetical protein FLJ11021 si 9758044 142 127 1909 122 387 382E-01 545E-01 1 Unchanged Low
095500 F06cd7 claudin 14 1830294 181 127 2815 163 6478 -524E 01 -1 90E-02 1 Unchanged Low
P14222 P02cd2 perform 1 (pore forming protein) 09 11893 135 127 3674 120 5243 362E-01 447E-01 1 Unchanged Low
Q9Y4C8 B06ef2 KIAA0682 gene product 1054769 146 1273803 1262206 272E-01 4 67E-01 1 Unchanged Low
Q9H3H5 M23ab4 dolichyl-phosphate (UDP-N-acet' 193 8179 108 127 5134 1432265 -604E-01 -8 39E 01 1 Unchanged Low
Q13433 G05cd8 LIV-1 protein, estrogen regulatec 118096 105 127 6623 1167563 1 12E-01 -1 76E-01 1 Unchanged Low
Q00059 O07cd2 transcription factor A, mitochondi 111 4615 131 1276629 1233486 1 96E 01 232E-01 1 Unchanged Low
Q15119 I06abβ pyruvate dehydrogenase kinase, 97 01115 135 127 6675 120 0132 396E-01 4 81 E-01 1 Unchanged Low
043791 F03cd3 speckle-type POZ protein 111 349 114 1277061 117 7111 1 98E 01 349E-02 1 Unchanged Low
Q14206 P10cd5 Down syndrome critical region ge 119 8147 263 127 7164 1702393 921E 02 1 14E+00 1 Unchanged Low
Q92926 N24cd1 SWI/SNF related matπx associa 115 147 105 1277503 116 1179 1 50E-01 -1 27E-01 1 Unchanged Low
Q9P288 G15ef3 BRCA2 and CDKN1 A interacting 148 9477 132 127 8623 136 3262 -220E-01 -1 72E-01 1 Unchanged Low
Q9NZU5 C16ef4 LIM and cysteine-πch domains 1 164 1438 128 1279349 1399549 -360E-01 -361 E-01 1 Unchanged Low
Q13569 013cd2 thymiπe-DNA glycosylase 83 16502 172 127 9545 127 6936 622E-01 1 05E+00 1 Unchanged Low
P48167 D17ef6 glycine receptor beta 109 5501 139 127 9738 1253664 224E-01 339E-01 1 Unchanged Low
Q9NQR1 I02gh4 PR/SET domain containing prate 154 2185 927 1280258 1249651 -269E-01 -735E-01 1 Unchanged Low
043405 B23ab4 coagulation factor C homolog, cc 1030764 121 128 1793 117417 3 14E-01 2 31 E-01 1 Unchanged Low
Q9P028 N24ef2 CCR4-N0T transcnption comple 1040341 133 1282089 121 9053 301 E-01 359E-01 1 Unchanged Low
Q9Y6E8 P04cd7 sirtuin silent mating type informal 109 1684 110 1282444 1156628 232E 01 537E-03 1 Unchanged Low
Q9NV65 H17gh3 hypothetical protein FLJ10901 9233747 188 128 3243 136 3658 475E-01 1 03E+00 1 Unchanged Low
Q9H0R8 M13gh7 GABA(A) receptor-associated pr< 122001 179 1283386 143 1503 720E-02 552E-01 1 Unchanged Low
095817 P02cd4 BCL2-assocιated athanogene 3 107 1752 114 1284319 1165745 2 61E 01 905E-02 1 Unchanged Low
P36956 K10cd2 sterol regulatory element binding 140 2284 109 128 532 125 9988 -1 26E-01 -3 60E-01 1 Unchanged Low
P08236 D05ab3 glucuronidase, beta 1237102 114 1286103 122 0379 560E-02 -1 21 E-01 1 Unchanged Low
Q13425 D12cd2 syntrophm, beta 2 (dystrophm-as 1067241 122 1286723 1192218 270E 01 1 96E-01 1 Unchanged Low
Q14676 E18gh1 KIAA0170 gene product 9341288 145 1287328 1222375 4 63E-01 630E-01 1 Unchanged Low
P16106 012gh6 H3 histone family, member F 98 02235 136 1287695 120 7804 394E-01 4 68E-01 1 Unchanged Low
Q14773 J03ab6 intercellular adhesion molecule 4 101 85 137 128 8098 122427 3 39E-01 424E-01 1 Unchanged Low
014736 N19gh4 putative methyltransfer ase 124 8741 126 1288151 126 6152 448E-02 1 47E 02 1 Unchanged Low
Q9Y2g7 N21cd4 beta-transducm repeat containmj 152 2864 142 128 8641 141 0555 -241 E-01 -1 01 E-01 1 Unchanged Low
Q13585 H16cd4 G protein-coupled receptor 50 121 9424 113 128 8853 121 1757 7 99E-02 -1 14E-01 1 Unchanged Low
060858 L24cd5 ret finger protein 2 110 1643 110 1288939 1162529 227E-01 609E-03 1 Unchanged Low
Q9Y2Z6 E06ef2 CGI-07 protein 9622816 139 1289272 121 3443 422E-01 529E-01 1 Unchanged Low
Q9UG66 P16ef7 hypothetical protein DKFZp586G 3183297 374 128 9795 2737118 -1 30E+00 232E 01 1 Unchanged Low
Q9Y6G5 N17ef2 PTD002 protein 107 7937 141 129 1324 125 8408 261 E-01 3 83E-01 1 Unchanged Low
P98155 E06cd3 very low density lipopratein recej 113 1365 104 129 1355 115483 1 91 E-01 -1 19E-01 1 Unchanged Low
Q9NP50 C07gh5 TERA protein 9463638 199 1292792 140 8474 4 50E-01 1 07E+00 1 Unchanged Low
P28328 C01ab8 peroxisomal membrane protein 3 321 6292 219 1293474 223 2274 -1 31 E+00 -5 56E-01 1 Unchanged Low
Q969T4 M24cd6 ubiquitin-conjugating enzyme E2 117 2071 100 1293512 1156428 1 42E 01 -224E-01 1 Unchanged Low
P19827 D1βab6 inter-alpha (globulin) inhibitor, H 2394455 186 1293613 185 0551 -888E-01 -3 62E-01 1 Unchanged Low
015096 M18ab8 phosphatidylinositol 4 kinase, ca 117 2574 115 1294365 120 4316 1 43E-01 -331E-02 1 Unchanged Low Q9Y5J6 J16cd7 fracture callus 1 homolog (rat) 102357 127 1294503 1194401 339E-01 306E-01 Unchanged Low
Q92889 M24ab4 excision repair cross-complemen 157 5735 97 6 1295255 128238 -283E-01 -6 91 E-01 Unchanged Low
P08697 C07ef1 seπne (or cysteine) proteinase in 138 5253 136 1295425 1348048 -967E-02 -2 29E-02 Unchanged Low
Q9UBX1 A05cd4 cathepsln F 1134065 118 1296557 1204495 1 93E-01 608E-02 Unchanged Low
Q9NPI7 D22ef1 hypothetical protein LOC51315 2405378 171 12976 1804148 -8 90E-01 -4 93E-01 Unchanged Low
P11586 D14ef7 methyleπetetrahydrofolate dehyd 141 2456 106 1298444 1257751 -1 21 E-01 -4 11 E-01 Unchanged Low
096010 J15cd4 LIM domain binding 1 90 9506 155 1298567 125 1912 5 14E-01 7 67E-01 Unchanged Low
Q13188 P13cd2 senne/threoπlπe kinase 3 (STE2I 117 4664 135 1298809 1274091 1 45E-01 1 99E-01 Unchanged Low
Q13845 121 ab3 B-cell CLUIymphoma 7B 1459359 88 3 1299273 121 3g88 -1 68E 01 -7 24E-01 Unchanged Low
Q9Y5W9 D07cd8 sorting nexm 11 1446605 198 1300152 157 7010 -1 54E-01 4 56E-01 1 Unchanged Low
060539 I02cd7 Ras association (RalGDS/AF-6) ι 1268466 102 1300346 1197412 358E-02 -3 10E-01 Unchanged Low
060885 I02ef3 bromodomain-containing 4 1149928 98 1 130 1093 1144111 1 78E-01 -229E-01 Unchanged Low
QgH2B0 016gh5 nucleosome assembly protein 1-1 122 5782 147 130 1112 133 1825 860E-02 2 61 E-01 Unchanged Low
P51582 C24ab8 pyπmidmergic receptor P2Y, G-p 1164263 109 130 158 118649 1 61 E-01 -9 03E-02 Unchanged Low
000585 F08cd1 small inducible cytokine subfamil 168745 216 130 1849 171 5056 -374E-01 353E-01 Unchanged Low
Q15131 B23ef5 cycliπ-depeπdent kinase (CDC2-I 168 6104 108 1302201 1357223 -373E-01 -638E-01 Unchanged Low
075148 FOβcdβ cryptochrome 2 (photolyase-like) 86 14249 172 13027 1295265 597E-01 999E-01 Unchanged Low
Q15691 G17cd8 mlcrotubule-associated protein, F 1737024 168 130 2758 157 4437 -4 15E-01 -4 51E-02 Unchanged Low
Q15779 H21ab8 procollagen (type III) N-endopepl 141 4408 133 1302905 1350227 -1 18E-01 -851E-02 Unchanged Low
Q9UHD2 K14cd8 TANK-binding kinase 1 8231867 172 1302947 128 1679 6 62E-01 1 06E+00 Unchanged Low
Q9NSS3 K15gh3 hypothetical protein DKFZp434E 1075389 115 130 3095 117 5518 2 77E-01 9 44E-02 Unchanged Low
Q13797 101 ef7 integrin, alpha 9 156 9946 85 1304752 124 1726 -267E-01 -884E-01 Unchanged Low
P46531 M10ef5 Notch homolog 1, translocation-s 8601963 164 1304897 1268111 601 E-01 930E-01 Unchanged Low
043262 C01cd6 deleted in lymphocytic leukemia, 7679463 195 1304943 1342594 7 65E-01 1 35E+00 Unchanged Low
Q9Y2H6 K12ef8 KIAA0970 protein 170 8655 128 1305238 1429858 -389E-01 -4 22E-01 Unchanged Low
P25788 J11ab8 proteasome (prosome, macropaii 2586025 285 1305899 2247239 -986E-01 1 40E-01 Unchanged Low
Q9BQS8 D00gh7 FYVE and coiled-coil domain cor 164 6348 207 1306451 1675571 -334E-01 333E-01 Unchanged Low
Q9Y396 J04ef1 elongation of very long chain fatt 1626431 82 2 130 6722 125 1558 -3 16E-01 -9 85E-01 Unchanged Low
Q9P0R7 K06ef2 hypothetical protein LOC51242 1267302 218 130 6804 1585209 443E-02 7 84E-01 Unchanged Low
015269 F17cd6 serine palmitoyltransferase, long 9742808 133 1307429 1203129 424E-01 4 46E-01 Unchanged Low
Q9UFX0 B02ef2 calcium binding atopy-related au 2335089 287 130 8943 217 1357 -835E-01 298E-01 Unchanged Low
Q9H663 F24gh5 likely ortholog of mouse actin rel 98 1679 128 130 9258 119 1698 4 15E-01 3 87E-01 Unchanged Low
075410 P17cd2 transforming, acidic coiled-coil cc 224 1188 133 130 9827 162703 -775E-01 -7 53E-01 Unchanged Low
Q9Y5N5 I14cd8 putative N6-DNA-methyltransfers 99 34841 133 131 0924 121 2285 4 00E-01 4 24E-01 Unchanged Low
QgBQ72 F02gh7 hypothetical protein MGC10471 1063824 115 131 126 1174135 302E-01 1 09E-01 Unchanged Low
Q9Y303 E10ef2 CGI-14 protein 1535787 101 131 2035 1285162 -227E-01 -608E-01 Unchanged Low
Q9P005 A22ef8 HSPC159 protein 341 3083 579 131 3146 3507027 -1 38E+00 7 64E-01 Unchanged Low
Q9Y3A1 H19ef2 DKFZP566O084 protein 200 4927 262 131 514 198 1031 608E-01 388E-01 Unchanged Low
Q15172 C12cd1 protein phosphatase 2, regulator 1683914 140 131 5524 146553 -3 56E 01 -2 69E-01 Unchanged Low
Q9BV19 I19gh6 hypothetical protein MGC955 9647316 141 131 6188 1228739 448E-01 543E-01 Unchanged Low
Q14534 E11cd2 squalene epoxidase 1555799 71 3 131 8107 119574 -239E 01 -1 13E+00 Unchanged Low
Q9BS43 G19gh8 hypothetical protein MGC12435 592 1694 121 131 9022 281 8569 -2 17E+00 -229E+00 Unchanged Low
P49788 D24ab8 retinoic acid receptor responder i 97 19637 135 131 9355 121 3412 441E 01 473E-01 Unchanged Low
Q9UP83 M10cd6 component of oligomenc golgi ce 100 2446 141 131 936 1243058 396E-01 4 89E-01 Unchanged Low
Q9Y2X0 N11cd5 thyroid hormone receptor-associ. 116 8982 97 9 131 9541 1155741 1 75E-01 -256E-01 Unchanged Low
Q9Y3E3 I15ef2 CGI-145 protein 9476733 132 131 9919 1195355 478E-01 476E-01 Unchanged Low
095183 J14cd6 vesicle-associated membrane pn 91 19765 157 1320539 1266473 534E-01 7 81 E-01 Unchanged Low
Q13242 N22cd3 splicing factor, arginme/seππe-πc 1560624 141 1320637 1430016 -241 E-01 -1 48E-01 Unchanged Low
Q9Y5R5 A06gh1 doublesex and mab-3 related trai 100 8446 162 132 1528 131 5571 3 90E 01 6 81 E-01 Unchanged Low
P04181 N02ab7 ornithlne aminotransferase (gyra 1123954 106 132 1687 116724 2 34E-01 -8 99E-02 Unchanged Low
Q14254 B15ab4 flotillin 2 130 1586 154 1322038 1386301 225E-02 238E-01 Unchanged Low
Q9Y6E6 P0Bcd7 sirtuin silent mating type informal 9440989 136 1322501 121 0265 4 86E-01 531 E-01 Unchanged Low
Q9H237 D20gh5 porcupine 1482204 258 1322656 1793923 -1 64E-01 7 98E-01 Unchanged Low
Q92785 N21ed2 requiem apoptosis response ziπi 1183718 108 1323893 1197533 1 61 E-01 -1 26E 01 Unchanged Low
095458 N11cd2 tubulm-specific chaperone d 128 9522 100 1324761 120 4814 389E-02 -367E-01 Unchanged Low
P20749 P23ef6 B-cell CLL/lymphoma 3 264 1174 186 132484 1942507 -9 95E-01 -505E-01 Unchanged Low
Q9H2N8 D24gh7 hypothetical protein GL012 1043233 160 1325137 132 1507 345E-01 6 14E-01 Unchanged Low
Q15020 M08gh1 squamous cell carcinoma antigei 1172757 147 132 5393 1322727 1 77E-01 3 26E 01 Unchanged Low
P42025 O01gh1 ARP1 actm-related protein 1 hoπ 243 7979 92 132554 156 1129 -879E-01 -1 41 E+00 Unchanged Low
P98173 I23gh5 2 19 gene 1130426 116 132 6703 120727 231E-01 431E-02 Unchanged Low
095295 C06cd8 SNARE associated protein snapl 3243312 119 1326986 1920882 -1 29E+00 -1 44E+00 Unchanged Low
Q9NVA1 F15gh3 chromosome 20 open reading frs 111 7508 100 1327232 1148529 248E-01 -1 59E 01 Unchanged Low
P35573 O03ab2 amylo-1 , 6-glucosιdase, 4-alpha- 111 9583 106 1327432 1168065 246E-01 -827E 02 Unchanged Low
Q13126 K13ab7 methylthioadenosiπe phosphoryl, 2028169 236 1329211 1904847 -6 10E-01 2 17E-01 Unchanged Low
P43034 C11ab8 platelet-activating factor acetylhy 106 8174 125 132987 121 4511 3 16E-01 2 22E-01 Unchanged Low
Q01844 E15ab5 Ewing sarcoma breakpoint reglor 111 2628 102 133001 1155021 2 57E-01 -1 22E-01 Unchanged Low
P27482 E18ab6 calmodulm-like 3 114 7017 104 133 018 1172725 2 14E-01 -1 40E 01 Unchanged Low
Q9NUW4 N23gh3 BRIX 2238591 77 1 1330208 1446673 -7 51 E-01 -1 54E+00 Unchanged Low
P78552 J23ab6 interleukin 13 receptor, alpha 1 1182476 93 9 1330765 1150740 1 70E-01 -333E-01 Unchanged Low
P51843 024ab2 nuclear receptor subfamily 0, gro 1047329 112 133 1401 1167757 346E-01 1 03E-01 Unchanged Low
P15822 L23ab5 human immunodeficiency virus tj 8326942 160 133 2118 1253078 678E-01 940E-01 Unchanged Low
Q9BXY9 013gh8 RALBP1 associated Eps domain 90 84238 140 133274 121 2561 5 53E-01 620E-01 Unchanged Low
Q9ULB4 P10ef1 cadheπn 9, type 2 (T1-cadheπn) 275 2974 137 1334641 181 8847 •1 04E+00 -1 01 E+00 Unchanged Low
Q9NZZ7 C08ef8 HSPC171 protein 214 9523 265 133 5412 204 594 -687E-01 304E-01 Unchanged Low
Q02086 C09cd2 Sp2 transcription factor 101 09βg 133 1335465 1223826 402E-01 3 90E-01 Unchanged Low
Q9BUV9 H14gh6 DKFZP586J0119 protein 102 1174 119 133 5923 1182651 3 88E-01 2 22E-01 Unchanged Low
Q9UHJ9 A09ef4 FGF receptor activating protein 1 100 7903 121 133 6008 1185627 4 07E-01 267E-01 Unchanged Low
Q16401 E11cd1 proteasome (prosome, macropaii 1436091 120 1336156 1322946 -1 04E-01 -263E-01 Unchanged Low
Q9Y4K4 D04cd6 mitogen-activated protein kinase 1324072 158 1336676 141 2069 1 37E-02 2 51 E-01 Unchanged Low
060463 H06cd3 phosphatidic acid phosphatase t< 1032417 151 133 6898 1292479 373E-01 547E-01 Unchanged Low
095639 P20cd6 cleavage and polyadenylation sp 183 1762 67 6 1337241 128 1539 -454E-01 -1 44E+00 Unchanged Low
P50539 N19ab7 MAX interacting protein 1 175 6646 187 1337304 1654016 -393E-01 8 87E-02 Unchanged Low
Q9UH62 I 5ef3 ALEX3 protein 182527 171 1337314 1409912 1 77E-01 532E-01 Unchanged Low
015525 C13ab7 v-maf musculoaponeurotic fibros 1053252 109 1337521 116 1167 345E-01 531E-02 Unchanged Low
Q9H8T0 H21gh5 fused toes homolog (mouse) 106 2145 241 1337606 1602791 333E-01 1 18E+00 Unchanged Low
Q9Y4X5 K03cd6 anadne homolog ubiquitin-conju 9g 46477 128 1338771 1204976 429E-01 366E 01 Unchanged Low Q9H9E1 O01gh5 ankynn repeat, family A (RFXAN 1726266 788 134 052 1284841 -365E-01 -1 13E+00 1 Unchanged Low
Q93063 F13ab3 exostoses (multiple) 2 1232886 161 1343466 1394501 1 24E-01 3 82E-01 1 Unchanged Low
Q9H992 D22gh5 axotrophln 8954768 149 1344784 1244411 587E-01 737E-01 1 Unchanged Low
043237 P02ab4 dynein, cytoplasmic, light interme 2906769 119 134 4914 1814903 -1 11 E+00 -1 28E+00 1 Unchanged Low
Q99643 H02cd1 succlnate dehydrogenase compli 1434474 125 134 5527 134443 -924E-02 -1 95E-01 1 Unchanged Low
P24386 F11ef1 choroidere ia (Rab escort protei 9386058 129 1345538 1190446 5 20E-01 4 56E-01 1 Unchanged Low
Q9Y5F7 F12gh4 protocadherin gamma subfamily 101 7878 114 134 5585 116632 403E-01 1 58E-01 1 Unchanged Low
P06756 D14ab6 integnn alpha V (vitronectin rece 2000782 219 134 6115 1846891 -5 72E-01 1 33E-01 1 Unchanged Low
Q9H5L7 C02gh6 chromosome 1 open reading frar 173 8106 148 134 6601 1520822 -3 68E-01 -234E-01 1 Unchanged Low
015517 A14efδ tumor necrosis factor receptor su 9233364 207 1346603 1447566 544E-01 1 17E+00 1 Unchanged Low
Q9P0N5 K24ef2 HSPC244 1079991 129 134 6618 1237736 3 18E-01 2 53E-01 1 Unchanged Low
Q9N T2 D19gh2 hypothetical protein FLJ20623 1078864 105 134 7112 1158334 320E-01 -4 05E-02 1 Unchanged Low
Q9Y2A0 O02cd7 TP53 target gene 1 127 408 882 134 84gl 1168334 8 19E-02 -5 30E-01 1 Unchanged Low
QgNZ43 N16gh4 uncharactenzed hematopoietic si 141 2528 137 134 9524 1377883 -658E-02 -424E-02 1 Unchanged Low
P27986 A10ef1 phosphoιπosιtide-3-kιnase, regul 111 3806 112 134 9586 1193503 277E-01 428E-03 1 Unchanged Low
Q9UBP6 J13ef1 methyltransferase-like 1 1072187 122 134986 121358 332E-01 1 85E-01 1 Unchanged Low
Q9BWK5 P24gh5 hypothetical protein MGC5242 101 1324 123 1349881 1198654 4 17E-01 288E-01 1 Unchanged Low
P54802 M24ab6 N-acetylglucosammidase, alpha- 206038 66 3 135077 1357965 -609E-01 - -1 64E+00 1 Unchanged Low
075963 H09cd7 G-protein coupled receptor 110 3886 184 135 3412 1433711 2 94E-01 7 40E-01 1 Unchanged Low
Q9NXZ4 F03ef4 ELG protein 124 5205 105 1353934 1215448 1 21 E-01 -2 50E-01 1 Unchanged Low
060353 B11cd3 fnzzled homolog 6 (Drosophila) 8564918 146 135 5169 1225147 6 62E-01 7 73E-01 1 Unchanged Low
Q9NQS6 F13gh4 latexin protein 94 21822 163 135 5761 130917 525E-01 7 90E-01 1 Unchanged Low
014776 A19cd7 transcnption elongation regulatoi 1133803 117 1356603 1221137 2 59E-01 490E 02 1 Unchanged Low
Q9Y5A2 L13ef1 putative zinc finger protein NY-R 154 0704 186 135 6708 1585684 -1 83E-01 271 E-01 1 Unchanged Low
P49842 G23cd6 seπne/threonme kinase 19 1333557 171 1357013 1465953 2 52E 02 3 56E-01 1 Unchanged Low
Q06546 J14ab5 GA binding protein transcription 1 8893312 138 1357488 120885 6 10E-01 634E-01 1 Unchanged Low
Q9Y2E7 I02ef8 KIAA0938 protein 109 8218 105 135 7763 116739 306E-01 -700E-02 1 Unchanged Low
Q9UM11 I02ef2 Fzr1 protein 80 82847 186 135 8949 13412 7 50E 01 1 20E+00 1 Unchanged Low
Q9g447 B14ab8 phosphate cytidylyltraπsferase 2 1748201 774 135988 12939 -362E-01 -1 18E+00 1 Unchanged Low
Q9H1R3 F22gh8 myosin light chain kinase 2, skeli 9358977 129 1360456 1195324 540E-01 4 63E-01 1 Unchanged Low
P28358 P05ab6 homeo box D10 108 9g05 102 136 1419 1156766 321 E-01 -971E-02 1 Unchanged Low
076070 P18cd1 synuclein, gamma (breast cancel 128551 140 136 1645 134744 830E-02 1 18E-01 1 Unchanged Low
Q9Y5A7 N07ef2 NEDD8 ultimate buster-1 1190653 195 1362606 149951 1 95E-01 7 08E-01 1 Unchanged Low
Q9N Y7 A16gh3 hypothetical protein FLJ20530 1037638 110 136 3026 1166328 394E-01 8 20E-02 1 Unchanged Low
043715 P02ef2 hypothetical protein HSPC132 1374694 110 1363043 1279562 -1 23E-02 -320E-01 1 Unchanged Low
Q9BY75 K19gh8 itchy homolog E3 ubiquitin protei 1185721 127 1365094 1273323 203E-01 9 81E-02 1 Unchanged Low
043431 A12ef7 endothelial differentiation, lysopr 1264659 171 136 5393 1446131 1 11E-01 4 34E-01 1 Unchanged Low
043567 D15cd7 nng finger protein 13 1104449 153 1365722 1333964 306E-01 472E-01 1 Unchanged Low
Q9Y2S7 P13ef8 DKFZP586F1524 protein 113 1366 104 1367041 1178414 273E-01 -1 26E-01 1 Unchanged Low
014582 024ef2 spondyloepiphyseal dysplasia, is 135 1666 135 1367342 1357349 1 66E 02 1 46E-03 1 Unchanged Low
075056 G12gh1 syndecan 3 (N-syndecan) 120 0661 162 136797 139562 1 88E-01 4 31 E-01 1 Unchanged Low
Q9P2Y2 D18gh4 beta-1 ,4 mannosyltransferase 89 6857 143 1368208 1232251 609E-01 6 75E-01 1 Unchanged Low
Q16595 M08ab3 Fπedreich ataxia 1395657 130 136 8314 1355917 -2 85E-02 -9 82E-02 1 Unchanged Low
Q14807 B18ab7 kinesm-like 4 1144726 94 2 1369298 1152048 258E-01 -2 81 E-01 1 Unchanged Low
Q9BZL4 L10gh6 protein phosphatase 1 , regulator 110 5367 123 1370777 1235234 3 10E-01 1 54E-01 1 Unchanged Low
P30876 I13ab8 polymerase (RNA) II (DNA direct 2655337 200 137 1153 2007168 -954E 01 -4 12E-01 1 Unchanged Low
Q9UGP6 B17cd7 coatomer protein complex, subur 9473601 134 137 3091 1220845 535E-01 502E-01 1 Unchanged Low
P52655 M01ef2 general transcription factor IIA, 1 121 4896 128 137 3707 1291154 1 77E-01 808E-02 1 Unchanged Low
Q9HB07 G23gh5 chromosome 12 open reading frs 121 2547 118 1374723 1255248 1 81 E-01 -4 11E-02 1 Unchanged Low
Q92940 H23ab7 MAD, mothers against decapen 414 4889 223 1376028 2583032 ■1 59E+00 -895E-01 1 Unchanged Low
Q9N N1 H19gh2 hypothetical protein FLJ20727 117 7514 120 1375351 1249938 225E-01 224E-02 1 Unchanged Low
043664 A10cd6 G protein-coupled receptor 66 108 1311 102 137 678g 1160604 349E 01 -790E-02 1 Unchanged Low
014647 C19ab4 chromodomain helicase DNA bin 9614904 164 1377441 1325407 5 19E-01 758E-01 1 Unchanged Low
075333 N15cd2 T-box 10 126 0065 129 1377737 1309257 1 29E-01 338E-02 1 Unchanged Low
Q16539 J04ef5 mitogen-activated protein kinase 1487339 219 137 8 1684312 -1 10E-01 557E 01 1 Unchanged Low
Q9NQG5 A07gh5 chromosome 20 open reading frs 86 80552 143 137 803 1224598 667E 01 7 18E-01 1 Unchanged Low
Q15149 E05ab8 plectm 1 , intermediate filament bl 1257248 83 9 1380785 1158848 1 35E 01 -584E-01 1 Unchanged Low
Q9NVZ7 G12gh3 hypothetical protein FLJ 10407 166213 175 138 1444 1596342 -267E-01 7 06E-02 1 Unchanged Low
Q15800 D02cd2 sterol-C4 methyl oxidase-like 171 8648 71 2 138 1497 1270641 -3 15E-01 -1 27E+00 1 Unchanged Low
Q9H0B6 D16gh5 hypothetical protein FLJ 12387 si 9654943 129 138 1542 1213672 5 17E-01 422E-01 1 Unchanged Low
P09001 K14cd7 mitochondπal πbosomal protein I 94 17331 128 138 1601 1201502 553E 01 444E-01 1 Unchanged Low
000301 D24cd3 H-(ype splicing regulatory prats 1260509 883 1383014 175428 1 34E-01 -5 14E-01 1 Unchanged Low
P55786 J19ef7 aminopeptidase puromycm sensi 2737328 g89 1383924 170346 -984E-01 -1 47E+00 1 Unchanged Low
Q9Y5Y9 B14cd2 sodium channel, voltage-gated, t 1273727 139 1384331 1349928 1 20E-01 1 28E-01 1 Unchanged Low
P19235 M01ef7 erythropoietin receptor 198 5g54 77 3 1384803 1381099 -520E 01 -1 36E+00 1 Unchanged Low
015228 A16ef3 glyceronephosphate O-acyltrans 225 1315 186 1385137 183349 -701 E-01 -272E-01 1 Unchanged Low
Q9UK97 K0Scd8 F-box only protein 9 151 0501 104 1385593 131097 -1 25E-01 -543E-01 1 Unchanged Low
P50990 D20cd6 chaperonln containing TCP1 , sut 274982 178 1386001 1971593 -988E 01 -628E-01 1 Unchanged Low
Q9NZM1 P19cd8 fer-1 -like 3. myoferlin (C elegam 218 8411 202 1386209 1864122 -659E-01 -1 17E-01 1 Unchanged Low
Q92924 N20cd1 SWI/SNF related, matπx associa 131 7669 827 1386764 117704 7 37E-02 -673E-01 1 Unchanged Low
075845 A18gh1 sterol-C5-desaturase (ERG3 delM01 9285 153 1387232 1311196 445E-01 583E-01 1 Unchanged Low
Q9NQ88 I10gh4 chromosome 12 open reading frε 80 2401 158 1388274 125605 7 91 E-01 975E-01 1 Unchanged Low
Q16515 C19ab2 amiloπde-sensitive cation channe 102 1159 109 1389915 1166136 445E-01 906E-02 1 Unchanged Low
P49759 F16ab5 CDC-like kinase 1 8624615 147 1390985 1242553 690E-01 773E 01 1 Unchanged Low
P33552 A22ab5 CDC28 protein kinase 2 1095671 96 139 1297 1148881 345E-01 -1 91 E-01 1 Unchanged Low
075808 H21cd2 small optic lobes homolog (Drosc 115654 989 1391625 1178898 267E 01 -226E-01 1 Unchanged Low
Q9NXR1 M07gh2 LIS1 -interacting protein NUDE1, 9620481 123 1391939 1195057 533E-01 356E-01 1 Unchanged Low
075381 L12ab8 peroxisomal biogenesis factor 14 473 8395 113 1392209 2418793 -1 77E+00 ■207E+00 1 Unchanged Low
060930 P23cd1 nbonuclease H1 1673611 111 1392393 1391464 -265E-01 -595E 01 1 Unchanged Low
014653 P14cd4 golgi SNAP receptor complex me 115 7917 897 1392541 114 9152 2 66E 01 -368E-01 1 Unchanged Low
Q16540 L24gh1 mitochondπal ribosomal protein t 2092433 120 1393426 156 1365 -5 87E-01 -804E-01 1 Unchanged Low
014658 P06cd2 ras-related C3 botulmum toxin SL 158 176 166 1393634 1546374 -1 83E-01 729E-02 1 Unchanged Low
Q15814 M17cd2 tubulm-specific chaperone c 103 3699 112 1396311 1182869 4 34E-01 1 14E-01 1 Unchanged Low
Q9Y3C9 J09ef2 CGI-127 protein 834762 163 139659g 128 8568 7 42E-01 969E-01 1 Unchanged Low
P18827 F22cd1 syndecan 1 1144045 927 1396607 115 5895 2 88E 01 -303E-01 1 Unchanged Low
P04150 B21ab3 nuclear receptor subfamily 3, gro 1066921 103 1396889 1166017 3 89E 01 -449E-02 1 Unchanged Low Q9Y301 N05ef1 CGI-12 protein 1080511 101 1397035 1163594 3 71 E-01 -927E-02 1
000626 F10cd1 small inducible cytoklπe subfamil 113478 106 1398189 1198588 301 E-01 -945E-02 1
B18cd8 neural precursor cell expressed, 108 1711 133 1399597 127 048 372E-01 298E-01 1
Q9Y311 C01ef2 mitochondπal nbosomal protein I 1628519 748 139 856 1258788 -2 1BE-01 1 12E+00 1
Q15633 K14cd2 TAR (HIV) RNA binding protein - 169 3779 125 140 0138 144 9588 -275E-01 -4 33E-01 1
P02278 M22gh6 H2B histone family, member K 100 2794 216 1400965 1522309 4 82E-01 1 11E+00 1
P53672 J11cd7 crystallin, beta A2 101 7321 187 1402804 142 8494 4 64E-01 875E-01 1
P09417 C05ab8 quinoid dihydropterldlne reducta' 126 6361 161 140 3564 1425395 1 48E-01 343E-01 1
Q9HAY2 K14gh5 MAGEF1 protein 96 01675 126 1403654 1209341 5 48E-01 397E-01 1
P30273 A20ab5 Fc fragment of IgE, high affinity I 88 48289 171 1404541 1333475 667E-01 9 51 E-01 1
Q92949 G10ab4 forkhead bo JI 2504112 167 140 5084 18589 -B 34E-01 -587E-01 1
Q9GZT9 G01gh7 egl nine homolog 1 (C elegans) 1128025 992 1406556 1175626 3 18E-01 -1 85E-01 1
P35658 023cd4 nucleopoπn 214kD (CAIN) 141 8279 137 1407761 139 B811 -1 07E-02 -496E-02 1
Q9HB40 G01gh5 likely homolog of rat and mouse I 105 9316 993 140 9548 1153964 4 12E-01 -932E-02 1
014686 016cd3 myeloid/lymphoid or mixed-lineac 117 844 157 141 0674 1385398 260E-01 4 11E-01 1
Q92911 012cd1 solute earner family 5 (sodium io 264 1256 125 141 0904 176 594 -905E-01 -1 08E+00 1
Q9Y5E4 B18ef3 protocadheπn beta 5 9508061 148 141 1894 1279379 570E-01 634E-01 1
Q13057 H17gh7 nucleotide binding protein 186 8796 125 141 2202 151 0906 -404E-01 -578E-01 1
Q14863 B23ab8 POU domain class 6, transcπptk 103 2077 103 141 3258 1157954 4 53E-01 -497E-03 1
P36610 G10ef3 frequenin homolog (Drosophila) 110 2191 136 141 4925 1290874 360E 01 2 08E-01 1
060240 012ab8 penlipin 1121 108 522 141 5046 4382653 299E+00 443E+00 1
Q9H9B4 P05gh5 hypothetical protein FLJ12876 87 99841 133 141 7125 120 8973 6 87E-01 5 06E-01 1
000584 J14cd3 πbonuclease 6 precursor 124 6932 250 141 8008 1720542 1 85E-01 1 OOE+00 1
Q9H658 M04gh7 G protein-coupled receptor 107 1582595 214 141 8139 171 1973 -1 58E-01 4 32E-01 1
P18858 K14ef6 ligase I, DNA, ATP-dependent 9233071 128 141 8761 120 8853 6 20E-01 476E-01 1
Q02877 D23cd1 nbosomal protein L26 449 1728 297 141 8851 2958854 1 66E+00 -599E-01 1
P15586 J07ab4 glucosamme (N-acetyl)-6-sulfata 261 466 119 141 968 1742861 -8 81E 01 -1 13E+00 1
P42696 H08ef4 KIAA0117 protein 110 9202 231 141 9948 161 4649 3 56E-01 1 06E+00 1
075710 A17ef1 molybdenum cofactor synthesis ' 105 3087 101 1420352 1162449 4 32E 01 -5 47E 02 1
Q9NPI8 C01gh2 Fancoπi anemia, complementatic 1938104 214 1420643 1833737 -448E-01 1 45E-01 1
Q9HAR6 O10gh5 uteπne-denved 14 kDa protein 118 9551 198 1420669 1528734 2 56E-01 7 32E-01 1
P15018 018ef7 leukemia inhibitory factor (cholim 253 8099 3og 1422733 2350602 -835E-01 284E 01 1
Q13546 A23cd4 receptor (TNFRSF) interacting si 1397074 131 1422746 1377012 2 63E-02 -9 15E-02 1
P24298 H01ab4 glutamic pyruvate transaminase 210426 97 1 1423123 1499584 -564E-01 -1 12E+00 1
Q14129 C22cd4 DiGeorge syndrome critical regio 112 1253 141 1424302 131 8973 345E-01 332E-01 1
Q9BQA2 K09gh8 KIAA1882 protein 164 9357 187 1424325 1647437 -2 12E-01 1 80E-01 1
Q9UJX9 B12ef3 hypothetical protein, estradiol-inc 121 7396 985 1425053 120 9085 227E-01 -306E-01 1
Q99590 101 cd5 splicing factor, arginine/seππe-nc 231 0328 199 142 5273 1907413 -697E-01 -2 1BE-01 1
014798 C06ef7 tumor necrosis factor receptor su 142 6951 213 1425294 166073 -1 68E-03 578E-01 1
P32238 P01ab3 cholecystokinin A receptor 487368 168 1425911 2659537 -1 77E+00 -1 54E+00 1
Q9UQ90 C17cd2 spastic paraplegia 7, paraplegin 101 2857 146 1426321 1299052 494E-01 526E-01 1
P82980 M03gh8 retinol binding protein 5 cellular 111 2191 93 9 1426923 115 9454 3 60E-01 -244E-01 1
P49716 P15ab5 CCAAT/enhancer binding proteir 169 1889 734 1428277 1284871 -244E-01 -1 20E+00 1
P20062 M12cd1 transcobalamin II, macrocytic am 125 6347 141 142 8402 1366279 1 85E-01 1 71 E-01 1
P21580 B06cd2 tumor necrosis factor, alpha-indu 2758225 317 1428664 245 0939 -9 49E-01 1 99E-01 1
Q09774 H01cd5 protein phosphatase 4, regulator 19585 173 143 1867 170 7835 -452E-01 -1 76E-01 1
Q9P0T1 A17ef3 hypothetical protein HSPC192 1044363 101 1432517 116 1881 456E-01 -5 OOE-02 1
P06737 B18ab8 phosphorylase, glycogen liver (I- 85 14818 139 1432732 1226343 7 51 E-01 7 12E-01 1
015063 K10gh1 KIAA0355 gene product 1499191 144 1432945 145705 -6 52E-02 -5 91E 02 1
P02743 K14ab2 amyloid P component, serum 108 0152 947 1433031 1153343 4 08E-01 -1 90E-01 1
Q9NVT0 I14gh3 hypothetical protein FLJ10534 1364264 109 1433056 1296057 7 10E-02 -323E-01 1
Q9Y4P3 O07ef3 transducin (beta)-like 2 1120852 104 1434853 1197013 3 56E 01 -1 14E-01 1
Q13886 N14ab3 basic transcription element bindn 1644049 887 1435269 1322194 -1 96E-01 -8 OOE-01 1
Q9NVP8 L19gh4 hypothetical protein FLJ10595 101 7056 106 1435829 117 1232 4 96E-01 5 83E-02 1
P08240 G05cd2 signal recognition particle recept 158 3565 132 1436823 144 5673 -1 40E 01 -2 66E-01 1
P49459 M19ef5 ubiquitin-conjugatlng enzyme E2 86462 170 14374 137 6267 543E-01 7 89E-01 1
Q9NVA8 L16gh2 solute carrier family 38, member 1126488 127 1437595 127 9498 352E-01 1 78E-01 1
P25325 K23cd3 ercaptopyruvate sulfurtransfers 288 1435 274 1438077 235 1972 -1 OOE+00 -7 45E-02 1
Q9UHI6 K08cd7 DEAD/H (Asp-Glu-Ala-Asp/His) t 135 6699 209 1438383 1627208 843E-02 621 E-01 1
P52298 H01cd7 nuclear cap binding protein subu 1389223 191 1438819 157996 506E-02 461 E-01 1
Q9NQ30 A10cd7 endothelial cell-specific moleculε 104 1846 122 1439703 1232921 4 67E-01 224E-01 1
000541 I08ef3 pescadillo homolog 1 , containing 180 43 204 1440988 176 2086 -324E-01 1 78E-01 1
Q9H2V9 B06gh7 hypothetical protein CDA08 173 5608 169 144 1057 1623327 -268E-01 -3 56E-02 1
Q9NNX1 F12gh1 tuftelin 1 147 0323 175 144106 1552699 -290E-02 249E-01 1
Q13508 H14ab2 ADP πbosyltransferase 3 1094052 101 144 1545 118095 3 98E-01 -1 19E-01 1
Q9NR30 B21gh6 DEAD/H (Asp-Glu-Ala-Asp/His) t 110 4836 130 1442348 1282929 385E-01 2 36E 01 1
Q14320 E15cd5 DNA segment on chromosome X 1025057 178 1442677 141 6929 4 93E-01 7 99E 01 1
Q04726 D03cd2 transducm-like enhancer of split 211 8773 115 1443217 1569544 -554E-01 -8 86E-01 1
P20061 N13cd1 transcobalamin I (vitamin B12 bir 117 3445 85 5 1444835 115787 3 OOE-01 -4 56E-01 1
Q9Y2Y1 J12ef2 polymerase (RNA) III (DNA direc 1537426 145 1445561 1477222 -8 89E-02 -858E-02 1
P35754 G22ab5 glutaredoxin (thioltransferase) 153 823 138 1447308 1454287 -879E 02 -1 59E-01 1
Q02978 F01cd3 solute carrier family 25 (mitochor 106 877 982 1447822 116628 438E-01 -1 22E-01 1
Og57g2 N20gh2 protein associated with PRK1 1306914 146 1447909 1405872 1 48E-01 1 63E-01 1
Q13232 D20ef7 non-metastatic cells 3, protein ex 90 7906 156 144 8861 130 592 674E-01 7 82E 01 1
Q9NVH2 L01ef8 DKFZP434B168 protein 117 6587 91 2 1449821 117 932 301 E-01 -368E-01 1
Q15561 015cd2 TEA domain family member 4 234 306 172 1453307 1838604 -6 89E-01 -446E-01 1
Q9UPN9 B01ef2 tnpartite motif-containing 33 1109269 135 1453321 1302668 390E-01 278E-01 1
Q14353 O06ab3 guanidmoacetate N-methyltransfi 109 1385 103 14537gβ 119 1987 4 14E-01 -824E-02 1
Q9NZM5 A18ef4 glioma tumor suppressor caπdidj 150 098 122 145587 139 1802 -4 40E-02 -301 E-01 1
043255 B11cd2 seven in absentia homolog 2 (Dn 114 6318 101 145653 120 4593 346E-01 -1 81 E-01 1
Q14331 G04ab5 FSHD region gene 1 1640964 176 145 6576 161 7807 -1 72E-01 977E-02 1
P18847 N23ab5 activating transcription factor 3 127 5442 154 1456654 142 52g9 1 92E-01 275E-01 1
060258 I07cd4 fibroblast growth factor 17 1597671 223 145 6821 1760472 -1 33E-01 47gE-01 1
P47929 P02ab6 lectm galactoside-blndmg, solub 151 1595 928 1456g9 129 8767 -5 31E-02 -7 04E-01 1
P35227 014cd4 zinc finger protein 144 (Me|-18) 1082295 151 1458554 1350089 430E-01 4 80E-01 1
Q15599 015cd5 solute earner family 9 (sodium/hy 168 9673 805 145 g93 131 8082 -2 11 E-01 -1 07E+00
Figure imgf000066_0001
1 Q9UKJ5 B20cd7 cystein-πch hydrophobic domain 1844717 206 1459967 1788637 -337E-01 1 60E-01 1 Unchanged Low
Q9HCB9 C10gh5 chromosome 1 open reading frar 94 16759 126 146.1683 122 1779 634E-01 4 22E-01 1 Unchanged Low
Q9Y3A0 K07ef2 CGI-92 protein 119 1033 178 146 1698 1477783 295E-01 5 80E-01 1 Unchanged Low
P49815 M17ef6 tuberous sclerosis 2 1060159 163 1462712 1384231 464E-01 620E-01 1 Unchanged Low
P25116 L19ab4 coagulation factor II (thrombln) re 8248228 143 1462742 1238585 827E-01 792E-01 1 Unchanged Low
075829 O01cd7 chondromodulin I precursor 121 7658 119 1464876 128 9495 267E-01 -3 81E-02 1 Unchanged Low
Q9NYI1 M16ef2 ECSIT 111 7926 110 1466345 1228588 391E-01 -2 14E-02 1 Unchanged Low
P24347 I24ef5 matπx metalloproteinase 11 (stro 97 57916 136 146649 126 9018 588E-01 4 84E-01 1 Unchanged Low
043189 K24ab8 PHD finger protein 1 112 1101 101 1466925 120038 388E-01 -1 46E-01 1 Unchanged Low
Q9P029 N22ef2 THMike (Drosophila) 201 2292 159 1466g98 1689188 -4 56E-01 -341 E-01 1 Unchanged Low
Q9NZP9 E17ef2 immediate early response 5 105 1683 157 146761 136 3041 481 E-01 578E-01 1 Unchanged Low
Q9UIA3 H2ef2 neutral sphiπgomyeilnase 1656408 147 1468134 1530756 -1 74E-01 -1 74E-01 1 Unchanged Low
Q99734 M12ef5 Notch homolog 2 (Drosophila) 2204251 263 147 0111 210 2011 -5 84E-01 2 56E-01 1 Unchanged Low
000411 C19cd1 polymerase (RNA) mltochondnal 120 5078 105 1470481 124 1084 287E-01 -202E-01 1 Unchanged Low
P28347 P04gh1 TEA domain family member 1 (S' 230 2101 174 147 0913 183776 -646E-01 -4 04E-01 1 Unchanged Low
Q13619 G19gh1 cullin 4A 153 1592 218 1472043 1726621 -572E-02 507E-01 1 Unchanged Low
094929 O06ef8 KIAA0843 protein 1087821 9g 4 147 2921 1184779 437E-01 -1 31 E-01 1 Unchanged Low
Q9P026 A02ef8 HSPC134 protein 1154895 184 147 3205 1490331 351 E-01 674E-01 1 Unchanged Low
P28067 D08ab5 major histocompatibility complex, 128 7098 100 147 3934 1254983 1 96E-01 -3 58E-01 1 Unchanged Low
Q14126 E11ef7 desmogleiπ 2 4268387 366 1474196 3133393 1 53E+00 -223E-01 1 Unchanged Low
Q14267 POIcdl regulatory factor X, 4 (influences 1277912 989 147 4351 124 7021 206E-01 -370E-01 1 Unchanged Low
P55197 H09ab2 myeloid/lymphold or mixed-lineac 160668 185 1474439 164 3164 -1 24E-01 2 02E-01 1 Unchanged Low
Q9NP87 O20cd8 polymerase (DNA directed), mu 115 1765 867 1474845 1164497 357E-01 -4 10E-01 1 Unchanged Low
P04155 A04cd2 trefoil factor 1 (breast cancer, esl 258058 136 147487 1804791 -807E-01 -9 25E-01 1 Unchanged Low
Q9C069 N02gh7 seo13-lιke protein 5265015 424 1475255 2079658 1 49E+00 301 E+00 1 Unchanged Low
P12270 G14cd2 translocated promoter region (to 104 4493 136 147 7447 1294065 500E-01 3 81 E-01 1 Unchanged Low
Q9UIG6 I14ef2 LPAP for lysophosphatidic acid p 2183106 325 1478779 230 2685 -562E-01 5 72E-01 1 Unchanged Low
015453 P08cd5 NBR2 9908545 108 147 9143 1182765 578E-01 1 22E-01 1 Unchanged Low
Q9UNW8 F17cd8 G protein-coupled receptor 2393255 347 148 021 2447569 -693E-01 536E-01 1 Unchanged Low
P06746 I10ef6 polymerase (DNA directed), beta 1425013 225 1480351 171 8166 550E-02 6 58E-01 1 Unchanged Low
015414 I08cd7 tnnucleotide repeat containing 4 131 6219 19g 1480947 1597305 1 70E-01 600E-01 1 Unchanged Low
015259 L22ab7 πephrcnophthlsis 1 (juvenile) 115 0436 110 1483613 124437 367E-01 -6 S9E-02 Unchanged Low
Q9NRA8 P05gh4 elF4E-transporter 106343 178 1484323 144 3142 4 81 E-01 7 45E-01 1 Unchanged Low
Q9NP77 C10ef8 HSPC182 protein 171 17 175 1485234 1650639 -205E-01 3 60E-02 Unchanged Low
Q06587 P17cd1 πng finger protein 1 192377 127 148 657 131 6381 3 18E-01 9 12E-02 1 Unchanged Low
Q9Y5Z5 E22ef2 heme binding protein 1 181 0758 196 1487681 1752357 -284E-01 1 13E-01 Unchanged Low
015327 I05cd4 ositol polyphosphate-4-phosph 1836815 131 148785 154 5722 -304E-01 -4 85E-01 Unchanged Low
P49646 P19cd1 regulator of mitotic spindle asseπ 143 9463 117 1488487 136 7074 4 83E-02 -295E-01 Unchanged Low
Q99809 F16cd5 conserved gene amplified In oste 134 0126 91 3 148 9901 1247728 1 53E-01 -553E-01 Unchanged Low
Q9UBM1 G02cd7 phosphatidylethanolamine N-mel 1384849 122 1490109 1363565 1 06E-01 -1 88E-01 Unchanged Low
P16403 G04ab6 H1 histone family, member 2 427 1258 558 149 1016 3779287 -1 52E+00 384E-01 Unchanged Low
075503 B01ab4 cerσid-lipofuscinosis, neuronal 5 148 9991 754 149 1361 124 5021 1 33E-03 -9 83E-01 Unchanged Low
P15814 P20gh6 Im unoglobulin lambda-like poly 78 91644 144 1492005 1239169 9 19E-01 864E-01 Unchanged Low
Q03164 N01ab7 myeloid/lymphoid or mixed-lineac 157 0713 81 9 149358 1294559 -726E-02 -939E-01 Unchanged Low
Q 13624 BOSefδ interleukin enhancer binding fact 1364076 130 1494265 138 6386 1 32E-01 -6 85E-02 Unchanged Low
Q14118 M02ab5 dystroglycan 1 (dystrophm-assoc 1057987 99 149 6192 118 1383 500E-01 -9 59E-02 Unchanged Low
Q13286 E20ab3 ceroid-lipofuscinosis, neuronal 3 240521 302 1496542 230 6187 -685E-01 3 27E-01 Unchanged Low
Q9Y5Q0 E15gh7 fatty acid desaturase 3 117 0825 115 149704 127 2281 355E-01 -272E-02 Unchanged Low
Q9P0R1 K08ef2 forkhead box P1 99 17408 114 1497517 1208481 595E-01 1 96E-01 Unchanged Low
P41182 C24ab5 B-cell CLL/lymphoma 6 (zinc fing 115 9704 859 149 853 117 2275 370E-01 -4 34E-01 Unchanged Low
075497 K14cd6 microspherule protein 1 145 7927 163 1499313 153 0143 4 04E-02 1 64E-01 Unchanged Low
Q14185 M19ab4 dedicator of cyto-kinesis 1 953322 112 1500398 1189819 654E-01 227E-01 Unchanged Low
095163 P05cd3 inhibitor of kappa light polypeptic 2030161 120 150 0489 1576357 -4 36E-01 -760E-01 Unchanged Low
Q14508 L05ef7 WAP four-disulfide core domain 1026084 201 1500782 151 3745 549E-01 973E-01 Unchanged Low
P25942 M21ef7 tumor necrosis factor receptor su 110 0933 239 150 083 1662403 447E-01 1 12E+00 Unchanged Low
Q9Y6E0 F15cd3 serine/ threonme kinase 24 (STE 2067079 225 150279 194 1145 -4 60E-01 1 25E-01 Unchanged Low
Q9UQF2 J21cd5 mitogen-activated protein kinase 229 9384 182 150 2902 187 4786 -6 13E-01 -336E-01 Unchanged Low
Q9Y285 D11ab5 phenylalanine-tRNA synthetase-l 1797613 145 1503716 158 2291 -2 58E-01 -3 14E-01 Unchanged Low
Q04762 F09ab4 cell matrix adhesion regulator 134 1594 176 150 3997 153 4581 1 65E-01 3 90E-01 Unchanged Low
Q9Y6J9 P19ef6 TAF6-lιke RNA polymerase II, p3 7759128 158 1504181 128 6968 955E-01 1 03E+00 1 Unchanged Low
043913 C06ab8 oπgin recognition complex, subui 1479187 168 1504866 1556272 248E-02 1 88E-01 Unchanged Low
P25208 M05cd1 nuclear transcπption factor Y, be 1064862 138 1505231 131 7807 4 99E-01 377E-01 ! Unchanged Low
Q9H9X4 F03gh5 hypothetical protein FLJ11618 18958 179 1505879 173 1977 -332E-01 -794E-02 Unchanged Low
095297 P17cd4 myelin protein zero-like 1 127461 121 150 7509 133 0095 242E-01 -772E-02 Unchanged Low
Q9UPG8 O06ab8 pleiomorphic adenoma gene-like 134 8747 165 150 9533 150 4388 1 62E-01 295E-01 Unchanged Low
P16333 H16ef5 NCK adaptor protein 1 237 1463 351 150 9549 2464108 -6 52E-01 566E-01 Unchanged Low
Q14108 I22ab5 CD36 antigen (collagen type I rei 155206 139 1509785 148 3416 -398E-02 -1 61 E-01 Unchanged Low
Q9UFF9 O05cd5 CCR4-NOT transcription comple 1629025 208 151 0687 174 1041 -1 09E-01 355E-01 1 Unchanged Low
015242 019ab8 nardilysin (N-arginine dibasic coi 210 0164 198 151 1245 186 2788 -4 75E-01 -872E-02 1 Unchanged Low
Q13442 N15ef3 PDGFA associated protein 1 156 1376 188 151 1314 1650545 -470E-02 2 67E-01 1 Unchanged Low
Q99755 A15ef6 phosphatιdylιnosιtol-4-phosphat- 1122177 146 151 3432 136 4804 432E-01 378E-01 1 Unchanged Low
Q9NZV1 E09gh2 cysteiπe-πch motor neuron 1 1125932 99 1 151 3541 121 0073 4 27E-01 -1 85E-01 I Unchanged Low
Q05195 C09ab7 MAX dimerization protein 1358995 254 151 5662 180 6838 1 47E-01 889E-01 I Unchanged Low
095671 J14ab2 acetylserotonm O-methyltransfer 9967178 98 5 151 7064 116 6189 606E-01 -1 74E-02 I Unchanged Low
Q9Y658 A09ef2 RNA helicase 1129715 953 151 8988 1200494 4 27E-01 -246E-01 1 Unchanged Low
Q9BTU6 N12gh6 phosphatidylmositol 4-kιnase typ 9730862 178 151 965 142 5367 643E-01 874E-01 1 Unchanged Low
Q9UPN6 G04ef8 KIAA1116 protein 127 681 113 1520268 130 9048 252E-01 -1 76E-01 1 Unchanged Low
000170 J03ab2 aryl hydrocarbon receptor interac 555 1127 223 152 0508 310 1793 -1 87E+00 -1 31 E+00 1 Unchanged Low
Q9UJW6 P01ef3 activity-regulated cytoskeleton-a' 221 8559 185 152 1474 1864423 -544E-01 -260E-01 1 Unchanged Low
Q9HCT0 N02ef8 fibroblast growth factor 22 1577471 126 1522042 145 1536 -5 16E-02 -3 30E-01 1 Unchanged Low
Q15459 O03cd6 splicing factor 3a, subunit 1, 1201 1634432 145 152 3945 153 5048 -1 01 E-01 -1 76E-01 1 Unchanged Low
095400 G16cd6 CD2 antigen (cytoplasmic tail) bn 1922313 238 1525257 194 1745 -3 34E-01 307E-01 1 Unchanged Low
P07954 M06ab3 fumarate hydratase 121 2546 142 152 5652 138 7259 331 E-01 231 E-01 1 Unchanged Low
Q9H6Z5 C16gh5 hypothetical protein FLJ21634 101 1467 152 152 6745 1352933 S 94E-01 588E-01 1 Unchanged Low
Q9HCN8 A05gh1 stromal cell-deπved factor 2-lιke 1365604 128 1529097 139 1775 1 63E-01 -927E-02 1 Unchanged Low
Q92890 A24cd4 ubiquitin fusion degradation 1-lιk 1572559 220 152 9538 1766159 -4 OOE-02 4 82E-01 1 Unchanged Low 043324 N24cd4 eukaryotic translation elongation 150 6748 112 1529613 1386164 2 17E-02 -4 25E-01 1 Unchanged Low
Q9NVU8 H10gh2 hypothetical protein FLJ10496 1454398 119 152 9651 139 1241 728E-02 -2 90E-01 1 Unchanged Low
Q9NQW6 H01ef4 anillin, actin binding protein (scrs 113 8655 856 152 992 1174953 426E-01 -4 11 E-01 1 Unchanged Low
Q9NWH4 L01gh2 mitαchondrlal nbosomal protein I 1734347 107 1530783 1443461 -1 80E-01 -7 03E-01 1 Unchanged Low
Q9UBV8 M13cd8 PEF protein with a long N-termin 1480371 144 1530828 1483188 484E-02 -4 15E-02 1 Unchanged Low
P15328 F10ab3 folate receptor 1 (adult) 1525051 123 153 1163 1427655 577E-03 -3 14E-01 1 Unchanged Low
Q9Y583 B01cd6 NS1 -associated protein 1 1436283 177 1532797 1578847 938E-02 299E-01 1 Unchanged Low
Q07326 MOBabβ phosphatidylinositol glycan, clas' 132 6521 93 1533084 1263257 209E-01 -5 12E-01 1 Unchanged Low
075396 M12cd5 SEC22 vesicle trafficking protein 1439018 153 153 3626 150 1024 9 19E-02 8 88E-02 1 Unchanged Low
Q9Y2Σ8 D09ef2 CGI-09 protein 1172g43 110 1535282 1268764 3 88E-01 -952E-02 1 Unchanged Low
Q9H3P7 N05gh5 golgi phosphoprotem 1 251 3681 258 153 65 2209899 -7 10E-01 3.73E-02 1 Unchanged
095678 E03cd5 cytokeratin type II 3393692 195 153797 2293684 1 14E+00 -8 OOE-01 1 Unchanged Low
P17026 M04cd4 zinc finger protein 22 (KOX 15) 152726 883 1538779 131 6407 1 08E-02 -7 90E-01 1 Unchanged Low
Q9Y3N9 M05gh7 olfactory receptor, family 2, subfε 1272527 137 153 9228 1394653 275E-01 1 09E-01 1 Unchanged Low
Q9BYT8 K08gh7 neurolysin (metallopeptidase M3 85 gg781 193 154 0005 144 2719 841 E-01 1 16E+00 1 Unchanged Low
Q9UHQ7 F02ef8 pp21 homolog 1i 2248 136 1540057 1365651 3 69E-01 1 95E-01 1 Unchanged Low
060921 A22ab7 HUS1 checkpoint homolog (S pc 1485718 204 154 126 1690172 529E-02 460E-01 1 Unchanged Low
000400 D05ab2 acetyl-Coenzyme A transporter 1969505 124 1542012 1583654 -3 53E-01 -6 68E-01 1 Unchanged Low
Q9Y690 H01gh6 mortality factor 4 2532426 259 1542307 222 1522 -7 15E-01 323E-02 1 Unchanged Low
Q9NZL9 L24ef7 methioπine adenosyltransferase 1284144 997 1542681 1274733 265E-01 -3 65E-01 1 Unchanged Low
060563 A05ab4 cycliπ T1 1795706 171 154 2911 168 3854 -2 19E-01 -681E-02 1 Unchanged Low
P20591 M03ab7 myxovirus (influenza virus) resist 4590611 873 154338 4954752 1 57E+00 927E-01 1 Unchanged Low
Q9BQC6 P14gh5 mitochondnal πbosomal protein E 1886422 743 154 357 139 1028 -289E-01 1 34E+00 1 Unchanged Low
P28838 J02ef1 leucine ammopeptidase 3 409 1007 383 1543828 3156553 1 41 E+00 -933E-02 1 Unchanged Low
Q9NZE5 P08ef1 hypothetical protein LOC51319 135 1502 171 1543904 1533881 1 92E-01 3 36E-01 1 Unchanged Low
Q9NX47 K10gh2 hypothetical protein FLJ20445 299 3918 338 1544327 2639291 -955E-01 1 75E-01 1 Unchanged Low
060612 K11cd2 supervillin 113628 270 1544497 179421 443E-01 1 25E+00 1 Unchanged Low
000559 F22cd4 estrogen receptor binding site as 181 5726 147 154679 1609495 -231 E-01 -3 09E-01 1 Unchanged Low
Q9NUU9 E17gh3 hypothetical protein F23149 140 3785 224 1547106 1729723 1 40E-01 6 73E-01 1 Unchanged Low
P22059 C10ab8 oxysterol binding protein 1332924 936 154 8714 1272507 2 16E-01 -5 10E-01 1 Unchanged Low
000408 I05ef6 phosphodiesterase 2A, cGMP-sti 8602983 169 1549688 394 9107 -247E+00 -2 34E+00 1 Unchanged Low
094935 P22ef7 SAC1 suppressor of actin mutatu 1460417 128 1549914 1429113 858E-02 -1 94E-01 Unchanged Low
P41134 H15ef5 inhibitor of DNA binding 1 , domir 434 1844 292 1550439 2938674 -1 49E+00 -570E-01 1 Unchanged Low
P24407 M08ab7 mei transforming oncogene (derr 224 1153 189 155 1684 1895598 -530E-01 -243E-01 1 Unchanged Low
000232 N05ab8 proteasome (prosome, macropaii 122517 139 1552465 1390276 342E-01 1 85E-01 Unchanged Low
Q01432 G04ab2 adenosme monophosphate dean 111 1766 117 155341 1277664 4 83E-01 7 10E-02 Unchanged Low
Q13525 G15cd4 Interleukin 1 receptor-like 2 1360802 130 1554674 1405051 1 92E-01 -663E-02 Unchanged Low
Q16611 N04ab3 BCL2-antagonιst/kιller 1 2804131 194 155 5414 2100516 -850E-01 -530E-01 Unchanged Low
Q9NPA3 C11gh5 hypothetical protein STRAIT114$ 112 5378 85 5 155 5531 117 8671 467E-01 -396E-01 Unchanged Low
Q9GZM8 D14gh7 LIS1-lnteractιπg protein NUDEL, 137 8235 131 1555611 141 4354 1 75E-01 -741E-02 Unchanged Low
P42702 P06ab6 leukemia inhibitory factor receptc 9244914 112 155 6189 1200363 751E-01 277E-01 Unchanged Low
Q05940 P07ef5 solute carrier family 18 (vesiculai 3744901 153 155637 2276447 -1 27E+00 -1 29E+00 Unchanged Low
Q9Y3Q5 H18cd6 putative DNA/chromatm binding I 7596908 150 1556726 1270621 1 04E+00 977E-01 Unchanged Low
Q15756 H08ab7 potassium inwardly-rectifying chε 1490689 80 9 1557504 128 583 633E-02 -8 81 E-01 Unchanged Low
075386 M17cd3 tubby like protein 3 128 6914 82.7 1557811 122 3782 276E-01 -639E-01 Unchanged Low
P50750 D03ef5 cyclin-dependeπt kinase 9 (CDC 270 8229 215 155 8317 2137777 -7 97E-01 -335E-01 Unchanged Low
Q9NWY6 A18gh3 hypothetical protein FLJ20531 91 85185 130 156 1332 1259 03 765E-01 501 E-01 Unchanged Low
P50391 K05cd1 pancreatic polypeptide receptor 1365278 112 156 1953 134 9143 1 94E-01 -285E-01 Unchanged Low
Q9NX07 L20gh6 tRNA seleπocysteine associated 258434 287 1562449 2339363 -7 26E-01 1 52E-01 Unchanged Low
075354 A15ab4 ectonucleoside tπphosphate dipt" 3864989 258 156 4638 267 133 -1 30E+00 -581E-01 Unchanged Low
Q9H832 L12gh5 hypothetical protein FLJ13855 1734437 307 1569292 2123427 -1 44E-01 822E-01 Unchanged Low
Q9UBW8 F18ef1 C0P9 constitutive photomorpho, 1028052 111 1570119 1234686 6 11E-01 1 05E-01 Unchanged Low
P14136 E23ab5 glial fibnllary acidic protein 108 166 866 157 2761 117 3353 540E-01 -321 E-01 Unchanged Low
Q9NYF3 F08ef1 chromosome 5 open reading frar 121 4116 94 3 1575806 1244392 376E-01 -364E-01 Unchanged Low
Q15056 A09gh2 Wil ams-Beureπ syndrome chror 202 4969 124 157 6763 161 3602 -361 E-01 -709E-01 Unchanged Low
015534 I16ab8 peπod homolog 1 (Drosophila) 2372007 143 157 7195 1793665 -589E-01 -7 28E-01 1 Unchanged Low
Q9Y399 021 ef2 mitochondπal nbosomal protein ϊ 2299134 139 1577339 1755893 -544E-01 -725E-01 Unchanged Low
014972 A04cd6 Down syndrome critical region ge 230 0837 267 1577386 218 3678 -545E-01 2 16E-01 1 Unchanged Low
Q14113 M15ab2 AE binding protein 1 12497 6 953 157 955 1260667 338E-01 -392E-01 1 Unchanged Low
095755 018cd5 RAB36, member RAS oncogene 1329919 97 1580474 129 3518 249E-01 -4 55E-01 1 Unchanged Low
Q9NPC3 I09gh4 enhancer of invasion 10 104 2128 121 158 1023 127 8011 601 E-01 2 17E-01 1 Unchanged Low
Q9Y6E9 N24cd7 sirtum silent mating type informal 111 8557 153 1582227 1409006 5 OOE-01 448E-01 1 Unchanged Low
Q9Y5B8 D17cd8 NME7 9269165 116 1582444 1224719 7 72E-01 330E-01 1 Unchanged Low
P49642 I21ab8 pπmase, polypeptide 1 (49kD) 1352376 70 2 158 2887 121 2327 227E-01 -947E-01 I Unchanged Low
060660 J04ab2 ash2 (absent, small, or homeotic 274 3502 177 1583372 203 1619 -7 93E-01 -634E-01 1 Unchanged Low
Q9H251 O08gh7 cadherin related 23 113 1038 184 1584524 151 9031 4 86E-01 703E-01 1 Unchanged Low
Q9Y6C2 A22cd7 elastin microfibπl interface locate 1079751 922 1586648 1196097 555E-01 -228E-01 I Unchanged Low
095825 D13cd5 crystallin, zeta (qulnone reductas 144 0183 133 1586719 145 1487 1 40E-01 -1 17E-01 1 Unchanged Low
Q9UHG3 J02ef2 prenylcysteine lyase 2503969 207 158 8419 2052993 -657E-01 -277E-01 1 Unchanged Low
000629 J18ab6 karyopheπn alpha 4 (importiπ alp 518 8184 295 158 8458 324 141 -1 71 E+00 -8 16E-01 1 Unchanged Low
Q15397 B14gh1 KIAA0020 gene product 109 8533 134 158 9595 134 3527 533E-01 2 89E-01 1 Unchanged Low
Q14999 H01gh1 KIAA0076 gene product 71 35119 173 1590037 1346153 1 16E+00 1 28E+00 1 Unchanged Low
Q12772 M18cd2 sterol regulatory element binding 1586108 94 6 159 1986 137 4667 5 34E-03 -7 46E-01 1 Unchanged Low
075150 F09gh1 ring finger protein 40 1292351 169 1592038 1523442 301 E-01 384E-01 1 Unchanged Low
043423 L07gh6 acidic (leucine-rich) nuclear phos 140 3006 143 1594372 147 5392 1 84E-01 2 63E-02 1 Unchanged Low
043311 D12cd8 muscleblind-like (Drosophila) 1652243 994 159 4681 141 3508 -5 12E-02 -7 34E-01 1 Unchanged Low
Q9NYX4 B07ef4 calcyon, D1 dopamine receptor-ii 2072791 147 1595302 171 42 -378E-01 -491 E-01 1 Unchanged Low
Q9HD71 G04gh4 hypothetical nuclear factor SBBI. 1237874 140 159 5491 141 2517 3 66E-01 1 82E-01 1 Unchanged Low
Q9NZH2 N03cd8 replication initiation region protei 2250949 179 1596113 187 9443 -496E-01 -330E-01 1 Unchanged Low
Q9NVH1 B05gh3 hypothetical protein FLJ10737 1374673 217 159 6304 171 2625 2 16E-01 657E-01 1 Unchanged Low
Q9NVG3 B11gh3 hypothetical protein FLJ10751 9628296 105 1596829 120 1783 7 30E-01 1 19E-01 1 Unchanged Low
P52179 A21cd4 myomesln 1 (skelemin) (185kD) 1570608 94 1598272 1369676 252E-02 -740E-01 1 Unchanged Low
094815 B09cd3 fnzzled homolog 1 (Drosophila) 93 g7877 101 159 9198 118 2939 7 67E-01 1 04E-01 1 Unchanged Low
Q9UBY9 G01ef4 heat shock 27kD protein family, r 9897552 102 160.1725 120 3216 694E-01 408E-02 1 Unchanged Low
Q9NVX7 G1Bgh3 hypothetical protein FLJ10450 111 5196 121 160 2507 130 905 523E-01 1 17E-01 1 Unchanged Low
095704 A02cd6 FE65-llke protein 2 9935088 115 160 3239 1247475 690E-01 206E-01 1 Unchanged Low P19801 A23ab2 amiloπde binding protein 1 (amin 1646296 683 1603477 1310836 -380E-02 127E+00 1
043709 L18ef3 Williams Beuren syndrome chrar 1278538 134 1604415 1407865 328E-01 684E-02 1
Q12839 N24ef1 H326 109677 116 1606141 1288096 550E-01 826E-02 1
043503 D10ab8 RAD51 homolog C (S cerevisiae 9634779 976 1606551 1181934 738E-01 183E-02 1
Q07898 J10cd4 CD163 antigen 8773563 177 1608614 1417231 875E-01 101E+00 1
096015 F22cd5 dynein, axonemal, light polypepti 9454055 251 1609963 1688465 768E-01 141E+00 1
Q92524 L11ab8 proteasome (prosome, macropaii 3966515 220 1610391 2591219 130E+00 -852E-01 1
Q92692 B06ab8 pollovirus receptor-related 2 (her 3027185 317 1612569 2602905 -909E 01 660E-02 1
Q9Y6Y8 I16cd7 Sec23-interactιng protein p125 1042429 131 1612684 1322965 630E-01 334E-01 1
Q9NZ78 J16gh3 uncharacterlzed bone marrow pn 1072001 127 1613587 1317449 590E-01 241E01 1
Q15120 G15cd1 pyruvate dehydrogenase kinase, 9664061 107 1616468 1216758 742E-01 143E-01 1
P35241 F22ab8 radixin 2766012 213 1617003 2169693 -774E-01 -380E-01 1
Q9Y326 D23ef2 brain specific protein 3593582 160 1617123 2270406 115E+00 117E+00 1
Q92600 J03cd5 RCD1 required for cell differentia 1156633 145 1617142 140923 484E-01 330E-01 1
000487 N14cd5 26S proteasome-associated pad 3293518 275 1618834 2554035 102E+00 -260E-01 1
Q9Y689 P21cd7 ADP-πbosylation factor-like 5 1377737 159 1618965 1529706 233E-01 209E-01 1
Q9ULB8 P05cd8 CMP-NeuAC (beta)-N-acetylgala 9101128 121 1619148 1245785 831E-01 409E-01 1
060897 L09cd7 RAB, member of RAS oncogene 8932474 112 1620127 1209939 859E-01 322E-01 1
P51809 J05cd2 synaptobrevm-like 1 2283546 141 1621052 1772043 -494E-01 -694E-01 1
075581 A03ab7 low density lipoproteln receptor-r 1224708 125 1621159 1364067 405E-01 253E-02 1
043795 F12ef4 myosin class I, myh-1c 2594543 282 162137 234504 -678E-01 120E-01 1
Q14188 H17ef5 transcnption factor Dp-2 (E2F dir 107308 204 1621489 1577494 596E-01 925E-01 1
P06280 B07ab3 galactosidase, alpha 1780238 304 1622871 2146169 -134E-01 770E-01 1
Q14541 017ab7 hepatocyte nuclear factor 4, gam 5498997 283 1624659 331895 -176E+00 -957E-01 1
P57723 E17gh8 poly(rC) binding protein 4 1862845 231 1625267 1931283 -197E-01 308E-01 1
Q9NWU3 A24gh3 DEAD/H (Asp Glu-Ala-Asp/His) t 15471 104 1626529 1405056 722E-02 -571E-01 1
Q9NPC5 J16ef8 nudix (nucleoside diphosphate Hi 1071863 984 1626929 1227442 602E-01 -124E-01 1
Q9Y3C5 B19ef3 nng finger protein 1 1600631 164 1627518 1623366 240E-02 368E-02 1
Q9NWX3 B01gh2 chromosome 20 open reading frs 9858482 956 1627744 1189844 723E-01 -444E-02 1
P52742 I22cd3 zinc finger protein 135 (clone pH 814141 121 1628382 1216363 1 OOE+00 568E-01 1
Q9Y313 D17ef2 PTD013 protein 9025232 116 1634053 1233545 856E-01 367E-01 1
Q9P2W9 B11ef4 syntaxm 18 1286426 188 1634277 1600555 345E-01 548E-01 1
P14778 F09ab6 interleukin 1 receptor, type I 2645401 539 1634432 3224754 -695E-01 103E+00 1
Q15464 112ef5 SHB (Src homology 2 domain coi 284291 301 1635379 2496096 -798E-01 824E-02 1
015444 H07cd2 small inducible cytokme subfamil 2446426 971 1636053 1684558 -580E-01 -133E+00 1
P49796 P14ef4 regulator of G-protem signalling 2202769 993 1636222 1610774 -429E-01 -115E+00 1
Q9NUS7 B04gh3 hypothetical protein FLJ11164 8176063 114 1636422 1197258 1 OOE+00 477E-01 1
P48651 L11ef3 phosphatidylseπne synthase 1 2118695 139 1636792 1715708 -372E-01 -606E 01 1
Q07706 F15cd4 tetracycline transporter-like prate 1430791 144 1637206 1502019 194E-01 731E-03 1
075143 B11gh1 KIAA0652 gene product 1065331 155 1637687 1416405 620E-01 537E-01 1
075039 L19gh1 KIAA0451 gene product 174142 135 1638572 1577714 -878E-02 -364E-01 1
P02261 M10gh6 H2A histone family, member N 9348591 273 1638621 1769259 810E-01 155E+00 1
Q9HgA0 L20gh5 hypothetical protein FLJ12895 8642599 130 1643655 1267707 927E-01 584E-01 1
Q9NV35 J21gh3 hypothetical protein FLJ10956 9915342 154 1644852 1391489 730E-01 633E-01 1
Q9P1G8 C05gh4 WW domain-containing adapter' 1194436 182 1645311 1553256 462E-01 608E-01 1
P26368 D11cd7 U2 small nuclear πbonucleoprot- 2170564 107 1648861 163126 -397E-01 -101E+00 1
Q9BSZ7 E11gh8 DEAD/H (Asp-Glu-Ala-Asp/His) t 1307858 111 1649084 1356059 334E-01 -235E-01 1
Q9Y391 G23ef2 androgen-regulated short-chain c 2223497 128 1649823 1717067 -431E-01 -799E-01 1
Q9NYRS E05ef3 HSPC126 protein 9937243 110 1652098 1248579 733E 01 146E-01 1
P05165 N12ab7 propionyl Coenzyme A carboxyla 100892 120 1656902 1289755 716E-01 254E-01 1
Q9NPF4 021 gh3 O-slaloglycoprotein eπdopeptida 1038223 112 1659716 1273658 677E-01 113E-01 1
P16106 D01 cd3 H3 histone family, member K 9919006 130 1661216 1316683 744E-01 387E-01 1
P35249 O03ef5 replication factor C (activator 1 ) < 1052406 987 1662092 1233812 659E-01 -927E-02 1
P28702 P18gh1 retinoid X receptor, beta 74914 142 1662214 1277227 115E+00 923E-01 1
P49674 K14ab4 casein kinase 1 , epsilon 9933956 145 1663564 1368564 744E-01 544E-01 1
Q9NXW2 103gh2 DnaJ (Hsp40) homolog, subfamil 2477g07 235 1664412 2165041 -574E-01 -747E-02 1
014672 101 ab2 a disintegπn and metalloproteina 3780042 226 1665417 2568185 -118E+00 -743E-01 1
Q9Y5B9 I20cd7 chromatin-specific transcπption e 1630543 188 1666045 1724726 311E-02 204E 01 1
Q9H9J2 H22gh5 mitochoπdπal nbosomal protein I 206428 256 1668142 2097386 -307E-01 310E01 1
P23759 G06ab8 paired box gene 7 0241833 200 1668514 1530178 852E-01 111E+00 1
Q16643 L05ab4 drebrin 1 265008 152 1669734 1947352 -666E 01 -800E-01 1
P48454 121 cd1 protein phosphatase 3 (formerly 1059496 169 1670428 1472674 657E-01 672E-01 1
Q9Y508 F21ef4 zinc finger protein 313 331595 395 1672366 2979139 -988E-01 252E-01 1
P19474 G09cd2 Sjogren syndrome antigen A1 (5: 3011776 183 167414 2171349 -847E 01 -720E-01 1
P46109 N13ab5 v-crk sarcoma virus CT10 oncogi 1512065 141 1677716 153202 150E-01 -105E-01 1
P54855 B19cd4 UDP glycosyltransferase 2 family 1378939 127 1678346 1442152 283E-01 -120E-01 1
Q14242 H14cd1 selectin P ligand 1129679 130 1679184 1368261 572E-01 198E-01 1
QgBSSI P17gh8 hypothetical protein FLJ14525 8675908 113 167974 122482 953E-01 378E-01 1
Q9Y3B2 L23ef1 homolog of yeast exosomal core 1520751 140 1679915 1532264 144E-01 -123E-01 1
P31391 N03cd1 somatostatin receptor 4 1473942 925 1680254 1359754 189E-01 -672E-01 1
060623 O03ab4 dipthena toxin resistance protein 2109658 170 1680762 1830009 -328E-01 -312E 01 1
Q99959 L24ab8 plakophilin 2 3629423 211 1681655 2474823 -111E+00 -780E-01 1
B21 gh7 leukocyte immunoglobulin-like re 1392571 234 1681829 1804876 272E-01 749E-01 1
Q01658 P18ab5 down-regulator of transcription 1 2052240 122 1682606 1650596 -287E-01 -754E-01 1
Q9HCS4 P10gh7 HMG-box transcπption factor TCI 7648423 156 1682926 1335936 114E+00 103E+00 1
Q9P035 N20ef2 butyrate-mduced transcript 1 102716 142 1683034 137599g 712E01 465E-01 1
Q9C0K7 P24gh3 amyotrophic lateral sclerosis 2 (jι 102352 108 1684355 1261345 719E-01 724E-02 1
Q9NYF4 I13ef3 chromosome 5 open reading frar 8072908 137 1684424 1317500 909E-01 611E-01 1
P30042 M19cd4 chromosome 21 open reading frs 9884241 975 1685171 1216076 770E-01 -203E-02 1
075325 K16cd6 glioma amplified on chromosome 1163239 833 1685172 122705 535E 01 -482E-01 1
Q9Y670 N01ef2 transient receptor potential catioi g641826 908 1685297 1185764 806E-01 -869E-02 1
Q9UPR8 I14ef8 KIAA1084 protein 1013235 111 1685336 126797 734E-01 126E-01 1
QgY2X7 121 ef4 G protein-coupled receptor kiπas 1607403 167 1687352 1655706 700E-02 572E-02 1
P47872 D24cd1 secretin receptor 1746672 209 168738 1841802 -49BE-02 260E-01 1
043353 C17cd4 receptor-interacting seπne-threoi 2725279 388 1687722 2765664 -691 E-01 511E-01 1
P32321 P14ab5 dCMP deammase 2185685 601 1688404 1491554 -372E-01 -186E+00 1
Figure imgf000069_0001
043612 J16ab4 hypocrelin (orexin) neuropeptlde 6645691 194 168 9064 1432577 1 35E+00 1 55E+00 1 Unchanged Low
Q92874 M15ab4 deoxynbonuclease l-llke 2 218 1787 146 168 9596 177 8201 -369E-01 -576E-01 1 Unchanged Low
Q9UI90 I15ef8 PRO0038 protein 89 17218 389 1689849 21561 9 22E-01 2 12E+00 1 Unchanged Low
P30519 N05ab6 heme oxygenase (decycliπg) 2 5863897 387 169 1269 380 9032 -1 79E+00 -599E-01 1 Unchanged Low
Q9NVE7 D03gh3 hypothetical protein FLJ10782 141 6695 148 1692644 1529293 2 57E-01 6 16E-02 1 Unchanged Low
Q9P010 A14ef8 HSPC154 protein 2279143 246 1694393 214 317 -4 28E-01 1 08E-01 1 Unchanged Low
Q9UH59 M04cd8 bromodomain-contalning 7 1476635 103 169 5045 1399456 1 99E-01 -524E-01 1 Unchanged Low
Q9UMB2 E01cd6 spermatogenesis associated 2 2307114 221 1696678 207 1298 -4 43E-01 -6 20E-02 1 Unchanged Low
Q9P2Y4 N14ef1 zinc finger protein 219 1056753 175 1697666 150 1216 684E-01 727E-01 1 Unchanged Low
Q9GZS3 H19gh7 recombination protein REC14 1247245 162 1699984 1523724 447E-01 381E-01 1 Unchanged Low
P07686 J17ab3 hexosaminidase B (beta polypep 217 0423 135 170 0092 174 0094 -3 52E-01 -6 85E-01 1 Unchanged Low
Q9NZV6 L06ef2 selenoprotein X, 1 241 3633 202 1700232 204 3052 -5 05E-01 -260E-01 1 Unchanged Low
014678 E17cd1 ATP-bindmg cassette, sub-family 77 65216 127 1700525 124 9148 1 13E+00 7 10E-01 1 Unchanged Low
P29972 O04ab2 aquapoπn 1 (channel-forming int 309 1218 134 1702078 2042885 -861 E-01 -1 21 E+00 1 Unchanged Low
095373 D03cd6 RAN binding protein 7 247 4368 113 17045 177 0459 -5 38E-01 -1 13E+00 1 Unchanged Low
Q15436 012cd6 Sec23 homolog A (S cerevisiae) 9005071 100 1709386 1203545 925E-01 1 52E-01 1 Unchanged Low
Q9BQ67 K23gh8 glutamate rich WD repeat proteir 1403198 112 170 966 141 0924 285E-01 -325E-01 1 Unchanged Low
P35321 D21gh6 small prolme-nch protein 1A 6228271 237 171 0104 1568515 1 46E+00 1 93E+00 1 Unchanged Low
Q9UPQ8 HOefβ KIAA1094 protein 7676245 123 171 0467 1234833 1 16E+00 676E-01 1 Unchanged Low
043292 A19cd4 GPAA1 P anchor attachment prat 9536294 924 171 0704 119 6038 843E-01 -4 59E-02 1 Unchanged Low
Q9UBM3 G02cd1 proteasome (prosome, macropaii 287 6026 204 171 1554 221 0285 -7 49E 01 -4 93E-01 1 Unchanged Low
P19338 M20ab7 nucleolin 1488642 87 6 171 2094 1358947 202E-01 -765E-01 1 Unchanged Low
Q9NPE6 E17gh1 sperm associated antigen 4 111 172 135 171 4356 139 3341 625E-01 284E-01 1 Unchanged Low
000442 J12cd3 RTC domain containing 1 2746701 279 171 531 241 6967 -679E-01 2 20E-02 1 Unchanged Low
P28356 D09ef1 homeo box D9 845638 106 171 5949 120 5873 1 02E+00 321 E-01 1 Unchanged Low
P49447 G06ef1 cytochrome b-561 1747152 167 171 6447 171 1671 -2 56E-02 -639E-02 1 Unchanged Low
Q9UQA4 P18cd4 nuclear factor (erythraid-deπved 2274253 470 171 8945 2897702 -404E-01 1 05E+00 1 Unchanged Low
015254 D09ab2 acyl-Coenzyme A oxidase 3, pπs 1922301 192 1720218 1852853 -1 60E-01 -471 E-03 1 Unchanged Low
QgNWWβ B11gh2 hypothetical protein FLJ20S59 1987861 220 1720281 1970098 -2 09E 01 1 48E-01 1 Unchanged Low
075391 M08cd5 sperm associated antigen 7 154 1159 140 1720658 1552376 1 59E 01 -1 43E-01 1 Unchanged Low
Q92959 H19cd2 solute earner family 21 (prostagl. 8625485 102 172 112 120 1434 9 97E 01 243E-01 1 Unchanged Low
000499 G06ab2 bπdging integrator 1 162 8584 111 1724453 148 8447 8 25E-02 -550E-01 1 Unchanged Low
Q14197 J05ab6 immature colon carcinoma transc 90 92583 102 1725526 121 725 924E-01 1 62E-01 1 Unchanged Low
Q9NXS9 K15gh2 hypothetical protein FLJ20071 121 4575 103 1725552 1323749 507E-01 -236E-01 1 Unchanged Low
075954 N18cd6 tetraspan transmembrane 4 sups 8306795 119 1725557 124 8565 1 05E+00 5 18E-01 1 Unchanged Low
Q9UJY9 E17cdS lifeguard 1565909 756 1726495 134 9529 1 41E-01 -1 05E+00 1 Unchanged Low
P82912 F10gh5 mitochondnal πbosomal protein J 1050578 196 1727091 1580886 7 17E-01 903E-01 1 Unchanged Low
Q12918 J02ab6 killer cell lectiπ like receptor subf 2056225 290 1728141 222 8453 -2 51 E-01 497E-01 1 Unchanged Low
Q14789 E01ab6 golgi autoantigen, golgin subfam 9609162 194 1730059 1542154 848E-01 1 01 E+00 1 Unchanged Low
Q04206 I23ef6 v-rel reticuloendotheliosis viral Ol 3289295 242 1730443 248 1566 -9-27E-01 -440E-01 1 Unchanged Low
P19838 M15ef5 nuclear factor of kappa light poly 2292262 277 1730997 226323 -405E-01 271E-01 1 Unchanged Low
Q92748 A24cd2 thyroid hormone responsive (SP( 101 3006 882 173314 120 9562 773E-01 -2 02E-01 1 Unchanged Low
O9S095 P13ab2 amyloid beta precursor protein (c 199951 201 1733314 191 35 -206E-01 5 88E 03 1 Unchanged Low
P52209 K18ab8 phosphogluconate dehydrogena- 211 8178 147 17342 1775327 -289E-01 -523E-01 1 Unchanged Low
P42566 H10ef5 epidermal growth factor receptor 194 9437 158 1734643 175 3861 -1 68E-01 -305E-01 1 Unchanged Low
Q13772 D05gh6 nuclear receptor coactivator 4 2735167 367 1735038 271 4641 -6 57E-01 4 26E-01 1 Unchanged Low
P43897 D09gh6 Ts translation elongation factor, I 3257575 226 173 8489 241 8156 -906E-01 -528E-01 1 Unchanged Low
P09329 D08ef7 phosphonbosyl pyrophosphate s 1037882 862 1745738 121 5057 7 50E-01 -269E-01 1 Unchanged Low
075618 F24cd4 death effector domain-containing 172 0163 176 1747689 174 3849 229E 02 3 61E 02 1 Unchanged Low
Q9UHI9 B18ef1 flavohemoprotein b5+b5R 169 2028 197 1747919 180 2862 469E-02 2 18E 01 1 Unchanged Low
Q9H824 J07gh6 F-box only protein 22 892751 161 17562 141 9533 976E-01 850E-01 1 Unchanged Low
Q9UQ43 G07ab3 BAH-associated protein 2 184 8198 165 1756399 175 1475 -735E 02 -1 64E-01 1 Unchanged Low
043173 N08ef1 sialyltransferase 8C (alpha2,3Ga 2209909 256 1759869 217 6266 -329E 01 2 12E-01 1 Unchanged Low
Q9BZZ2 G13gh7 sialoadhesm 147 52 189 1759952 170 7942 255E-01 3 56E-01 1 Unchanged Low
Q92611 H6gh1 KIAA0212 gene product 963144 943 1760348 1222106 870E-01 -308E-02 1 Unchanged Low
Q969V6 K14gh7 megakaryoblastic leukemia (tran 1356533 161 1760531 157 6423 376E-01 249E-01 1 Unchanged Low
P08107 K14ab7 heat shock 70kD protein 1B 153 5141 106 176 1145 145 1219 1 98E-01 -5 38E-01 1 Unchanged Low
Q9BQ24 E21gh6 hypothetical protein MGC2550 1539741 255 1763889 1952182 1 96E-01 7 29E-01 1 Unchanged Low
Q9H7X1 N07gh5 hypothetical protein FLJ14153 155291 236 1765938 1892S19 1 85E 01 603E-01 1 Unchanged Low
Q99616 D09cd2 small inducible cytokine subfamil 130 1641 100 176 5958 1356192 440E-01 -379E-01 1 Unchanged Low
Q928g6 L04cd7 golgi apparatus protein 1 97 73429 903 176622 121 5361 8 54E-01 -1 15E-01 1 Unchanged Low
Q14S82 J16ef6 Mad4 homolog 2103185 244 1766383 210 1876 -2 52E-01 2 12E-01 1 Unchanged Low
Q13505 K21ab7 etaxin 1 199 1231 168 1766745 181 2437 -1 73E-01 -246E-01 1 Unchanged Low
Q13722 024cd8 chromosome 3p21 1 gene seque 8585963 144 1767101 1356336 1 04E+00 7 49E-01 1 Unchanged Low
P01308 I10ab6 insulin 367 022 113 1767437 218 8465 -1 05E+00 -1 70E+00 1 Unchanged Low
000405 D19ab8 protein phosphatase 1, regulator 2330866 306 1768763 2386383 -398E-01 392E-01 1 Unchanged Low
P41215 E03ab5 fatty-acid-Coenzyme A ligase, loi 267 9822 199 177 1301 2148046 -597E-01 -427E-01 1 Unchanged Low
P31314 F04ef6 homeo box 11 (T-cell lymphoma 107 4127 170 1774236 151 5175 724E-01 660E-01 1 Unchanged Low
095427 G21cd8 phosphatidylmositol glycan das' 8422817 116 177 4629 125 81B9 1 08E+00 4 59E-01 1 Unchanged Low
Q12981 C24ef5 BCL2/adenovιπJS E1B 19kD ιnteι 8238214 998 1775246 1199152 1 11E+00 2 77E-01 1 Unchanged Low
Q9Y5V1 L10ef1 HSPC042 protein 212074 184 1777635 191 3703 -2 55E-01 -203E-01 1 Unchanged Low
Q9H4B4 022ab4 cytokme-inducible kinase 161 982 194 177788 177 8629 1 34 E-01 2 59 E-01 1 Unchanged Low
Q9H6D1 P15gh5 chromosome 20 open reading frs 9543432 108 177 8526 1269312 898E-01 1 72E-01 1 Unchanged Low
060504 J18cd5 vmexin beta (SH3-contaιnιng adi 1093831 998 177 8876 1290088 7 02E-01 -1 33E-01 1 Unchanged Low
Q9UNK0 I02cd5 syntaxiπ 8 2182149 171 177 9777 1890342 -294E-01 -3 53 E-01 1 Unchanged Low
095657 B24cd4 praline-seπne-threoπine phosph- 369 9485 158 1780072 2352956 -1 06E+00 -1 23E+00 1 Unchanged Low
P20645 C05ab7 mannose-6 phosphate receptor ( 355 8249 234 178 1318 2560667 -998E-01 -603E 01 1 Unchanged Low
014569 B03ab2 putative tumor suppressor 1224884 792 178 136 12662 540E-01 -628E 01 1 Unchanged Low
015293 D18cd3 MAP-kmase activating death don 157092 114 178 1677 1498523 1 82E-01 -459E-01 1 Unchanged Low
P00390 E14ef7 glutathione reductase 282 1492 196 178 741 218 8246 -663E-01 -524E-01 1 Unchanged Low
Q9HBV3 K24gh5 PP3111 protein 2292714 361 1784093 256 1517 -362E-01 654E-01 1 Unchanged Low
014558 H17ab8 phosphonbosyl pyrophosphate s 301 219 227 1784567 235 5213 -7 55E-01 -409E-01 1 Unchanged Low
014710 F01ef5 cell cycle progression 2 protein 261 2178 189 1787923 2097103 -547E-01 -466E-01 1 Unchanged Low
Q9UJ70 J10ef3 N-acetylglucosamine inase 151 2986 276 1787992 201 9381 241E-01 866E-01 1 Unchanged Low
Q13397 M18cd6 zinc finger protein 238 215 883 285 1789318 2265893 -271E-01 4 OOE-01 1 Unchanged Low
Q9NRG4 B21gh4 HSKM-B protein 143 1326 279 178999 200 3335 3 23E 01 9 62E-01 1 Unchanged Low P51449 B01cd2 RAR-related orphan receptor C 2366977 97 2 1790372 170 992 -403E-01 1 28E+00 1 Unchanged Low
Q9H768 021 gh7 synaptotagmln-like 2 8378255 121 1790813 1280355 1 10E+00 533E-01 1 Unchanged Low
Q14332 F22ef5 fnzzled homolog 2 (Drosophila) 86 25011 129 179 1323 131 3078 1 05E+00 576E-01 1 Unchanged Low
Q13207 N13cd2 T-box 2 1189378 108 179 1858 1352524 591 E-01 -1 44E-01 1 Unchanged Low
Q9H6BB Bigghδ hypothetical protein similar to mc 134338 129 179 5015 147 5119 4 18E-01 -6 19E-02 1 Unchanged Low
000462 J09ab7 mannosidase, beta A, lysosomal 8323817 107 1796953 1232365 1 11 E+00 359E-01 1 Unchanged Low
Q9Y3D8 H14ef2 adrenal gland protein AD-004 1784931 163 1797989 1737578 1 05E-02 -1 31 E-01 1 Unchanged Low
P17900 F19ab3 GM2 ganglioslde activator proteli 1247747 232 179914 1789056 528E-01 895E-01 1 Unchanged Low
Q9P0M4 O10cd8 Interleukin 17C 2608753 223 180 0241 221 2511 -535E-01 -227E-01 1 Unchanged Low
F13gh8 G protein-coupled receptor 54 8792591 133 1800735 133 5723 1 03E+00 5 94E-01 1 Unchanged Low
Q9NZ92 J02gh3 SWI/SNF related, matnx associa 2677307 247 180 206 231 4963 -571 E-01 -1 10E-01 1 Unchanged Low
Q9NX94 L18gh6 hypothetical protein FLJ20154 1336318 165 180 3424 1597713 432E-01 307E-01 1 Unchanged Low
P04049 G12ef5 v-raf-1 murine leukemia viral one 225086 183 1803925 196 2063 -3 19E-01 -298E-01 1 Unchanged Low
Q13181 B06cd1 ATP-bindmg cassette, sub-family 1679383 127 1804651 1585133 1 04E-01 -402E-01 1 Unchanged Low
P22102 M05ab6 phosphonbosylglycinamide formv 2950489 180 1805026 2184202 -709E-01 -7 15E-01 1 Unchanged Low
Q9NQZ8 A09gh5 endothelial zinc finger protein inc 9679284 " 138 1807283 138 4428 901 E-01 5 10E-01 1 Unchanged Low
Q9UN30 D04cd2 sex comb on midleg-like 1 (Drosc 9747885 86 181 0121 121 4921 893E-01 -1 81 E-01 1 Unchanged Low
P26651 J04ef6 zinc finger protein 36, C3H type, 2860733 162 181 0638 209 8211 -660E-01 -8 17E-01 1 Unchanged Low
P18887 O06ef6 X-ray repair complementing defe 85 61601 102 181 0778 1229254 1 08E+00 254E-01 1 Unchanged Low
Q9Y2S0 P14ef1 RNA polymerase 1 16 kDa subun 1829338 149 181 2184 170 8985 -1 36E-02 -3 OOE-01 1 Unchanged Low
P49023 I05ef7 paxillm 3137788 334 181 2995 2763491 -791 E-01 900E-02 1 Unchanged Low
P49321 O03ab7 nuclear autoantigenio sperm prat 119903 782 181 3524 1264866 597E-01 -6 17E-01 1 Unchanged Low
Q13428 M14cd1 Treacher Collms-Franceschetti s 164 3621 123 181 4282 1562838 1 43E-01 -4 18E-01 1 Unchanged Low
Q9HCS6 G07gh4 vacuolar protein sorting 11 (yeas 1772833 302 181 4601 2200848 336E-02 766E-01 1 Unchanged Low
P20813 I02gh6 cytochrome P450, subfamily IIB ( 1223562 162 181 476 1553947 569E-01 4 08E-01 1 Unchanged Low
000459 C05cd1 phosphoιnosιttde-3-kιnase, regul 1453741 160 181 534 162 3275 320E-01 1 39E-01 1 Unchanged Low
P50151 H24ab4 guanme nucleotide binding prate 186 5329 193 1820963 187 0796 -347E-02 4 62E-02 1 Unchanged Low
Q16850 D12ab3 cytochrome P450, 51 (lanosterol 353 9667 116 182 1309 2173331 -9 50E-01 -1 61 E+00 Unchanged Low
QgULW3 J09cd8 TATA-bindiπg protein -binding pre 9723454 207 182 1565 1620616 9 06E-01 1 09E+00 1 Unchanged Low
Q16378 O20cd7 proline πch 4 (iacnmal) 81 91 152 1823589 1388678 1 15E+00 8 95E-01 1 Unchanged Low
P41240 J14ab4 c-src tyrosine kinase 1751285 153 1824257 1700806 58gE-02 -1 98E-01 Unchanged Low
Q16649 G05cd1 nuclear factor, interleukin 3 regul 3536698 169 1824266 235 1072 -955E-01 -1 06E+00 1 Unchanged Low
Q9Y3M2 J03ef8 chromosome 22 open reading frs 7427488 194 182 6022 1502264 1 30E+00 1 38E+00 Unchanged Low
Q9UK58 M14gh4 cyclin L anla-6a 191 3619 313 1826351 2290134 -673E-02 7 10E-01 Unchanged Low
P47874 M23cd1 olfactory marker protein 2503691 172 18273 201 6274 -454E-01 -543E-01 Unchanged Low
095620 O03cd7 protein similar to E coll yhdg and 227 8932 207 183 1055 2058925 -3 16E-01 -1 41 E-01 Unchanged Low
Q9UHV2 J11cd8 CDK4-bιndιng protein p34SEI1 1442806 163 1835211 163 6559 347E-01 1 77E-01 Unchanged Low
P02810 F07gh6 proline-nch protein Haelll subfan 4103478 392 1836977 3286668 -1 16E+00 -662E-02 Unchanged Low
O94g03 K04cd7 proline synthetase co-transcπbec 2422062 146 1839744 1907733 -3 97E-01 -729E-01 Unchanged Low
Q9P0W6 I03ef4 lipopolysacchaπde specific respc 149 1418 177 1840725 16 g232 304E-01 243E-01 Unchanged Low
Q9H8X4 015gh5 stromal membrane-associated pr 358 1542 342 1840879 2946026 -g 60E-01 -684E-02 Unchanged Low
P02786 D24ef5 transferππ receptor (p90, CD71) 3208365 257 1842545 254 0696 -8 OOE-01 -3 19E-01 Unchanged Low
E15ef1 immunoglobulin heavy constant i 386489 176 1843533 2490303 -1 07E+00 -1 13E+00 Unchanged Low
Q99717 J01ab7 MAD, mothers against decapente 227 5817 153 184 3978 1884757 -304E-01 -569E-01 Unchanged Low
Q15036 B23gh1 sorting nexin 17 3038909 411 1844831 2996453 -720E-01 434E-01 Unchanged Low
P31751 A08ab2 v-akt uπne thymoma viral oncoi 2537531 253 184 8245 2304512 -4 57E-01 -5 57E-03 Unchanged Low
P11177 G21ab8 pyruvate dehydrogenase (lipoam 229 1486 150 1850719 188 1769 -308E-01 -608E-01 Unchanged Low
Q9UEQ6 F22ab2 arrest , beta 2 1907331 128 185 1221 1679086 -431E-02 -577E-01 Unchanged Low
Q16531 J11ab5 damage-specific DNA binding pn 205 1934 229 185 1363 206 5357 -1 48E-01 1 60E 01 Unchanged Low
P28698 G24cd3 zinc finger protein 42 (myeloιd-s[ 76 12612 105 1853347 1223029 1 28E+00 470E-01 1 Unchanged Low
P41968 N12ef4 melanocortin 3 receptor 2253987 287 1855363 2326783 -281E-01 349E-01 Unchanged Low
P54920 E03cd4 N-ethylmaleimide-seπsltive factoi 306753 267 185697 252 9933 -724E-01 -203E-01 1 Unchanged Low
Q99487 C19ab8 platelet-activating factor acetylhy 2284138 241 1857091 2185222 -209E-01 8 OOE-02 Unchanged Low
Q9H0C8 N15gh7 iπtegπn-linked kinase-associated 1208459 109 1857532 138 517 620E-01 -1 49E-01 Unchanged Low
P17252 F17ab8 protein kinase C alpha 1083851 74 1858466 1227553 778E-01 -5 50E-01 Unchanged Low
P06493 B01ef5 cell division cycle 2, G1 to S and 108 1696 762 185 8754 1234207 7 81 E-01 -505E-01 1 Unchanged Low
000139 C14ab7 kinesm heavy chain member 2 1404141 205 1859437 177 1988 4 05E-01 548E-01 1 Unchanged Low
P54259 N05ef6 dentatorubral-pallidoluysian atroi 1655295 152 1860962 167773 1 69E-01 -1 26E-01 1 Unchanged Low
Q99757 G10cd8 thioredoxiπ 2 3090415 163 186 106 2194587 -7 32E-01 -921 E-01 1 Unchanged Low
Q9NW68 B12gh2 hypothetical protein FLJ10276 1074044 242 186 1575 1786551 7 93E-01 1 17E+00 1 Unchanged Low
P16106 016gh6 H3 histone family, member J 137 9914 135 1862589 152 9203 4 33E-01 -3 60E-02 1 Unchanged Low
P40692 M06ef6 mutL homolog 1 , colon cancer, n 9877988 108 1862872 131 0441 9 15E-01 1 30E-01 I Unchanged Low
Q99798 E01ab2 aconitase 2, mitochondria] 615211 291 186 5524 364 1757 -1 72E+00 -1 08E+00 I Unchanged Low
P53618 A11ef3 coatomer protein complex, subur 2384 51 102 186 6268 175 716 -354E-01 -1 23E+00 1 Unchanged Low
Q9UJ69 N24gh2 Toll-interacting protein 211 4055 259 1866408 2190188 -1 80E-01 293E-01 1 Unchanged Low
Q9NRM2 P22ef8 zinc finger protein 277 232 9567 227 186 8854 215 6334 -3 18E-01 -370E-02 1 Unchanged Low
Q92879 B06cd6 CUG triplet repeat, RNA binding 2173752 198 187 122 200 6744 -2 16E-01 -1 38E-01 1 Unchanged Low
075399 H22gh1 deformed epidermal autoregulatc 189 8387 266 1872872 2144669 -1 95E-02 488E-01 1 Unchanged Low
Q9BZE4 I17cd8 G protein-binding protein CRFG 151 2547 214 187 3094 184 3092 308E-01 5 03E-01 1 Unchanged Low
Q9NXB2 G08gh2 hypothetical protein FLJ20343 2590672 285 187 4246 243 8822 -4 67E-01 1 38E-01 1 Unchanged Low
095424 M06ef4 MYLE protein 1032077 184 187 5574 158 2861 862E-01 8 35E-01 1 Unchanged Low
P54577 D14cd3 tyrosyl-tRNA synthetase 1455748 108 187 5756 1469084 3 66E-01 -4 36E-01 1 Unchanged Low
043692 N03ef7 protease inhibitor 15 102 529g 163 1877565 150 9471 873E-01 6 65E-01 1 Unchanged Low
060507 J03cd3 tyrosylprotein sulfotransferase 1 190 271 136 188 0843 171 4862 -1 67E-02 -4 83E-01 1 Unchanged Low
Q9BYS9 B15gh5 MMS19-lιke (MET18 homolog, S 9929429 117 188 1006 1347877 922E-01 236E-01 1 Unchanged Low
P32780 G11ab6 general transcription factor IIH, p 258 9396 180 188 3175 209 0492 -4 59E-01 -5 25E-01 1 Unchanged Low
Q14004 D07ef5 cell division cycle 2-lιke 5 (cholin 9256943 158 1883656 146 1954 1 02E+00 7 68E-01 1 Unchanged Low
Q15910 L08ab5 enhancer of zeste homolog 2 (Dr 213 1801 306 188 8314 2359636 -1 75E-01 5 21 E-01 1 Unchanged Low
P47974 H22ab4 zinc finger protein 36, C3H type-l 1877102 163 188 8801 179 8162 896E-03 -205E-01 1 Unchanged Low
Q13177 E20ab8 p21 (CDKN1A) activated kinase 3677706 232 188 9048 2629597 -961 E-01 -6 63E-01 1 Unchanged Low
P16gh8 baculoviral IAP repeat-containmς 251 3679 126 1890052 1886409 -4 11 E-01 -1 OOE+00 1 Unchanged Low
P98172 J01ef7 ephrιn-B1 1228828 109 1895198 1404039 625E-01 -1 75E-01 1 Unchanged Low
Q9BQB1 N04gh6 hypothetical protein FLJ10342 113906 172 1897648 1584309 7 36E-01 591 E-01 1 Unchanged Low
075472 H11cd5 DπaJ (Hsp40) homolog, subfamil 227 1041 204 189 9354 206 8756 -258E-01 -1 58E-01 1 Unchanged Low
075608 K06cd6 lysophospholipase I 357 6112 374 190 1833 3072824 -911 E-01 648E-02 1 Unchanged Low
000193 E14ef3 small acidic protein 223 9793 284 190 2397 2327223 -236E-01 3 42E-01 1 Unchanged Low Q 14452 B0βab5 glucocorticold receptor DNA bine 1568451 147 190439 1646255 280E-01 -975E-02 1
P55268 P18ef6 laminin, beta 2 (laminin S) 1250717 152 1905787 155 8763 608E-01 2 81 E-01 1
Q9P006 A20ef8 mitochondrial nbosomal protein t 114 6952 151 1906578 152 156 733E-01 398E-01 1
Q9Y3B5 P07ef1 CG1-111 protein 1586983 176 190 6804 1752567 2 65E-01 1 52E-01 1
Q9NQ34 A10gh4 chromosome 11 open reading frs 1443438 161 1 o 6944 1653815 4 02E-01 1 59E-01 1
Q9NWY4 014gh2 hypothetical protein FLJ20534 70 02507 110 191 0561 1235579 1 45E+00 646E-01 1
Q9UBS8 P17ab2 nng finger protein 14 227 9827 247 91 1542 221 9109 -2 54E-01 1 13E-01 1
Q9UBS4 J06ef2 DnaJ (Hsp40) homolog, subfamil 181 8446 175 191 2168 1827428 7 25E-02 -5.40E-02 1
Q12797 J22ab2 aspartale beta-hydroxylase 101 2251 865 191 3988 1263618 9 19E-01 -227E-01 1
Q9H4I9 P10gh8 hypothetical gene supported by / 1675049 219 191 4831 1927801 1 93E-01 389E-01 1
014907 E24ef8 Tax interaction protein 1 351 7729 403 191 7684 3156313 -875E-01 1 97E-01 1
Q14673 B09gh1 Bcl-2-assocιated transcnption fat 97 16912 117 191 9499 135 533 9 82E-01 274E-01 1
Q9NWB7 P01gh2 estrogen-related receptor beta III 567 7076 84 6 1920982 281 455 1 56E+00 -275E+00 1
Q9BVH4 G21gh6 hypothetical protein MGC3196 1648572 169 1924133 1754765 223E-01 372E-02 1
P22897 I17ab7 aππose receptor, C type 1 7730638 100 1924612 1234215 1 32E+00 378E-01 1
P19012 L04ab6 keratin 15 146 5532 130 1926097 1565003 394E-01 -1 69E 01 1
Q14738 C16cd1 protein phosphatase 2, regulator 2244642 183 1927984 200 124 -219E-01 -2 94E-01 1
095152 F04cd4 vesicle trafficking protein 1976319 196 192 9314 ig53686 -347E-02 -1 53E-02 1
P78426 A09cd3 NK6 transcription factor homolog 1985291 353 1930203 2482544 -4 06E-02 831 E-01 1
Q14790 P14ab3 caspase 8, apoptosis-related cys 124 8603 284 193 1013 2006718 629E-01 1 19E+00 1
P07711 N13ab4 cathepsm L 137 16 121 193 1454 150 5861 494E-01 -1 5E-01 1
P32942 B02ab6 intercellular adhesion molecule 3 1403673 140 1931656 1576897 461 E-01 -857E-03 1
L18ab2 ATPase, Na+/K+ transporting, all 1889371 131 194 2503 171 3764 4 00E-02 -529E-01 1
Q9NWS0 F13gh2 hypothetical protein FLJ20643 81 29108 107 1944652 127 6547 1 26E+00 3 g9E-01 1
QgNWZ5 O06gh2 uridine kmase-like 1 176 188 358 ig44782 2429739 1 42E-01 1 02E+00 1
075792 D15cd6 nbonuclease HI, large subunit 1003515 996 194705 131 5441 9 56E-01 -1 12E-02 1
P05141 I04ab2 solute earner family 25 (mitochor 4549832 311 1947577 3203918 -1 22E+00 -547E-01 1
Q9NX38 K22gh2 hypothetical protein FLJ20457 1407383 161 1952668 1657012 472E-01 1 95E-01 1
Q9Y682 A18cd8 sec22 homolog 1937656 271 1953918 220 1941 1 21E-02 4 86E-01 1
P78381 C02cd4 solute carrier family 35 (UDP-gal 276 1892 207 1956585 2264009 -4 97E-01 -4 14E-01 1
Q9UMP5 B23ef3 replication Initiation region protei 2704297 179 1956957 214 9641 -4 67E-01 -5 97E-01 1
Qgpooo C15ef3 hypothetical protein HSPC228 1296054 241 1957376 188838 595E-01 896E-01 1
Q9UBQ3 M12cd7 polyamiπe-modulated factor 1 18943g7 172 1957465 1857473 472E-02 -1 39E-01 1
P27540 D22ab2 aryl hydrocarbon receptor nudes 2394814 258 195776 231 071 -291 E-01 1 07E-01 1
Q9Y2W1 F03cd5 thyroid hormone receptor-associ. 1602008 248 1957775 201 3236 2 89E-01 630E-01 1
P82267 E15ab4 adaptor-related protein complex 1986022 231 1957793 208 571 -2 07E-02 220E-01 1
P00918 C16ab3 carbonic aπhydrase II 2834506 172 1959099 2169569 -533E-01 -725E-01 1
Q9Y663 E07cd6 heparan sulfate (glucosamme) 3 259 052 998 196 1045 1849847 -402E-01 -1 38E+00 1
Q9NX40 K18gh2 ovanan carcinoma Immuπoreacti 1196155 247 196 1836 1877106 7 14E-01 1 05E+00 1
P50222 L09ab7 mesenchyme homeo box 2 (grow 1653048 223 1965502 1950839 2 50E-01 4 34E-01 1
Q13610 C16cd7 nuclear phosphoprotem similar tc 160 8948 331 1967055 2294375 290E-01 1 04E+00 1
P49591 B12cd2 seryl-tRNA synthetase 1525268 696 1967944 1396467 368E-01 -1 13E+00 1
P04554 C19gh5 protamine 3 3148934 296 1969835 2693189 -677E-01 -8 89E-02 1
P02538 N12ef6 keratin 6A 227 8925 277 197 1759 2339139 -209E-01 2 80E-01 1
Q13637 G23cd7 RAB32, member FiAS oncogene 3 20158 2βg 1972609 286 1382 -991 E-01 -543E-01 1
P39086 J02ab3 glutamate receptor, lonotropic, k. 1843318 210 197334 1972285 9 83E-02 1 88E-01 1
Q9H8F9 H20gh5 hypothetical protein 24432 28708 202 197402 2288927 -540E-01 -506E-01 1
Q99460 L13ab8 proteasome (prosome, macropaii 2983527 228 197 4025 241 22 -596E-01 -3 B9E-01 1
Q9UKP6 D20gh1 G protein-coupled receptor 14 2133717 142 1975131 1843366 -1 11 E-01 -586E-01 1
Q16589 A04ef5 cyclin G2 9961434 214 197 5658 1703526 9 88E-01 1 10E+00 1
095316 M03cd5 nbosomal protein S6 kinase, 90k 1448234 145 197 5662 162 324 448E-01 -240E-03 1
014545 A09cd7 FLN29 gene product 2384292 288 1978936 241 5146 -269E-01 274E-01 1
Q9Y249 P03cd6 homologous to yeast nitrogen pe 191 1146 224 198 1049 2044863 5 18E-02 231 E-01 1
Q92794 K12cd4 zinc finger protein 220 134 123 179 198312 1703523 5 64E-01 4 13E-01 1
P36B94 A12ab3 bone morphogenetic protein recs 1492953 236 1984963 194 5315 4 11E-01 6 59E-01 1
P79525 L21ab7 MHC class I polypeptide-related 120 8289 125 1985782 1480291 7 17E-01 453E-02 1
014947 K04ab6 laminin, beta 3 (nicein (125kD), k 3608887 284 1992636 281 2972 -857E-01 -347E-01 1
Q12899 K16cd3 tnpartite motif-containing 26 1886935 250 19g 2998 212 5994 7 89E-02 405E-01 1
M24gh8 zinc finger protein 289, ID1 regul 91 37228 137 19 4969 1424645 1 13E+00 579E-01 1
Q9UIJ5 A18ef2 zinc finger, DHHC domain contai 436 5048 452 19g 696 3627132 -1 13E+00 501E-02 1
P46821 J11ab7 microtubule-associated protein 1 121 2356 136 1998286 1524972 7 21 E-01 1 70E-01 1
060906 P04cd1 sphlngomyelm phosphodiesteras 2825771 281 199835 2545351 -500E-01 -708E-03 1
P04040 018ab5 catalase 1607098 230 1999283 1998034 3 15E-01 571E-01 1
O60709 B16cd5 dynamin 1-like 8533527 220 1999492 1684792 1 23E+00 1 37E+00 1
Q14714 A02cd4 sarcospaπ (Kras oncogene-assoi 378 724 148 200 1413 242 1486 -9 20E-01 -1 36E+00 1
P39687 F01cd4 acidic (leuciπe-πch) nuclear phoe 2268272 108 200 186 1783873 -1 80E-01 -1 07E+00 1
075341 K16cd4 BRCA1 associated protein 151 895 209 2002666 187 1088 399E-01 462E-01 1
Q9NUN1 D16gh3 hypothetical protein FLJ11259 152 5767 196 200 5435 182989 3 94E-01 360E-01 1
Q9UHR5 2ef7 transcriptional regulator protein 225 1172 345 200 7483 2569591 -1 65E-01 6 16E-01 1
Q9UMX3 D15gh8 BCL2-related ovarian killer 1852616 176 200 9857 1874707 1 18E-01 -7 26E-02 1
Q02297 J05ef6 πeuregulm 1 8951288 234 201 3025 1750464 1 17E+00 1 39E+00 1
Q9BQ83 A21gh6 hypothetical protein MGC5178 3027768 398 201 3498 3007124 -589E-01 395E-01 1
043491 C22ab4 erythr ocyte membrane protein bε 265 5557 144 201 5206 2036633 -3 98E-01 -8 84E-01 1
Q92922 Nl6cd1 SWI/SNF related, matπx associa 251 3134 195 201 571 2160309 -3 18E-01 -364E-01 1
Q16099 J11ef3 glutamate receptor, lonotropic, k> 2000311 288 201 66 229 9201 1 17E-02 526E-01 1
095328 B06gh4 hypothetical protein 628 2532751 240 201 6989 231 7737 -329E-01 -756E-02 1
Q06265 C15cd1 polymyositis/scleroderma autoan 1673169 182 2022097 1839827 273E-01 1 25E-01 1
Q01780 K12gh6 polymyositis/scleroderma autoan 1969508 270 2022308 223 1866 3 82E-02 4 57E-01 1
Q9NPF9 G07ef3 HeLa cyclin-dependent kinase 2 251 6953 170 202 5242 207 9337 -3 14E-01 -570E-01 1
Q9P1U0 B03ef4 zinc πbbon domain containing, 1 1107474 151 2027351 1548483 8 72E-01 448E-01 1
Q13480 C02ab5 GRB2-assoclated binding proteir 171 5634 150 203065 1747367 243E-01 -1 98E-01 1
095205 O05gh1 C3H-type zinc finger protein, sim 1367838 267 2033797 2022261 572E-01 962E-01 1
076091 H1cd1 nitnlase 1 19424 179 2034317 1922638 6 67E-02 -1 17E-01 1
Q9Y364 F21ef2 DKFZP434J154 protein 208 15 322 2035516 2444561 -322E-02 628E-01 1
P51116 I14cd5 fragile X mental retardation, auto 2159784 213 203 6388 210 8166 -849E-02 -2 12E-02 1
P49915 H19cd4 guanine monphosphate syntheta 1755001 115 2036534 1646237 2 15E-01 -6 13E-01
Figure imgf000072_0001
1 Q9UHR3 O04cdB nasopharyngeal carcinoma susα 1200173 195 2038212 1733257 7 64E-01 7 09E-01 1 Unchanged Low
Q15007 O10cd5 Wilms' tumour 1-assoclafing prot 237 1077 258 204228 2330967 -2 15E-01 1 22E-01 1 Unchanged Low
P24941 B03ef5 cyclin-dependent kinase 2 9860804 214 204 3554 1722468 1 05E+00 1 12E+00 1 Unchanged Low
P53634 L01ef7 cathepsln C 97 3314 77 9 204771 1266548 1 07E+00 -322E-01 1 Unchanged Low
Q13123 K03ef7 IK cytoklne, down-regulator of Ht 1086134 153 2049565 1555636 9 16E-01 4 95E-01 1 Unchanged Low
Q9NUT6 P21gh3 hypothetical protein FLJ11151 285 3106 565 2050219 351 7208 -477E-01 85E-01 1 Unchanged Low
Q9Y279 B23cd7 lg superfamily protein 3568489 226 2050366 2626019 -7 99E-01 -6 59E-01 1 Unchanged Low
075319 H07cd3 dual specificity phosphatase 11 ( 250 2151 205 205 1456 2202678 -2 87E-01 -2 84E-01 1 Unchanged Low
Q9NYH9 L08ef3 hepatocellular carclnoma-associ. 287 2586 283 205223 2586032 -4 85E-01 -1 99E-02 1 Unchanged Low
Q9UNF0 M20cd7 protein kinase C and casein klna 4385503 349 20553 331 0599 -1 09E+00 -329E-01 1 Unchanged Low
060437 D03ab8 penplakin 4439882 301 2055879 3168358 1 11 E+00 -5 61 E-01 1 Unchanged Low
Q9NZN8 N22cd8 CCR4-N0T transcnption comple 189665 224 205673 2065153 1 17E-01 241 E-01 1 Unchanged Low
Q14232 A18ab4 eukaryotic translation initiation fa 2737271 210 2057436 2299659 -4 12E-01 -379E-01 1 Unchanged Low
000142 C03ef5 thymidine kinase 2, mitochondπa 124 7128 147 2059951 159 1674 724E-01 2 35E-01 1 Unchanged Low
060443 N15ab5 deafness, autosomal dominant 5 1224035 264 2063187 1974327 7 53E-01 1 11 E+00 1 Unchanged Low
095406 J20cd5 cornichon-like 181 7181 138 2064442 1754375 1 84E-01 -3 95E-01 1 Unchanged Low
Q12841 E24cd7 follistatin-like 1 8093058 97 7 2065097 1283877 1 35E+00 272E-01 1 Unchanged Low
015217 B04ab5 glutathione S-transferase A4 7838055 91 3 2066118 125424 1 40E+00 2 20E-01 1 Unchanged Low
P10645 E01ab4 chromograniπ A (parathyroid sec 1157467 283 2068714 201 8922 838E-01 1 29E+00 1 Unchanged Low
Q9HA66 D09gh5 G protein beta subunit-like 198 1992 192 2069573 199 1923 624E-02 -4 27E-02 1 Unchanged Low
Q9Y439 BOSefβ PRP31 pre-mRNA processing fai 1757234 310 207 0904 2309065 237E-01 8 19E-01 1 Unchanged Low
Q9Y386 G08ef2 CGI-78 protein 3256509 246 2077702 2597061 -648E-01 -4 06E-01 1 Unchanged Low
P539g0 D21gh1 KIAA0174 gene product 230 1187 401 207 9831 279676 -1 46E-01 801E-01 1 Unchanged Low
095865 011ef3 dimethylarginiπe dimethylamlnoh 125 0105 57 2080048 163 3476 7 35E-01 329E-01 1 Unchanged Low
B21ef1 immunogiobulm lambda-like poly 1427367 230 208 1338 1935142 544E 01 686E-01 1 Unchanged Low
Q 5834 I17cd7 hepatitis delta antigen-mteracttπj 3207647 226 208 1753 251 6031 -624E-01 -506E-01 1 Unchanged Low
P18846 H05ab4 activating transcπption factor 1 470 9776 206 2083404 2952222 1 18E+00 -1 19E+00 1 Unchanged
Q14349 A23cd7 HLA-B associated transcript 8 138 8938 175 208 5984 174 3142 587E-01 337E-01 1 Unchanged Low
Q9NVM5 M08gh3 hypothetical protein FLJ10637 98 19923 115 2090315 140 794 1 09E+00 230E-01 1 Unchanged Low
P12955 N18ab7 peptidase D 1338157 192 2090325 1782362 643E-01 520E-01 1 Unchanged Low
Q9g700 D14cd1 spinocerebellar ataxia 2 (olivopoi 191 0044 240 2090555 213 1956 1 30E-01 327E-01 1 Unchanged Low
Q9UJA2 E21gh3 chromosome 20 open reading frs 1342553 316 209227 219 8275 640E-01 1 23E+00 1 Unchanged Low
Q02246 J21ef6 contactin 2 (axonal) 108 0043 688 2093915 1287469 955E-01 -650E-01 1 Unchanged Low
P48553 E06cd2 transmembrane protein 1 1480375 238 2094168 1984177 500E-01 6 84E-01 1 Unchanged Low
Q99639 K03cd2 suppressor of Ty 5 homolog (S c 225 1962 296 209795 2435051 -1 02E-01 3 92E-01 1 Unchanged Low
Q9NQX5 N02gh4 neural proliferation, differeπtiatioi 1880695 206 2098245 201 225 1 58E 01 1 30E-01 1 Unchanged Low
Q9g799 O08cd6 nuclear RNA export factor 1 2054132 175 2099237 1967655 3 13E-02 -2 32E-01 1 Unchanged Low
Q9BZV1 J05gh7 UBX domain-containing 1 1277069 236 2099733 191 2074 7 17E-01 886E-01 1 Unchanged Low
Q03113 M19ab5 guanine nucleotide binding prate 140 2412 112 2099975 154 1344 582E-01 -322E-01 1 Unchanged Low
P01130 B21ab6 low density lipoprotein receptor ( 301 1179 394 210369 301 7776 -5 17E-01 3 87E-01 1 Unchanged Low
Q9UHN6 L11cd8 transmembrane protein 2 1823012 130 2105088 174 2344 2 08E-01 -489E-01 1 Unchanged Low
Q99738 A03cd3 pinm, desmosome associated pr< 2007164 204 210 6944 2050214 7 OOE-02 2 10E-02 1 Unchanged Low
Q9Y576 N03ef2 ankyπn repeat and SOCS box-cc 121 1139 762 2108606 1360527 800E-01 -669E-01 1 Unchanged Low
P02304 B03gh6 H4 histone, family 2 81 15302 191 210 8651 161 1405 1 38E+00 1 24E+00 1 Unchanged Low
P01118 I08ab7 v-Kι-ras2 Kirsten rat sarcoma 2 v 2094177 239 211 0234 219 9522 1 10E-02 1 93E-01 1 Unchanged Low
P15924 K13ef7 de5moplakιn (DPI, DPII) 2499083 263 211 0334 241 3819 -244E-01 7 48E-02 1 Unchanged Low
043597 A19cd6 sprouty homolog 2 (Drosophila) 1195051 155 211 0573 161 8627 821 E-01 375E-01 1 Unchanged Low
P09622 I06ab3 dihydrolipoamlde dehydrogenase 3463029 232 211 1679 2632128 -7 14E-01 -577E-01 1 Unchanged Low
Q08257 G16ef7 crystallin, zeta (quinoπe reductas 514 6998 301 211 6448 3424839 -1 28E+00 -773E-01 1 Unchanged Low
Q9UHY8 J09cd7 fasciculation and elongation pro. 86 8735 95 1 211 8371 131 2705 1 29E+00 1 31 E-01 1 Unchanged Low
P10646 P23cd2 tissue factor pathway inhibitor (li| 5968869 458 2120146 422403 -1 49E+00 -381E-01 1 Unchanged Low
Q92685 L08cd5 Not56 (D melanogaster)-lιke pro 1952017 217 2122397 208 1394 1 21 E-01 1 53E-01 1 Unchanged Low
P34949 I13ab7 mannose phosphate isomerase 1022281 135 2123424 149 8251 1 05E+00 400E-01 1 Unchanged Low
Q9NPE9 M21ef8 HSPC055 protein 91 56792 157 212 3544 1537649 1 21 E+00 7 81 E-01 1 Unchanged Low
Q99853 J24ef7 forkhead box B1 141 4272 105 2124773 1530918 5 87E-01 -425E-01 1 Unchanged Low
Q9HD41 C24gh4 CHMP1 5 protein 2802988 230 2128608 241 047 -397E-01 -285E-01 1 Unchanged Low
Q16625 A10ab8 occludin 859 5688 338 2129222 470 2634 -201 E+00 -1 35E+00 1 Unchanged Low
P45973 L18efS chromobox homolog 5 (HP1 alph 1649514 124 213 1315 167 3186 370E-01 -4 13E-01 1 Unchanged Low
Q9NVI9 012gh3 hypothetical protein FLJ10707 1360971 136 213 1484 161 8885 647E-01 342E-03 1 Unchanged Low
P371 3 O09ef7 transforming growth factor, beta I 1124415 208 2133211 178 0564 g 24E-01 8 90E-01 1 Unchanged Low
Q9UKF7 021 cd8 retinal degeneration B beta 3336061 287 213 5389 277 9863 -644E-01 -2 18E-01 1 Unchanged Low
P16870 J23ef7 carboxypeptidase E 81 85341 137 2135973 144 0377 1 38E+00 740E-01 1 Unchanged Low
P00374 D16ab3 dihydrofolate reductase 1488142 596 2136217 140 6638 522E-01 -1 32E+00 1 Unchanged Low
P19957 M04ab8 protease inhibitor 3, skm-denved 202 9357 582 2139068 333 0661 760E-02 1 52E+00 1 Unchanged Low
075962 J24cd2 tπple functional domain (PTPRF 2337849 197 2139409 2150154 -1 28E-01 -245E-01 1 Unchanged Low
P16050 C24ab2 arachidonate 15-lιpoxygenase 2885504 87 3 2139824 196 6194 -431 E-01 -1 72E+00 1 Unchanged Low
Q9Y3D2 N14cd7 pilin-like transcnption factor 200 9397 224 2140069 2130068 9 09E-02 1 57E-01 1 Unchanged Low
000505 J16ab6 karyophenn alpha 3 (import alp 358 8945 313 214 0819 295 4165 -7 45E-01 -1 96E-01 1 Unchanged Low
Q9NZD8 N15ef1 acid cluster protein 33 222816 223 2142958 2200079 -562E-02 621E-04 1 Unchanged Low
P46937 G10cd6 Yes-associated protein 1 , 65 kD 2190427 268 214 3846 233924 -3 10E-02 293E-01 1 Unchanged Low
P53384 O05ab7 nucleotide binding protein 1 (Mm 2724995 223 2145051 236 5867 -3 45E-01 -2 91 E-01 1 Unchanged Low
Q9UI28 K10ef4 AD-003 protein 1204834 147 2147067 160 6424 8 34E-01 284E-01 1 Unchanged Low
Q14651 O20ab8 plasltn 1 (1 isofαrm) 5177448 303 214 7993 3452493 -1 27E+00 -772E-01 1 Unchanged Low
P10914 K01ef6 interferon regulatory factor 1 310 699 395 2149514 306 8604 -5 32E-01 346E-01 1 Unchanged Low
P21281 A03ab3 ATPase, H+ transporting, lysosoi 29907 638 2150012 383 914 -476E-01 1 09E+00 1 Unchanged Low
P53701 G19ab6 holocytochrome o synthase (cyto 251 8825 415 215 1177 2938906 -2 28E-01 7 19E-01 1 Unchanged Low
Q9Y2B1 C18ef3 transmembrane protein 5 1034737 123 2152492 1472535 1 06E+00 250E-01 1 Unchanged Low
Q14166 D23ef8 KIAA0153 protein 3325834 276 2154465 2747657 -6 26E-01 -268E-01 1 Unchanged Low
Q15738 B09ef4 NAD(P) dependent steroid dehyc 253061 171 2155558 213 0647 -2 31 E-01 -569E-01 1 Unchanged Low
Q 16586 I06cd1 sarcoglycan, alpha (50kD dystroj 358221 129 2158058 234 3861 -7 31 E-01 -1 47E+00 1 Unchanged Low
Q9Y6J8 L05ef2 map kinase phosphatase-like pre 2750054 326 2159987 2724953 -3 48E-01 248E-01 1 Unchanged Low
Q9H5F2 P17gh5 hypothetical protein FLJ23499 2041242 332 216 178 2508425 824E-02 703E-01 1 Unchanged Low
Q05655 E02cd1 protein kinase C, delta 4197056 297 216 1184 310 8344 -958E-01 -500E-01 1 Unchanged Low
Q9NXU7 M03gh3 hypothetical protein FLJ20048 2404802 235 216 1338 2306008 -1 54E-01 -321E-02 1 Unchanged Low
015498 P21cd6 SNARE protein Ykt6 1889561 242 2167243 2157355 1 98E-01 3 54E-01 1 Unchanged Low
Q92664 F07ab4 general transcnption factor IIIA 3 8 1862 193 2167575 2425829 -554E-01 -723E-01 1 Unchanged Low Q9Y223 N03cd5 UDP-N-acetylglucosamiπe-2-epιr 207311 295 21 1156 2399617 667E-02 5 11E-01 1 Unchanged Low
095816 E21ab3 BCL2-asεocιated athanogene 2 847224 942 2174827 132 1461 1 36E+00 1 53E-01 1 Unchanged Low
Q9H0K5 A21gh8 hypothetical protein DKFZp434H 193 1934 324 2176924 244 8706 1 72E-01 745E-01 1 Unchanged Low
Q9BTJ1 C03ef2 ribosomal protein S27-lιke 132 1497 411 2182702 2537125 7 24E-01 1 64E+00 1 Unchanged Low
Q9NRR5 J23gh4 chromosome 1 open reading frar 1382192 201 2184149 185 8791 660E-01 540E-01 1 Unchanged Low
Q9Y5L3 A13ab4 ectonucleoside tnphosphate dipt" 2352745 316 2184547 256 4569 -1 07E-01 4 24E-01 1 Unchanged Low
075351 K06cd5 suppressor of K+ transport defec 2745936 311 2186389 267 9692 -329E-01 1 78E-01 1 Unchanged Low
075443 F07cd2 tectoπn alpha 1834591 150 2187282 1842202 254E-01 -286E-01 1 Unchanged Low
Q9H7X4 K04gh7 KIAA1085 protein 2682576 372 2187527 2862489 -2 94E-01 471 E-01 1 Unchanged Low
000255 K22abS multiple endocrine neoplasia I 1347209 117 2189335 156 9374 7 01 E-01 -2 02E-01 1 Unchanged Low
Q9BV94 D05gh3 chromosome 20 open reading frs 319259 316 2192324 284 912 -542E-01 -1 37E-02 1 Unchanged Low
014813 D10ab2 anstaless homeobox (Drosophila 2263057 320 2192567 255 131 -4 57E-02 4 99E-01 1 Unchanged Low
P35269 D15ab4 general transcnption factor IIF, p 243 8395 213 21 g 8975 2254377 -1 49E-01 -1 98E-01 1 Unchanged Low
Q12891 E08ef5 hyaluronoglucosamlmdase 2 331 3833 311 2204462 2876363 -588E-01 -9 12E-02 1 Unchanged Low
015162 L08gh1 phosphollpid scramblase 1 440 6448 597 2206688 419 5068 -998E-01 439E-01 1 Unchanged Low
Q14469 O08ab7 hairy homolog (Drosophila) 151 2148 251 221 0242 207739 548E-01 731 E-01 1 Unchanged Low
P06241 P13ab4 FYN oncogene related to SRC, F 1064214 825 221 2951 1367385 1 06E+00 -367E-01 1 Unchanged Low
Q9BVG9 P17gh7 phosphatidylseπne synthase 2 225 5812 200 221 5588 215 8454 -260E-02 -1 71 E-01 1 Unchanged Low
Q9P0P9 K12ef2 hypothetical protein LOC51249 2904444 434 2226323 315 5648 -3 84E-01 578E-01 1 Unchanged Low
Q9UMF9 L14cd3 eukaryotic translation initiation fa 207 6515 242 2226344 2242505 1 01 E-01 224E-01 1 Unchanged Low
Q03527 L07ab8 proteasome (prosome, macropaii 441 6371 284 2226794 316 1666 -988E-01 -636E-01 1 Unchanged Low
P31153 J15ab7 methionme adenosyltransferase 2452111 134 2227802 200 5541 -1 38E-01 -875E-01 1 Unchanged Low
Q04741 D21ef1 empty spiracles homolog 1 (Dros 2403769 189 222791 217 4148 -1 10E-01 -346E-01 1 Unchanged Low
Q13153 L22ef5 p21/Cdc42/Rad -activated kinasi 243 198 277 2228583 247 6258 -1 26E-01 1 87E-01 1 Unchanged Low
Q9Y388 H15ef2 CGI-79 protein 1007214 181 2232467 1682598 1 15E+00 844E-01 1 Unchanged Low
Q9HC14 K17gh5 mitochondnal nbosomal protein S 1587783 200 2232594 193 9429 492E-01 3 31 E-01 1 Unchanged Low
P30281 O08ef5 cyclin D3 1074859 167 2232751 1660499 1 05E+00 S 39E-01 1 Unchanged Low
Q9UFK2 P05ef8 DKFZP564K1964 protein 1330476 210 2234229 188 8934 748E-01 6 60E-01 1 Unchanged Low
Q13011 023ab4 enoyl Coenzyme A hydratase 1 , | 337 9818 273 2237187 2782904 -595E-01 -307E-01 1 Unchanged Low
P09601 E20ef7 heme oxygenase (decycling) 1 1864519 425 2237447 278 3661 263E-01 1 19E+00 1 Unchanged Low
Q9BVZ8 P23gh8 hypothetical protein FLJ14936 126689 127 2240692 159346 823E-01 671E-03 1 Unchanged Low
Q13889 A11ab5 general transcnption factor IIH, p 112 1935 202 224 1653 179 5227 9 99E-01 8 50E-01 1 Unchanged Low
P49703 P23ab2 ADP-πbosylation factor 4-lιke 1256732 91 2 224 1896 147 0234 835E-01 -462E-01 1 Unchanged Low
Q9GZU7 G11gh4 nuclear LIM iπteraclor-interacllnc 3055546 150 2242596 2265474 -4 46E-01 -1 03E+00 1 Unchanged Low
P10253 M22ab3 glucosidase, alpha, acid (Pompe 187 3998 156 2242782 1890733 2 59E-01 -269E-01 1 Unchanged Low
Q9Y3V5 B18ef8 hypothetical protein DKFZP586F 303 8477 426 2244103 318 897 -437E-01 4 89E-01 1 Unchanged Low
014773 P17ef7 ceroid-lipofuscinosis, neuronal 2 1696468 214 2244535 2027117 404E-01 3 35E-01 1 Unchanged Low
P22061 G13cd1 protein-L-isoaspartate (D-asparte 118 1783 163 2245569 1686387 926E-01 4 66E-01 1 Unchanged Low
P14868 K21ab4 aspartyl-tRNA synthetase 117 1946 78 1 2250996 140 1468 9 42E-01 -5 85E-01 1 Unchanged Low
Q14938 D16ef6 nuclear factor l/X (CCAAT-bindin 9458773 849 2253458 1349545 1 25E+00 -1 55E-01 1 Unchanged Low
075968 P21ef3 pannexm 1 2159189 216 2255368 219 072 629E-02 -1 06E-03 1 Unchanged Low
Q9H779 C15gh6 hypothetical protein MGC2821 1384597 313 225 8086 225 7323 706E-01 1 18E+00 1 Unchanged Low
Q9BX72 C02gh8 IFP38 1689682 172 2258249 188 9468 4 18E-01 261E-02 1 Unchanged Low
043563 G24cd1 solute carrier family 22 (organic c 1337352 149 225 8428 1694168 7 56E-01 1 53E-01 1 Unchanged Low
015142 D17ab2 ARP2 aciin-related protein 2 hoπ 2503086 215 2260552 2303003 -1 47E-01 -222E-01 1 Unchanged Low
Q9UJ41 K17ef4 putative Rab5 GDP/GTP excham 121 9096 165 2265205 171 2118 8 94E-01 4 38E-01 1 Unchanged Low
P05231 F21ef7 interleukin 6 (mterferon, beta 2) 2402349 673 226 529 379972 -848E-02 1 49E+00 1 Unchanged Low
Q9Y2H0 G24ef8 KIAA0964 protein 2796086 310 226545 271 9604 -3 04E-01 1 48E-01 1 Unchanged Low
Q9UJT9 E15cd8 F-box and ieucine-πch repeat pre 287 9128 294 226762 2695315 -344E-01 298E-02 1 Unchanged Low
Q9Y306 023ef2 pelota homolog (Drosophila) 146 8037 190 2268083 1877391 6 28E-01 369E-01 1 Unchanged Low
QgY6A6 N04ef3 transcnption factor (p38 interactn 174 5425 171 2269539 1908287 3 79E-01 -2 97E-02 1 Unchanged Low
075300 K18cd2 πbosome binding protein 1 homo 9867954 737 227 0651 133 1515 1 20E+00 -4 21 E-01 1 Unchanged Low
P51708 L03ef1 chlonde channel 7 2784282 282 228 319 2630106 -2 86E-01 1 98E-02 1 Unchanged Low
Q1483g C21ab4 chromodomaiπ hellcase DNA bin 1048847 161 228322 1648091 1 12E+00 620E-01 1 Unchanged Low
060299 018gh1 KIAA0552 gene product 1325981 337 228426 2326614 785E-01 1 35E+00 1 Unchanged Low
Q9Y6F1 H03ab2 ADP-ribosyltransferase (NAD+, c 248 9844 399 2285355 292 1577 -1 24E-01 680E-01 1 Unchanged Low
015212 E04ef3 HLA class II region expressed ge 250 113 292 2285629 2567661 -1 30E-01 222E-01 1 Unchanged Low
Q9Y2W2 J14ef2 WW domain binding protein 11 335 0512 304 228 6314 289 1386 -551 E-01 -1 42E-01 1 Unchanged Low
Q9UKN5 O03cd8 PR domain containing 4 2526208 806 228639 187 2825 -1 44E-01 -1 65E+00 1 Unchanged Low
Q00978 C24cd6 iπlerferon-sli ulated iraπscπptioi 3037171 404 2287768 312 2774 -4 ogε-01 4 13E-01 1 Unchanged Low
Q9UHY0 L08ef1 HP1-BP74 2959512 267 2288435 263 8122 -371 E-01 -1 50E-01 1 Unchanged Low
Q9Y248 L13ef2 HSPC037 protein 92 39515 703 2290541 1305748 1 31 E+00 -395E-01 1 Unchanged Low
096019 E21ab2 BAF53 2289673 345 2295696 267 9206 379E-03 592E-01 1 Unchanged Low
P10276 K19ab8 retinoic acid receptor, alpha 250 0312 122 2297466 2007048 -1 22E-01 -1 03E+00 1 Unchanged Low
Q9BUC7 P22gh8 hypothetical protein MGC4172 1364413 398 2298471 254 8265 7 52E-01 1 55E+00 1 Unchanged Low
Q9HAC1 D01gh5 praja 1 1434188 97 5 230 0154 156 9785 681 E-01 -557E-01 1 Unchanged Low
Q9307B M16gh6 H2B histone family, member H 1799656 203 2302553 204 3058 3 56E-01 1 72E-01 1 Unchanged Low
P0B572 N22ef6 collagen, type IV, alpha 2 70 14126 87 3 230 3868 129 2665 1 72E+00 3 15E-01 1 Unchanged Low
P15056 G10ef5 v-raf munne sarcoma viral oncog 194 1803 174 231 0687 1997155 2 51 E-01 -1 59E-01 1 Unchanged Low
Q15543 J15cd2 TAF13 RNA polymerase II, TAT 222 3129 262 231 2695 238 5733 570E-02 238E-01 1 Unchanged Low
014901 J05cd3 TGFB inducible early growth res| 277 9069 277 231 5621 262 1749 -263E-01 -4 43E-03 1 Unchanged Low
N10gh8 diphosphate di ethylallyl diphos 313 8915 257 231 841 267 6704 -437E-01 -2 87E-01 1 Unchanged Low
P51965 013cd3 ubiquitin-conjugatmg enzyme E2 2542693 673 232 1178 3864499 -1 32E-01 1 40E+00 1 Unchanged Low
Q9Y3R2 G04cd8 transportm-SR 33845 219 2322301 263 1006 -543E-01 -6 31 E-01 1 Unchanged Low
094829 G10gh1 importin 13 1608646 247 2323109 2133188 530E-01 6 17E-01 1 Unchanged Low
Q92859 M13ab8 neogenm homolog 1 (chicken) 1530455 249 2326926 211 5326 604E-01 7 01 E-01 1 Unchanged Low
Q12846 O02cd2 syntaxm 4A (placental) 3235547 93 2 2329973 2165887 -4 74E-01 -1 80E+00 1 Unchanged Low
P01286 G15ef1 growth hormone releasing hormc 237 6384 263 233028 2446261 -2 83E-02 1 47E-01 1 Unchanged Low
Q9UH92 L01cd8 transcnption factor-like 4 1727135 195 233 1639 200 1328 433E-01 1 72E-01 1 Unchanged Low
075323 P09ab5 glioblastoma amplified sequence 1783893 168 233 5843 1932783 389E-01 -878E-02 1 Unchanged Low
Q9UQ33 P07ef2 microtubule-associated protein, f 101 7866 134 2342195 1565563 1 20E+00 3 93E-01 1 Unchanged Low
Q9Y3A7 A17ef2 CGI-101 protein 4021639 210 2343057 2822981 -779E-01 -934E-01 1 Unchanged Low
Q9Y2Z0 A17cd7 suppressor of G2 allele of SKP1 , 184 6693 256 234 3223 2249662 344E-01 471E-01 1 Unchanged Low
P56211 F16ab2 cyclic AMP phosphoprotein, 19 k 2769734 386 2343401 2992676 -241 E-01 4 81 E-01 1 Unchanged Low
P21127 013ef1 cell division cycle 2-lιke 2 159 1108 304 234454 2324012 559E-01 9 32E-01 1 Unchanged Low
Q07866 B23ab7 kinesm 2 (60-70kD) 2545932 408 2345156 299 1796 -1 19E-01 682E-01 1 Unchanged Low Q9BTI3 H11ef8 KIAA1068 protein 2287025 230 2345211 231 0835 3 62E-02 8 33E-03 1 Unchanged Low
Q9H2J4 E11gh6 hypothetical protein MGC3062 2387573 256 2350353 2432412 -227E-02 1 OOE-01 1 Unchanged Low
Q9NXE5 E10gh2 hypothetical protein FLJ20296 193 8379 399 235 1468 275 9024 279E-01 1 04E+00 1 Unchanged Low
Q92572 E17ab4 adaptor-related protein complex 8623952 209 2352813 176703 1 45E+00 1 27E+00 1 Unchanged Low
Q9NXT6 K05gh2 FtsJ homolog 3 (E coll) 2547485 277 2354026 255685 -1 14E-01 1 20E-01 1 Unchanged Low
015321 F05cd6 transmembrane 9 εuperfamily me 295 1129 227 235 695 252 5647 -324E-01 -3 79E-01 1 Unchanged Low
015383 F07cd6 HIV-1 Tat interactive protein 2 3 4028554 444 2357849 3607235 -773E-01 1 39E-01 1 Unchanged Low
060403 B06cd8 olfactory receptor, family 10, sub 237 7465 262 235906 2452774 -1 12E-02 1 41 E-01 1 Unchanged Low
P49354 K24ab4 farnesyltransferase, CAAX box, ε 1739344 193 235 9155 201 1077 440E-01 1 54E-01 1 Unchanged Low
P48039 B07ef6 melatoπin receptor 1A 3050267 208 236 1249 2497986 -3 69E-01 -5 51 E-01 1 Unchanged Low
043562 COβabδ solute earner family 22 (organic ( 1154101 125 236 1587 1589844 1 03E+00 1 20E-01 1 Unchanged Low
QgHC89 N24ef8 calpain 10 2120136 242 236247 2302337 1 56E-01 1 93E-01 1 Unchanged Low
P00790 M13ef1 pepsiπogen 5, group I (pepsinogi 256009 266 2366918 2530491 -1 13E-01 577E-02 1 Unchanged Low
Q9NVP1 G01cd6 DEAD/H (Asp-Glu-Ala-Asp/His) t 7840555 89 2367778 134724 1 59E+00 1 83E-01 1 Unchanged Low
Q9UBN1 F23ef3 calcium channel, voltage-depend 2699719 360 2370557 2890967 -1 88E-01 4 16E-01 1 Unchanged Low
P35659 M22cd3 DEK oncogene (DNA binding) 8002159 77 8 237 1934 131 6712 1 57E+00 -4 06E-02 1 Unchanged Low
P54252 N09ef6 Machado-Joseph disease (spinoi 1567549 274 2372775 2225126 598E-01 803E-01 1 Unchanged Low
Q14152 L12cd3 eukaryotic translation initiation fa 3645131 268 237302 28995g -6 19E-01 -443E-01 1 Unchanged Low
Q9Y314 E16ef2 eNOS interacting protein 1233313 219 237 3058 193 3594 944E-01 8 31 E-01 1 Unchanged Low
Q9NRC7 E23ef3 sirtuin silent mating type informal 1360486 328 237 5194 2337238 804E 01 1 27E+00 1 Unchanged Low
P02533 N02ef6 keratin 14 (epidermolysis bullosa 2034102 190 2376951 2104458 225E-01 -9 66E-02 1 Unchanged Low
060907 J19cd2 transducin (beta)-lιke 1 X-Iinked 1759553 171 2377396 1948701 434E-01 -4 19E 02 1 Unchanged Low
P4315S B16ab3 carπitine acetyltransferase 288355 190 237 8908 238 6829 -278E-01 -603E-01 1 Unchanged Low
Q15077 H08ab8 pyπmidmergic receptor P2Y, G-p 3899746 248 238 1475 292 1056 -7 12E-01 -6 52E-01 1 Unchanged Low
Q12840 I06ab7 kinesm family member 5A 2383605 282 2382407 252 8959 -725E-04 2 43E 01 1 Unchanged Low
P26599 A05cd3 polypyπmidme tract binding prote 1604912 345 2384 247 8557 571 E-01 1 10E+00 1 Unchanged Low
Q9Y316 M11ef2 C21orf19-lιke protein 4506398 327 2385981 3388101 -9 17E-01 -462E-01 1 Unchanged Low
P243g4 018ab6 interleukin 4 receptor 3095199 330 2386201 292 7071 -375E-01 9 24E-02 1 Unchanged Low
P32418 J22gh1 solute earner family 8 (sodium/cε 171 4835 134 2387225 181 3894 477E-01 -3 56E-01 1 Unchanged Low
P42694 N01ef3 helicase with zinc finger domain 1657017 146 2387561 1836122 527E-01 -1 79E-01 1 Unchanged Low
060755 L09cd3 galaπm receptor 3 1626185 268 2387669 223 2368 5 54E-01 7 22E-01 1 Unchanged Low
Q16204 A18cd4 DNA segment, single copy, probi 1920586 225 2388166 2186477 314E 01 229E 01 1 Unchanged Low
Q12980 N15cd7 Conserved gene telomeπc to alpl 1837714 174 2389231 198 8702 379E-01 -7 95E-02 1 Unchanged Low
P08559 N16ab7 pyruvate dehydrogenase (lipoam 375 1479 206 2394879 273 612 -648E 01 -8 63E-01 1 Unchanged Low
Q9Y2U9 K02ef3 host cell factor homolog 127 5142 154 239623 173 6438 9 10E-01 2 70E 01 1 Unchanged Low
Q9Y2T2 P17cd7 adaptor-related protein complex 3369686 395 2396299 323 8714 -4 92E-01 229E-01 1 Unchanged Low
Q13105 10cd3 zinc finger protein 151 (pHZ-67) 1779188 243 240018 220 1539 432E-01 447E-01 1 Unchanged Low
Q9H1J1 J12gh5 similar to yeast Upf3, variant A 154 12 183 241 0316 192 8261 645E-01 2 50E-01 1 Unchanged Low
Q08752 E01cd1 peptidylprolyl isomerase D (cycle 446371 203 241 0389 296 8872 -889E-01 -1 13E+00 1 Unchanged Low
P38159 F14ab7 RNA binding motif protein, X chrc 3424693 176 241 0429 2532584 -507E-01 -9 58E-01 Unchanged Low
Q9Y337 A12cd8 kallikrein 5 2155515 312 241 2144 256 4089 1 62E-01 536E-01 Unchanged Low
P25445 A02ef6 tumor necrosis factor receptor su 1023524 215 241 2257 1860304 1 24E+00 1 07E+00 Unchanged Low
Q9BZH1 P02gh5 membrane-spanning 4-domaιns 3508825 212 241 5154 2682725 -539E-01 -724E-01 1 Unchanged Low
043633 012ef4 putative breast adenocarcinoma 3084601 232 241 573 260 7188 -3 53E-01 -4 10E-01 Unchanged Low
Q99536 B03cd6 vesicle amine transport protein 1 2228504 400 241 6698 288 1564 1 17E-01 844E-01 Unchanged Low
P24557 N11cd1 thromboxane A synthase 1 (plate 3264482 236 241 6841 268 1689 -4 34E-01 -4 66E-01 Unchanged Low
075369 G16ab4 filamm B beta (actin binding prol 331 6975 459 241 7672 344 1714 -455E-01 469E-01 Unchanged Low
P50453 H10ab8 serine (or cysteine) protemase in 4398605 370 2424005 350 7941 -860E-01 -249E-01 Unchanged Low
P35680 018cd1 transcπption factor 2, hepatic, LF 2355021 174 2425943 217 2497 428E-02 -440E-01 Unchanged Low
Q03924 101 gh7 zinc finger protein 117 (HPF9) 257 8571 301 2427729 267 2646 -870E-02 224E-01 Unchanged Low
Q9NRQ5 F17gh4 FN5 protein 361 924 325 2428257 309 8867 -576E 01 -1 56E-01 Unchanged Low
Q99867 G12gh7 tubulin beta polypeptide 4 mem 3767361 247 2436773 289 1694 -629E-01 -608E-01 Unchanged Low
Q9H682 B19gh7 A20-bιndιng inhibitor of NF-kapp 2056095 365 2437949 271 5091 246E-01 828E-01 Unchanged Low
000148 N12cd5 DEAD/H (Asp-Glu-Ala-Asp/His) t 259 196 140 244 0023 2143036 -871E-02 -892E-01 Unchanged Low
F11cd8 TCF3 (E2A) fusion partner (in ch 1707519 295 2440153 2367141 5 15E-01 7 91E 01 Unchanged Low
Q9UG51 N05ef3 anaphase-promotmg complex su 2744079 331 2440324 283 0875 -1 69E-01 270E-01 Unchanged Low
075175 F12cd8 CCR4-NOT transcπption comple 230 1579 253 2440384 242329 845E-02 1 35E-01 Unchanged Low
Q9GZQ8 C05gh2 microtubule-associated proteins 261 5987 3g5 244 0725 300 1702 -1 00E-01 5 94E-01 Unchanged Low
P19438 A04ef6 tumor necrosis factor receptor su 2333188 197 2443384 224 9565 666E-02 -243E-01 Unchanged Low
Q9NRR8 O04gh4 small protein effector 1 of Cdc42 3382133 329 244 5729 303 9389 -468E-01 -397E-02 1 Unchanged Low
095162 N10ef8 peroxisomal short-chain alcohol i 154 9486 108 2449155 169 1352 6 60E-01 -527E-01 1 Unchanged Low
095279 J22cd3 potassium channel, subfamily K 2743417 127 2449972 2155542 -1 63E-01 -1 11 E+00 Unchanged Low
Q9NTW4 N21ef8 DKFZP564A2416 protein 4034188 219 245 1953 289 1446 -7 18E-01 -883E-01 1 Unchanged Low
QgNWM9 H21gh2 hypothetical protein FLJ20730 121 538 207 245 69 191 4607 1 02E+00 7 69E-01 1 Unchanged Low
P40121 P23ab5 capping protein (actin filament), s 4522006 414 2458846 3707982 -879E 01 -1 26E-01 1 Unchanged Low
Q92466 104ab3 damage-specific DNA binding pπ 99 17314 220 246 0478 188 2839 1 31 E+00 1 15E+00 1 Unchanged Low
043365 K05gh7 homeo box A3 1327369 196 2462071 191 5647 891 E-01 560E-01 1 Unchanged Low
Q9NVJ7 O02gh3 DEAD/H (Asp-Glu-Ala-Asp/His) t 336 1927 284 2463831 2887892 -4 48E-01 -244E-01 1 Unchanged Low
Q9NVY5 H08ef7 serologically defined colon cance 1824596 178 2467633 202 4155 436E-01 -3 55E-02 1 Unchanged Low
QgBY40 G12ghB CDA11 protein 141 0763 131 2468975 1730132 807E-01 -1 06E-01 1 Unchanged Low
Q9NZE2 O06ef2 hypothetical protein LOC51321 7641026 135 247 0025 152 875 1 69E+00 823E-01 1 Unchanged Low
P29275 K11ab2 adenosine A2b receptor 3545115 191 2470615 264 0659 -521 E-01 -895E-01 1 Unchanged Low
Q9NZE0 P22ef1 WW domain-containing adapter > 8272809 71 1 247 6094 133 8159 1 58E+00 -2 18E-01 1 Unchanged Low
Q03111 N03ab7 myeloid/lymphoid or mixed-lineac 225 1377 162 247 8275 211 7891 1 39E-01 -471 E-01 I Unchanged Low
Q08499 G21ef6 phosphodiesterase 4D, cAMP-sp 1255177 929 248 1727 155 5405 983E-01 -434E-01 1 Unchanged Low
Q15628 A20ef6 TNFRSFIA-associated via death 214 1641 250 2482613 237 3623 2 13E-01 221 E-01 1 Unchanged Low
Q9Y657 C07cd7 spindlm 217 9487 202 2484185 222 9201 1 89E-01 -1 07E-01 1 Unchanged Low
Q9UHQ1 I09cd8 nuclear prelamm A recognition fs 3129614 303 248 5926 288 0624 -332E-01 -484Ξ-02 1 Unchanged Low
P17980 H24efδ proteasome (prosome, macropaii 331 1488 193 2486286 257 496 -4 13E-01 -7 81 E-01 1 Unchanged Low
P45877 I19ab8 peptidylprolyl isomerase C (cycle 1650716 169 2489851 194 3167 593E-01 3 30E 02 1 Unchanged Low
095340 A23cd5 3'-phosphoadenosιne 5'-phosphc 1109876 886 2490622 149 5355 1 17E+00 -326E-01 1 Unchanged Low
Q9H9Z7 F18gh5 hypothetical protein FLJ12448 158 5794 279 249 1478 228 8009 6 52E-01 8 13E-01 1 Unchanged Low
015172 E11cd4 phosphoseπne phosphatase-like 321 9068 291 2493629 2874495 -368E 01 -1 45E 01 1 Unchanged Low
P01298 F05ab8 pancreatic polypeptide 5440034 194 249376 329 1527 -1 13E+00 -1 49E+00 1 Unchanged Low
Q13395 J17cd2 TAR (HIV) RNA binding protein 1 2607056 234 2493777 2480711 -641E-02 -1 55E-01 1 Unchanged Low
015551 G23ab4 claudin 3 2799519 250 2494618 259744 -1 66E-01 -1 64E-01 1 Unchanged Low P55060 G20ef6 CSE1 chromosome segregation 322 1588 276 2495903 282 6907 -3 68E-01 -2 21 E-01 1 Unchanged Low
043286 E13ab3 UDP-Gal betaGlcNAc beta 1,4- c 316581 468 249 8072 344 9578 -342E-01 565E-01 1 Unchanged Low
P04424 J10ab2 arglnlnosucclnate lyase 5949833 269 250 046 371 2796 -1 25E+00 -1 15E+00 1 Unchanged Low
Q9NWR5 C10gh3 hypothetical protein FLJ20657 171 9643 252 250 1961 2246496 5 41 E-01 550E-01 1 Unchanged Low
Q9BUN8 M21gh6 hypothetical protein MGC3067 1656904 175 2502847 197005g 595E-01 7 92E-02 1 Unchanged Low
P49760 G01ab4 CDC-like kinase 2 6923701 97 1 250 3266 138 B925 1 85E+00 4 88E-01 1 Unchanged Low
Q9UEG3 E01gh7 myotubulann related protein 3 367 623 236 250553 284 5589 -5 53E-01 -642E-01 1 Unchanged Low
Q9P0Y6 N07ef1 chromosome 3 open reading frar 268 1158 256 2506098 2582636 -g 74E-02 -663E-02 1 Unchanged Low
Q92535 M06ab8 phosphatidylmositol glycan, das' 2182502 172 2509192 213 6071 201 E-01 -346E-01 1 Unchanged Low
Q00577 A24gh7 punne-πch element binding prate 8396 273 251 0214 454 6488 -1 74E+00 -1 62E+00 1 Unchanged Low
075717 L21ab2 AND-1 protein 2259974 250 251 1522 2422724 1 52E-01 1 44E-01 1 Unchanged Low
P04278 L09cd1 sex hormone-binding globulin 2156067 196 251 1944 221 0173 220E-01 -1 36E-01 1 Unchanged Low
P51124 G19ab5 granzyme M (lymphocyte met-asi 1089072 114 251 2498 158 1827 1 21 E+00 7 09E-02 1 Unchanged Low
P15259 P04ab7 phosphoglycerate mutase 2 (mus 3332442 363 251 6606 315 8301 -405E-01 1 22E-01 1 Unchanged Low
Q12893 013cd7 PL6 protein 1743077 280 2520241 2353565 532E-01 682E-01 1 Unchanged Low
P57738 A11gh2 T-cell leukemia translocation alts 1665683 232 2522165 2170429 5 ggε-01 4 80E-01 1 Unchanged Low
P24863 022ef5 cyclm C 668 8634 523 2523632 481 4089 -1 41 E+00 -355E-01 1 Unchanged Low
Q9Y370 H03ef2 CGI-60 protein 1536349 157 2525036 187 603 7 17E-01 282E-02 1 Unchanged Low
QgHDβg E04gh4 found in inflammatory zone 3 1898748 182 2527224 2082163 4 13E-01 -607E-02 1 Unchanged Low
014807 N04cd7 muscle RAS oncogene homolog 105 1243 181 2528147 1795238 1 27E+00 7 81 E-01 1 Unchanged Low
Q13435 I07cd7 splicing factor 3b, subunit 2, 1451 2703354 268 2528473 2636077 -g 65E-02 -1 45E-02 1 Unchanged Low
QgUMY4 F19cd8 sorting nexm 12 1788659 227 2530136 219 6698 500E-01 345E-01 1 Unchanged Low
043g29 C04ab8 ongin recognition complex, subui 267 5605 354 253265 291 5955 -7 92E-02 4 04E-01 1 Unchanged Low
Q9BZQ1 H14gh7 chromosome 1 open reading frar 2196632 362 2535183 2784192 207E-01 721 E-01 1 Unchanged Low
P55042 K03ef5 Ras-related associated with diab 300 5794 514 2535279 355 8906 -246E-01 773E-01 1 Unchanged Low
Q92870 K18ef1 amyloid beta (A4) precursor proti 76 07104 779 2535714 1358422 1 74E+00 340E-02 1 Unchanged Low
P33778 C19gh7 H2B histone family, member F 1694431 391 2539554 271 5522 584E-01 1 21 E+00 1 Unchanged Low
Q9ULZ3 K22cd8 apoptosls-associated speck-like 2559554 517 2540856 342 2046 -1 06E-02 1 01 E+00 1 Unchanged Low
Q13485 A20ef5 MAD, mothers against decapentε 163 1373 181 254 1546 19 935 640E-01 1 51 E-01 1 Unchanged Low
Q9H684 C24gh5 zinc finger protein 335 3266826 261 2543385 2805396 -361 E-01 -326E-01 1 Unchanged Low
Q9H7F8 O06gh7 hypothetical protein FLJ20958 190 1073 258 2547196 2342579 4 22E-01 440E-01 1 Unchanged Low
Q92508 B17gh1 KIAA0233 gene product 241 1859 216 2550491 2372652 806E-02 -1 62E-01 1 Unchanged Low
Q9UM47 C15ab8 Notch homolog 3 (Drosophila) 64 97745 132 2550839 150 552 1 97E+00 1 02E+00 1 Unchanged Low
P18084 E17ef7 integπn, beta 5 2592818 129 255 1335 2146124 -233E-02 -1 OOE+00 1 Unchanged Low
Q99462 K22gh6 ubiquitin-conjugatmg enzyme E2 207 6691 179 2552632 213 9424 298E-01 -2 15E-01 1 Unchanged Low
075619 J10ef7 RNA helicase-related protein 198 1059 335 2556713 2627733 3 68E-01 7 56E-01 1 Unchanged Low
Q92733 K07cd1 papillary renal cell carcinoma (trε 2003207 260 256 1407 238 8334 355E-01 376E-01 1 Unchanged Low
Q15796 H21ab7 MAD, mothers against decapentε 3768422 446 2562171 3595423 -5 57E-01 242E-01 1 Unchanged Low
P15291 E07ab3 UDP-Gal betaGlcNAc beta 1,4- c 411 9325 403 2569006 357 1444 -681 E-01 -331E-02 1 Unchanged Low
Q99417 I07cd8 c-myc binding protein 264 1386 256 2569088 259037 -400E-02 -448E-02 1 Unchanged Low
P06732 D09ab4 creatme kinase, muscle 202 527 127 257 2272 1954365 345E-01 -678E-01 1 Unchanged Low
P50570 K13ab5 dynamiπ 2 248 1380 228 257 2474 244 4335 520E-02 -1 23E-01 1 Unchanged Low
Q9Y5A9 F20ef2 high-glucose-regulated protein 8 359385 371 257 3917 3292557 -482E-01 4 5gE-02 1 Unchanged Low
Q92841 B17cd6 DEAD/H (Asp-Glu-Ala-Asp/His) t 2298916 270 257 9255 2524572 1 66E-01 230E-01 1 Unchanged Low
P51808 B22cd2 t-complex-associated-testis-expn 1822992 245 257 9487 2282619 501E-01 424E-01 1 Unchanged Low
095758 H23cd5 R0D1 regulator of differentiation 411 9888 462 258 1758 377 5392 -674E-01 1 67E-01 1 Unchanged Low
P32970 I15ef5 tumor necrosis factor (ligand) su| 4434158 456 258 4229 3860177 -779E-01 4 11E-02 1 Unchanged Low
075689 K21cd7 centaunn, alpha 1 191 7263 327 2586362 259 1653 432E-01 771 E-01 1 Unchanged Low
P55072 O06cd4 valosin-containing protein 4667034 363 258 8411 362 8018 -850E-01 -363E-01 1 Unchanged Low
P47813 A16ab4 eukaryotic translation initiation fa 4866493 337 2590481 3607943 -910E-01 -531 E-01 1 Unchanged Low
Q15532 J03cd2 synovial sarcoma translocation, c 190 8535 212 259 1488 220 5805 441 E-01 1 50E-01 1 Unchanged Low
Q15813 M19cd2 tubulm-specific chaperone e 151 2337 166 259 2747 192 1296 778E-01 1 33E-01 1 Unchanged Low
P14373 B08cd2 ret finger protein 2825757 270 2593599 2705765 -1 24E-01 -668E-02 1 Unchanged Low
014980 G02cd3 export 1 (CRM1 homolog, yeas 2394965 207 2597187 235 5264 1 17E-01 -2 08E-01 1 Unchanged Low
P07942 P20ef6 laminin, beta 1 71 03574 924 2597579 141 0764 1 87E+00 380E-01 1 Unchanged Low
P53041 C20cd1 protein phosphatase 5, catalytic • 2725094 196 2598136 2427533 -688E-02 -476E-01 1 Unchanged Low
Q07820 E12ef6 myeloid cell leukemia sequence 3625007 243 2600329 288 4688 -479E-01 -578E-01 1 Unchanged Low
P53816 E04cd7 HRAS-like suppressor 3 6060957 558 260 1565 474 8201 -1 22E+00 -1 19E-01 1 Unchanged Low
Q9P1C8 E09gh4 hypothetical protein PR02577 2389909 205 2603147 2348631 1 23E-01 -2 19E-01 1 Unchanged Low
P51966 021cd3 ubiquitin-conjugatmg enzyme E2 1483528 243 260 3185 217 1092 8 11E-01 7 10E-01 1 Unchanged Low
Q99739 M03cd7 plm-2 oncogene 178694 274 2604482 237 5556 544E-01 6 14E-01 1 Unchanged Low
P35913 N14ab7 phosphodiesterase 6B, cGMP-sp 19g 3654 173 2605708 210 8879 386E-01 -207E-01 1 Unchanged Low
P52756 J24cd5 RNA binding motif protein 5 280 6537 230 261 0637 2572441 -1 04E-01 -287E-01 1 Unchanged Low
Q9NXX5 K17gh3 hypothetical protein FLJ20004 130 163 197 261 2642 196 0576 1 01 E+00 596E-01 1 Unchanged Low
Q14498 O06cd5 RNA-bmding region (RNP1, RRti 1960463 216 261 5829 2244664 4 16E-01 1 38E-01 1 Unchanged Low
P28069 A03ab8 POU domain, class 1 , transcriptic 261 1822 206 261 7763 243064 328E-03 -341 E-01 1 Unchanged Low
P51397 E20ab5 death-associated protein 348 1009 312 261 9342 307 4499 -4 10E-01 -1 57E-01 1 Unchanged Low
Q9NUI8 C24gh7 putative methyltransferase 1573551 329 2620287 2494637 736E-01 1 06E+00 1 Unchanged Low
000322 M09cd7 uroplakin 1A 2235286 295 2620828 260 1175 230E-01 3 99E-01 1 Unchanged Low
P78368 I09ab4 casein kinase 1, gamma 2 211 1048 272 262 1137 248 257 3 12E-01 363E-01 1 Unchanged Low
Q01081 I22cd4 U2(RNU2) small nuclear RNA au 138 1533 91 3 2621811 163878 924E-01 -598E-01 1 Unchanged Low
043193 J15ab5 G protein-coupled receptor 38 6957316 206 262301 179 1305 1 91 E+00 1 56E+00 1 Unchanged Low
Q9Y3B0 M03ef2 CGI-105 protein 1745026 177 262 5458 204 6742 589E-01 203E-02 1 Unchanged Low
Q9NV80 H05gh3 WD repeat domain 12 1785139 279 2626286 2399609 557E-01 643E-01 1 Unchanged Low
Q9Y473 018cd4 zinc finger protein 175 141 3794 275 263 1099 226 3406 8 96E-01 957E-01 1 Unchanged Low
Q9Y548 L20gh2 hypothetical protein DJ167A19 1 2335442 240 2634412 2457773 1 74E-01 4 14E-02 1 Unchanged Low
Q13952 N15ef6 nuclear transcnption factor Y, ga 241 7469 354 2636055 2864173 1 25E-01 5 50E-01 1 Unchanged Low
P18615 K17cd3 RD RNA-biπdmg protein 237 0199 242 2637642 2477362 1 54E-01 325E-02 1 Unchanged Low
P33241 B23ef1 lymphocyte-specific protein 1 94 80267 131 264242 1634955 1 48E+00 471 E-01 1 Unchanged Low
015116 C01ef4 Lsm1 protein 3448146 479 264 6979 362 8572 -3 81 E-01 4 74E-01 1 Unchanged Low
P50897 A11ab8 palmitαyl-protein thioesterase 1 ( 1266311 142 2648236 1779418 1 06E+00 1 69E-01 1 Unchanged Low
F20gh8 MADP-1 protein 134 6124 228 264 9564 209 3298 977E-01 7 63E-01 1 Unchanged Low
Q9Y3A5 G12ef2 CG1-97 protein 4694567 544 2650744 4262946 -825E-01 2 14E-01 1 Unchanged Low
Q9BVT1 G03gh6 leukocyte receptor cluster (LRC) 282 5457 32S 265 5443 291 959g -895E-02 2 14E-01 1 Unchanged Low
Q9UM44 E10cd7 HERV-H LTR-associatlng 2 1807238 119 265 5625 1885666 555E-01 -5 98E-01 1 Unchanged Low
Q9UGC7 A05gh3 similar to prokaryotic-type class I 289 9756 362 2657778 3060797 -1 26E-01 3 22E-01 1 Unchanged Low P491 6 G01ab8 neuropeplide Y receptor Y2 2220084 578 2659266 181 9126 260E-01 1 94E+00 1 Unchanged Low
P54687 I03ab3 branched chain amlnotraπsferast 1034218 93 8 2660547 1544299 1 36E+00 -1 41 E-01 1 Unchanged Low
060884 O09cd6 DnaJ (Hsp40) homolog, subfamil 3303137 367 266 0819 321 0577 -3 12E-01 1 51 E-01 1 Unchanged Low
Q9NVC6 J01cd7 cofactor required for Sp1 transcπ 1830562 150 2661556 1998392 540E-01 -284E-01 1 Unchanged Low
043399 G06cd2 tumor protein D52-llke 2 2834636 348 2662168 299 1558 -906E-02 295E-01 1 Unchanged Low
075880 K22cd2 SCO cytochrome oxidase deficle 1567184 117 2662419 1798238 7 65E-01 -4 28E-01 1 Unchanged Low
P49406 F01gh1 mitochondπal ribosomal protein I 5770339 353 2663918 3986973 1 12E+00 -7 10E-01 1 Unchanged Low
Q9NYK5 E15gh2 mitochondrial nbosomal protein I 4732712 449 2667642 3963322 -827E-01 -7 61E-02 1 Unchanged Low
015428 P18cd2 protein (peptldyl-prolyl cls/trans I 185 1313 249 267 1449 2336377 5 29E-01 425E-01 1 Unchanged Low
014842 K04ab5 G protein-coupled receptor 40 2226002 170 2674241 2198563 2 65E-01 -393E-01 1 Unchanged Low
015262 I06cd6 ring finger protein 3 243 845 401 2674275 304 1323 1.33E-01 7 18E-01 1 Unchanged Low
Q9NP61 J01ef3 ADP-πbosylation factor GTPase 344 6989 175 267443 2624544 -3 66E-01 -976E-01 1 Unchanged Low
015491 P22cd5 WD-repeat protein 2546166 355 2676951 2924461 7 23E-02 4 80E-01 1 Unchanged Low
075390 P01ab5 citrate synthase 656561 312 2680488 412 1526 1 29E+00 1 07E+00 1 Unchanged Low
P57088 I12gh3 hypothetical protein FLJ10S25 377 5067 349 268 1833 331 588 -4 93E-01 -1 13E-01 1 Unchanged Low
Q9NRY6 K06gh4 phospholipid scramblase 3 2720774 334 2682248 291 4542 -2 06E-02 296E-01 1 Unchanged Low
015403 E0Scd5 solute earner family 16 (monocar 38429g2 735 2683423 2420422 -518E-01 239E+00 1 Unchanged Low
Q9BPZ5 K09gh6 hypothetical protein MGC3123 1273745 286 2687928 227 363 1 08E+00 1 17E+00 1 Unchanged Low
P10301 P01cd2 related RAS viral (r-ras) oncoger 3144g78 204 2688367 2624726 -2 26E-01 -624E-01 1 Unchanged Low
A20gh7 HLA-B associated transcnpt 4 1680802 234 2690656 223 8166 679E-01 479E-01 1 Unchanged Low
Q9P018 AOβefβ HSPC142 protein 1961899 346 2695447 2706564 458E-01 820E-01 1 Unchanged Low
Q9Y4H2 L10cd3 insulin receptor substrate 2 297 029 329 2704962 298 8227 -1 35E-01 1 47E-01 1 Unchanged Low
Q9UJX3 F04ef2 anaphase-promoting complex su 2102906 204 270642 2284449 364E-01 -4 10E-02 1 Unchanged Low
Q9H5X0 O01gh6 hypothetical protein MGC2941 3335834 308 270759 304 1289 -301 E-01 -1 15E-01 1 Unchanged Low
Q92820 H23cd4 gamma-glutamyl hydrolase (conji 78 13783 101 271 925 150359 1 80E+00 3 70E-01 1 Unchanged Low
Q9UKK3 K15ab2 ADP-πbosyltransferase (NAD+, c 337297 450 271 9 44 3529975 -3 10E-01 4 15E-01 1 Unchanged Low
Q9NWC8 N13gh2 hypothetical protein FLJ10120 3157654 301 2720013 296 1206 -2 15E-01 -7 10E-02 1 Unchanged Low
014965 I07cd2 senne/threonlne kinase 6 1392727 101 272 158 170 6789 967E-01 -4 69E-01 1 Unchanged Low
P50613 B11ef5 cyclin-dependent kinase 7 (M011 286 8535 423 272 2018 327 4234 -7 56E-02 561 E-01 1 Unchanged Low
Q9H1C4 H08gh7 unc-93 homolog B1 (C elegans) 3488713 501 2723385 374 1085 -357E-01 522E-01 1 Unchanged Low
P21851 E13ab4 adaptor-related protein complex 3387753 373 2724617 328 1045 -3 14E-01 1 39E-01 1 Unchanged Low
Q9UGJ0 B14ef2 protein kinase, AMP-aclivated, g 4253015 543 272 5312 4134782 -642E-01 3 51 E-01 1 Unchanged Low
P04035 D17ab6 3-hydroxy-3-methylglutaryl-Coen 2429132 169 2732324 228 5315 1 70E-01 -520E-01 1 Unchanged Low
Q9UKY7 K03gh3 hypothetical protein H41 6430085 272 273736 3962551 -1 23E+00 -1 24E+00 1 Unchanged Low
095478 B18gh1 hypothetical protein YR-29 2482059 221 2738047 247 5607 1 42E-01 -1 70E-01 1 Unchanged Low
Q9Y3W9 B16ef8 sentnπ/SUMO-specifie protease 2204064 333 274 1753 2757642 3 1SE-01 594E-01 1 Unchanged Low
Q9Y325 A20ef2 CGI-36 protein 346618 338 274 2434 3194542 -338E-01 -385E-02 1 Unchanged Low
Q92854 B09cd6 sema domain, immunoglobulln di 3426474 183 2744146 2668232 -320E-01 -902E-01 1 Unchanged Low
P16106 O08gh6 H3 histone family, member C 1054744 221 274 8424 200 5879 1 38E+00 1 07E+00 1 Unchanged Low
043143 M05ab4 DEAD/H (Asp-Glu-Ala-Asp/His) t 4127015 349 274 9731 345 6042 -5 86E-01 -241 E-01 1 Unchanged Low
Q 13547 L12ef6 histone deacetylase 1 3755725 372 2752293 340 9663 -448E-01 -1 34E-02 1 Unchanged Low
Q9H6F9 D11gh5 hypothetical protein FLJ22313 3065811 290 275269 2906336 -1 55E-01 -8 OOE-02 1 Unchanged Low
Q9NX18 M08gh2 hypothetical protein FLJ20487 311 71 394 2756418 327 1007 -1 77E-01 338E-01 1 Unchanged Low
094764 P03cd5 RAN binding protein 9 2563223 268 275 8144 2665947 1 06E-01 624E-02 1 Unchanged Low
P82909 N18gh8 mitochσπdπal nbosomal protein 5 261 4618 343 2758463 293 6016 773E-02 394E-01 1 Unchanged Low
Q9UI07 D18ef8 likely ortholog of mouse heat she 1998914 199 276 061 225 0966 4 66E-01 -4 OOE-03 1 Unchanged Low
P20337 M01ef5 RAB3B, member RAS oncogene 2148304 126 276 148 2058132 362E-01 -765E-01 1 Unchanged Low
Q07960 B22ab2 Rho GTPase activating protein 1 21998 218 276 184 237 9303 328E-01 -1 55E-02 1 Unchanged Low
P49448 P03cd7 Glutamate dehydrogenase-2 344 3683 229 2762751 2832713 -3 18E-01 -588E-01 1 Unchanged Low
Q9NX48 K08gh2 hypothetical protein FLJ20442 4937568 601 276 8343 457 1855 -835E-01 283E-01 1 Unchanged Low
Q9NV56 J03gh3 chromosome 20 open reading frs 1389543 104 2774945 1736478 998E-01 -4 11 E-01 1 Unchanged Low
000154 L21cd7 brain acyl-CoA hydrolase 1735669 189 277 5737 2134547 677E-01 1 2SE-01 1 Unchanged Low
Q9UI70 B04ef1 nucleolar protein ANKT 3077657 349 277 6076 311 4328 -1 49E-01 1 81 E-01 1 Unchanged Low
P26045 N17ab8 protein tyrosine phosphatase, no 412292 315 277 6603 334 8518 -570E-01 -390E-01 1 Unchanged Low
Q9Y2A8 C24ef3 CD209 antigen-like 7221222 91 3 277 8103 147 0989 1 94E+00 338E-01 1 Unchanged Low
Q9BZ89 F08gh7 phospholipase A2, group XII 175384 216 277 9804 2230558 664E-01 2 99E-01 1 Unchanged Low
P35052 J24ab4 glypican 1 2144355 173 2782085 221 7567 376E-01 -3 13E-01 1 Unchanged Low
Q9H0S9 K21gh7 nuclear receptor binding factor-2 80 19669 155 2784321 171 2074 1 80E+00 9 51 E-01 1 Unchanged Low
Q15654 I07ef7 thyroid hormone receptor interac 264295 238 2788016 2604802 7 71E-02 -1 49E-01 1 Unchanged Low
P51948 I09ab7 menage a trols 1 (CAK assembly 239 1769 272 2789368 2632799 222E-01 1 84E-01 1 Unchanged Low
Q13133 B20cd5 nuclear receptor subfamily 1, gro 2765554 260 279 1408 2720232 1 34E-02 -870E-02 1 Unchanged Low
Q9P0J9 H22gh3 goliath protein 3373229 215 2795646 277 1331 -2 71 E-01 -653E-01 1 Unchanged Low
Q 5546 G23cd8 monocyte to macrophage differei 136 5038 94 2796415 170 0401 1 03E+00 -539E-01 1 Unchanged Low
P28325 E09ab5 cystatin D 371 6792 309 2797092 3202206 -4 10E-01 -265E-01 1 Unchanged Low
094985 O04ef8 calsyntenin 1 137 0471 205 279921 207 2587 1 03E+00 580E-01 1 Unchanged Low
P48634 M03cd4 HLA-B associated transcript 2 266 8369 179 280 5497 241 9692 7 23E-02 -5 80E-01 1 Unchanged Low
Q9BRL6 015gh7 Splicing factor, argιnιπe/senne-rn 220 3804 304 280 5881 2684079 348E-01 4 65E-01 1 Unchanged Low
094851 E06gh1 K1AA0750 gene product 108 6672 172 280 9738 1872889 1 37E+00 664E-01 1 Unchanged Low
Q9NW56 E20gh3 hypothetical protein FLJ 10305 240453B 314 281 002 278 4551 225E-01 3 85E-01 1 Unchanged Low
Q9H6X6 P19gh5 CasL interacting molecule 1833739 302 281 185 2554932 6 17E-01 7 19E-01 1 Unchanged Low
P41217 N13ab7 antigen identified by moπodonal 325 1642 166 281 3505 2575072 -2 09E-01 -970E-01 1 Unchanged Low
P31512 P04ab4 flavin containing moπooxygenase 1924074 276 281 6555 2499252 5 50E-01 5 19E-01 1 Unchanged Low
Q15425 H05cd2 SA hypertension-associated horr 1862788 151 281 9205 2064709 598E-01 -301 E-01 1 Unchanged Low
P40306 L05ab8 proteasome (prosome, macropaii 408 3043 513 281 9429 400975 -534E-01 328E-01 1 Unchanged Low
Q9NWZB O02gh2 hypothetical protein FLJ20514 287569 146 281 9498 2383826 -2 85E-02 -982E-01 1 Unchanged Low
P57073 E22efB SRY (sex determining region Y)-l 202 5886 268 281 9705 251 002 477E-01 406E-01 1 Unchanged Low
Q9Y450 H22cd6 HBS1-lιke (S cerevisiae) 2308266 312 2824288 2749973 291 E-01 434E-01 1 Unchanged Low
P04062 O08ab3 glucosidase, beta, acid (includes 2055318 389 2826453 322 2918 -643E-02 395E-01 1 Unchanged Low
075065 E22gh1 phosphodiesterase 4D iπteractim 168 0201 154 282 6456 201 6823 7 50E-01 -1 22E-01 1 Unchanged Low
Q9ULX2 F09ef3 NIMA (never in mitosis gene a)-n 2885578 208 283 1715 259 9871 -272E-02 -471 E-01 1 Unchanged Low
Q99871 C06ef4 three pnme repair exonudease 2 205 6083 225 2832504 237 9086 462E-01 1 29E-01 1 Unchanged Low
Q93065 I15cd6 PERB11 family member in MHC < 295 7132 457 2834269 3453524 -6 12E-02 628E-01 1 Unchanged Low
043837 B12ab7 isocitrate dehydrogenase 3 (NAC 348 9961 298 283 6422 310 0846 -299E 01 -2 30E-01 1 Unchanged Low
Q9H9L3 L06gh7 hypothetical protein FLJ12671 2095906 279 2836912 2574051 4 37E-01 4 12E-01 1 Unchanged Low
Q13740 A18ab2 activated leucocyte cell adhesior 231 4555 253 2837582 256 0277 294E-01 1 28E-01 1 Unchanged Low
Q12888 L09cd2 tumor protein p53 binding proteir 132 9276 223 283 8572 213 3434 1 09E+00 748E-01 1 Unchanged Low P78318 J13ab6 immunoglobulln (CD79A) bindinc 4238715 512 283 9511 4064772 - -578E-01 271 E-01 1 Unchanged Low
P48436 K24cd1 SRY (sex determining region Y)-l 3452087 197 2840786 2753736 -281 E-01 - -8 10E-01 1 Unchanged Low
P18065 B19ef1 Insulm-llke growth factor binding 2866516 283 2342331 284 4952 -1 22E-02 -205E-02 1 Unchanged Low
Q9ULW6 F22cd8 nucleosome assembly protein 1-1 2230694 148 284717 218587 3 52E-01 -5 92E-01 1 Unchanged Low
095154 N03cd7 aldo-keto reductase family 7, mei 2999079 298 284 8919 294 419 ■741E-02 -700E-03 1 Unchanged Low
095169 P14ab8 NADH dehydrogenase (ublquinoi 374 2624 199 2850096 286 0758 -3 93E-01 -9 12E-01 1 Unchanged Low
Q99982 C24ef4 XIAP associated fador-1 63 10609 116 2850252 154 8111 2 18E+00 882E-01 1 Unchanged Low
Q99470 F14cd2 stromal cell-derived factor 2 230 3684 316 285 1394 277 1416 3 08E-01 4 56E-01 1 Unchanged Low
P16104 N19ab5 H2A histone family, member X 234 8351 195 2852056 238.3532 2 80E-01 -268E-01 1 Unchanged Low
Q9UG25 B04ef8 SOCS box-containing WD proten 213293 398 2855392 298 9147 421 E-01 9 OOE-01 1 Unchanged Low
Q13158 C21cd4 Fas (TNFRSF6)-assocιated via d 2630157 281 2859553 276784 1 21 E-01 974E-02 1 Unchanged Low
Q9NW32 D10gh2 hypothetical protein FLJ10346 2350532 386 2863524 3026214 285E-01 7 17E-01 1 Unchanged Low
095153 M05cd5 peπpheral benzodiazepine recep 155 1824 231 287 1271 224 5106 8 88E-01 575E-01 1 Unchanged Low
Q9BQ73 H06gh7 hypothetical protein FKSG28 2120736 297 287201 2653817 4 37E-01 4 85E-01 1 Unchanged Low
Q15426 C02ef7 protein tyrosine phosphatase, rei 2969619 441 287 2583 341 7927 -479E-02 571 E-01 1 Unchanged Low
Q92858 L12ab2 atonal homolog 1 (Drosophila) 611 3779 278 2872641 3923029 - -1 09E+00 - -1 14E+00 1 Unchanged Low
Q16849 P15ab8 protein tyrosine phosphatase, rei 1459896 556 2873262 1629842 977E-01 ■ ■1 39E+00 1 Unchanged Low
P11279 D07ab7 lysosomal-associated membrane 3699g25 310 287 3935 3225735 -364E-01 -2 54E-01 1 Unchanged Low
Q96II1 I16gh7 hypothetical protein MGC14961 1037251 807 2874071 157 2667 1 47E+00 -363E-01 1 Unchanged Low
P78504 O20ab2 jagged 1 (Alagille syndrome) 2550045 347 2874633 2964108 1 72E-01 443E-01 1 Unchanged Low
075937 G06ef3 DnaJ (Hsp40) homolog, subfamil 2949992 264 287 503 282 0586 -371E-02 -1 62E-01 1 Unchanged Low
060575 016ef4 senne protease inhibitor, Kazal t' 1422326 152 2879 194 1988 1 02E+00 1 OOE-01 1 Unchanged Low
Q9NYP7 KOSghδ homolog of yeast long chain poly 2992029 187 288 1627 257 9759 -542E-02 -681E-01 1 Unchanged Low
095436 H01cd6 solute earner family 34 (sodium f 2386021 425 2883247 317 3784 273E-01 834E-01 1 Unchanged Low
095324 B15ab2 ATP-bindmg cassette, sub-family 267704 275 2884558 2770901 1 08E-01 3 94E-02 1 Unchanged Low
Q9UQF6 B08ef3 ribosomal protein L36 5192003 425 2885855 410 9115 -8 47E-01 -2 89E-01 1 Unchanged Low
P13010 K12ef6 X-ray repair complementing defe 1746996 256 2889405 2398403 726E-01 551E-01 1 Unchanged Low
Q9UJZ1 P03cd8 stomatin (EPB72)-like 2 4906115 272 2892003 350 5499 -7 63E-01 -8 52E-01 1 Unchanged Low
P50281 I18ab7 matrix metalloproteinase 14 (mer 1267204 196 280 8803 204 0657 1 19E+00 626E-01 1 Unchanged Low
P15927 B08cd1 replication protein A2 (32kD) 1000172 194 2903306 1947022 1 54E+00 954E-01 1 Unchanged Low
075496 B02ef1 geminm 4664376 454 2907216 4037854 -6 82E-01 -3 84E-02 1 Unchanged Low
Q9P1E3 C23gh4 presemlins associated rhomboid 2325496 263 291 2445 2623787 325E-01 1 79E-01 1 Unchanged Low
P40189 B14ab6 interleukin 6 signal transducer (g 3308834 315 291 3287 3125572 -1 84E-01 -6 89E-02 1 Unchanged Low
Q9Y259 H03ab4 cholme kiπase-like 328 1801 375 291 3288 331 557 -1 72E-01 1 93E-01 1 Unchanged Low
000633 C12ef5 phosphatase and tensin homoloc 1997323 189 291 6118 2267943 546E-01 -7 94E-02 1 Unchanged Low
Q13432 H13cd5 unc-119 homolog (C elegans) 127 1818 268 291 793 2290999 1 20E+00 1 08E+00 1 Unchanged Low
Q9Y677 E03ef2 C0P9 constitutive photomorphoc 1869367 204 291 9539 2277917 643E-01 1 29E-01 1 Unchanged Low
Q9BW24 D03ef8 KIAA0676 protein 1703265 240 2929835 234 5628 7 83E-01 4 97E-01 1 Unchanged Low
Q9NSD9 B12cd5 phenylalanyl-tRNA synthetase be 2266641 219 293 111 246 1288 371 E-01 -522E-02 1 Unchanged Low
Q9NWQ0 C16gh3 hypothetical protein FLJ20695 4974612 656 293 1504 482328 -763E-01 4 OOE-01 1 Unchanged Low
Q9NWT6 C02gh3 hypoxia-inducible factor 1, alpha 521 7793 276 2937543 363 8746 -8 29E-01 -9 18E-01 1 Unchanged Low
Q9UPN3 J12ef7 microtubule-act crossliπkmg fat 5783578 563 2941533 4786344 -975E-01 -378E-02 1 Unchanged Low
Q96HW0 A06gh7 zinc finger protein 38 (KOX 25) 1267599 355 2943016 2587634 1 22E+00 1 49E+00 1 Unchanged Low
Q14257 F18ab8 reticulocalbm 2, EF-hand calciuπ 237 969 217 295 1469 249 8842 3 11E-01 -1 36E-01 1 Unchanged Low
Q9NRJ5 J05gh4 poly(A) polymerase beta (testis s 3792857 276 2957341 31691 -359E-01 -460E-01 1 Unchanged Low
P23280 P02ab3 carbonic anhydrase VI 1376155 102 296 1358 1786789 1 11 E+00 -428E-01 1 Unchanged Low
Q14677 I02gh1 KIAA0171 gene product 330738 204 296 1674 2770019 -1 59E-01 -696E-01 1 Unchanged Low
Q9Y394 H17ef2 CGI-86 protein 471 0368 358 296758g 375 1673 -6 67E-01 -397E-01 1 Unchanged Low
Q9UKX5 L1Bcd7 mtegππ, alpha 11 99 18133 126 2970397 173 978 1 58E+00 342E-01 1 Unchanged Low
Q92539 G02gh1 lipm 2 2607493 235 297 1151 2643623 1 88E-01 -1 49E-01 1 Unchanged Low
Q9NW01 G10gh3 hypothetical protein FLJ10402 165 6121 135 297 1276 1S9 1936 843E-01 -297E-01 1 Unchanged Low
Q9NUW5 N21gh3 hypothetical protein FLJ11099 2283252 247 2975163 2574882 382E-01 1 11 E-01 1 Unchanged Low
Q9BYC4 C13gh8 mitochondria! πbosomal protein S 478 9122 408 297754 394 9285 -6 86E-01 -231 E-01 1 Unchanged Low
P02545 F01ab7 lamm A/C 7077874 294 297 9921 433 306 -1 25E+00 -1 27E+00 1 Unchanged Low
060585 A17cd6 seπne/arginine repetitive matrix ' 318399 331 2982057 315 g302 -945E-02 568E-02 1 Unchanged Low
P23458 L12ef5 Janus kinase 1 (a protein tyrosm 3857348 441 2982124 375 1408 -3 71 E-01 1 95E-01 1 Unchanged Low
Q9BY13 O06gh8 hook3 protein 4350319 471 2982969 401 4116 -544E-01 1 14E-01 1 Unchanged Low
Q9UBC2 C05gh5 epidermal growth factor receplor 171 9695 271 2986179 2473586 7 96E-01 6 59E-01 1 Unchanged Low
076022 A14cd7 E1 B-55kDa-assocιated protein 5 256 9682 243 2987615 266 0871 2 17E-01 -834E 02 1 Unchanged Low
P33993 K04ef6 MCM7 mlnichromoso e mainten 2390601 165 298875 2344011 322E-01 -533E-01 1 Unchanged Low
Qg2963 F02cd2 Ric-like, expressed In many tissu 447 2008 499 299 9377 4154004 -576E-01 1 58E-01 1 Unchanged Low
Q9HAF1 P09gh5 hypothetical protein FLJ11730 2704702 414 3000397 3280993 1 50E-01 6 13E-01 1 Unchanged Low
Q9NZ36 P02gh4 uncharactenzed hypothalamus p 5057323 333 300 1219 379485 -7 53E-01 -605E-01 1 Unchanged Low
Q9BQQ3 C09gh8 golgi phosphoprotein 5 2083671 343 300 1696 283 9342 527E-01 720E-01 1 Unchanged Low
Og5214 P09ef3 leptin receptor overlapping transi 292 4076 419 300 357 337 2896 387E-02 5 19E-01 1 Unchanged Low
Q9Y294 A21ef8 DKFZP547E2110 protein 1665906 243 301 1573 237 0749 854E-01 547E-01 1 Unchanged Low
095810 O01cd4 serum deprivation response (phe 279903 272 301 2133 284 3868 1 06E-01 -4 11E-02 1 Unchanged Low
P30670 L21ab4 guanine nucleotide binding prate 470 8713 466 301 8899 412 8188 -641 E-01 -1 59E-02 1 Unchanged Low
P51946 014ef5 cyclin H 1804218 244 301 9337 2422819 743E-01 438E-01 1 Unchanged Low
Q15290 G18cd1 retinoblastoma binding protein 6 2984739 346 3020906 3154543 1 74E-02 2 12E-01 1 Unchanged Low
Q9NX11 A03gh3 hypothetical protein FLJ20498 1653845 190 302.1175 2192418 8 69E-01 2 02E-01 1 Unchanged Low
Q9P0S3 A23ef2 hypothetical protein LOC51240 1872653 229 302 318 2395316 691 E-01 290E-01 1 Unchanged Low
P04554 H11ab8 protamlne 2 393 1528 362 3023989 3524183 -379E-01 -1 20E-01 1 Unchanged Low
015243 O05ef4 leptin receptor gene-related proti 3293033 391 302 5417 340 9139 -1 22E-01 247E-01 1 Unchanged Low
043717 G03cd7 tumor differentially expressed 1 284 4848 364 302 9444 317004 907E-02 3 54E-01 1 Unchanged Low
095876 J10ef1 hypothetical protein LOC51057 1727128 226 3029853 2338891 8 11E-01 3 88E-01 1 Unchanged Low
Q9H8D5 N17gh5 tumor endothelial marker 6 247 105 190 3034837 2467925 296E-01 -3 81 E-01 1 Unchanged Low
Q9Y3B6 D24ef1 CGI-112 protein 493 6755 288 3037855 361 6747 -701 E-01 -7 80E-01 1 Unchanged Low
Q9P0S7 E13ef2 hypothetical protein LOC51238 1430704 139 303 896 1953392 1 09E+00 -4 11E-02 1 Unchanged Low
060630 D22ab4 deltex homolog 1 (Drosophila) 310 6617 221 3039702 2784627 -3 14E-02 -4 93E-01 1 Unchanged Low
095285 O07gh1 macrophage erythroblast attache 3322343 413 304 0714 3497511 -1 28E-01 3 14E-01 1 Unchanged Low
Q08945 G17cd2 structure specific recognition pro 335 05 229 304 6617 2B9 639 -1 37E-01 -548E-01 1 Unchanged Low
043583 D08cd3 density-regulated protein 2030088 253 304 7034 253 5145 586E-01 3 17E-01 1 Unchanged Low
095149 D04cd5 RNA, U transporter 1 186 979 254 304 889 2485641 705E-01 441E-01 1 Unchanged Low
Q9HAS8 N10gh4 elaC homolog 2 (E coll) 243 3076 331 304 8937 293 0254 326E-01 4 44E-01 1 Unchanged Low
Q9BQ39 A23gh6 nu eolar protein GU2 2343353 160 3052734 233 2592 3 82E-01 -549E-01 1 Unchanged Low O15304 C06ef6 CD27-blπding (Siva) protein 8875727 153 3054708 1823257 1 78E+00 7 83E-01 1 Unchanged Low
Q15394 I08gh1 basic leucine-zlpper protein BZA 3477168 384 3056252 3456465 -1 86E-01 1 42E-01 1 Unchanged Low
Q9NZA3 N09ef1 CDA14 235 1955 312 3057623 2B42776 379E-01 407E-01 1 Unchanged Low
P26022 P23ab8 pentaxln-related gene, rapidly ini 97 61703 61 3 305 8598 154 9189 1 65E+00 -672E-01 1 Unchanged Low
Q00536 L24ef5 PCTAIRE protein kinase 1 290 1914 359 3060473 3185577 768E-02 309E-01 1 Unchanged Low
Q9UMW5 E19ef2 cerebral cell adhesion molecule 5228353 234 3066326 1976582 255E+00 2 16E+00 1 Unchanged Low
095353 J17cd6 Cdc42 effector protein 3 9565314 208 306 7186 2034709 1 68E+00 1.12E+00 1 Unchanged Low
095808 B03ef2 arsenate resistance protein ARS 187 799 225 3074311 2400311 7 11 E-01 260E-01 1 Unchanged Low
Q9BXJ8 017gh8 transmembrane protein Induced I 411 8484 646 3082116 4555065 -4 18E-01 650E-01 1 Unchanged Low
P36776 A06cd5 protease, serine, 15 3904608 365 308 5755 3546324 -340E-01 -978E-02 1 Unchanged Low
Q9BUR9 M19gh6 hypothetical protein MGC4614 250 3191 338 3087431 299 1204 303E-01 435E-01 1 Unchanged Low
Q9Y3R1 F23cd6 Rab acceptor 1 (prenylated) 1589446 207 3087948 2247776 9 58E-01 378E-01 1 Unchanged Low
Q92997 D03ef7 dishevelled, dsh homolog 3 (Dro' 2400941 305 309 2314 2846254 3 65E-01 343E-01 1 Unchanged Low
014682 N17cd3 ectodermal-neural cortex (with B 3260664 189 309539 2747193 -7 50E-02 -7 90E-01 1 Unchanged Low
Q9Y255 I08cd8 px19-lιke protein 533 9688 455 3097497 432 9739 -7 86E-01 -2 30E-01 1 Unchanged Low
Q16664 017ef4 protein \AV" 354 4762 286 3102736 3169703 -1 92E-01 -309E-01 1 Unchanged Low
P31943 O04ab7 heterogeneous nuclear nbonuole 690 0051 250 310 5901 4169005 1 15E+00 1 46E+00 1 Unchanged Low
P49848 J09cd2 TAF6 RNA polymerase II, TATA 151 1422 133 310 9274 1982917 1 04E+00 -1 87E-01 1 Unchanged Low
Q04984 P19ab6 heat shock 10kD protein 1 (chap> 338 1568 327 311 1011 3254422 -1 20E-01 -4 81E-02 1 Unchanged Low
P20719 N08ef4 homeo box A5 271 4135 326 311 2742 3028287 1 98E-01 263E-01 1 Unchanged Low
Q9H5Y0 D21gh7 hypothetical protein FLJ22795 325 1674 305 311 3753 313 8457 -625E-02 -924E-02 1 Unchanged Low
P19021 G15ab8 peptidylglyciπe alpha-amidating i 2195791 273 311 913 2680943 506E-01 3 13E-01 1 Unchanged Low
Q92544 B13gh1 KIAA0255 gene product 270 8313 307 3120297 296 5662 204E-01 1 80E-01 1 Unchanged Low
Q12907 G07cd7 chromosome 5 open reading frar 3130938 222 312 5092 282 474 -270E-03 -4 97E-01 1 Unchanged Low
Q9BW91 C03gh6 nudix (nucleoside diphosphate III 346395 314 312 5575 324 483 -1 48E-01 -1 3gε-oι 1 Unchanged Low
P53365 M23cd8 partner of RAC1 (arfaptln 2) 2932566 349 312 9335 318 382 937E-02 2 51 E-01 1 Unchanged Low
P35869 017ab2 aryl hydrocarbon receptor 2495731 417 313 1153 3265306 327E-01 740E-01 1 Unchanged Low
Q13145 H9cd8 putative transmembrane protein 490 8698 608 313616 4707589 -646E-01 3.08E-01 1 Unchanged Low
014747 A18ef6 death-associated protein 6 3482382 450 313 7398 370593 -1 51 E-01 369E-01 1 Unchanged Low
Q9GZT5 H03gh7 wingless-type MMTV integration 3620025 327 3139764 334369 -205E-01 -1 46E-01 1 Unchanged Low
P081 4 M19ef1 decay accelerating factor for corr 705 5781 457 314 0939 492 3204 ■1 17E+00 -626E-01 1 Unchanged Low
Q9H689 K01gh4 hypothetical protein RG083M05 241 9641 291 314 1855 2823328 377E-01 2 65E-01 1 Unchanged Low
Q9P0T7 K05ef2 hypothetical protein LOC51235 266 1575 324 314 3982 301 4061 240E-01 2 82E-01 Unchanged Low
Q9H2V7 I12gh8 spinster-like protein 2759977 394 3144425 328 1261 1 88E-01 5 13E-01 1 Unchanged Low
Q9NWT0 D23gh2 hypothetical protein FLJ20625 420 628 488 3146523 407 636 -4 19E-01 2 13E-01 1 Unchanged Low
Q9Y6X2 E22cd6 protein inhibitor of activated STA 1490425 237 315009 2337882 1 08E+00 671 E-01 1 Unchanged Low
Q9P1P1 F10ef8 clone FLB1727 (LOC51215) 4199659 330 3150092 355 1102 -4 15E-01 -3 46E-01 1 Unchanged Low
P23919 H04cd7 deoxythymldylate kinase (thymid 1234582 84 1 315562 174 3854 1 35E+00 -5 53E-01 Unchanged Low
P37140 D09ab8 protein phosphatase 1 , catalytic ' 3550781 503 3157751 391 3748 -1 69E-01 503E-01 1 Unchanged Low
Q9NW54 B22gh2 homolog of rat πadnn 4323799 670 3158314 4728474 -453E-01 6 33E-01 Unchanged Low
Q9UMS0 C05ef4 HIRA interacting protein 5 504 0153 382 3158386 4006081 -674E-01 -400E-01 1 Unchanged Low
P14207 E23ef1 folate receptor 2 (fetal) 2355291 154 3160649 235 1893 424E-01 -6 13E-01 Unchanged Low
Q9UHC7 L05ef4 makonn, πng finger protein, 1 243752 243 3163297 267 5313 376E-01 -7 36E-03 Unchanged Low
075844 K23cd6 zinc metalloproteinase (STE24 h 338221 174 3163789 2762357 -963E-02 -958E-01 Unchanged Low
P1Bgh8 LIM homeobox protein 4 87 11814 84 8 3166454 1628523 1 86E+00 -3 90E-02 Unchanged Low
P16587 P19ab2 ADP-πbosylatlon factor 3 4443724 348 317 1873 369 9292 -4 86E-01 -3 S2E-01 Unchanged Low
Q9NVY2 F18gh2 hypothetical protein FLJ 10439 4204716 399 3172936 3787795 -406E-01 -7 72E-02 Unchanged Low
Q9Y3I1 J09ef4 F-Dox only protein 7 3687457 422 317 6515 369 3121 -2 15E-01 1 93E-01 Unchanged Low
Q9H320 P21cd8 variable charge, X chromosome 147 0814 348 3184769 271 2531 1 11 E+00 1 24E+00 Unchanged Low
P49903 J11ef4 selenium donor protein 329031 446 3189322 364 5082 -4 50E-02 4 37E-01 Unchanged Low
000506 BOScdδ seπne/lhreαnlne kinase 25 (STE 273696 275 319317g 289 4017 2.22E-01 7 86E-03 Unchanged Low
000273 F14ab5 DNA fragmentation factor, 45 kD 328993 401 31 634 3500198 -4 16E-02 2 87E-01 Unchanged Low
Q08170 H11cd2 splicing factor, arginine/seπne-nc 231 1994 193 3197733 247 9554 468E-01 -2 61 E-01 Unchanged Low
Q9Y3B8 N15ef8 small fragment nuclease 120 8094 282 3200578 240 8904 1 41 E+00 1 22E+00 Unchanged Low
Q9P0N0 E11ef2 mltochondnal πbosomal protein t 3776692 391 320 1382 362 9626 -238E-01 503E-02 Unchanged Low
Q9BRI3 D11gh8 hypothetical protein MGC11303 > 3735695 391 3204318 361 6895 -221 E-01 660E-02 Unchanged Low
Q9Y319 D19ef2 CGI-30 protein 107 1253 123 3204576 1834471 1 58E+00 1 97E-01 Unchanged Low
Q16514 M17gh1 TAF12 RNA polymerase II, TAT/> 1163618 304 3208611 2469777 1 46E+00 1 38E+00 Unchanged Low
P13489 D13ef7 πbonuclease/angiogenin inhibitoi 224 1663 232 321 0805 259 1076 5 1BE-01 500E-02 Unchanged Low
Q99987 P08ef5 vaccinia related kinase 2 205 9202 194 321 2364 240 3908 642E-01 -8 59E-02 Unchanged Low
P56181 H21ef1 NADH dehydrogenase (ubiqumoi 4350715 319 321 3696 3584382 -437E-01 -448E-01 Unchanged Low
P51148 N18ab8 RAB5C, member RAS oncogene 3297976 358 321 5906 336 6203 -364E-02 1 20E-01 1 Unchanged Low
Q9HD34 E12gh4 CGI-203 protein 257 866 249 322345 276 3612 322E-01 -5 12E-02 Unchanged Low
Q9HAN2 F02gh6 pumilio homolog 2 (Drosophila) 291 9641 326 3224096 313 4126 1 43E-01 1 58E-01 Unchanged Low
P08107 K13ef5 heat shock 70kD protein 1 A 5354871 382 3226223 413 3803 -7 31 E-01 -4 B7E-01 Unchanged Low
O6049g N18cd3 syntaxiπ 10 189 7411 304 3227738 2722579 766E-01 681 E-01 1 Unchanged Low
Q9HBL3 M19gh4 N-termiπal kmase-like 1652938 224 3232472 237 4707 968E-01 438E-01 1 Unchanged Low
Q9BSJ8 D22gh6 KIAA0747 protein 549 1645 575 3235208 4824222 -763E-01 653E-02 1 Unchanged Low
060838 G09gh7 SAC2 suppressor of actin mutatic 2160571 254 3244643 264 8237 587E-01 233E-01 Unchanged Low
Q9BTM6 M11gh8 hypothetical protein MGC3195 371 9412 334 324 5103 343 6429 -1 97E-01 -1 53E-01 1 Unchanged Low
Q9H4L0 K06gh5 leucine zipper protein FKSG14 47 34403 706 3246661 147 5387 278E+00 577E-01 Unchanged Low
P50402 I14ab3 emeπn (Emery-Dreifuss muscula 321 3743 304 324 6751 3166654 1 47E-02 -804E-02 1 Unchanged Low
Q9NZP7 G05ef3 calcium binding protein Cab45 pi 336.1107 239 3246956 299844 -498E-02 -4 94E-01 1 Unchanged Low
P49116 G22cd2 nuclear receptor subfamily 2, gro 295 9342 224 325 1253 2B1 6482 1 36E-01 -403E-01 1 Unchanged Low
P11234 D14ab8 v-ral simian leukemia viral oπcog 565699 444 3255924 444 9874 -7 97E-01 -3 51 E-01 I Unchanged Low
P15408 D21ab5 FOS-like antigen 2 265 6989 437 3258448 342 8236 2 94E-01 7 18E-01 Unchanged Low
Q9P1Q8 N05cd8 RAB3A interacting protein (rabin 3578493 253 3262784 3122142 -1 33E-01 -503E-01 1 Unchanged Low
P39060 P16ef6 collagen, type XVIII, alpha 1 151 6584 212 326 8288 230 0488 1 11 E+00 4 81 E-01 1 Unchanged Low
Q9Y2N3 N05gh1 KIAA0618 gene product 378 8717 252 3268347 3190933 -2 13E-01 -5 91E-01 1 Unchanged Low
P02749 M22ab2 apolipoprotein H (beta-2-glycopπ 4087454 226 327 1228 320758 -321 E-01 -852E-01 1 Unchanged Low
Q9P189 L20gh3 hypothetical protein PR01855 3923328 358 327 1908 359 0228 -262E-01 -1 34E-01 1 Unchanged Low
043822 B19ab4 chromosome 21 open reading frs 2499987 297 3278679 291 7148 391 E-01 250E-01 1 Unchanged Low
Q9UNZ2 N15ef2 likely ortholog of rat p47 413 5167 519 3279429 420 0654 -335E-01 327E-01 1 Unchanged Low
Q9Y4G5 B22cd8 dynein, cytoplasmic, heavy polyp 3766624 426 3279518 376 7971 -200E-01 1 77E-01 1 Unchanged Low
Q13310 C13cd4 poly(A) binding protein, cytoplasi 316 8746 338 328 1257 327507 503E-02 9 11E-02 1 Unchanged Low
P45974 014cd3 ubiquitin specific protease 5 (isoj 268 1073 316 3288257 304 4284 295E-01 239E-01 1 Unchanged Low P55317 A04ab7 hepatocyte nuclear factor 3, alph 2737527 306 328 8562 3028162 2 65E-01 1 60E-01 1 Unchanged Low
043364 H06cd8 homeo box A2 511 053 468 329 1292 435 9554 -635E-01 -1 28E-01 1 Unchanged Low
P5S345 H15ab6 HMT1 hnRNP methyltraπsferase 3648758 307 3295023 3338774 -1 47E-01 -248E-01 1 Unchanged Low
P48230 022cd2 transmembrane 4 superfamily me 565 1635 417 330 825 4375376 -7 73E-01 -4.40E-01 1 Unchanged Low
QgBUY3 C21gh5 sorting nexln 6 1665144 297 3308949 264 7192 991 E-01 834E-01 1 Unchanged Low
000115 B01ef6 deoxyπbonuclease II, lysosomal 2752503 372 331 0554 3260947 266E-01 4 34E-01 1 Unchanged Low
043318 M11cd2 mitogen-activated protein kinase 1867739 247 331 1308 254 8269 826E-01 4 01 E-01 1 Unchanged Low
095572 B08gh1 mitofusin 2 2527846 277 331 4516 287 175 391 E-01 1 33E-01 1 Unchanged Low
P35080 K12ab8 profilln 2 111 4363 859 3322299 176518 1 58E+00 -3 76E-01 1 Unchanged Low
Q9NW29 E24gh3 hypothetical protein FLJ10350 219 5611 173 3328499 241 9521 6 OOE-01 -3 40E-01 1 Unchanged Low
Q9NZE9 O07ef2 BRAF35/HDAC2 complex (80 kD 2193916 348 3328813 299 9861 601 E-01 664E-01 1 Unchanged Low
Q9BYV2 C E05gh8 ππg finger protein 30 500.2246 338 3339675 390 6938 -583E-01 -5 66E-01 1 Unchanged Low
Q9UJX4 F02ef2 aπaphase promoting complex sul 237 1218 269 3345884 280 1684 4 97E-01 1 81 E-01 1 Unchanged Low
000302 B19cd6 calcium homeostasis eπdoplasmi 327 1489 382 3347371 347 7981 331E-02 2 22E-01 1 Unchanged Low
Q92886 K23cd1 neurogenin 1 2902357 283 335 1054 3027027 207E-01 -376E-02 1 Unchanged Low
014929 P07cd3 histone acetyltraπsferase 1 344 9153 130 3354301 270 1111 -402E-02 1 41 E+00 1 Unchanged Low
Q9NVK7 M18gh3 chromosome 19 open reading frs 281 2043 287 3354383 301 1995 254E-01 2 92E-02 1 Unchanged Low
Q9UBN0 P09ef4 proline πch 3 3099093 344 3354526 3297234 1 14E-01 1 50E-01 1 Unchanged Low
043611 E14cd3 cytoplasmic linker 2 180 9108 220 336 1459 2455832 894E-01 2 80E-01 1 Unchanged Low
094777 G23cd4 dolichyl-phosphate mannosyltran 294 1356 244 3367183 291 5641 1 95E-01 -2 71 E-01 1 Unchanged Low
Q14669 K05gh1 thyroid hormone receptor Interac 4869829 397 3370199 4068782 -531 E-01 -2 96E-01 1 Unchanged Low
Q9NUR0 B20gh3 hypothetical protein FLJ11196 6309205 107 337 0769 1689127 242E+00 756E-01 1 Unchanged Low
Q16822 L08ab8 phosphoenolpyruvate carboxykin 2624601 156 337 1655 251 B272 3 61 E-01 -7 52E-01 1 Unchanged Low
Q9Y640 A14cd8 stramal cell denved factor recept 2152348 220 3372906 257 3848 648E-01 292E-02 1 Unchanged Low
P48595 C01cd1 seππe (or cysteine) protemase in 6204001 410 3373872 2697194 244E+00 272E+00 Unchanged Low
P26639 M15cd2 threonyl-tRNA synthetase 355 1309 422 337 8401 371 5003 -720E-02 247E-01 1 Unchanged Low
P29597 O03cd3 tyrosine kinase 2 2093427 258 338 1471 2685377 692E-01 3 02E-01 Unchanged Low
060671 B02ab8 RAD1 homolog (S po be) 1882716 104 339 1461 2103983 849E-01 -859E-01 1 Unchanged Low
Q9NW97 P17gh2 hypothetical protein FLJ1019g 2623124 536 3393086 3790815 3 71 E-01 1 03E+00 1 Unchanged Low
Q9P027 023ef8 HSPC133 protein 6160461 363 339 3102 439 5495 -8 60E-01 -7 62E-01 1 Unchanged Low
095772 E20gh8 hypothetical protein MGC3251 1959084 227 3393844 254 0574 793E-01 2 12E-01 Unchanged Low
Q9NF128 N13gh4 second mitochondπa-deπved act 271 4457 543 3398107 3847351 324E-01 1 OOE+00 Unchanged Low
P11413 F15ab3 glucose-6-phosphate dehydrogei 2580938 135 3400217 244 4906 398E-01 -931 E-01 Unchanged Low
Q99567 A04ab8 nucleopoπn 88kD 4644826 320 340 5878 3750149 -448E-01 -538E-01 Unchanged Low
Q9BZR9 F22gh7 nng finger protein 27 206791 B 398 3407239 315 1764 7 20E-01 945E-01 Unchanged Low
043632 L22cdS ga ma-tubulin complex protein 5 328 0052 322 341 4805 3304468 581E-02 -273E-02 Unchanged Low
Q9Y305 I05cd8 Mitochondrial Acyl-CoA Thioeste 447 9229 475 341 5085 421 5064 -3 91 E-01 849E-02 Unchanged Low
P17096 L14ef6 high-mobility group (nonhistone < 3934158 266 341 5301 33378 -204E-01 -5 62E-01 Unchanged Low
P2B677 E10cd3 vismin-like 1 235283 241 341 6123 272797 538E-01 376E-02 Unchanged Low
Q9UBX5 K04cd6 fibulm 5 7952593 108 341 7638 1764964 2 10E+00 444E-01 Unchanged Low
Q9Y304 E12ef2 ovaπan cancer overexpressed 1 3260044 238 341 8947 301 8585 6 87E-02 -4 56E-01 Unchanged Low
015379 L16ef6 histone deacetylase 3 1980005 380 3423529 3068418 7 90E-01 941E-01 Unchanged Low
Q02790 H16ab5 FK506 binding protein 4 (59kD) 3235993 240 3434254 3022597 8 58E-02 -433E-01 Unchanged Low
Q9H240 K12ef5 Notch homolog 2 (Drosophila) 270 5904 566 3434339 393 3189 344E-01 1 06E+00 Unchanged Low
076095 P22cd6 jumping translocation breakpoint 2528696 227 343482 2744316 4 42E-01 -1 56E-01 Unchanged Low
Q9Y5Q8 P07cd7 general transcnption factor IIIC, | 5456403 324 3439958 4046602 -666E-01 -750E-01 Unchanged Low
Q9NNW5 H06ef8 WD repeat domain 6 254 1607 369 3440253 322 3381 4 37E-01 537E-01 Unchanged Low
P01121 C09ef6 ras homolog gene family, memb- 241 7544 304 3440732 296 4811 509E-01 329E-01 Unchanged Low
Q9H0V7 K18gh8 hypothetical protein DKFZp5540 568248 304 3442985 405 6684 -7 23E-01 -g OOE-01 Unchanged Low
060664 P02cd5 cargo selection protein (mannose 5200919 232 3445523 365 5782 -5 94E-01 -1 16E+00 Unchanged Low
P56554 015cd3 ubiquitin-conjugatmg enzyme E2 3744383 417 3450269 378 959 -1 18E-01 1 57E-01 Unchanged Low
000330 O06cd3 Pyruvate dehydrogenase comple 3459372 430 3452213 3736892 -2 99E-03 3 14E-01 Unchanged Low
060784 N17cd5 target of mybl (chicken) 3643098 317 3452431 342086 -7 76E-02 -202E-01 1 Unchanged Low
Q9NQZ0 H03ef4 CMP-N-acetyineurammic acid sy 788 5176 339 3453498 491 0715 -1 19E+00 -1 22E+00 1 Unchanged Low
P52790 A04ab5 hexokmase 3 (white cell) 260 6034 430 3454621 3452169 4 07E-01 721 E-01 1 Unchanged Low
P52815 B10cd1 mitochondnal nbosomal protein I 2343191 277 3457776 2857775 5 61 E-01 243E-01 t Unchanged Low
014983 O10ef1 ATPase, Ca++ transporting, card 167 4066 223 346 1734 2454613 1 05E+00 4 12E-01 1 Unchanged Low
P04259 D01ab7 keratin 6B 534 1837 405 347 6543 4289832 -6 20E-01 -399E-01 1 Unchanged Low
P16455 M04ef6 0-6-methylguanιne-DNA methylti 299 0887 307 3480545 318 0812 2 19E-01 3 81E-02 1 Unchanged Low
Q9Y5L9 N04cd6 Snf2-related CBP activator protei 2852875 187 3480925 2732945 2 87E-01 -6 13E-01 1 Unchanged Low
P4121 A16gh1 ligatm 2370742 307 3485538 2974677 556E-01 372E-01 Unchanged Low
Q9H6U4 P13gh5 hypothetical protein FLJ21865 4192747 175 3488375 314 4039 -2 65E-01 -1 26E+00 1 Unchanged Low
Q15393 L10ef7 splicing factor 3b, subunit 3, 1301 242 1115 239 3496571 277 0735 530E-01 -1 59E-02 1 Unchanged Low
P55055 C04gh1 nuclear receptor subfamily 1, gra 3256291 368 3498393 347 7942 1 03E-01 1 76E-01 I Unchanged Low
P51805 M03ef4 SEX gene 3030664 383 3506414 3454093 2 10E-01 336E-01 Unchanged Low
075815 G23ab3 breast cancer anti-estrogen resis 249 1903 293 3509571 297768 4 94E-01 234E-01 1 Unchanged Low
Q9Y2Y9 F19ef2 Kruppel-like factor 13 241 1753 366 351 0501 319 2905 5 42E-01 6 OOE-01 1 Unchanged Low
Q99633 D04cd3 pre-mRNA processing factor 18 405046 348 351 3478 368 1886 -205E-01 -2 18E-01 1 Unchanged Low
P05155 C08ab3 seπne (or cysteine) protemase in 3033386 334 351 5074 3297432 2 13E-01 1 41 E-01 1 Unchanged Low
Q9UN50 016cd7 EAP30 subunit of ELL complex 321 9045 326 351 5535 333 1657 1 27E-01 1 84E-02 1 Unchanged Low
Q14011 E11ab4 cold inducible RNA binding prate 2925107 412 351 6685 3520144 2 66E-01 494E-01 1 Unchanged Low
075807 M02ef3 protein phosphatase 1 , regulator 371 7509 652 352 5048 458 6852 -7 67E-02 8 10E-01 1 Unchanged Low
Q 14457 K19ab3 beclin 1 (coiled-coil, myosm-like 3684142 678 3529542 4664393 -6 18E-02 8 80E-01 1 Unchanged Low
Q02818 J06ef6 nucleobmdin 1 330 8747 213 353 1168 298 8382 939E-02 -639E-01 1 Unchanged Low
015235 L10gh1 mitochondnal πbosomal protein S 3551234 467 3532438 391 6738 -766E-03 394E-01 1 Unchanged Low
Q9Y3E0 A02ef2 CGI-141 protein 152 8668 320 353 6986 2754907 1 21 E+00 1 07E+00 1 Unchanged Low
Q9NQZ5 H19gh4 START domain containing 7 2772941 280 3537264 3035369 351 E-01 1 19E-02 1 Unchanged Low
Q9UHW4 D24efB protein x 0001 266 9848 291 3537644 303 9535 4 06E-01 1 25E-01 1 Unchanged Low
P82914 P04gh7 mitochondπal πbosomal protein ! 444 1517 417 3544965 4050567 -325E-01 -927E-02 1 Unchanged Low
P25787 L11ef7 proteasome (prosome, macropaii 432 9379 526 355 1116 437 9448 -2 86E-01 2 80E-01 1 Unchanged Low
P26447 D02cd1 S100 calcium binding protein A4 1987401 273 355 1396 275 5734 838E-01 457E-01 1 Unchanged Low
Q9Y605 P02gh8 T-cell activation protein 411 1148 356 3551531 373935g -2 11 E-01 -2 10E-01 1 Unchanged Low
Q14776 K14cd4 leucine-zipper-like transcnptiona 2020365 273 3554522 276788 8 15E-01 434E-01 1 Unchanged Low
P30837 C02ab2 aldehyde dehydrogenase 1 famil 631 0407 451 3557998 479 1158 -827E-01 -4 86E-01 1 Unchanged Low
P09668 L03ef7 cathepsin H 460 8488 564 3567735 460 5856 -3 69E-01 292E-01 1 Unchanged Low
Q02313 J02ghβ Krueppel-related zinc finger proti 4022B9 391 3569162 3834797 -1 73E-01 -4 02E-02 1 Unchanged Low Q13148 H11cd7 TAR DNA binding protein 3225816 353 357 1404 344 328 1 47E-01 1 31 E-01 1 Unchanged Low
Q16645 K24ab5 FK506 binding protein 1 B (12 6. 2167704 486 3572698 353 4204 721 E-01 1 17E+00 1 Unchanged Low
N02gh8 protein phosphatase 1 , regulator 77 529g3 71 1 3572714 168643 220E+00 -1 24E-01 1 Unchanged Low
P57739 F18gh1 claudin 2 188 162 238 357443 261 2968 926E-01 341 E-01 1 Unchanged Low
060568 F13cd4 procollagen-lyslne, 2-oxoglutarat 332 5306 269 357 5594 319 8117 1 05E-01 -304E-01 1 Unchanged Low
Q9HAU4 N11gh5 E3 ubiquitin ligase SMURF2 4255948 665 3576911 4827167 -2 51 E-01 644E-01 1 Unchanged Low
P49914 J01cd6 5,10-methenyItetrahydrofolate sy 3402344 238 3580826 312027 7 38E-02 -5 17E-01 1 Unchanged Low
060510 E11cd8 atrophιn-1 interacting protein 1 , - 171 9425 265 358342 265 2168 1 06E+00 626E-01 1 Unchanged Low
Q9BX68 L15gh8 histidine tπad nucleotide binding 2070703 360 3585328 3086409 792E-01 79gE-01 1 Unchanged Low
P29084 B02ab5 general transcnption factor HE, p 261 3572 225 358 821 281 687 4 57E-01 -2 17E-01 1 Unchanged Low
P09526 C05ef6 RAP1 B, member of RAS oncogei 320 4156 355 3590861 3449493 1 64E-01 1 49E-01 1 Unchanged Low
015471 P01ef4 leukocyte immunoglobulin-Iike re 2198277 260 3592909 279 8225 709E-01 244E-01 1 Unchanged Low
Q9UEE9 K03ab3 craniofacial development protein 1240304 245 359 5047 242684 1 54E+00 979E-01 1 Unchanged Low
Q15011 L03ef3 homocysteine-induαble, endopla 3524459 183 3597095 2985074 2 04E-02 -943E-01 1 Unchanged Low
Q9BWG8 A13gh6 hypothetical protein MGC2491 170 1162 203 360 534 2446389 1 08E+00 257E-01 1 Unchanged Low
Q9Y397 A04ef2 zinc finger, DHHC domain contai 431 1743 495 3606182 428 8727 -258E-01 1 99E-01 1 Unchanged Low
Q14596 H17ab7 membrane component, chromosc 303 2476 402 361 5265 355 749g 2 54E-01 408E-01 1 Unchanged Low
P23497 C13cd2 nuclear antigen Sp100 331 8296 491 361 9825 394 8464 1 25E-01 5 64E-01 1 Unchanged Low
Q16633 A24cd1 POU domain, class 2, associatiro 103 1231 9 3 3620007 188 1549 1 81 E+00 -539E-02 1 Unchanged Low
Q9gg61 J12cd1 SH3-domaιπ GRB2 -like 1 231 086 247 362 8536 280235 651 E-01 947E-02 1 Unchanged Low
Q07021 N20ab3 complement component 1 , q subi 471 8742 202 3633385 345 9018 -377E-01 • ■1 22E+00 1 Unchanged Low
Q16513 E04cd1 protein kinase C-like 2 546 0111 561 3644852 490 5792 -5 83E-01 3 97E-02 1 Unchanged Low
Q0H070 H10cd8 adaptor-related protein complex 3532901 278 3647541 331 9695 4 61E-02 -346E-01 1 Unchanged Low
Q13227 A16ab5 G protein pathway suppressor 2 557 5311 352 364 8449 424 6909 -6 12E-01 -6 65E-01 1 Unchanged Low
P20330 M03ef5 RAB5A, member RAS oncogene 4046579 664 3657139 478 1731 -1 46E 01 7 15E-01 1 Unchanged Low
QgNXX4 G15gh2 hypothetical protein FLJ20005 1552731 246 3659622 255 5867 1 24E+00 6 61 E-01 1 Unchanged Low
Q92900 N17cd1 regulator of nonsense transcπpts 3282926 316 3662931 3367297 1 58E-01 -569E-02 1 Unchanged Low
Q9H2K4 I05gh3 chromosome 11 open reading frs 1986548 155 3664866 240 051 883E-01 -358E-01 1 Unchanged Low
014917 E17ef4 protocadhenn 17 2503859 311 366 6879 309 398 550E-01 3 13E-01 1 Unchanged Low
Q9NZ88 J06gh3 chromosome 6 open reading frar 199 6701 362 367 2681 3097781 87gE-01 8 60E-01 1 Unchanged Low
QgBYC8 C15gh8 mitochondrial nbosomal protein I 257 9414 429 367 9727 351 4981 5 13E-01 7 33E-01 1 Unchanged Low
Q15311 C21cd7 ralA binding protein 1 2954648 411 3686028 3583107 3 19E-01 476E-01 1 Unchanged Low
Q9NWE9 E02gh3 hypothetical protein FLJ10074 4553747 383 3694489 402 6031 -302E-01 -250E-01 1 Unchanged Low
095571 G22ef3 protein expressed in thyroid 3980124 507 369925 425 0962 -1 06E-01 3 50E-01 1 Unchanged Low
P36941 A09ab7 lymphotoxin beta receptor (TNFF 4030565 454 370 0343 409094 -1 23E-01 1 72E-01 1 Unchanged Low
P49790 F11cd5 nucleopoπn 153kD 264 6175 316 370 2793 317 116 4 85E-01 2 58E-01 1 Unchanged Low
Q99607 C06ab4 E74-like factor 4 (ets domain trar 267 135 268 371 3515 302 1703 475E-01 4 79E-03 1 Unchanged Low
Q9UIV1 H05cd8 CCR4-N0T transcription comple 201 095g 465 371 6771 345 061 8 86E-01 1 21 E+00 1 Unchanged Low
QgY3E4 013ef2 CGI-146 protein 107 5317 262 371 8333 247 1535 1 79E+00 1 29E+00 1 Unchanged Low
Pig367 D17ab3 hexokmase 1 5120647 215 371 9817 3664437 -461 E-01 -1 25E+00 1 Unchanged Low
Q14250 J15cd5 enigma (LIM domain protein) 22 1944 218 371 9927 2729152 699E-01 -752E-02 1 Unchanged Low
Q9UL33 B20ef2 unknown 343 1533 636 3724427 4504535 1 18E-01 890E-01 1 Unchanged Low
Q15019 H03ef5 neural precursor cell expressed 4890601 274 3729279 378666 -3 91 E-01 -836E-01 1 Unchanged Low
Q13084 H05cd6 melanoma-associated antigen re 421 8259 278 3730512 357 6504 -1 77E-01 -601 E-01 1 Unchanged Low
CrøUMR2 018cd7 DEAD/H (Asp-Glu-Ala-Asp/His) t 383 654 423 3730622 393 1434 -4 04E-02 1 40E-01 1 Unchanged Low
P55855 H06cd2 SMT3 suppressor of mif two 3 ho 454 011 444 373596 4240867 -2 84E-01 -358E-02 1 Unchanged Low
Q13155 G20cd4 JTV1 gene 3226641 409 3737416 3684203 2 12E-01 342E-01 1 Unchanged Low
P78371 H11cd6 chaperonm containing TCP1, sut 4805464 430 374014 428 2475 -362E-01 -1 60E-01 1 Unchanged Low
P08173 P17ab3 choiinergic receptor, muscaπnic 4442461 514 3744117 444 3189 -247E-01 2 11E-01 1 Unchanged Low
060478 E02cd2 transmembrane 7 superfamily me 2747639 438 374 61 3624989 447E-01 673E-01 1 Unchanged Low
060429 D16gh4 hypothetical protein FLJ12886 142 8322 257 3750573 258 282 1 39E+00 847E-01 1 Unchanged Low
075935 O04cd7 dynactm 3 (p22) 4089696 432 375 1224 4054281 -1 25E-01 7 97E-02 1 Unchanged Low
Q13147 J05ab2 abl-interactor 2 299098 249 375379 307 9098 328E-01 -2 63E-01 1 Unchanged Low
Q9NPH4 E14gh3 LUC7-like (S cerevisiae) 207 38 302 3763768 2954166 860E-01 545E-01 1 Unchanged Low
Q9UJ96 C13cd8 potassium voltage-gated channe 582717 448 3764373 468 9343 -6 30E-01 -380E-01 1 Unchanged Low
P17081 C13ef6 likely ortholog of mouse TC10-al| 293 1604 417 3764996 362 2816 3 61 E-01 509E-01 1 Unchanged Low
P11166 J05ef5 solute carrier family 2 (facilitated 351 7333 393 376564 3738343 984E-02 1 61 E-01 1 Unchanged Low
Q14820 D12ef6 splicing factor 1 382 846 408 3767779 3892167 -2 30E 02 9 19E-02 1 Unchanged Low
Q92935 I06ab5 exostoses (multιple)-lιke 1 6599005 276 3768548 437 6869 -8 08E-01 -1 26E+00 1 Unchanged Low
P31749 E20ef6 v-akt murine thymoma viral oncoi 3854669 303 3769169 355 1851 -3 24E 02 -346E-01 1 Unchanged Low
Q13454 L05cd7 Putative prostate cancer tumor si 326 9146 363 3770852 3555691 206E-01 1 50E 01 1 Unchanged Low
P35520 C24ab3 cystathionme-beta-synthase 70 85109 68 1 377 1148 1720203 241 E+00 -572E-02 1 Unchanged Low
P53602 M01ab7 mevalonate (diphospho) decarbc 682 0309 178 378 114 412 6357 -8 51 E-01 -1 94E+00 1 Unchanged Low
Q9H7G3 C04gh6 mitochondnal πbosomal protein I 3336677 207 378 1396 306 3867 1 81 E-01 -6 86E-01 1 Unchanged Low
Q13123 C06ab7 IK cytokme, down-regulator of Ht 257 7332 439 378 1806 3583456 553E-01 7 69E-01 1 Unchanged Low
014744 G14cd6 SKB1 homolog (S pombe) 348 0026 410 3784165 378 8177 1 21 E-01 237E-01 1 Unchanged Low
Q9Y566 D16ef8 SH3 and multiple ankyπn repeat 209 2687 281 3795197 290 0718 8 59E-01 427E-01 1 Unchanged Low
Q9BUJ9 A03gh7 Mov10, Moloney leukemia virus 385 0517 472 380 308 412 4352 -1 79E-02 294E-01 1 Unchanged Low
P51790 I02ab5 chloπde channel 3 330 2251 237 3803105 3157621 204E 01 -4 80E-01 1 Unchanged Low
014547 J09cd6 PRP6 pre-mRNA processing fact 2390005 256 380 5886 291 9777 671 E-01 1 01 E-01 1 Unchanged Low
Q99753 A05cd7 cisplatin resistance associated 257 1873 397 3807894 345 0384 566E 01 627E-01 1 Unchanged Low
Q9NQC8 H15gh4 hypothetical protein LOC56912 185 2607 276 381 0416 280 7773 1 04E+00 575E-01 1 Unchanged Low
043919 M01ef6 linker for activation of T cells 206 6586 105 381 2059 230 823 8 83E-01 -9 82E-01 1 Unchanged Low
P78345 F15cd6 πbonuclease P (38kD) 321 791 530 381 5687 411 2575 246E-01 7 21 E-01 1 Unchanged Low
P54257 A03ef5 huntingtin-associated protein 1 (i 450 2874 322 382 6029 384 9948 -2 35E-01 -483E-01 1 Unchanged Low
Q9Y3F4 G18cd7 uπr-iπteractmg protein 390 9437 335 3826142 369 3734 -3 11E-02 -225E-01 1 Unchanged Low
P29536 F14cd7 leiomσdin 1 (smooth muscle) 343 3731 209 3829438 311 936 1 57E-01 -7 13E-01 1 Unchanged Low
075g25 K03cd4 protein inhibitor of activated STA 423 99 2 606 3837943 471 2944 -1 44E-01 5 15E-01 1 Unchanged Low
Q9UMX5 J23ef4 secreted protein of unknown func 344 8668 306 3845676 345 2233 1 57E-01 -1 71 E-01 1 Unchanged Low
Q9UMZ9 N02cd7 interleukin enhancer binding fact 3487866 278 384 7729 337 1554 1 42E-01 -328E-01 1 Unchanged Low
Q92905 P03ef6 C0P9 constitutive photomorphoj 257 5597 392 386 1452 345 1985 5 84E-01 606E-01 1 Unchanged Low
Q9NSD7 L20ef1 G-protein coupled receptor SALF 734 6282 277 3867193 466 2798 -9 26E-01 -1 40E+00 1 Unchanged Low
Q9P2W3 G01ef3 guanine nucleotide binding prote 70 71144 81 4 3867442 1796321 245E+00 204E-01 1 Unchanged Low
Q9BVI7 N14gh5 mitochondnal πbosomal protein J 367 7177 520 386 igβ 424 8293 7 34E-02 4 99E-01 1 Unchanged Low
Q9Y4L1 B23cd6 oxygen regulated protein (150kD 413 0575 372 3875372 390 9975 -9 20E-02 -1 40E-01 1 Unchanged Low
Q02363 F18ab7 inhibitor of DNA binding 2, domir 484 7132 359 3882552 410 6421 -320E-01 -433E-01 1 Unchanged Low Q9Y5J8 E06cd8 translocase of inner mltochondriε 440 2763 542 38B 4554 4568557 -1 81 E-01 2 99E-01 Unchanged Low
E22ef1 G protein-coupled receptor 26 499 1316 450 389 582 4462248 -357E-01 -1 50E-01 Unchanged Low
Q99501 N11cd6 growth arrest-specific 2 like 1 3598065 540 3896398 4296515 1 15E-01 584E-01 Unchanged Low
Q00613 M17ef5 heat shock transcription factor 1 363 3847 375 389 8695 3762292 1 01 E-01 471E-02 Unchanged Low
Q9H5Z1 H16gh4 DEAD/H (Asp-Glu-Ala-Asp/His) t 136589g 124 3899835 2170007 1 51 E+00 -1 35E-01 Unchanged Low
P09661 P24cd1 small nuclear ribonucleoprotein f 441 1409 115 3902085 3155701 -1 77E-01 1 94E+00 Unchanged Low
P54709 P05ef5 ATPase, Na+/K+ transporting, be 4256647 432 391 8135 4165779 -1 20E-01 222E-02 Unchanged Low
P13164 M06ef5 interferoπ induced transmembrar 45 13817 256 392 1204 2311336 3 12E+00 250E+00 Unchanged Low
Q9Y6E2 A23ef8 HSPC028 protein 329 8857 363 3922431 3616248 2 50E-01 1 37E-01 Unchanged Low
Q9NVG2 B13gh3 vacuolar protein sorting 35 (yeas 3590233 557 3922574 4360g59 1 28E-01 634E-01 Unchanged Low
P27448 E10ef5 MAP/micratubule affinity-regulatn 3977845 369 3923918 3864633 -1 97E-02 -1 08E-01 Unchanged Low
015438 P18cd3 ATP-bindmg cassette, sub-family 6180409 488 3928159 4996643 -654E-01 -340E-01 Unchanged Low
Q9UL48 I04ef2 CK2 interacting protein 1 , HQOO! 176 5553 215 3934111 2618209 1 16E+00 2 88E-01 Unchanged Low
094763 A11cd4 RPB5-medιatιng protein 3336215 533 3939448 4203384 240E-01 6 77E-01 Unchanged Low
Q13190 I19cd2 syπtaxιn 5A 179 6148 235 393985 26959g5 1 13E+00 3 89E-01 Unchanged Low
Q13122 D21ef3 EBNA-2 co-activator (100kD) 381 3069 375 3945999 3837948 494E-02 -222E-02 Unchanged Low
075312 L01cd4 zinc finger protein 259 3487542 422 3948016 3883905 1 79E-01 274E-01 Unchanged Low
P37837 D20cd2 transaldolase 1 3992717 326 395693 3737275 -1 30E-02 -292E-01 Unchanged Low
075762 G19cd6 ankyππ-like with transmembrane 222 8517 364 3957427 3273962 828E-01 7 06E-01 Unchanged Low
Q99969 K19ef3 retinoic acid receptor respoπder i 2835705 257 3960287 3120672 4 82E-01 -1 44E-01 Unchanged Low
Q9UNP2 H15cd2 solute earner family 1 (neutral an 149 1019 138 3965014 2277665 1 41 E+00 -1 15E-01 Unchanged Low
P56524 C23cd6 histone deacetylase 4 3286037 303 3971317 3429334 273E-01 -1 17E-01 Unchanged Low
QgH644 C19gh6 hypothetical protein MGC5585 1409811 228 3972624 2553931 1 49E+00 693E-01 Unchanged Low
Q13627 019ab4 dual-specificity tyrosιne-(Y)-phos 498 484 327 3973922 4077774 -3 27E-01 -606E-01 Unchanged Low
Q03405 O01ef5 plasminogen activator, urokmase 500 1391 396 3982456 4313524 -329E-01 -338E-01 Unchanged Low
Q9NPQ8 L18gh4 likely ortholog of mouse synembr 372 8251 443 3984083 4046217 957E-02 248E-01 Unchanged Low
Q15375 A10ab5 EphA7 2430574 290 3985414 310569 7 13E-01 255E-01 Unchanged Low
P05114 G04ab7 high-mobility group (nonhistone t 196 8334 278 3987327 2912748 1 02E+00 4 9gE-01 Unchanged Low
Q9UKU4 C13ef2 retinal short-chain dehydrogenas 370 8225 497 3994413 4224244 1 07E-01 423E-01 Unchanged Low
P08195 E21ab7 solute earner family 3 (activators 442 5453 345 3995678 395768 -1 47E-01 -3 58E-01 Unchanged Low
Q15545 J11cd2 TAF7 RNA polymerase II, TATA 400 689 526 4011308 4425426 1 59E-03 392E-01 Unchanged Low
D24gh8 hypothetical protein FLJ14511 2463293 225 4013816 2908781 7 04E-01 -1 31 E-01 Unchanged Low
005307 L20ef5 PTK2 protein tyrosine kinase 2 3898718 440 4014713 4102909 423E-02 1 73E 01 Unchanged Low
Q9Y6G1 C21ef8 PTD011 protein 434 6906 483 4015119 4398467 -1 15E-01 1 53E-01 Unchanged Low
P41212 023ef5 ets vanant gene 6 (TEL oncogen 3157331 502 4018428 4066035 348E-01 670E-01 Unchanged Low
014737 G05cd5 programmed cell death 5 498 729 430 4023091 4437457 -3 10E-01 -2 13E-01 Unchanged Low
Q9UHB9 A10ef3 signal recognition particle 68kD 2125357 247 4023276 2872236 921 E-01 2 16E-01 Unchanged Low
Q96D21 C20ef8 RASD family, member 2 395909 486 4024304 4279499 236E-02 2 94E-01 Unchanged Low
Q9Y4I1 J05ef1 myosin VA (heavy polypeptide 1. 371 5954 353 402453 3758247 1 15E-01 -723E-02 Unchanged Low
Q9Y5L4 L14ef7 translocase of inner mitochondriε 291 7019 369 4040738 3549111 4 70E-01 339E-01 Unchanged Low
075439 N22cd4 peptidase (mitochondπal process 5129004 184 4045715 3670789 -342E-01 -1 48E+00 Unchanged Low
P55010 K22ab4 eukaryotic translation initiation fa 427 4989 296 4054996 3763076 -7 62E-02 -531 E-01 Unchanged Low
Q9BY44 G10gh8 CDA02 protein 453 6064 401 405956 4201404 -1 60E-01 -1 78E-01 Unchanged Low
Q13164 B21ef5 mitogen-activated protein kinase 209 1026 256 406234 2905304 958E-01 2 93E-01 Unchanged Low
P53667 P08ab6 LIM domain kinase 1 3594655 392 4065183 3860829 1 77E-01 1 26E-01 Unchanged Low
Q9UNH6 F05ef2 sorting nexm 7 4796898 396 4067812 4273762 -238E-01 -278E-01 Unchanged Low
000258 K17cd4 tryptophaπ πch basic protein 3393172 500 4071504 4155431 263E-01 5 60E-01 Unchanged Low
Q9Y3I0 I12ef3 hypothetical protein 4582693 546 4072408 4703717 -1 70E-01 2 52E-01 Unchanged Low
Q9Y368 D13cd8 parvm, beta 114 232 159 4073882 2269908 1 83E+00 480E-01 Unchanged Low
P14866 H13ab6 heterogeneous nuclear πbonucle 4425489 274 4074025 3746383 -1 19E-01 -6 92E-01 Unchanged Low
Q13885 K01cd3 tubulin, beta polypeptide 441 2669 413 4078683 4208456 -1 14E-01 -941E-02 Unchanged Low
043765 J06cd1 small glutamine-πch tetratncopef 378 9705 438 4086453 4086939 1 09E-01 2 10E-01 Unchanged Low
014632 B12ef4 homeodomam interacting protein 394 449 535 4088773 4461081 5 18E-02 4 40E-01 Unchanged Low
P31939 L10ab2 5-amιnoιmιdazole-4-carboxamιde 501 3028 386 4093069 432286 -2 92E-01 -376E-01 Unchanged Low
P28331 P18ab8 NADH dehydrogenase (ubiqumoi 490 4347 417 4093283 4387901 -2 61 E-01 -235E-01 Unchanged Low
P41970 P05ef6 ELK3, ETS-domam protein (SRF 205 9453 359 4108037 3253706 9 96E-01 803E-01 Unchanged Low
Q92973 J22ab6 karyopheππ (importin) beta 2 3936551 234 4109425 3461733 620E-02 -7 51 E-01 Unchanged Low
P36507 J10ef5 mitogen-activated protein kinase 39522 437 4114052 4146953 579E-02 1 46E-01 Unchanged Low
Q16512 F21ab8 protein kinase C-like 1 4562727 486 4118245 4514528 -1 48E-01 9 18E-02 Unchanged Low
043447 M08cd6 peptidyl prolyl isomerase H (cycli 179441 222 4119165 2710162 1 20E+00 305E-01 Unchanged Low
P30040 M13ef3 chromosome 12 open reading frs 3466792 296 4122064 3515665 2 50E-01 -229E-01 Unchanged Low
095399 C19cd7 urotensin 2 452 0721 366 4131451 4104914 -1 30E-01 -304E-O1 Unchanged Low
M01ab3 UDP-Gal betaGal beta 1,3-galae 4999529 290 4133454 4010113 -274E-01 -7 87E-01 Unchanged Low
Q12792 N11ab8 protein tyrosine kinase 9 476 3952 364 4134208 418007 -205E-01 -3 87E-01 Unchanged Low
Q14318 J02cd7 FK506 binding protein 8 (38kD) 461 2322 432 4134238 4356453 -1 58E-01 -935E-02 Unchanged Low
075955 N10cd5 flotillm 1 304 6674 310 4154364 343496 4 47E-01 268E-02 Unchanged Low
Q9BVY8 B09gh7 hypothetical protein MGC5499 4902382 417 41602 4409559 -237E-01 -235E-01 Unchanged Low
Q16288 019ef5 neurotrophic tyrosine kinase, rec 1267467 186 4164128 2430358 1 72E+00 5 53E-01 Unchanged Low
O75360 J20ab8 NADH dehydrogenase (ubiquinoi 4495778 413 4164836 4264999 -1 10E-01 -1 21 E-01 Unchanged Low
Q9BY51 B15gh8 hypothetical protein GL009 429 1998 354 4173575 4000464 -4 04E-02 -2 80E-01 Unchanged Low
Q9BVK3 E19gh6 hypothetical protein MGC2463 4625828 387 4177046 4225145 -1 47E-01 -256E-01 Unchanged Low
Q9P0N3 A24ef2 hypothetical protein FLJ10597 1377487 289 417999 281424 1 60E+00 1 07E+00 Unchanged Low
P24534 D03ab4 eukaryotic translation elongation 3472405 328 4180152 3645026 268E-01 -8 11E-02 Unchanged Low
P49336 C01ab4 cyclin-dependent kinase 8 426 3751 281 418121 3752575 -282E-02 -600E-01 Unchanged Low
P34130 P16cd2 neurotrophin 5 (neurotrophin 4/5 3274146 223 4186011 3230643 3 54E-01 -553E-01 Unchanged Low
075425 P06gh5 hypothetical protein AF053356_C 340 4357 339 4193637 3661692 301 E-01 -7 34E-03 Unchanged Low
Q15293 F16ab8 reticulocalbin 1 , EF-hand calciuπ 241 6383 250 4205597 3041243 799E-01 501E-02 Unchanged Low
095376 D08ab2 anadne homolog 2 (Drosophila) 254 1122 322 4208229 3322465 728E-01 341 E-01 Unchanged Low
075489 J16ab8 NADH dehydrogenase (ubiquinoi 3757034 327 4223772 3751108 1 69E-01 -1 99E-01 Unchanged Low
P28482 B15ef5 mitogen-activated protein kinase 493 835 452 4224625 4561064 -225E-01 -1 28E-01 Unchanged Low
P20823 B09cd1 transcription factor 1 , hepatic, LF 3224782 527 4234405 4243654 393E-01 7 09E-01 Unchanged Low
015250 I04cd4 X-prolyl ammopeptidase (amiπop 524 8 88 542 4237387 4967532 -309E-01 457E-02 Unchanged Low
P55769 P22ab8 NHP2 non-histone chromosome i 137 3557 479 4240031 34668 1 63E+00 1 80E+00 Unchanged Low
094817 N21ab2 APG12 autophagy 12-lιke (S cei 631 6055 402 4243577 4859574 -574E-01 -652E-01 Unchanged Low
075352 K08cd5 mannose-P-dolichol utilization de 272444 523 4248266 4067998 641 E-01 941 E-01 Unchanged Low
Q16585 I16cd1 sarcoglycan, beta (43kD dystropl 2562113 293 4251172 324 9166 731 E-01 1 96E-01 Unchanged Low Q9H7X7 B16gh5 hypothetical protein FLJ14117 261 957S 463 4253725 3835805 699E-01 8 23E-01 1 Unchanged Low
015173 I16cd6 progesterone receptor membrane 2950481 244 4258728 321 6602 529E-01 -2 74E-01 1 Unchanged Low
Q9GZX9 A16gh4 twisted gastrulaiion 8461732 147 426 1124 2193062 233E+00 7 99E-01 1 Unchanged Low
Q16594 M09cd2 TAF9 RNA polymerase II, TATA 171 3507 520 426 7606 3726331 1 32E+00 1 60E+00 1 Unchanged Low
000479 017gh1 high-mobility group (nonhlstone c 265695 354 4267642 348 S168 684E-01 4 15E-01 1 Unchanged Low
P54760 C22ab5 EphB4 5287066 413 427 0543 4564179 -308E-01 -3 55E-01 1 Unchanged Low
P25490 F06ef6 YY1 transcπption factor 481 2844 530 427 184 4794548 -1 72E-01 1 39E-01 1 Unchanged Low
Q9UJY0 B07ef3 putative nucleotide binding prote 5059493 431 427 3544 454 8441 -244E-01 -2 31 E-01 1 Unchanged Low
Q09666 A22ef1 AHNAK nucleoproteln (desmoyol 392 0671 399 427 3828 406041 1 24E-01 241E-02 1 Unchanged Low
015305 P22ab7 phosphomannomutase 2 3250777 480 4283778 411 2528 3 98E-01 563E-01 1 Unchanged Low
060492 M09ab4 7-dehydrocholesterol reductase 388 5228 213 428 5923 3433316 1 42E-01 -8 68ε-01 1 Unchanged Low
Q9UND3 G11cd6 nuclear pore complex interacting 2808175 312 428 5952 340 6147 6 10E-01 1 54ε-01 1 Unchanged Low
Q9HB15 M15gh5 potassium channel, subfamily K, 4735589 408 4289306 4369131 -1 43E-01 -2 14E-01 1 Unchanged Low
Q9Y3B4 H23ef2 CGI-110 protein 2909669 331 429 1497 3504808 561E-01 1 87E-01 1 Unchanged Low
Q14107 F05ef5 D123 gene product 387 0465 405 4299331 4073091 1 52E-01 652E-02 1 Unchanged Low
P52435 A22cd1 polymerase (RNA) II (DNA direct 5270446 461 4299488 4727272 -2 94E-01 -1 93E-01 1 Unchanged Low
Q9Y262 L11ef2 eukaryotic translation initiation fa 591 5767 311 4306788 444385 -458E 01 -928E-01 1 Unchanged Low
P10163 L20cd2 proliπe-nch protein BstNI subfam 521 4154 251 431 1299 401 2036 -274E-01 -1 05E+00 1 Unchanged Low
P38378 F01cd8 protein transport protein SEC61 . 6355838 369 431 9958 478 7225 -557E-01 -7 86E-01 1 Unchanged Low
P48735 B06ab6 isocitrate dehydrogenase 2 (NAC 600 2178 338 432 1616 456 8577 -474E-01 -828E-01 1 Unchanged Low
Q9NPF5 F02gh4 DNA methyltransferase 1-associi 451 5343 382 4323473 421 964 -626E-02 -241 E-01 1 Unchanged Low
014616 K22cd4 zinc finger protein-like 1 194 5B71 348 4324885 324 9789 1 15E+00 838E-01 1 Unchanged Low
Q00839 A12ab7 heterogeneous nuclear πbonucle 4165145 410 432 5188 419 7665 544E 02 -2 18E-02 1 Unchanged Low
095563 J15ef8 DKFZP564B167 protein 390 848 389 432 8082 404 2972 1 47E-01 -596E-03 1 Unchanged Low
Q92974 I03cd6 rho/rac guaπiπe nucleotide exchε 1423392 124 4332386 2332947 1 61 E+00 -1 95E-01 1 Unchanged Low
Q9UEE5 M07cd5 seπne/threon e kinase 17a (ape 3978599 472 4334221 4344129 1 24E-01 246E-01 1 Unchanged Low
Q9NXB1 019gh3 BTB (POZ) domain containing 2 1753887 206 43348 1 271 6819 1 31 E+00 233E-01 1 Unchanged Low
Q9NXF9 O01gh3 0-lιnked mannose betal ,2-N-ace 477 6375 353 4342027 421 54 -1 37E-01 -438E-01 1 Unchanged Low
P98171 F13ef1 Rho GTPase activating protein 4 3689887 231 4353585 345 0241 239E-01 -677E-01 1 Unchanged Low
P56192 H4ab7 methionine-tRNA synthetase 2630076 295 435894 331 1505 729E-01 1 63E-01 Unchanged Low
095411 K09cd5 TGFB1 -induced anti-apoptotic fa 2333926 310 4362684 326 6136 902E-01 4 10E-01 1 Unchanged Low
P09132 E23cd2 signal recognition particle 19kD 227 8193 595 4365994 4197603 938ε-01 1 38E+00 1 Unchanged Low
Q92537 024gh1 KIAA0247 gene product 291 1054 232 437 1141 319914 586E-01 -3 30E-01 1 Unchanged Low
P49761 G03ab4 CDC -like kinase 3 4589286 562 437 5601 486 0405 -688E-02 291 E-01 Unchanged Low
Q9HDC4 019gh4 junctophilm 3 3467829 388 439282 391 3835 341 E-01 1 62E-01 1 Unchanged Low
P98160 A13ef7 heparan sulfate proteoglycan 2 (| 5056962 372 439 9544 439 0807 -201 E-01 -444E-01 Unchanged Low
Q9NQV6 022gh4 PR domain containing 10 369 157 514 4405347 441 3923 2 55E-01 479E-01 1 Unchanged Low
Q9NRX6 J09gh4 protein x 013 324 5306 345 4408995 370 1383 442E-01 8 82E-02 Unchanged Low
076084 A13cd4 catenm (cadheπn associated pro 471 1305 211 441 7617 3746479 -929E-02 -1 16E+00 Unchanged Low
P23197 E19cd7 chromobox homolog 1 (HP1 beta 480 8183 362 441 9595 428 3076 -1 22E 01 -409E-01 Unchanged Low
Q99439 E10ab6 calponin 2 429 1961 304 442 4148 391 978 438E 02 -496E 01 Unchanged Low
014656 O04ef6 dystonia 1 , torsion (autosomal dc 4153893 533 4429429 463 6417 927E 02 3 59E-01 Unchanged Low
Q9NPJ3 P04gh4 uncharactenzed hypothalamus p 411 0811 430 4432575 428 1718 1 09E-01 655E-02 Unchanged Low
P41226 B10ef7 ubiquitiπ-activating enzyme E1-lιl 2986597 342 443334 361 2685 570E-01 1 95E 01 Unchanged Low
Q9Y478 C24cd1 protein kinase AMP-activated, bι 3060158 165 443 5049 3047576 535E 01 -8 93E-01 Unchanged Low
P06cd8 nodal homolog (mouse) 3494202 252 4437188 348 2928 345E 01 -473E-01 Unchanged Low
Q12904 O06ef7 small Inducible cytokine subfamil 3746683 459 445 5171 4265346 250E-01 294E-01 Unchanged Low
P20264 C02cd1 POU domain, class 3, transcrlptu 4586994 302 447 8929 402 9521 -344E 02 -602E-01 Unchanged Low
Q15428 B11cd4 splicing factor 3a, subunit 2, 66kl 2840454 334 4486652 3557289 660E-01 236E-01 Unchanged Low
P49771 G06ef6 f s related tyrosine kinase 3 ligs 4496827 417 452 1329 4394747 784E-03 -1 10E-01 Unchanged Low
P49005 A18cd1 polymerase (DNA directed), delti 363 5225 232 4526832 3493417 3 16E-01 -649E-01 Unchanged Low
Q99879 M14gh6 H2B histone family, member E 3259523 483 452 8012 4207323 474E 01 5 69E-01 Unchanged Low
P49821 G20cd1 NADH dehydrogenase (ubiqu oi 511 5488 392 454 6223 4525721 -1 70E-01 -386E-01 Unchanged Low
P10644 H22ef5 protein kinase, cAMP-dependent 420 8225 518 454 8256 464 5909 1 12E-01 3 OOE-01 Unchanged Low
Q9Y5J4 L17gh6 pyrrollne 5-carboxylate reductase 1456987 303 455 1667 301 448 1 64E+00 1 06E+00 Unchanged Low
P31040 K02cd2 succmate dehydrogenase compli 671 3369 351 4562212 4927974 -557E-01 -936E-01 Unchanged Low
Q9UHA2 F04ef8 synovial sarcoma translocation g 4386951 480 456469 4584094 573E-02 1 30E-01 Unchanged Low
Q9UBF6 C02ef3 nng finger protein 7 3156541 400 4569368 390 7196 534E-01 340E-01 Unchanged Low
Q9Y5S2 C21cd6 CDC42 binding protein kinase be 3869683 447 456 g709 430 2759 240E-01 208E-01 Unchanged Low
P20809 H07ef7 interleukin 11 399048 140 4581544 3323748 1 99E-01 -1 51 E+00 Unchanged Low
Q13526 F21ef5 protein (peptidyl-prolyl cis/trans I 3334194 460 4582237 417 3666 459E-01 466E-01 Unchanged Low
Q9NWQ9 H01gh2 hypothetical protein FLJ20671 4307122 577 4582293 488 6936 893E-02 422E-01 Unchanged Low
Q9Y6J0 E05cd8 calclneurin binding protein 1 4743964 117 4587489 350 127 -4 84E 02 -202E+00 Unchanged Low
Q9Y4Z6 B13cd7 vacuolar protein sorting 45A (yes 115 1679 276 4588586 2833006 1 99E+00 1 26E+00 Unchanged Low
Q01433 G02ab2 adenosme monophosphate dean 3525251 390 4592935 400 6864 3 82E-01 1 47E-01 Unchanged Low
043181 M07ab8 NADH dehydrogenase (ubiquinoi 4174586 432 4602425 4366589 1 41E 01 503E-02 Unchanged Low
Q9NWT5 D15gh2 hypothetical protein FLJ20618 3543599 523 460 3326 445 8286 377E-01 561 E-01 Unchanged Low
075431 P19cd6 metaxin 2 2824791 443 460 352 395 1258 705E 01 648E-01 Unchanged Low
P09543 A18gh7 2',3'-cyclιc nucleotide 3' phospho 2582862 510 462033 4099513 839E-01 980E-01 Unchanged Low
Q9BTE1 B05gh8 dynactiπ 4 5626142 460 4624054 494 9234 -2 83E-01 -291E-01 1 Unchanged Low
P16152 H14ab5 carbonyl reductase 1 2343184 240 463 6916 312 5841 985E-01 330E-02 1 Unchanged Low
015121 D06cd3 degenerative spermatocyte home 2647024 270 4644612 333 1906 8 11E-01 308E-02 1 Unchanged Low
060909 E09ab3 UDP-Gal betaGlcNAc beta 1,4- c 3658881 379 4649697 403 197 346E-01 498E-02 1 Unchanged Low
075223 C11gh6 hypothetical protein MGC3077 4939011 276 4657709 411 9427 -846E-02 -839E-01 1 Unchanged Low
Q9BQA1 K03gh6 MEP50 protein 379 1943 303 466 1997 382 8783 2 98E-01 -322E-01 1 Unchanged Low
043427 F20cd4 fibroblast growth factor (acidic) Ir 323 6471 325 4668724 371 8858 529E-01 663E-03 1 Unchanged Low
Q9BWG6 A15gh6 hypothetical protein MGC3180 3093486 596 4680924 457 7257 598E-01 945E-01 1 Unchanged Low
Q9Y6R2 M04cd6 chromosome 4 open reading frar 3377358 352 4699502 386 6911 477E-01 6 13E-02 1 Unchanged Low
Q9HBK7 M07gh4 NPD007 protein 3674893 489 471 1924 4424205 359E-01 4 11 E-01 1 Unchanged Low
P52758 E04ef7 translational inhibitor protein p14 324 9333 318 471 2741 371 3427 536E-01 -3 19E-02 1 Unchanged Low
P47897 E19cd1 glutamlnyl-tRNA synthetase 400 1718 364 4725359 4122837 240E-01 -1 36E-01 1 Unchanged Low
Q9BWQ6 P20gh5 hypothetical protein MGC3262 2888083 483 4730084 4150843 7 12E-01 743E-01 1 Unchanged Low
P35325 H22cd2 small prolme-πch protein 2B 3905307 584 4742762 4830992 280E-01 5 82E 01 1 Unchanged Low
Q9HA68 023gh5 hypothetical protein FLJ12154 5563676 383 474 593 471 3877 -229E-01 -538E-01 1 Unchanged Low
P49366 P16ab5 deoxyhypusme synthase 4586886 481 477 1999 4722313 571E-02 679E-02 1 Unchanged Low
Q9UKZ7 J18ef1 colon carcinoma related protein 5050182 450 4784787 4777496 -779E-02 -1 67E-01 1 Unchanged Low P01730 K15ef5 CD4 antigen (p55) 5164046 432 478 8033 475788 -1 09E-01 -257E-01 1 Unchanged Low
P20674 L06cd4 cytochrome c oxidase subunit Va 5124055 372 4802708 454 7764 -9 34E-02 -463E-01 1 Unchanged Low
Q12828 H02ef6 far upstream element (FUSE) bin 462592 312 480 5079 418 2868 548E-02 -5 69E-01 1 Unchanged Low
Q8Y6A4 J18ef3 similar to mouse Glt3 or D malar 3599248 485 4808661 442 0882 4 18E-01 4 32E-01 1 Unchanged Low
060888 B09ef2 divalent cation tolerant protein C 2986981 304 481 136 361 3342 6 88E-01 262E-02 1 Unchanged Low
075716 F08cd3 seπne/threonine kinase 16 364 1875 379 481 1652 408 0382 4 02E-01 566E-02 1 Unchanged Low
P30711 E18ef7 glutathione S-transferase theta 1 327 8121 533 481 9461 447 6268 556E-01 702E-01 1 Unchanged Low
Q15008 L03gh1 KIAA0107 gene product 4756485 506 4823327 488 0851 201E-02 9 OOE-02 1 Unchanged Low
P17174 N07ab4 glutamic-oxaloacetic transaminas 4125293 224 4844384 373 5229 232E-01 -884E-01 1 Unchanged Low
P13798 K16ab2 N-acylaminoacyl-peptide hydrola 365 1218 351 48444 400 3314 408E-01 -551E-02 1 Unchanged Low
Q9P2R8 E15ef4 Misshapen/NIK-related kinase 4695725 511 484 515 4884865 4 52E-02 1 23E-01 1 Unchanged Low
Q9UNT1 E20cd7 RAB, member of RAS oncogene 268916 347 484 9919 366 9843 851 E-01 368E-01 1 Unchanged Low
075607 L11cd7 nucleophosmin/πucleoplasmin, 3 3502387 272 4855671 369 1972 471 E-01 -366E-01 1 Unchanged Low
094925 B20gh1 glutamiπase 4104357 471 4868946 4560458 246E-01 1 98E-01 1 Unchanged Low
095390 A06ab3 growth differentiation factor 11 264606 324 489 3912 359 3416 8 87E-01 292ε-01 1 Unchanged Low
075956 K13cd6 tumor suppressor deleted in oral 524962 482 489 6212 498 9664 -1 01 E-01 -1 22E-01 1 Unchanged Low
095573 I23ab5 fatty-acid-Coenzyme A ligase, loi 354 1387 174 4896455 3392885 467E-01 1 02E+00 1 Unchanged Low
Q9BXH1 N23gh6 Bcl-2 binding component 3 4933887 433 492 1083 472 8963 -375E-03 -1 88E-01 1 Unchanged Low
P13662 L20cd5 nuclear transport factor 2 392576 479 4924942 4547336 327E-01 287E-01 1 Unchanged Low
Qg2793 H05ab5 CREB binding protein (Rubinstel 468559 474 494 3525 478 8243 773E-02 1 53E-02 1 Unchanged Low
Q9P0H6 K23ef4 AD-012 protein 4064789 469 495 1858 456 7944 285E-01 206E-01 1 Unchanged Low
Q9P0R3 C05ef3 hypothetical protein HSPC213 3390916 509 4952656 447 9021 547E-01 5 87E-01 1 Unchanged Low
075094 E11gh1 slit homolog 3 (Drosophila) 3459855 439 496 3612 426952 521 E-01 342E-01 1 Unchanged Low
Q9P011 P10ef2 non-canonical ubquitm conjugatn 4604398 538 497 256 498 5084 1 11 E-01 224E-01 1 Unchanged Low
Q92504 M12cd4 HLA class II region expressed gs 251 7256 339 497 6138 362 6669 983E-01 42βε-01 1 Unchanged Low
095190 L12cd8 ornithine decarboxylase antizymi 421 0592 441 4976839 453 1247 241 E-01 655E-02 1 Unchanged Low
Q9Y230 N12cd6 RuvB-like 2 (E coli) 3420841 300 4977767 379 9805 541 E-01 -1 89E-01 1 Unchanged Low
Q9BSG0 M16gh8 chromosome 2 open reading frar 3245321 458 497 8462 426 9191 6 17E-01 4 98E-01 1 Unchanged Low
Q9Y366 I17ef2 chromosome 20 open reading frs 278 1968 453 498 3057 409 8539 841 E-01 7 04E-01 1 Unchanged Low
Q14094 024ef5 cyclm 1 4076242 354 4996223 42031 294E-01 -205E-01 1 Unchanged Low
P43403 H04ef5 zeta-cham (TCR) associated pro 3960583 396 500 6282 430 7684 338E-01 -1 60E-03 1 Unchanged Low
P52803 H23ef7 ephrin-A5 357 5339 316 501 0718 391 4643 487E-01 -1 79E-01 1 Unchanged Low
095402 E18cd5 cofactor required for Sp1 transcπ 1060683 587 501 9814 222 265 224E+00 -852E-01 1 Unchanged Low
000233 L23ab8 proteasome (prosome, macropaii 581 8818 39g 502 2082 494 287 -2 12E-01 -545E-01 1 Unchanged Low
Q9H1K6 018gh7 mesoderm development Candida 432735 560 5027516 498 6205 2 16E-01 373E-01 1 Unchanged Low
Q9BXL6 K15gh6 caspase recruitment domain prat 425 1251 523 502 8514 483629 242E-01 299E-01 1 Unchanged Low
Q9H173 H03gh5 endoplasmlc reticulum chaperom 4565646 449 5035156 4696418 1 41 E-01 -246E-02 1 Unchanged Low
Q9NV83 H03gh3 hypothetical protein FLJ10876 4239423 497 504 9702 4754325 252E-01 2 30E-01 1 Unchanged Low
P11926 A12ab8 ornithine decarboxylase 1 591 3922 362 505 3016 486 3355 -227E-01 -707E-01 1 Unchanged Low
Q04743 D23ef1 empty spiracles homolog 2 (Dros 531 3866 311 5057367 449 3322 -7 14E-02 -7 73E-01 Unchanged Low
Q9BVK2 G11gh6 hypothetical protein MGC2840 si 3888682 383 5059804 4259595 380E-01 -2 18E-02 Unchanged Low
043251 I16ef3 RNA binding motif protein 9 3466445 530 5070674 461 1452 549E-01 6 12E-01 Unchanged Low
Q99829 L13cd4 copme I 3553783 268 5084915 377 1688 5 17E-01 -409E-01 Unchanged Low
095777 B10ef2 U6 snRNA-assoclated Sm-like pr 391 981 311 5088683 403 8183 377E-01 -336E 01 Unchanged Low
Q9UN53 C19ef2 calcium binding protein Cab45 pi 327721 407 5093316 4146963 636E-01 3 13ε-01 Unchanged Low
P24310 F03ab4 cytochrome c oxidase subunit VII 1840695 288 5094504 327 1972 1 47E+00 646E-01 Unchanged Low
Q9H929 N09gh5 hypothetical protein FLJ13055 387341 500 510 1197 4657217 3 97E-01 3 67E-01 Unchanged Low
P10768 K19ef1 esterase D/formylglutathione hyd 5963068 102 510 5002 402 8142 -224E-01 -255E+00 Unchanged Low
095287 D17cd5 golgi autoantigen, golgiπ subfam 346 1135 560 510 6433 4723714 561 E-01 695E 01 Unchanged Low
Q01105 H18cd1 SET translocation (myeloid leuke 3286513 403 511 1477 4142142 637E-01 294E 01 Unchanged Low
Q9UK45 B08ef2 U6 snRNA-associated Sm-like pr 3884486 551 511 9386 483 7088 398E-01 504E-01 Unchanged Low
P35611 I17ab2 adducin 1 (alpha) 4350349 519 5126447 488 7819 2 37E-01 2 S4E-01 Unchanged Low
014681 K22cd5 etoposide-mduced mRNA 451 5599 324 5165292 430 8211 1 94E-01 -477E-01 Unchanged Low
P80303 AOScdl nucleobindm 2 296 1418 236 5167037 349 5918 803E-01 -328ε-01 Unchanged Low
Q9NWC0 N19gh2 F-box only protein 4 4345394 477 5177728 476 3476 253E-01 1 34E-01 Unchanged Low
P00367 B06ab5 glutamate dehydrogenase 1 3606 303 5182525 3940342 523E-01 -250E-01 Unchanged Low
000469 I09ab8 procollageπ-lysine, 2-oxoglutarat 7358327 238 5186446 497 4006 -5 05E-01 -1 63E+00 Unchanged Low
Q9U104 M18ef4 mitochondnal πbosomal protein I 364 1383 336 520 377 4067523 5 15E-01 -1 17E-01 Unchanged Low
P20338 N08ab8 RAB4A, member RAS oncogene 487 9427 457 5207608 488 5317 939E-02 -949E-02 1 Unchanged Low
Q9HCU8 I19gh4 polymerase (DNA-directed), delte 513 52 431 522 5153 489 0161 2 51E-02 -2 53E-01 1 Unchanged Low
P00519 I06ef5 v-abl Abelson muπne leukemia v 2324636 301 522 7624 352 0574 1 17E+00 373E-01 1 Unchanged Low
Q13880 O02cd5 brain and reproductive organ-exf 5724849 263 5239906 4530588 -1 28E-01 -1 12E+00 1 Unchanged Low
P25789 L13ef7 proteasome (prosome, macropaii 436 5895 534 526 397 498 9408 270E-01 290E 01 1 Unchanged Low
043805 J16cd3 Sjogren's syndrome nuclear auto 368 0123 539 526 5215 4777167 5 17E-01 550E-01 1 Unchanged Low
075817 A13cd6 P0P7 (processing of precursor, i 375 1187 433 5266432 445 0255 4 89E-01 2 08E-01 1 Unchanged Low
Q9UBI1 N11cd7 BUP protein 337 1018 428 526 9646 430701 645E-01 345E-01 1 Unchanged Low
P03950 G12ab2 angiogeπin, πbonuclease, RNase 3950198 200 5277882 3744251 4 18E-01 -979E-01 1 Unchanged Low
P78423 F20cd1 small inducible cytokme subfamil 201 965 747 5302357 4932272 1 39E+00 1 89E+00 1 Unchanged Low
Q9P1D0 E07gh4 hypothetical protein PR02533 5804051 733 531 5331 2209467 320E+00 336E-01 1 Unchanged Low
P03999 K05ab3 opsm 1 (cone pigments), short-w 1165093 37 9 532 8048 2290786 2 19E+00 -1 62E+00 1 Unchanged Low
095793 M22cd2 staufeπ, RNA binding protein (Dr 417 7687 498 5348626 4836536 3 56E-01 254E-01 1 Unchanged Low
P22750 M05ef2 RAB4B, member RAS oncogene 2973584 346 5384665 393 9782 857E-01 2 19E-01 1 Unchanged Low
B06gh8 ubiquitin UBF-fl 431 0731 472 540 8482 481 1517 327E-01 1 29ε-01 1 Unchanged Low
Q9NRX8 J15gh4 oxidoreductase UCPA 1687047 523 544 0864 411 9671 1 69E+00 1 63E+00 1 Unchanged Low
QgUHQ3 J20gh4 stromal cell protein 4698784 214 546 1893 410 1503 2 17E-01 -1 13E+00 1 Unchanged Low
Qg6S52 J22gh8 phosphatidylmositol glycan, das' 4049498 287 546 8906 412 8095 4 34E-01 -4 99E 01 1 Unchanged Low
Q9H3F6 C24gh8 MSTP028 protein 4429007 396 549 0707 462 5636 3 10E-01 -1 63E 01 1 Unchanged Low
P3719B K03cd8 nucleopoπn 62kD 4282961 499 550 8083 4927531 3 63E-01 2 21 E-01 1 Unchanged Low
Q9H1D4 B05gh4 arginyl aminopeptidase (amiπope 430 3273 477 551 8541 4862744 359E-01 1 47E-01 1 Unchanged Low
075350 K04cd5 glycoprotein, synaptic 2 4807082 436 552 8489 4899278 202E-01 -1 40E-01 1 Unchanged Low
Q9P024 D16ef3 Huntingtm interacting protein K 369 5132 480 5535493 467714 5 83E-01 378E-01 1 Unchanged Low
Q9Y224 H21ef2 CGI-99 protein 449089 472 5546607 4920453 305E-01 730E-02 1 Unchanged Low
Q13361 012cd3 Microfibπl-associated glycoprotei 1942B 354 557 066 368553 1 52E+00 867E-01 1 Unchanged Low
Q02535 F01ef1 inhibitor of DNA binding 3, domir 8405787 174 559513 2726788 273E+00 1 05E+00 1 Unchanged Low
095864 L24cd4 fatty acid desaturase 2 2984502 113 5596571 323 8122 907E-01 -1 40E+00 1 Unchanged Low
P53621 H16ab4 coatomer protein complex, subur 4092779 471 560 6313 480 1571 4 54E-01 201 E-01 1 Unchanged Low P35638 N03ab4 DNA-damage-iπduclble transcπp 3225942 318 565361 4019484 809E-01 -212E-02 1 Unchanged Low
P22307 D22cd1 sterol carrier protein 2 3543674 356 5691558 426421 684E-01 558E-03 1 Unchanged Low
Q92543 D15gh1 KIAA0254 gene product 3283511 356 5695472 4178592 795E-01 115E-01 1 Unchanged Low
P78330 N06ab8 phosphosenne phosphatase 2534253 220 5699825 3478406 117E+00 -203E-01 1 Unchanged Low
Q9UNX3 G15ef2 nbosomal protein L26-llke 1 4013697 445 5723441 4728205 512E-01 148E-01 1 Unchanged Low
P49189 C10ab2 aldehyde dehydrogenase 9 famil 446252 277 579314 4342707 376E-01 -687E-01 1 Unchanged Low
Q9ULX0 H03gh6 inorganic pyrophosphatase 4883446 402 5796142 4899828 247E-01 -281E-01 1 Unchanged Low
015353 H21cd3 winged-helix nude 4079375 497 5806191 4952368 509E-01 285E-01 1 Unchanged Low
Q9NRP2 D21gh4 DC13 protein 3828544 421 5815421 461731 603ε-01 136E-01 1 Unchanged Low
Q16280 E18ef1 cydic nucleotide gated channel s 4640608 360 5848035 4696748 334E-01 -366E-01 1 Unchanged Low
P04183 C04cd2 tlϊymldine kinase 1 , soluble 3467317 289 5883101 4078979 763E-01 -264E-01 1 Unchanged Low
Q12824 017ef5 SWI/SNF related, matrix associa 2188831 554 5902326 4543734 143E+00 134E+00 1 Unchanged Low
Q99719 B09ab8 peanut-like 1 (Drosophila) 4195269 410 5922598 4740479 497E-01 -319E-02 1 Unchanged Low
P46100 H07ab3 alpha thalasse ia/mental retards 3098648 167 5943041 3569983 940E-01 -893E-01 1 Unchanged Low
Q16610 O05ab5 extracellular matπx protein 1 2383172 335 596 691 3896774 132E+00 489E-01 1 Unchanged Low
P39656 E23ab6 dolichyl-diphosphooligosacchanc 4335719 367 5980668 4664028 464E-01 -239E-01 1 Unchanged Low
P53814 G07cd3 smoothelln 5174102 269 59816 4615158 209E-01 -944E-01 1 Unchanged Low
Q9P0N4 P24ef1 hypothetical protein LOC51260 6099142 286 6019324 499258 -190E-02 ■ 109E+00 1 Unchanged Low
Q9BXZ1 A02gh7 peptidylprolyl isomerase (cyclopt 4654301 362 6038737 4771895 376E-01 -362E-01 1 Unchanged Low
Q9Y2Q4 H19ef8 HSPC002 protein 3375615 391 6049187 444641 842E-01 214E-01 1 Unchanged Low
015527 A18ab8 8-oxoguanιne DNA glycosylase 3304852 282 6053444 4060683 873E-01 -227E-01 1 Unchanged Low
Q04323 G01ef2 ORF 497159 255 6101121 4542076 295E-01 -961E-01 1 Unchanged Low
P12004 G18ab8 proliferating cell nudear antigen 3321465 303 612821 4160883 884E-01 -131E-01 1 Unchanged Low
Q99720 M11cd6 sigma receptor (SR31747 bindmi 3638609 379 6150729 4526168 757E-01 585E-02 1 Unchanged Low
P43307 G13cd2 signal sequence receptor, alpha 2261566 322 6189554 3890352 145ε+00 510E-01 1 Unchanged Low
Q9H3Y8 O05gh6 chromosome 20 open reading frs 2212984 246 6194944 3624108 149ε+00 155E-01 1 Unchanged Low
Q9NRX2 A08ghS mitochondπal πbosomal protein t 2846282 305 6279834 4059846 114E+00 101E-01 1 Unchanged Low
Q9P2X0 L10gh2 dollchyl-phosphate maπnosyltran 285542 431 6386696 4518107 116E+00 595E-01 1 Unchanged Low
Q9Y5Z8 E05cd7 male-specific lethal 3-ilke 1 (Dros 3617331 394 6397431 4650297 823E-01 122E-01 1 Unchanged Low
P78524 F01cd2 suppression of tumongenicity 5 3434117 289 643333 4251425 906E-01 -250E-01 1 Unchanged Low
P55145 F02ab2 arginiπe-πch, mutated in early sL 4131582 420 6566324 4964892 668E-01 226E-02 1 Unchanged Low
P33551 023ab5 CDC28 protein kinase 1 2963533 355 6714891 440861 118E+00 259E-01 1 Unchanged Low
Q9BVQ0 E09gh6 hypothetical protein MGC5363 4330788 545 6812449 2596855 398E+00 332E-01 1 Unchanged Low
P34897 D15cd2 seπne hydroxymethyltransferase 4409652 290 6856584 4721838 637E-01 -605E-01 1 Unchanged Low
Q9Y5B4 L23ef2 andragen induced protein 2684081 519 6859395 4911814 135E+00 952E-01 1 Unchanged Low
Q9Y2V5 B15ef2 transforming growth factor beta 1 2491479 327 7123879 429636 152E+00 394E-01 1 Unchanged Low
Q13953 B19cd2 solute earner family 12 (potassiu 3425865 428 7292688 4999658 109E+00 321E-01 1 Unchanged Low
Q92686 I11ef6 neurograπin (protein kinase C su 3308792 299 7362348 4554495 115E+00 -145E-01 1 Unchanged Low
060565 J05cd8 cysteine knot superfamlly 1, BMF 1066904 151 7810154 3463594 287E+00 505E-01 1 Unchanged Low
Q9Y4M4 121gh3 putative UDP-GalNAc polypeptid 346098 251 8464309 4812315 129E+00 -463E-01 1 Unchanged Low
P16581 E01ef7 selectin E (endothelial adhesion 1093094 378 8751666 4540605 3 OOE+00 179E+00 1 Unchanged Low
014733 P02ef5 mitogen-activated protein kinase 9883312 140 888014 3755944 317E+00 502E-01 1 Unchanged Low
Q16623 M24cd2 syπtaxin 1A (brain) 4032337 165 9265022 4983425 120E+00 -129E+00 1 Unchanged Low
Q9P1M5 P12gh3 WW domain containing oxidored 3893 193 129223 4501426 505E+00 -101E+00 1 Unchanged Low
060613 L18cd4 15 kDa selenoproteιn 1220902 1110 128507 1205045 739E-02 -138E-01 2 Unchanged Medium
Q16698 M07ab4 2,4-dιenoyl CoA reductase 1 , mit 4699997 706 6153087 5972594 389E-01 588E-01 2 Unchanged Medium
Q9HBA8 D23gh1 24-dehydrocholesterol reductase 7680888 278 6260195 5572677 -295E-01 -147E+00 2 Unchanged Medium
Q9P0I2 M13ef4 30 kDa protein 546352 691 6145795 6174113 170E-01 339E-01 2 Unchanged Medium
Q9UL53 P24cd7 5'-3' exoπbonuclease 2 648132 604 4302235 5606322 -591E-01 -103E-01 2 Unchanged Medium
P49902 N16cd7 5'-nucleotιdase, cytosolic II 1040523 1220 4400817 9009404 -124E+00 232E-01 2 Unchanged Medium
095336 P09cd7 6-ρhosphoglucoπolactoπase 5243104 755 8125955 6974428 632E 01 527E-01 2 Unchanged Medium
Q03393 A23ab8 6-pyru.oyltet.ahydropterin synthi 3580591 700 5174355 5250184 531E-01 966E-01 2 Unchanged Medium
Q13443 P01ef7 a dismtegnn and mefalloproteiπa 1306754 481 4453663 7445037 -155E+00 -144E+00 2 Unchanged Medium
075173 F15ab2 a dislntegπn-like and metalloprot 7865151 1060 1254«04 1033446 674E-01 429E-01 2 Unchanged Medium
P51572 O03gh1 accessory proteins BAP31/BAP2 9851381 889 6566554 8436943 -585E-01 -148E-01 2 Unchanged Medium
P42765 D03ab2 acetyl-Coenzyme A acyltransfera 8496041 1280 1204131 1111329 503E-01 592E-01 2 Unchanged Medium
P24666 E05ab2 add phosphatase 1 , soluble 1642966 1970 1890909 1833204 203E-01 259E-01 2 Unchanged Medium
Q92688 D21cd6 acidic (leucine-rich) nuclear pho: 4708575 289 8359103 5319498 828E-01 -704E-01 2 Unchanged Medium
014639 B21ab2 actin binding LIM protein 1351973 393 358779 7012899 -191E+00 -178E+00 2 Unchanged Medium
015143 F06ab2 actin related protein 2/3 complex 6960033 513 3490474 5193549 -996E-01 -440E-01 2 Unchanged Medium
015509 F12ab2 actin related protein 2/3 complex 9090832 889 807751 8686913 -171E-01 -318E-02 2 Unchanged Medium
015511 F14ab2 actin related protein 2/3 complex 7321996 619 4661372 6058842 -651E-01 -242E-01 2 Unchanged Medium
P12718 A08ab6 actin, gamma 2, smooth muscle, 5853438 846 209596 1175856 184E+00 532E-01 2 Unchanged Medium
Q9P0I6 O09ef4 AD-015 protein 9470366 837 1259571 1014448 411E-01 -179E-01 2 Unchanged Medium
043747 M13ab2 adaptor-related protein complex 1104332 532 4194712 6852957 -140E+00 -105E+00 2 Unchanged Medium
P20172 A11ab6 adaptor-related protein complex 128683 1280 2285193 1617354 828E-01 -763E-03 2 Unchanged Medium
014617 H07ab2 adaptor-related protein complex 6794847 495 3570868 5104994 -928E-01 -457E-01 2 Unchanged Medium
P07741 M24ab2 adenine phosphoπbosyltransfera 1885065 862 8238455 1190468 -119E+00 -113E+00 2 Unchanged Medium
P00568 A02ab2 adenylate kinase 1 2404119 399 3543768 1052361 -276E+00 -259E+00 2 Unchanged Medium
Q9UIJ7 106ef2 adenylate kinase 3 alpha like 7587288 1060 6628834 8283999 -195E-01 487E-01 2 Unchanged Medium
P30566 M07ab2 adenylosucclnale lyase 4958874 622 5184238 5454304 641E-02 327E-01 2 Unchanged Medium
Q16186 M11cd7 adhesion regulating molecule 1 6223901 610 5745888 6022578 -115E-01 -295E-02 2 Unchanged Medium
Q9NVF6 B19gh3 ADP-nbosylation factor 1 GTPas 4493679 623 6761878 5829297 590E-01 472E-01 2 Unchanged Medium
P26438 B04ab2 ADP-πbosylation factor 6 7321241 818 8769277 8091342 260E-01 161E-01 2 Unchanged Medium
P40616 D12ab2 ADP-πbosylatioπ factor-like 1 8271898 1220 114192 1064016 465E-01 564E-01 2 Unchanged Medium
P36404 D14ab2 ADP-nbosylation factor-like 2 1751048 1550 1871661 172374 961E-02 -177E-01 2 Unchanged Medium
P56559 D20ab2 ADP-nbosylation factor-like 7 4854552 598 5686824 5505764 228E-01 300E-01 2 Unchanged Medium
P35368 K17ab2 adrenergic, alpha-1 B-, receptor 1433715 1510 1335995 1426069 -102E-01 734E-02 2 Unchanged Medium
P15144 G24ab2 alanyl (membrane) amiπopeptida 9873343 222 4801162 5632289 -104E+00 -215E+00 2 Unchanged Medium
P30038 L09ab2 aldehyde dehydrogenase 4 famil 1179797 598 6574315 8117082 -844E-01 -981E-01 2 Unchanged Medium
P14550 L05ab2 aldo-keto reductase family 1 , mei 555464 886 6099901 6839189 135E-01 674E-01 2 Unchanged Medium
043488 L07ab2 aldo-keto reductase family 7, mei 546409 525 7485424 6066855 454E 01 -574E-02 2 Unchanged Medium
P09972 C16ab2 aldolase C, fructose-bisphosphal 8785714 1050 9475062 960156 109E-01 263E-01 2 Unchanged Medium
043590 G12ef4 alpha-actιnιn-2-assocιated LIM p 7763757 1070 5011993 783883 -631E-01 468E-01 2 Unchanged Medium
Q08117 M19ab2 amino-ter minal enhancer of split 1779707 1430 1219695 1476318 -545E-01 -316E-01 2 Unchanged Medium
Q13438 G05cd7 amplified in osteosarcoma 6580513 638 8023407 6996136 286E-01 -436E-02 2 Unchanged Medium O96018 M01gh1 amyloid beta (A4) precursor proti 7623898 750 1117682 8766611 552E-01 -238E-02 2 Unchanged Medium
Q13564 P11ab2 amyloid beta precursor protein bl 587 5144 664 786 6426 679 5497 421 E-01 1 78E-01 2 Unchanged Medium
Q9Y679 B08cd7 ancient ubiquitous protein 1 1191 741 1270 1022771 1160442 -221 E-01 8 81E-02 2 Unchanged Medium
Q9UKB4 B12ef2 aπgiomoim like 2 5237253 776 568 8766 6227291 1 19E-01 5 66E-01 2 Unchanged Medium
Q13725 H19ab2 angiotensln receptor 1 1495332 1360 1058942 1304 886 -498E-01 -1 36E-01 2 Unchanged Medium
P08133 I20ab2 annexln A6 2530936 413 879 9474 515 5041 1 80E+00 7 08E-01 2 Unchanged Medium
P20073 I22ab2 anπexin A7 650 1591 481 4204945 5170979 -629E-01 -4 36E-01 2 Unchanged Medium
P03971 E22ab2 anti-Mullenan hormone 1140812 948 640 7158 9099247 -832E-01 -2 67E-01 2 Unchanged Medium
P30041 O08cd5 anti-oxidaπt protein 2 (πon-seleπi 1248922 1160 3067945 1824225 1 30E+00 -1 12E-01 2 Unchanged Medium
P27695 K06ef6 APEX nuclease (multifunctional t 6659854 653 8356897 7182149 327E-01 -2 85E-02 2 Unchanged Medium
Q9Y4J7 P01ab2 apoptosis inhibitor 5 1850534 684 1474186 6887802 • ■365E+00 ■ ■476E+00 2 Unchanged Medium
Q9Y5L7 L03ef2 apoptosis related protein APR-3 662 9122 583 1426489 690 7729 1 11 E+00 -1 86E 01 2 Unchanged Medium
094778 014ab2 aquaponn 8 1475036 1420 1474307 145501 -7 13E-04 -5 92E-02 2 Unchanged Medium
015296 E02ab2 arachidonate 15-lιpoxygenase, s 8268209 607 720 2105 718 1334 -1 99E 01 -4 45E-01 2 Unchanged Medium
P48444 018ab2 archain 1 1291 871 1200 1374 223 1288 649 892E-02 -1 07E-01 2 Unchanged Medium
P00966 J24ab2 arginmosuccinate synthetase 1049688 1600 9494889 1199548 -1 45E-01 6 08E-01 2 Unchanged Medium
P42024 D15ab2 ARP1 actin-related protein 1 hon 1054286 1720 1777 944 1518 804 7 54E-01 7 10E-01 2 Unchanged Medium
043681 J16ab2 arsA arsenite transporter, ATP-bi 5403448 724 5953348 6200089 1 40E-01 423E-01 2 Unchanged Medium
Q9ULX3 E02ef4 ART-4 protein 7287274 595 5093934 611 0757 -5 17E-01 -2 92E-01 2 Unchanged Medium
096030 H16ab2 artemin 881 7849 728 6382016 749363 -466E 01 -276E-01 2 Unchanged Medium
P15289 F24ab2 arylsulfatase A 1639546 1230 1012 121 1294 172 -6 96E-01 -4 14E-01 2 Unchanged Medium
P08243 J18ab2 asparagine synthetase 891 3027 643 1540 113 1024719 7 89E-01 -472E-01 2 Unchanged Medium
095630 L17ab2 associated molecule with the SH 6603522 872 7292383 7537548 1 43E-01 401 E-01 2 Unchanged Medium
095135 B09ab2 ataxin 2 related protein 9024529 345 342 3299 5300852 • •1 40E+00 - -1 39E+00 2 Unchanged Medium
014530 N15ab2 ATP binding protein associated v B274646 1390 766257 993482 -1 11 E-01 7 45E-01 2 Unchanged Medium
P30049 N20ab2 ATP synthase, H+ transporting, r 6250408 468 441 4691 511 6658 -502E-01 -4 16E-01 2 Unchanged Medium
Q9UII2 I10ef2 ATPase inhibitor precursor 7764612 1220 641 2787 8785341 -276E-01 649E-01 2 Unchanged Medium
Q9Y5K8 F17ef2 ATPase, H+ transporting, lysosoi 9980597 1670 1029 886 123291 453E-02 7 43E-01 2 Unchanged Medium
075787 P15ab2 ATPase, H+ transporting, lysosoi 815707 945 1081 688 9475842 407E-01 2 13E-01 2 Unchanged Medium
P05023 P09ef5 ATPase Na+/K+ transporting, all 1299236 517 7090882 841 8422 -874E-01 -1 33E+00 2 Unchanged Medium
P45844 P13ef5 ATP-bindmg cassette, sub-family 863 8068 381 606 1642 6168957 -5 11 E-01 - -1 18E+00 2 Unchanged Medium
Q9HAP7 M08gh5 baculoviral IAP repeat-containinc 1507 175 1740 1945 196 1730 54 368E-01 207E-01 2 Unchanged Medium
094812 G09ab3 BAI1-assocιated protein 3 107367 983 8266524 961 2437 -377E-01 -1 27E-01 2 Unchanged Medium
P35613 B14ef7 basigin (OK blood group) 6034821 474 8652409 647414 520E-01 -3 50E-01 2 Unchanged Medium
Q9BSR6 A20gh8 BBP-like protein 1 816219 1320 914 1927 1015 173 1 64E-01 688E 01 2 Unchanged Medium
000512 K01ab3 B-cell CLL/lymphoma 9 1357 15 767 8036541 504741 •408E+00 -4 15E+00 2 Unchanged Medium
Q12983 E19ab5 BCL2/adenovιrus E1B 19kD mtei 7637046 548 991 4529 7675569 377E-01 -4 80ε-01 2 Unchanged Medium
Q92934 K24ef1 BCL2-antagoπιst of cell death 5388191 727 6035103 623 2249 1 64E-01 4 33E-01 2 Unchanged Medium
Q07817 E10ef6 BCL2-like 1 2062673 2510 1097 372 1890 905 -9 10E-01 285E-01 2 Unchanged Medium
043892 M23ab3 Bicaudal D homolog 1 (Drosophll 654 9397 414 5487409 539 1375 -255E-01 -6 63E-01 2 Unchanged Medium
P53004 019ab3 biliverdin reductase A 4900724 569 5122807 523696 639E-02 2 15E-01 2 Unchanged Medium
060629 G21ab3 bladder cancer associated protei 6079847 1180 1083411 956 1289 833E-01 953E-01 2 Unchanged Medium
Q9HBX3 N21gh6 brain and nasopharyngeal carcm 1672 876 54 44 02379 5902997 -525E+00 -4 95E+00 2 Unchanged Medium
P56945 H23ef3 breast cancer anli-estr ogen resis 133488 1300 1304356 1312 13 -334E-02 -4 14E-02 2 Unchanged Medium
015255 G21cd6 CAAX box l 7336878 577 1202 182 837 48 7 12E-01 -348E-01 2 Unchanged Medium
P12830 C16ef5 cadheπn 1 , type 1 , E-cadheπn (e 109464 924 4695012 8358959 -1 16E+00 -245Ξ-01 2 Unchanged Medium
P19022 E03ef7 cadherin 2, type 1 , N-cadheππ (n 337 5528 540 747 1198 541 7151 1 15E+00 679E-01 2 Unchanged Medium
P22223 K19ef7 cadherln 3, type 1, P-cadheπn (p 8968467 1200 372 3054 8236929 -1 27E+00 422E 01 2 Unchanged Medium
P22676 N07ab5 calbindin 2, (29kD, calretinin) 1781 134 1500 2116438 1797589 249E-01 -2 52E-01 2 Unchanged Medium
Q99828 019gh1 calcium and integrin binding 1 (c 1130 551 1320 8383709 1096979 -431 E-01 226E-01 2 Unchanged Medium
P02593 I18ab4 calmodulin 1 (phosphorylase km, 1076 299 787 983 6302 949 1389 -1 30E 01 -451E 01 2 Unchanged Medium
Q13942 L01ab5 calmodulm 3 (phosphorylase km, 902 667 464 871 1455 7460174 -5 13E 02 -9 59E-01 2 Unchanged Medium
P27824 I05ef1 calnexm 1492644 1370 1543709 14704 4 85E-02 -1 19E-01 2 Unchanged Medium
P17655 C20ef6 calpain 2, (m/ll) large subunit 671 5939 837 5494365 685847 -290E-01 3 17E-01 2 Unchanged Medium
P04632 C22ef6 calpain small subunit 1 1565935 1650 1258 047 1490643 -3 16E-01 736E 02 2 Unchanged Medium
Q15417 P17ab5 calponm 3, acidic 911 495 603 737 1204 750 6841 -306E-01 -595E-01 2 Unchanged Medium
Q9UEG5 D17ef8 capicua homolog (Drosophila) 6290213 486 4396052 518 1163 -5 17E-01 -373E-01 2 Unchanged Medium
P52907 O08ab4 capping protein (actin filament) n 8480436 684 5847035 7055063 -536E-01 -3 11E-01 2 Unchanged Medium
Q9GZX3 N16gh1 carbohydrate (N-acetylglucosami 793 1054 929 751 3352 8245253 -7 81E-02 228E-01 2 Unchanged Medium
Q16619 K01ab4 cardiotraphin 1 1478 249 1220 1559477 1420784 772ε-02 -272E-01 2 Unchanged Medium
Q9UBD9 I24cd8 cardiotrophin like cytokine, neurc 361 4077 893 4896592 581 3157 438E-01 1 30E+00 2 Unchanged Medium
Q15699 M16cd4 cartilage paired-class homeoprot 747 0317 596 1109 834 817569 571 E-01 -326E-01 2 Unchanged Medium
P48729 A22ab6 casein kinase 1 , alpha 1 690 8551 1150 9029474 914 9218 386E-01 736E 01 2 Unchanged Medium
P48730 L07ab4 casein kinase 1, delta 951 5238 1160 1111 571 1073796 224E-01 284E 01 2 Unchanged Medium
P19138 L08ef5 casein kinase 2 alpha 1 polypep 4836062 597 461 8036 5139702 -666E-02 303E 01 2 Unchanged Medium
P49662 C12ef6 caspase 4, apoptosis-r elated cys 2013 957 2460 1017425 1831 485 -9 85E-01 290E-01 2 Unchanged Medium
P21964 F19ef6 catechol-O-methyltransferase 697 5886 1170 1268869 1046831 863E-01 751 E-01 2 Unchanged Medium
P26232 K01ef7 catenin (cadheπn-associated pro 797 8639 717 810257 774 9896 2 22E-02 -1 54E 01 2 Unchanged Medium
P35222 G07ef7 catenin (cadheπn-associated pro 969252 1290 1103619 1121 277 1 87E-01 4 14E 01 2 Unchanged Medium
P07339 N23ef7 cathepsin D (lysosomal aspartyl i 125301 947 1133 879 1111 314 -1 44E-01 -4 04E-01 2 Unchanged Medium
Q99967 C18cd6 Cbp/p300-ιnteractιng transactiva 1293 915 1600 2245 133 1711 366 7 95E-01 302E-01 2 Unchanged Medium
P49715 N17ef6 CCAAT/enhaπcer binding proteir 882 9323 884 104545 937 3612 244E-01 1 26E-03 2 Unchanged Medium
P53567 N22ab5 CCAAT/enhancer binding proteir 8269569 1160 1584869 1191 643 938E-01 492E-01 2 Unchanged Medium
095627 B21cd8 CCR4-N0T transcription comple 6064629 851 6924535 7167046 1 91 E-01 4 89E-01 2 Unchanged Medium
Q04900 G02cd4 CD164 antigen sialomuciπ 750 3086 570 6737234 664 5986 -1 55E-01 -3 97E 01 2 Unchanged Medium
P07766 P07ab3 CD3E antigen epsilon polypeptit 1808209 1410 2643721 1953 844 548E-01 -3 59E 01 2 Unchanged Medium
P34810 A21ab4 CD68 antigen 2460 227 1100 1293 961 1617 586 -927E-01 -1 16E+00 2 Unchanged Medium
P18582 B21ab5 CD81 antigen (target of aπtipralif 1303 144 938 1598276 1279761 295E-01 -4 75E-01 2 Unchanged Medium
Q16181 F09ef5 CDC10 cell division cycle 10 hon 4266642 443 751 3623 5403444 8 16E-01 542E-02 2 Unchanged Medium
Q16543 H01ef5 CDC37 cell division cycle 37 hon 1085 897 1050 1336 155 1158574 299E-01 -435E 02 2 Unchanged Medium
014735 I14cd6 CDP-diacylglycerol-inositol 3-ph 241 7793 1180 311 7422 5794931 367E-01 229E+00 2 Unchanged Medium
P30260 F13ef5 cell division cycle 27 1060812 1470 1469824 1334733 470E-01 474E-01 2 Unchanged Medium
P49427 B12ef7 cell division cycle 34 762 5808 1300 7666343 9420784 7 74E-03 7 66E-01 2 Unchanged Medium
P29373 F01ef7 cellular retinoic acid binding prat 1226236 803 1350 177 1126 373 1 39E-01 -6 11 E-01 2 Unchanged Medium
P41208 F09ab5 centπn, EF-haπd protein, 2 539 1633 672 676 8582 6293345 328E-01 3 18E-01 2 Unchanged Medium
000522 F05ab4 cerebral cavernous malformation 8704309 631 723 1482 741 4854 -267E-01 -4 64E-01 2 Unchanged Medium 015183 B12cd3 CGG tπplet repeat binding protei 402 949 610 8833283 6320808 1 13E+00 5 98E-01 2 Unchanged Medium
Q9Y2Z5 D07ef2 CGI-06 protein 721 6709 674 1177 641 857 6492 706E-01 -9 94E-02 2 Unchanged Medium
Q9Y3C3 J05ef2 CGI-120 protein 1229537 1360 2124304 1572302 789E-01 1 49E-01 2 Unchanged Medium
Q9Y3D0 J11ef2 CGI-128 protein 1592767 2370 2011 685 1992 502 337E-01 5 75E-01 2 Unchanged Medium
Q9Y3E5 J17ef2 CG1-147 protein 532425 788 5670634 6293057 909E-02 5 66E-01 2 Unchanged Medium
Q9Y3ES C08ef2 CGI-150 protein 785276 924 7780449 829 1206 -1 33E-02 2 35E-01 2 Unchanged Medium
Q9Y320 A19ef2 CGI-31 protein 7450314 932 7037829 7934541 -822E-02 3 22E-01 2 Unchanged Medium
Q9Y357 P16ef1 CGI-40 protein 817 7272 769 4186337 668441 -966E-01 -8 87E-02 2 Unchanged Medium
Q9Y360 A10e(2 CGI-45 protein 7860567 914 7966229 8322061 1 93E-02 2 17E-01 2 Unchanged Medium
Q9Y512 B04ef3 CGI-51 protein 9673508 859 1045638 957 4201 1 12E-01 -1 71 E-01 2 Unchanged Medium
Q9Y390 K21ef2 CGI-81 protein 1391 902 802 1140 01 1111 152 -2 88E-01 -7 96E-01 2 Unchanged Medium
P40227 N20ab4 chaperonm containing TCP1, sut 1011 613 436 5924944 679 9043 -7 72E-01 • ■1 22E+00 2 Unchanged Medium
Q99832 H07cd6 chaperonm containing TCP1 , sut 1190644 1090 1548 874 1274 983 379E-01 -1 33E-01 2 Unchanged Medium
Q9UBR5 I23ef4 chemokine-like factor 1 1047 63 1800 1059437 1303 992 1 62ε-02 7 85E-01 2 Unchanged Medium
Q9UHN8 N05ef4 chemokine-like factor 1 1568851 2030 1237728 1611 343 -342E-01 3 70E-01 2 Unchanged Medium
P54105 L07ef5 chloπde channel, nucleotide-sen 471 0775 487 6406855 5329217 444E-01 4 80ε-02 2 Unchanged Medium
Q14781 F09ef1 chromobox homolog 2 (Pc class l 795873 749 713815 7530305 -1 57E-01 -8 6βε-02 2 Unchanged Medium
Q9BXS4 K12cd5 chromosome 1 open reading frar 8740189 1370 904 3066 1050 603 4 91E 02 652E-01 2 Unchanged Medium
Q9NPA0 H07gh4 chromosome 11 hypothetical pro 998 8577 834 858794 897 3389 -2 18E-01 -2 60E-01 2 Unchanged Medium
Q9UKR5 G14cd7 chromosome 14 open reading frs 1181 962 1160 1285 11 1207747 1 21 E-01 -3 18E-02 2 Unchanged Medium
P56378 M16cd5 chromosome 14 open reading frs 503 5233 690 890 9975 694 9486 823E-01 4 55E-01 2 Unchanged Medium
095433 B22cd7 chromosome 14 open reading frs 656 1775 563 4389755 552 8428 -5 80E-01 -2 20E-01 2 Unchanged Medium
Q9NV31 J23gh3 chromosome 15 open reading frs 853 8367 832 861 2221 848 9729 1 24E-02 -376E-02 2 Unchanged Medium
Q9NVE2 D09gh3 chromosome 2 open reading frar 64849 671 4686352 5960999 -4 69E-01 4 96E-02 2 Unchanged Medium
Q9UI05 L04gh4 chromosome 20 open reading frs 2518951 2140 1201 051 1952 881 • •1 07E+00 -2 36E 01 2 Unchanged Medium
Q9P0A7 M09ef8 chromosome 20 open reading frs 581 9098 1080 1200655 954 524 1 04E+00 893E-01 2 Unchanged Medium
Q9Y3B1 H22ef1 chromosome 20 open reading frs 1691 B64 1230 7837799 1235 108 - •1 11 E+00 -4 60E-01 2 Unchanged Medium
Q9BQ89 C01gh8 chromosome 20 open reading frs 1460 875 952 1221 732 1211 641 -2 58E-01 -6 17E-01 2 Unchanged Medium
Q96C58 J19gh7 chromosome 6 open reading frar 1254647 1080 480 9999 9400036 -1 38E+00 -2 10E-01 2 Unchanged Medium
Q9Y5Z4 K12ef3 chromosome 6 open reading frar 915 3818 988 3723119 758 6366 - -1 30E+00 1 10E-01 2 Unchanged Medium
Q00610 I12cd5 clathππ, heavy polypeptide (He) 1639759 1210 143744 1427503 -1 90E-01 4 44E-01 2 Unchanged Medium
P56749 F04cd7 claudin 12 2262278 2480 1233472 1992755 -875E-01 1 34E-01 2 Unchanged Medium
043809 M15cd7 cleavage and polyadenylation sp 640 2301 503 6833467 608 9825 940E-02 -347E-01 2 Unchanged Medium
096005 G05ab4 cleft lip and palate associated tra 1353338 1170 1394 845 1304 597 4 36E-02 -2 15E-01 2 Unchanged Medium
Q16740 E20cd4 ClpP casemolytic protease ATP 625 8711 528 4750848 543 0367 -398E-01 -245ε-01 2 Unchanged Medium
P55085 024ab5 coagulation factor II (thrombln) re 8297537 979 3927495 734 -1 08E+00 239E-01 2 Unchanged Medium
P13726 B05ab4 coagulation factor III (thrombopla 1079 841 880 442 6212 800 9723 -1 29E+00 -294E-01 2 Unchanged Medium
Q9Y678 D14ef8 coat protein gamma-cop 8157993 738 1009756 854 5161 308E 01 -1 45E-01 2 Unchanged Medium
Q15363 M11ef3 coated vesicle membrane proteir 706 3054 804 8702118 7936589 3 01 E-01 1 88E-01 2 Unchanged Medium
043513 N06cd4 cofactor required for Sp1 transcπ 591 8619 481 798 8706 623 9284 4 33E-01 -299E-01 2 Unchanged Medium
Q9Y281 N18cd8 cofiliπ 2 (muscle) 671 9394 270 1093534 6786369 703E-01 -1 31 E+00 2 Unchanged Medium
P04141 G22gh6 colony stimulating factor 2 (grani. 1162139 1290 165718 522783 512E-01 3 47E+00 2 Unchanged Medium
P02745 L06ef1 complement component 1 , q subi 6834431 1650 7982366 1042465 224E-01 1 27E+00 2 Unchanged Medium
P29279 I16ab4 connective tissue growth factor 596 4123 537 1071 517 734 8489 845E-01 -1 52E-01 2 Unchanged Medium
043191 B02cd3 C0P9 constitutive photomorpho. 8558616 1030 1302 334 1062925 606E-01 268E-01 2 Unchanged Medium
Q99627 C01cd7 C0P9 homolog 7882297 968 1 95 497 984 0634 601 E-01 297E-01 2 Unchanged Medium
015387 G21cd7 C0P9 subunit 6 (M0V34 homolo 590 9973 382 628 5041 533 8251 8 88E-02 -630E-01 2 Unchanged Medium
Q9ULV4 K18ef3 coronm, actin binding protein, 1C 1594037 1200 1362 545 1385 839 -226E-01 -409E 01 2 Unchanged Medium
Q9BR76 I14gh7 coroπm, actin-bindmg protein 1E 708 5653 1080 690 8568 827 7864 -365E-02 6 13E-01 2 Unchanged Medium
Q14061 B22cd5 C0X17 homolog, cytochrome c c 889 1581 1440 745 8658 1026 374 -2 54E-01 7 OOE-01 2 Unchanged Medium
Q9Y6B2 E02ef8 CREBBP/EP300 inhibitory protei 9469513 1030 1988 725 1323308 1 07E+00 1 27E-01 2 Unchanged Medium
Q9NY68 C06gh4 CTL2 gene 1381 821 804 7885002 991 4995 -8 09E 01 -7 81 E-01 2 Unchanged Medium
P24385 O04ef5 cyclin D1 (PRAD1 parathyroid a 1214611 2150 1100478 1486 769 -1 42E-01 821 E-01 2 Unchanged Medium
Q9NXT4 K09gh2 cyclin M2 1560 659 1720 1582 768 162099 203E-02 1 40E-01 2 Unchanged Medium
P01034 I11ab6 cystat C (amyloid angiopathy a 1067 127 970 1366396 1134612 3 57E-01 -1 37E-01 2 Unchanged Medium
Q15828 H3ab4 cystatm E/M 967 1669 2790 451 3932 1404 267 -1 10E+00 1 53E+00 2 Unchanged Medium
P01036 C02ab6 cystatln S 1261 605 466 1069756 932 4892 -2 38E-01 -1 44E+00 2 Unchanged Medium
P52943 I05ab4 cysteme-nch protein 2 874 1939 499 1277819 88382 548E 01 -808E 01 2 Unchanged Medium
P13498 G18ab3 cytochrome b-245, alpha polypef 7089954 1050 3593156 7077483 -9 81 E-01 573E 01 2 Unchanged Medium
P00167 C04ab6 cytochrome b-5 2187 128 1480 1034 311 1565 893 -1 08E+00 -5 67E 01 2 Unchanged Medium
P00001 N24gh6 cytochrome c 547 6708 442 5176125 5024786 8 14E 02 -309E-01 2 Unchanged Medium
P10606 I24gh6 cytochrome o oxidase subunit Vb 1364 01 2100 2087456 1851 225 6 14E-01 624E-01 2 Unchanged Medium
P08574 P10ab5 cytochrome c-1 667 9346 443 441 6771 517 4383 -5 97E-01 -593E-01 2 Unchanged Medium
Q99426 C17gh1 cytoskeleton-associated protein 560 9411 684 7773269 673 9633 4 71 E-01 285E-01 2 Unchanged Medium
Q07065 G13cd7 cytoskeleton-associated protein • 602 5101 575 1785 415 987 5887 1 57E+00 -678E 02 2 Unchanged Medium
Q15038 L13ef3 DAZ associated protein 2 808 0755 890 5647611 7544305 -5 17E-01 1 40E-01 2 Unchanged Medium
Q9H2L4 B18gh8 DC32 4080427 702 7802878 630 0414 935E-01 7 82E-01 2 Unchanged Medium
Q9NPA8 G22gh7 DC6 protein 944 3094 1570 1514 164 1342 189 6 81 E 01 732ε-01 2 Unchanged Medium
060231 H13cd3 DEAD/H (Asp-Glu-Ala-Asp/His) t 7538815 873 7996561 8087915 8 50E-02 2 1 ε-01 2 Unchanged Medium
Q9GZR7 E02gh4 DEAD/H (Asp-Glu-Ala-Asp/His) t 80342 984 774 3765 854 0965 -531E-02 293E-01 2 Unchanged Medium
P17844 F04ab4 DEAD/H (Asp-Glu-Ala-Asp/His) t 1482642 1440 1670 104 1530 749 1 72E-01 -426E 02 2 Unchanged Medium
Q08211 M03ab4 DEAD/H (Asp-Glu-Ala-Asp/His) t 907 5859 658 9074343 824 2193 -241E-04 -4 65E-01 2 Unchanged Medium
Q9UJV9 D08ef2 DEAD-box protein abstrakt 976 8378 1230 8703672 1024437 -1 66E-01 328E-01 2 Unchanged Medium
P51398 G18ef6 death associated protein 3 9203044 981 8143518 905 1904 -1 76E-01 920E-02 2 Unchanged Medium
Q13437 G22cd4 Deleted in split-hand/split-foot 1 1 1565 344 1500 1721 872 1596672 1 37E-01 -588E-02 2 Unchanged Medium
060735 O06cd6 dendritic cell protein 858 6375 502 467 3432 6092393 -878E-01 -7 75E-01 2 Unchanged Medium
Q16854 M06ab5 deoxyguanosme kinase 858 1918 885 989 3036 910 8082 205E-01 443E-02 2 Unchanged Medium
Q9Y295 H04ab8 developmentally regulated GTP i 736 3786 634 660 7023 6769267 -1 56E-01 -2 17E 01 2 Unchanged Medium
P00387 F09ab3 diaphorase (NADH) (cytochrome 1402 134 1030 143574 1290 593 342E-02 -440E-01 2 Unchanged Medium
Q9UHY9 I08ef2 dicarbonyl/L-xylulose reductase 544 2125 740 9387807 741 1 7 87E-01 444E-01 2 Unchanged Medium
P36957 C06ab6 dihydrolipoamide S-succmyltranε 625 9037 713 3937165 577 6196 -6 69E-01 1 88E-01 2 Unchanged Medium
Q99075 M12ef7 diphtheria toxin receptor (hepanr 721 8431 638 197 117 5189525 -1 87E+00 -1 78E-01 2 Unchanged Medium
Q9UFN1 H10gh6 DKFZP564B147 protein 9665927 947 1469 105 1127 658 604E-01 -2 91E-02 2 Unchanged Medium
095882 C13ef8 DKFZP564C1940 protein 941 4076 865 804 639 870 3185 -226E-01 -1 22E-01 2 Unchanged Medium
Q9Y269 C07ef8 DKFZP564M082 protein 6758991 1110 1208543 9984411 838E-01 7 17E-01 2 Unchanged Medium
Q9NWE3 J11ef8 DKFZP566C243 protein 419 5607 770 625 8483 605084 577E-01 876E-01 2 Unchanged Medium Q9H6Y7 H04gh6 DKFZP566H073 protein 1390389 1480 1191 195 1352 292 -223E-01 8 55E-02 2 Unchanged Medium
Q9Y3X0 P23ef8 DKFZP586M1019 protein 588 3603 505 6724872 5885767 1 93E-01 -221 E-01 2 Unchanged Medium
060762 G19cd4 dolichyl-phosphate mannosyltran 407 0059 581 605 8353 531 3373 574E-01 5 14E-01 2 Unchanged Medium
P53805 B11ab5 Down syndrome critical region ge 370 0907 663 511 9248 5150794 4.68E-01 842E-01 2 Unchanged Medium
Q13597 N13ef3 downregulated In ovarian cancer 5946931 693 623702 636 966 6 87E-02 220E-01 2 Unchanged Medium
Q9C005 J05gh8 dpy-30-like protein 8104585 1210 1174 001 1064 132 535E-01 576E-01 2 Unchanged Medium
Q13448 J03cd6 DR1 -associated protein 1 (negati 1240359 1140 2382895 1586 247 942E-01 -1 27E-01 2 Unchanged Medium
Q9UHF9 K01ef4 dual oxidase 2 1146 14 648 3166462 703 5318 - •1 86E+00 -823E-01 2 Unchanged Medium
P51 52 N22ab4 dual specificity phosphatase 3 (v 649 6813 605 4735652 576 1845 -4 56E-01 -1 02E-01 2 Unchanged Medium
Q14203 A13ab6 dynactin 1 (p150, glued homolog 507 5942 529 6236948 5535576 297E-01 6 06E-02 2 Unchanged Medium
Q13561 D19cd6 dyπactm 2 (p50) 1565567 1380 1173024 1372261 -4 16E-01 -1 84E-01 2 Unchanged Medium
Q13409 I16ef1 dynein, cytoplasmic, intermediate 793 3207 604 4649675 620 6506 -771 E-01 -394E-01 2 Unchanged Medium
Q09472 C18ab4 E1 A binding protein p300 1496409 2120 1342944 1651 644 -1 56E-01 5 OOE-01 2 Unchanged Medium
D20gh8 EAF1 protein 642 1587 652 4696834 5880816 -4 51 E-01 228E-02 2 Unchanged Medium
P78365 N19ab4 early development regulator 2 (p> 894 3715 1070 761 5923 907 5945 -2 32E-01 2 54E-01 2 Unchanged Medium
Q99848 G11cd7 EBNA1 binding protein 2 977 8671 611 8186583 8023778 -256E-01 -679E-01 2 Unchanged Medium
Q12805 A21ab6 EGF-contalning fibulin-like extrae 1002 82 332 4589563 597 7763 -1 13E+00 -1 60E+00 2 Unchanged Medium
Q9Y6I3 D21cd8 EH domain-binding mitotic phosp 7366984 500 629 1845 621 9752 -2 28E-01 -5 60E-01 2 Unchanged Medium
Q15717 C04ab4 ELAV (embryonic lethal, abπorm, 850 8493 800 8434463 831 3485 -1 26E-02 -8 94E-02 2 Unchanged Medium
P13804 I24ab3 electron-transfer-flavoproteln, alf 918 8391 545 5292866 664 3533 -7 96E-01 -7 54E-01 2 Unchanged Medium
Q14247 K17ef6 ems1 sequence (mammary tumoi 1135 188 1050 1002084 10639 -1 80E-01 -1 06E-01 2 Unchanged Medium
P42892 021 ab4 endothelm converting enzyme 1 6024294 799 8097071 737 1982 427E-01 4 08E-01 2 Unchanged Medium
P30084 A17ab6 enoyl Coenzyme A hydratase, sh 802 3114 1210 741 2226 917 9548 -1 14E-01 593E-01 2 Unchanged Medium
P07099 I20ab3 epoxide hydrolase 1 , micr osomal 1231 48 1840 1198 169 1424 661 -396E-02 5 83E-01 2 Unchanged Medium
P29692 H04ab5 eukaryotic translation elongation 1329756 744 1110 87 1061 631 -259E-01 -8 37E-01 2 Unchanged Medium
P20042 L05cd4 eukaryotic translation initiation fa 1489433 603 956 276 1016 24 -639E-01 -1 30E+00 2 Unchanged Medium
P41091 A20ab4 eukaryotic translation initiation fa 7425843 474 4787249 5652535 -6 33E-01 -646E-01 2 Unchanged Medium
Q99613 L16cd3 eukaryotic translation initiation fa 1140022 853 9987488 997 2011 -1 91 E-01 -4 19E-01 2 Unchanged Medium
P78344 C02ab4 eukaryotic translation initiation fa 1562952 1520 1177 845 1419665 -408E-01 -4 19E-02 2 Unchanged Medium
P23588 A24ab4 eukaryotic translation initiation fa 1343019 1010 1125825 1160 659 -254E-01 -4 07E-01 2 Unchanged Medium
Q13541 C03ab5 eukaryotic translation initiation fa 1655 926 1060 2293236 1669873 4 70E-01 -643E-01 2 Unchanged Medium
Q13542 A19ab6 eukaryotic translation initiation fa 1620 111 1850 1663 197 1712605 379E-02 1 95E-01 2 Unchanged Medium
060573 G16cd5 eukaryotic translation initiation fa 7997789 883 8193679 833 9147 349E-02 1 42E-01 2 Unchanged Medium
Q16394 K02ab3 exostoses (multiple) 1 5137526 428 8132693 584 9471 663E-01 -264E-01 2 Unchanged Medium
P37268 C17ab6 farnesyl-diphosphate farnesyltrai 7260862 455 6490518 610 2023 -1 62E-01 -673E-01 2 Unchanged Medium
P55899 L22ab5 Fc fragment of IgG, receptor, trar 450 8629 771 476 1039 566 0193 7 86E-02 774E-01 2 Unchanged Medium
Q9UK73 P05ef3 fem-1 homolog b (C elegans) 5482677 547 530 801 541 9489 -4 67E-02 -393E-03 2 Unchanged Medium
P21333 G14ab4 filamin A, alpha (actin binding pn 9460465 675 1277458 966 2982 433E-01 -4 86E-01 2 Unchanged Medium
P26885 P07ab4 FK506 binding protein 2 (13kD) 8146357 510 661 4593 662 0387 -301 E-01 -676E-01 2 Unchanged Medium
Q13451 F15ab4 FK506 binding protein 5 1366 905 1110 812 8568 1097 248 -7 50E-01 -298E-01 2 Unchanged Medium
095633 M01cd6 follistatin-like 3 (secreted glycopi 1312 174 1280 109299 1227 557 -264E-01 -3 86E-02 2 Unchanged Medium
P15407 A20cd4 FOS-like antigen 1 1696 135 1350 1218491 1421 01 -477E-01 -3 31 E-01 2 Unchanged Medium
Q14192 G02ab4 four and a half LIM domains 2 3099219 591 1210 635 7037424 1 97E+00 930E-01 2 Unchanged Medium
Q9NZA0 N17gh6 fuse-binding protein-interacting r 9242347 911 1110468 981 791 265E-01 -2 13E-02 2 Unchanged Medium
P35637 P19ab4 fusion, deπved from t(12,16) mall 8663996 654 1159792 893 3381 421 E-01 -406E-01 2 Unchanged Medium
E21gh7 FXYD domain-containing ion trar 9426126 1060 8028679 9356666 -232E-01 1 71 E-01 2 Unchanged Medium
Q9Y653 B02cd5 G protein-coupled receptor 56 2010 489 2160 1501 617 1889 081 -4 21 E-01 1 00E-01 2 Unchanged Medium
Q9H1C0 E18gh4 G protein-coupled receptor 92 712 1007 750 7197999 727 2869 1 55E-02 747E-02 2 Unchanged Medium
P15170 L13ab4 G1 to S phase transition 1 2042425 1410 1109721 1521 226 -880E-01 -533E-01 2 Unchanged Medium
095166 D09cd7 GABA(A) receptor-associated pn 1280 495 2210 1227378 157236 -6 11E-02 787E-01 2 Unchanged Medium
008765 D21cd7 GABA(A) receptor-associated pn 1241 27 1130 9188337 1095 839 -434E-01 -1 39E-01 2 Unchanged Medium
P16278 O05ef1 galactosidase, beta 1 5394222 B00 6560518 6653025 282E-01 569E-01 2 Unchanged Medium
P7B537 J23ab4 GCN5 general control of amino-ε 8133309 637 9195196 7900409 1 77E-01 -352E-01 2 Unchanged Medium
P31150 F14ab4 GDP dissociation inhibitor 1 6336157 894 640 108 722 7008 1 47E-02 497E-01 2 Unchanged Medium
P06396 B23ab3 gelsolm (amyloidosis, Finnish typ 330 1567 577 6332269 5134286 940E-01 805E-01 2 Unchanged Medium
P52657 E03ab6 general transcnption factor IIA, 2 5386557 685 700 1857 641 1721 378E-01 346E-01 2 Unchanged Medium
Q00403 F08ef6 general transcnption factor IIB 5004565 791 4548328 582 2035 -1 38E-01 661 E-01 2 Unchanged Medium
P48060 I23cd7 glioma pathogenesis-related prol 6764844 692 7527928 707 2232 1 54E-01 335E-02 2 Unchanged Medium
P06744 B19ab3 glucose phosphate isomerase 900 9772 553 7264749 7267688 -3 11 E-01 -7 05E-01 2 Unchanged Medium
P30101 G13ab5 glucose regulated protein, 58kD 1708658 1250 2220 105 1726668 378E-01 -450E-01 2 Unchanged Medium
043836 I22ef1 glutamate receptor, lonotropic, N 1729777 1890 1655 131 1758 853 -636E-02 1 29E-01 2 Unchanged Medium
P15104 H22ab5 glutamate-ammonia ligase (gluta 117059 1040 1180 088 1130 151 1 17E-02 -1 71 E-01 2 Unchanged Medium
Q06210 A23ab5 glutamlne-fructose-6-phosphate I 869494 600 863 157 777 6585 -1 06E-02 -534E-01 2 Unchanged Medium
Q9Y3D4 M19ef2 glutaredoxln 2 8885406 894 1099209 9604756 307E-01 832E-03 2 Unchanged Medium
Q9Y2Q3 C24ef2 glutathione S-transferase subuπi 841 3959 346 414 7892 533 8957 -1 02E+00 -1 28E+00 2 Unchanged Medium
P48637 D01ab3 glutathione synthetase 650 8496 429 4886663 522 9685 -4 13E-01 -600E-01 2 Unchanged Medium
P78417 E20cd5 glutathione-S-transferase like, gli 1983 626 2020 1805489 1937 888 -1 36E-01 295E-02 2 Unchanged Medium
P49840 J14ef4 glycogen synthase kinase 3 alph 1057368 1460 1247816 1254087 239E-01 463E-01 2 Unchanged Medium
P13224 F23ab3 glycoprotein lb (platelet), beta pc 487 4684 530 6534727 5570977 423E-01 1 22E-01 2 Unchanged Medium
Q9UBQ7 L08cd7 glyoxylate reductase/hydroxypyn 9470262 977 997 593 9739926 7 50ε-02 4 55E-02 2 Unchanged Medium
Q9P2T1 C02ef2 GMPR2 for guanosine monophoi 762 0126 1070 817 0496 8824154 1 01 E-01 487E-01 2 Unchanged Medium
Q9H4A6 104gh5 golgi phosphoprotem 3 (coat-pro 1027603 1210 1209783 114894 235E-01 235E-01 2 Unchanged Medium
P28799 B19ab5 granulin 1611 298 1750 1238745 1532 188 -379E-01 1 16E-01 2 Unchanged Medium
Q14393 H10ab3 growth arrest-specific 6 484 489 563 739 1661 5955619 6 09E-01 2 17E-01 2 Unchanged Medium
P29354 H06ef5 growth factor receptor-bound pro 721 5894 854 6630587 7463732 -1 22E-01 244E-01 2 Unchanged Medium
Q14451 D20ab4 growth factor receptor-bound pro 7123296 846 6368962 731 6029 -1 61 E-01 247E-01 2 Unchanged Medium
Q9Y6G2 E04ef8 growth hormone inducible transn 1289256 1020 974263 109342 -404E-01 -343E-01 2 Unchanged Medium
P04899 J09ab4 guanine nucleotide binding prate 8609208 1390 1748649 1334 01 1 02E+00 694E-01 2 Unchanged Medium
P11016 M13ef5 guanine nucleotide binding prate 758629 773 8366295 789 4586 1 41 E-01 273E-02 2 Unchanged Medium
Q 3905 G09ab6 guanine nucleotide-releasmg fac 4100949 569 535 1889 50461 384E-01 471 E-01 2 Unchanged Medium
Q16774 L16ab3 guanylate kinase 1 968 5867 1340 9758911 1095 967 1 08E-02 472E-01 2 Unchanged Medium
Q9Y649 K16ef4 GW128 protein 1663305 2420 1834 174 1971 464 1 41 E-01 539E-01 2 Unchanged Medium
P07305 G13ab6 H1 histone family, member 0 1780353 1870 1746555 1797448 -277E-02 673E-02 2 Unchanged Medium
075367 M14cd5 H2A histone family, member Y 1065311 837 4555967 7860181 -1 23E+00 -348E-01 2 Unchanged Medium
P17317 C24ab6 H2A histone family, member Z 591 0013 461 1570489 874 2269 1 41 E+00 -358E-01 2 Unchanged Medium
P02278 M16gh6 H2B histone family, member G 586 8773 852 684 6287 707 973 222E-01 5 38E-01 2 Unchanged Medium Q9NS37 A03gh5 HCF-blndlng transcπption factor 8573143 717 601 7268 725 1835 -5 11 E-01 -2 59E-01 2 Unchanged Medium
096004 E02cd5 heart and neural crest denvative1 7055163 612 621 033 6463401 -1 84E-01 -204E-01 2 Unchanged Medium
P10809 M11ef5 heat shock 60kD protein 1 (chapi 1693 23 1020 127641 1330235 -408E-01 -7 30E-01 2 Unchanged Medium
P34932 I11ef1 heat shock 70kD protein 4 1402505 1610 1042 113 1352 283 -428E-01 201 E-01 2 Unchanged Medium
P07900 G18ef7 heat shock 90kD protein 1 , alpha 2405793 1430 1512258 1783374 -670E-01 -748E-01 2 Unchanged Medium
P08238 B20ab7 heat shock 90kD protein 1 , beta 2781 462 1950 979 1145 1903 993 - -1 51 E+00 -511 E-01 2 Unchanged Medium
075506 H17ab6 heat shock factor binding protein 1132 126 1300 1081 748 1171 256 -6 57E-02 1 99E-01 2 Unchanged Medium
Q9UHG4 K18ef4 heme-regulated Initiation factor 2 4132841 659 5763971 549 5035 480E-01 673E-01 2 Unchanged Medium
P09105 J21ab4 hemoglobin, theta 1 702445 484 7692336 651 9692 1 31 E-01 -537E-01 2 Unchanged Medium
043504 D23cd6 hepatitis B virus x interacting pro 1008655 1340 949 0116 1097 672 -879E-02 405E-01 2 Unchanged Medium
Q9H2I6 N10gh5 hepatitis C virus core-binding pre 6767297 620 4739328 590 1783 -5 14E-01 -1 27E-01 2 Unchanged Medium
P51858 K16ef7 hepatoma-deπved growth factor i 894 1008 1170 4907456 850 7213 -8 65E-01 385E-01 2 Unchanged Medium
Q04150 A08ab7 heterogeneous nuclear πbonucle 9433857 870 1065597 959787 1 76E-01 -1 16E-01 2 Unchanged Medium
Q13151 E15cd7 heterogeneous nuclear πbonucle 906986 944 1143 552 998 1703 3 34E-01 577E-02 2 Unchanged Medium
P22626 N09ab6 heterogeneous nuclear ribonucle 1021 87 1010 1584 855 1206298 633E-01 -1 38E-02 2 Unchanged Medium
P07910 A10ab7 heterogeneous nuclear ribonucle 7475309 718 1059 349 841 6601 5 03E-01 -579E-02 2 Unchanged Medium
014979 L09cd5 heterogeneous nuclear πbonucle 1057699 1990 1646 172 1563717 6 38E-01 9 10E-01 2 Unchanged Medium
P52597 G06ab7 heterogeneous nuclear ribonucle 1902 939 1280 1517274 1567536 -327E-01 -5 69E-01 2 Unchanged Medium
Q07244 N13ab6 heterogeneous nuclear πbonucle 8476967 667 6844978 733 1055 -3 09E-01 -346E-01 2 Unchanged Medium
Q15584 P03ab7 heterogeneous nuclear nbonucle 7253651 569 8582829 7174409 243E-01 -351 E 01 2 Unchanged Medium
P12081 J12ab4 histidyl-tRNA synthetase 5555578 565 4243904 514 8575 -3 89E-01 2 34E-02 2 Unchanged Medium
Q9UBN7 E 1cd6 histone deacetylase 6 6855336 407 695 1552 595 8457 2 01E-02 -7 53E-01 2 Unchanged Medium
Q13838 M07cd4 HLA-B associated transcπpt 1 681 4666 604 921 7532 735 5784 4 36E-01 -1 75E-01 2 Unchanged Medium
Q99873 H02ef7 HMT1 hnRNP methyltransferase 890 1184 836 1209 872 978 6584 4 43E-01 -905E-02 2 Unchanged Medium
Q9H063 M14gh8 homolog of yeast MAF1 7449951 921 1013 86 893 139 4 45E-01 305E-01 2 Unchanged Medium
P51610 L21ab5 host cell factor C1 (VP16-access 5837478 580 735 1691 6329786 3 33E-01 -9 25E-03 2 Unchanged Medium
000165 I04cd6 HS1 binding protein 1482068 1490 2425818 1800489 7 11E-01 1 12E-02 2 Unchanged Medium
Q9Y2Q5 P24ef7 HSPC003 protein 6207783 1010 6256574 752 165 1 13E-02 702E-01 2 Unchanged Medium
Q9Y2R0 A05ef8 HSPC009 protein 1507 005 1720 1784 568 1668909 244E-01 1 87E-01 2 Unchanged Medium
Q9Y2T0 A17ef8 HSPC022 protein 4530964 733 326 4215 504 1821 -4 73E-01 6 94E-01 2 Unchanged Medium
Q9UNZ5 C17ef8 HSPC023 protein 8253888 1310 1347488 1159538 707E-01 6 62E-01 2 Unchanged Medium
Q9P032 019efB HSPC125 protein 5588905 602 8430953 668 1435 5 93E-01 1 08E-01 2 Unchanged Medium
Q9P019 A06ef8 HSPC141 protein 717 9096 1700 1519292 1312254 1 08E+00 1 24E+00 2 Unchanged Medium
Q9P004 A24ef8 HSPC160 protein 1182006 1070 5458523 9327666 - -1 11 E+00 -1 43E-01 2 Unchanged Medium
Q9P003 C04ef8 HSPC163 protein 801 5204 1410 1148378 1118 827 5 19E-01 8 11E-01 2 Unchanged Medium
Q9P000 C06ef8 HSPC166 protein 5082074 921 5233806 650 7428 4 24E-02 8 57E-01 2 Unchanged Medium
Q9Y684 N09ef2 HSPC034 protein 5699533 628 797 4819 665 044 4 B5E-01 1 39E-01 2 Unchanged Medium
Q9NRG2 D01gh4 HTGN29 protein 1276 132 1470 1639451 14628 361 E-01 207E-01 2 Unchanged Medium
Q16775 G15ab6 hydroxyacyl glutathione hydrolas 511 3412 676 407 0538 531 4885 -3 29E-01 4 03E-01 2 Unchanged Medium
P40939 D07ab3 hydroxyacyl-Coenzyme A dehydr 1814498 1770 1617578 1733575 -1 66E-01 -3 69E-02 2 Unchanged Medium
P55084 D09ab3 hydroxyacyl-Coenzyme A dehydr 5392691 890 1218 105 882 3271 1 18E+00 7 22E-01 2 Unchanged Medium
Q14526 B13ab5 hypermethylated in cancer 1 9183678 904 1008759 943 6552 1 35E-01 -230E-02 2 Unchanged Medium
Q9UBS2 A15ef1 hyperpolaπzation activated cyclic 6769289 688 520 6835 6286277 -379E-01 240E-02 2 Unchanged Medium
Q96EW8 P08gh8 hypothetical gene ZD52F10 7274433 605 223 8014 518 5858 -1 70E+00 -267E-01 2 Unchanged Medium
Q9Y2S6 D01ef2 hypothetical protein 1188199 1490 1593015 1423596 423E-01 326E-01 2 Unchanged Medium
Q9UKZ1 I23gh3 hypothetical protein C40 6572427 614 506 0272 5923978 -377E-01 -9 84E-02 2 Unchanged Medium
Q9UJJ9 D21gh8 hypothetical protein CAB56184 432491 695 601 25 576 3525 4 75E-01 685E-01 2 Unchanged Medium
095891 D08ef8 hypothetical protein CL25022 1675 198 2070 1477 523 1741 841 -1 81 E-01 3 07E-01 2 Unchanged Medium
Q9UJI9 F08gh6 hypothetical protein DJ328E19 C 1119481 935 1005691 1019 924 -1 55E-01 -260E-01 2 Unchanged Medium
Q9H0U3 K20gh8 hypothetical protein DKFZp564K 1287 049 1080 1145302 1169228 -1 68E-01 -2 59E-01 2 Unchanged Medium
Q9NWD8 N05gh2 hypothetical protein FLJ10099 7549838 758 710 8818 741 1753 -8 68E-02 5 11E-03 2 Unchanged Medium
Q9NW90 P21gh2 hypothetical protein FLJ10211 4925962 551 601 7235 5483816 289E-01 1 61 E-01 2 Unchanged Medium
Q9NW61 B18gh2 hypothetical protein FLJ10297 7720358 844 620 8513 7457235 -3 14E-01 1 29E-01 2 Unchanged Medium
Q9NW16 G04gh3 hypothetical protein FLJ10374 7562846 543 467 9722 5890741 -693E-01 -4 78E-01 2 Unchanged Medium
Q9NVZ3 G14gh3 hypothetical protein FLJ10420 437 615 702 362923 5007932 -270E-01 6 81 E-01 2 Unchanged Medium
Q9NVC3 D23gh3 hypothetical protein FLJ10815 1402842 928 598595 9766359 -1 23E+00 -595E-01 2 Unchanged Medium
Q9H9K7 B10gh5 hypothetical protein FLJ12681 446 1454 657 5935606 565 6072 4 12E-01 5 59E-01 2 Unchanged Medium
Q9H8H4 H06gh5 hypothetical protein FLJ12800 1058023 775 1421 894 1084852 426E-01 -4 50E-01 2 Unchanged Medium
Q9P0R5 L02ef1 hypothetical protein FLJ14868 702 1841 684 1117 168 8344521 670E-01 -378E-02 2 Unchanged Medium
Q9NXQ4 M07gh3 hypothetical protein FLJ20113 1503987 1520 1545 141 1521 653 389E-02 1 13E-02 2 Unchanged Medium
Q9NXI2 M21gh3 hypothetical protein FLJ20234 6434985 877 1780291 5663149 -1 βsε+oo 4 47E-01 2 Unchanged Medium
Q9NXD5 E18gh2 hypothetical protein FLJ20309 617 1482 1420 7580334 932 5386 297E-01 1 20E+00 2 Unchanged Medium
Q9NX64 H6gh2 hypothetical protein FLJ20419 9388958 825 981 6359 9152399 642E-02 -1 86E-01 2 Unchanged Medium
Q9NWX1 A20gh3 hypothetical protein FLJ20552 1366306 1800 1533352 1565249 1 66E-01 3 95E-01 2 Unchanged Medium
Q9NWT8 D11gh2 hypothetical protein FLJ20608 980 6383 915 907 2393 9342965 -1 12E-01 -999E-02 2 Unchanged Medium
Q9NWM3 C20gh3 hypothetical protein FLJ20739 381 202 593 689893 554 671 856E-01 6 37E-01 2 Unchanged Medium
Q9H7C7 D05gh5 hypothetical protein FLJ21044 si 551 5395 708 585 1487 6150164 8 53E-02 361 E-01 2 Unchanged Medium
Q9H6R6 J23gh5 hypothetical protein FLJ21952 425 3152 396 679 1125 500 0538 675E-01 -1 04E-01 2 Unchanged Medium
Q9H673 F11gh5 hypothetical protein FLJ22548 si 1394825 1220 5305646 1047 134 -1 39E+00 -1 98E-01 2 Unchanged Medium
095476 H15efβ hypothetical protein HSA011916 1310097 1040 1485684 1279962 1 81 E-01 -327E-01 2 Unchanged Medium
Q9Y244 B23ef2 hypothetical protein HSPC014 1668 101 1530 1243802 1481 658 -423E-01 -1 22E-01 2 Unchanged Medium
Q9P022 P04ef2 hypothetical protein HSPC138 666 1765 521 643 5979 610 0993 -4 97E-02 -3 56E-01 2 Unchanged Medium
Q9P013 P06ef2 hypothetical protein HSPC148 916 5214 1450 1133 279 1167 03 306E-01 6 63ε-01 2 Unchanged Medium
Q9P009 P14ef2 hypothetical protein HSPC155 1031 658 1330 6622481 1008218 -640E-01 367E-01 2 Unchanged Medium
Q9P0S9 A19ef3 hypothetical protein HSPC194 1336 172 1570 1957 055 1622 51 551 E-01 236E-01 2 Unchanged Medium
Q9NPI0 A23ef3 hypothetical protein HSPC196 280 0356 644 672086 5320086 1 26E+00 1 20E+00 2 Unchanged Medium
095887 C18ef2 hypothetical protein LOC51061 7775591 709 551 8354 6793596 -495E-01 -1 34E-01 2 Unchanged Medium
Q9P0T9 K02ef2 hypothetical protein LOC51234 1224 056 1290 1457 544 1322295 252E-01 7 04E 02 2 Unchanged Medium
Q9P0Q1 K10ef2 hypothetical protein LOC51248 376 8259 933 1014441 774 623 1 43E+00 1 31 E+00 2 Unchanged Medium
Q9P0PO K20ef2 hypothetical protein LOC51255 1301 286 2190 1904375 1798292 549E-01 7 50E-01 2 Unchanged Medium
Q9P0N9 K22ef2 hypothetical protein LOC51256 540326 374 604 1319 5060883 1 61 E-01 -532E-01 2 Unchanged Medium
Q9NZD9 M23ef2 hypothetical protein LOC51323 600 1582 715 5068479 607 2015 -244E-01 2 52E-01 2 Unchanged Medium
075207 M02gh4 hypothetical protein LOC57019 6638685 644 6807704 663 0017 3 63E-02 -430E-02 2 Unchanged Medium
Q9BWL0 L24gh7 hypothetical protein MGC 5244, 5698856 436 7329891 579 5932 363E-01 -3 87E-01 2 Unchanged Medium
Q9BW61 C09gh6 hypothetical protein MGC2594 1446395 2460 1354 586 1754667 -946E-02 7 68E-01 2 Unchanged Medium
Q9BQ49 K05gh6 hypothetical protein MGC2747 527 9287 679 677 2851 628 1009 359E-01 3 63E-01 2 Unchanged Medium Q9BQD3 E17gh6 hypothetical protein MGC2749 841 5499 889 899 9017 876 8925 967E-02 7 95E-02 2 Unchanged Medium
Q9BQ61 A09gh6 hypothetical protein MGC2803 1234395 2170 1980421 1794 728 682E-01 8 13E-01 2 Unchanged Medium
Q9BTV4 023gh6 hypothetical protein MGC3222 561 6572 502 5835781 548 9637 552E-02 -1 63E-01 2 Unchanged Medium
Q9BVX2 C17gh6 hypothetical protein MGC5576 747 2749 762 6043725 704 7101 -306E-01 291E-02 2 Unchanged Medium
Q9H773 I17gh6 hypothetical protein MGC5627 799 182 819 5840079 734 1306 -4 53E-01 3 57E-02 2 Unchanged Medium
Q9BPX5 L02gh7 hypothetical protein similar to acl 5834076 424 6324101 5466359 1 16E-01 -4 60E-01 2 Unchanged Medium
Q9UJX8 B09ef3 hypothetical protein, estradiol-inc 1184334 948 1116899 1083 179 -846E-02 -321E-01 2 Unchanged Medium
P00492 P12cd6 hypoxanthine phosphoπbosyltrar 1210 895 233 5660945 669 g437 - 1 10E+00 •2 38E+00 2 Unchanged Medium
P22304 I04ab6 iduronate 2-sulfatase (Hunter syr 11973 1320 1095895 1205085 -1 28E-01 1 43E-01 2 Unchanged Medium
Q03827 F02ef6 immediate early protein 6506358 537 5362705 574 4805 -279E-01 -278E-01 2 Unchanged Medium
P12268 F11ab6 IMP (inosiπe monophosphate) de 1254916 567 1293693 103844 439E-02 ■1 15E+00 2 Unchanged Medium
Q9Y6K9 P03cd3 inhibitor of kappa light polypeptic 8223859 788 807 6888 805 9933 -260E-02 -6 18E-02 2 Unchanged Medium
Q14573 F04ab6 mositol 1 ,4,5-tnphosphate recepl 5559397 646 6276143 6099521 1 75E-01 2 17E-01 2 Unchanged Medium
015357 L09ab6 Inositol polyphosphate phosphat, 9977512 1150 1290473 1146828 371 E-01 2 08E-01 2 Unchanged Medium
015503 B05ab7 insulin Induced gene 1 4720202 428 6157553 5052037 3 84E-01 -1 42E-01 2 Unchanged Medium
P52945 L13gh6 insulin upstream factor 1 1437 285 3700 746514 1961 135 -945E-01 1 36E+00 2 Unchanged Medium
P51460 B07ab7 insulin-like 3 (Leydig cell) 1227 459 1290 1040 851 1184891 -238E-01 6 76E-02 2 Unchanged Medium
P46977 D20ab6 Integral membrane protein 1 1693474 1790 2514977 1998711 571E-01 7 81E-02 2 Unchanged Medium
Q13418 H08ef5 integπn-IInked kinase 1340442 962 1599336 1300 502 2 55E-01 -4 79E-01 2 Unchanged Medium
P48551 021 ef7 interferon (alpha, beta and omeg 605 1613 669 389 178 554 33 -6 37E-01 1 44E-01 2 Unchanged Medium
P15260 A02ef7 Interferon gamma receptor 1 1165784 2500 1179083 1648 504 1 64E-02 1 16E+00 2 Unchanged Medium
P38484 D12ef5 interferon gamma receptor 2 (ιnt< 593 8133 773 5502678 6389669 -1 10E-01 3 80E-01 2 Unchanged Medium
014896 K05ef6 interferon regulatory factor 6 4959782 951 4069438 617 9736 -2 85E-01 939E-01 2 Unchanged Medium
G13ef5 interfer on-gamma receptor (IFNC 6164461 474 4578757 515 9592 -4 29E-01 -380E-01 2 Unchanged Medium
Q14116 L03ab6 interleukin 18 (interferon-gamma 1525444 1610 556 9614 1230 βSS - •1 45E+00 7 71E-02 2 Unchanged Medium
075874 H11ab7 isocitrate dehydrogenase 1 (NAC 6609773 496 904 897 βS? 2716 4 53E-01 -4 14E-01 2 Unchanged Medium
P51553 I21gh1 isocitrate dehydrogenase 3 (NAC 8155318 899 784 1063 832 7908 -5 67E-02 1 40E-01 2 Unchanged Medium
P41252 P23ab6 isoleucine-tRNA synthetase 643 6728 316 992267 6506946 624E-01 -1 03E+00 2 Unchanged Medium
Q9UE99 J07ef7 jagged 2 6579935 460 6965019 6047722 821E-02 -5 17E-01 2 Unchanged Medium
P52292 J14ab6 karyophenn alpha 2 (RAG cohort 1105911 1270 1670406 1350 126 5 95E-01 2 04E-01 2 Unchanged Medium
P24390 E07cd7 KDEL (Lys-Asp-Glu-Leu) endopl, 1556 771 1210 1411 383 1392 342 -1 41 E-01 -3 65E-01 2 Unchanged Medium
P08779 D03ab7 keratin 16 (focal non-epidermolyl 8155106 786 6630228 7547055 -299E-01 -539E-02 2 Unchanged Medium
Q04695 024ab6 keratin 17 5803123 1180 1056274 937 9159 8 64E-01 1 02E+00 2 Unchanged Medium
Q07666 B04cd6 KH domain containing, RNA bind 1212 816 780 1103092 1031 926 -1 37E-01 -6 37E-01 2 Unchanged Medium
Q14165 016gh1 KIAA0152 gene product 2850232 348 1374 81 6693755 227E+00 2 8gE-01 2 Unchanged Medium
Q12765 F03gh1 KIAA0193 gene product 951 658 1000 981 6527 9790013 4 48E-02 7 68E-02 2 Unchanged Medium
043310 F11gh1 KIAA0427 gene product 482 1741 589 5560999 5423144 206E-01 288E-01 2 Unchanged Medium
043167 J03gh1 KIAA0441 gene product 1398 244 982 1102589 1160 899 -343E-01 -5 10E-01 2 Unchanged Medium
Q9H7D5 H8gh7 KIAA1191 protein 8864026 1930 1061 302 1291 483 260E-01 1 12E+00 2 Unchanged Medium
Q9HD9S L03cd8 LAG1 longevity assurance homol 1319272 798 1016572 1044 592 -3 76E-01 -72SE-01 2 Unchanged Medium
000182 P04ab6 lectin, galactoside-bindmg, solub 7606622 1300 5276081 8644149 -5 28E-01 779E-01 2 Unchanged Medium
Q99538 B04ef7 legumain 464 5 517 1105037 6953901 1 25E+00 1 53E-01 2 Unchanged Medium
095751 G01cd8 leuciπe zipper, down-regulated ir 874 8344 274 970 923g 706 7407 1 50E-01 -1 67E+00 2 Unchanged Medium
015468 P03ef4 leukocyte immunoglobuliπ-like re 8268073 939 1120204 9620679 4 38E-01 1 84E-01 2 Unchanged Medium
Q9UBB4 I06cd8 like mouse brain protein E46 877 3997 623 6925911 731 0054 -341 E-01 -4 94E-01 2 Unchanged Medium
Q9UFW4 N17ef8 likely ortholog of rat golgi stackm 1680361 1700 2121 05 1834238 3 36E-01 1 79E-02 2 Unchanged Medium
Q14847 P09ab7 LIM and SH3 protein 1 6646143 758 895 1972 772769 430E-01 1 91 E-01 2 Unchanged Medium
000158 M09ef3 LIM domain only 4 4574088 299 1353355 7030924 1 56E+00 -6 16E-01 2 Unchanged Medium
Q9HAP6 M16gh5 Lin-7b protein, likely ortholog of i 2114 229 1550 2175236 1945862 4 10E-02 -4 50E-01 2 Unchanged Medium
P38571 K08ab6 lipase A, lysosomal acid, choles. 6040401 587 512 8879 568 1283 -236E-01 -402E-02 2 Unchanged Medium
Q99732 I18cd5 LPS- duced TNF-alpha factor 680 3876 893 4494711 674 31 -598E-01 392E-01 2 Unchanged Medium
Q9Y4Z1 021 ef4 Lsm3 protein 1641 224 1300 1596905 1511 517 -3 g5E-02 -340E-01 2 Unchanged Medium
075896 D05cd7 lung cancer candidate 690 6061 772 601 3296 6880098 -2 OOE-01 1 51 E-01 2 Unchanged Medium
Q06643 O07ef6 lymphotoxm beta (TNF superfam 4057368 1040 2989254 5827217 -441 E-01 1 36E+00 2 Unchanged Medium
095372 J04ef7 lysophospholipase II 480 0562 737 7527079 656485 649E-01 6 18E-01 2 Unchanged Medium
P13473 N06ab6 lysosomal-associated membrane 952 6393 2000 1277773 140892 424E-01 1 07E+00 2 Unchanged Medium
Q083g7 F09ab7 lysyl oxidase-like 1 1391 453 1630 2243025 1753 531 689E-01 2 25E-01 2 Unchanged Medium
Q15046 B17ab7 lysyl-tRNA synthetase 900 8177 556 539813 665 5485 -7 39E-01 -6 96E-01 2 Unchanged Medium
Q13312 D17cd3 MAD1 mitotic arrest deficient-like 8077267 503 5744266 628231 -492E-01 -6 85E-01 2 Unchanged Medium
Q09160 A05ab6 major histocompatibility complex, 1524076 2710 1290 783 1841 106 -240E-01 830E-01 2 Unchanged Medium
P40925 J23ab7 malate dehydrogenase 1 , NAD (s 1144218 788 1089 134 1007 157 -7 12E-02 -53BE-01 2 Unchanged Medium
P40926 L01ab7 malate dehydrogenase 2, NAD (r 1525837 1020 1212 544 1251 158 -332E-01 -5 88E-01 2 Unchanged Medium
Q16626 J15ef3 male-enhanced antigen 1253 21 1530 1827301 1536 52 544E-01 287E-01 2 Unchanged Medium
Q9NQG1 C06gh5 maπnosidase, beta A, lysosomal 5332883 800 736627 6899075 4 66E-01 5 85E-01 2 Unchanged Medium
P26572 G11ab7 mannosyl (alpha-1 ,3-)-glycoprote 619 6733 369 887 6535 625 3732 5 18E-01 -749E-01 2 Unchanged Medium
Q10469 G15ab7 mannosyl (alpha-1, 6-)-glycoprote 600 1049 583 636621 6064146 852E-02 -4 29E-02 2 Unchanged Medium
P41223 L09cd4 maternal G10 transcript 3722443 563 5757695 5035179 6 29E-01 5 96E-01 2 Unchanged Medium
Q9Y5V3 G13cd6 melanoma antigen, family D, 1 3974495 952 1674 881 1008268 208E+00 1 26E+00 2 Unchanged Medium
P43121 I22ef5 melanoma cell adhesion molecul 886 0756 795 432 1718 7044837 -1 04E+00 -1 56E-01 2 Unchanged Medium
Q92494 D11ef1 membrane cofactor protein (CD4 973 352 1050 834044 952 9144 -223E-01 1 11 E-01 2 Unchanged Medium
Q14444 H15ab7 membrane component, chromost 549 4803 666 464 8174 560 0583 -241 E-01 277E-01 2 Unchanged Medium
Q9I.PE2 012ef2 mesenchymal stem cell protein C 749 8938 932 108526 922 5469 533E-01 3 14E-01 2 Unchanged Medium
Q92571 G07ab7 mesoderm specific transcnpt hon 617581 446 537 1735 5334868 -201 E-01 -471 E-01 2 Unchanged Medium
095204 N11ef3 metalloprotease 1 (pitrilysm famil 735 157 349 4788153 520 899 -6 19E-01 -1 08E+00 2 Unchanged Medium
P80297 H20ab7 metallothionein 1L 589 6327 502 6564441 582747 1 55E-01 -2 32E-01 2 Unchanged Medium
Q99735 C18ef7 microsomal glutathione S-transfe 527 4698 686 3739779 529 1741 -496E-01 3 79E-01 2 Unchanged Medium
Q9BXW5 D13gh8 microtubule-associated protein 1 247 2817 692 8876299 609 0447 1 84E+00 1 49E+00 2 Unchanged Medium
Q9Y6C9 M14ef3 mitochondnal earner homolog 2 1874893 1910 1893062 1892 145 1 39E-02 256E-02 2 Unchanged Medium
Q9Y3B7 E07ef2 mitochondnal nbosomal protein 1 401 0368 421 732 113 517 9208 8 68E-01 688E-02 2 Unchanged Medium
Q9P015 A12ef8 mitochondnal nbosomal protein I 553658 760 5890617 634 2498 8 94E-02 4 57E-01 2 Unchanged Medium
Q9NX20 M06gh2 mitochondnal πbosomal protein I 642 9143 496 701 1442 6134293 1 25E-01 -374E-01 2 Unchanged Medium
Q9H0U6 013ef8 mitochondnal nbosomal protein I 741 5383 1000 8268816 856 3674 1 57E-01 432E-01 2 Unchanged Medium
Q9NZE8 O04ef2 mitochondnal πbosomal protein L 914 9722 910 956 7888 927 2731 645E-02 -777E-03 2 Unchanged Medium
Q9P0P3 K18ef2 mitochondnal nbosomal protein L 1217 101 891 1196 143 1101 306 -2 51E-02 -4 50E-01 2 Unchanged Medium
Q9Y317 M15ef2 mitochondnal πbosomal protein I 799 6979 1020 1372 352 1063499 779E-01 349E-01 2 Unchanged Medium
Q9Y6G3 C19ef8 mitochondnal πbosomal protein t 571 7264 810 6893229 690 2211 270E-01 502E-01 2 Unchanged Medium mitochondrial ribosomal protein I 490 5463 665 619 0928 5 i 6118 336E-01 439E-01 2 Unchanged Medium
Q9Y3D3 B12ef1 mitochondnal πbosomal protein i 9667611 1020 1006 958 997 1495 588E-02 7 41E-02 2 Unchanged Medium
Q9Y676 C15ef8 mitochondnal nbosomal protein i 6832889 580 761 9887 674 9976 1 57E-01 -2 37E-01 2 Unchanged Medium
Q9Y3D5 G19ef2 mitochondπal ribosomal protein i 6963306 1080 825557 8658021 246E-01 627E-01 2 Unchanged Medium
P82921 011gh7 mitochondrial nbosomal protein i 748082 1190 11155 101933 576E-01 675E-01 2 Unchanged Medium
P82S50 D07gh4 mitochondrial nbosomal protein { 554 1784 515 470683 513 1921 -236E-01 -1 07E-01 2 Unchanged Medium
Q9Y2Q9 A03ef8 mitochondrial nbosomal protein i 1439076 1420 1329749 1395 534 -1 14E-01 -2 15E-02 2 Unchanged Medium
Q9NP92 F02ef3 mitochondrial nbosomal protein i 669 1652 532 617 3223 606 105 -1 16E-01 -331 E-01 2 Unchanged Medium
Q02750 J08ef5 mitogen-activated protein kinase 615689 701 4538702 590 1129 -440E-01 1 87E-01 2 Unchanged Medium
Q02779 K09ab7 mitogen-activated protein kinase 597 1743 423 509 6637 510095 -229E-01 -4 96E-01 2 Unchanged Medium
Q12851 N10abβ mitogen-activated protein kinase 9880971 1020 9767391 994 1804 -1 67E-02 426E-02 2 Unchanged Medium
P49137 J06ef5 mitogen-activated protein kinase 942 7459 1000 1068579 1004 624 1 81 E-01 B 87E-02 2 Unchanged Medium
Q9BYG3 O02gh8 MKI67 (FHA domain) Interacting 791 8688 407 307 4404 5020002 - •1 36E+00 -961 E-01 2 Unchanged Medium
Q15014 C17cd8 MORF-related gene X 114648 1030 1262273 1144 777 1 39E-01 -1 61E-01 2 Unchanged Medium
F22ef4 mRNA, clone P02ST9 1052442 1040 9052614 999 5166 -2 17E-01 -1 60E-02 2 Unchanged Medium
Q15773 M18ef5 myelold leukemia factor 2 5774585 467 7666809 603749 4 09E-01 -306E-01 2 Unchanged Medium
P35579 O01ef1 myosin, heavy polypeptide 9, nor 1426003 1150 1203964 1261 007 -244E-01 -3 07E 01 2 Unchanged Medium
Q9Y6D2 C21ef2 N-acetyltransferase 5 (ARD1 hor 531 5485 708 2749715 5049319 -951 E-01 4 14E-01 2 Unchanged Medium
P41227 G13gh1 N-acetyltransferase homolog of 8006676 905 8182554 841 2057 3 13E-02 1 76E-01 2 Unchanged Medium
Q13510 H20ab2 N-acylsphmgosiπe amidohydrola 752 1534 1660 6775006 1028456 -1 51 E-01 1 14E+00 2 Unchanged Medium
043678 O09ab7 NADH dehydrogenase (ubiquinoi 1366754 1930 2137 906 1810699 645E-01 4 96E-01 2 Unchanged Medium
095167 E24ab7 NADH dehydrogenase (ubiquinoi 1431 655 1770 1506934 1570 238 7 39E-02 308E-01 2 Unchanged Medium
P56556 011ab7 NADH dehydrogenase (ubiqumoi 1650612 916 7958725 1120 973 - •1 05E+00 -849E 01 2 Unchanged Medium
095182 K06ab7 NADH dehydrogenase (ubiquinoi 750 0893 777 725 1711 750 6457 -4 87E-02 503E-02 2 Unchanged Medium
P51970 L04cd8 NADH dehydrogenase (ubiqumoi 554 1995 728 1021 163 7676928 882E-01 393E 01 2 Unchanged Medium
096000 J10ab8 NADH dehydrogenase (ubiquinoi 1110 197 1440 111 615 1219 156 1 84E-03 371E-01 2 Unchanged Medium
095178 J06ab8 NADH dehydrogenase (ubiqumoi 925 3926 768 815266 8363224 -1 83E-01 -268E-01 2 Unchanged Medium
095139 M03ab8 NADH dehydrogenase (ubiquinoi 1392873 1480 2162279 1678472 634E-01 878E-02 2 Unchanged Medium
P17568 H02ab8 NADH dehydrogenase (ubiquinoi 787 0681 567 591 1924 6483703 -4 13E-01 -474E-01 2 Unchanged Medium
Q9Y6M9 P16ab8 NADH dehydrogenase (ubiqumoi 1299803 1450 746 8017 1164 524 -7 99E-01 1 55E-01 2 Unchanged Medium
043677 M05ab8 NADH dehydrogenase (ubiquinoi 5865059 601 532551 5732205 -1 39E-01 343E-02 2 Unchanged Medium
000217 M09abβ NADH dehydrogenase (ubiqumoi 1383411 1130 1194 001 1234 615 -2 12E-01 -296ε-01 2 Unchanged Medium
P19404 M07ef1 NADH dehydrogenase (ubiqu oi 1151 224 443 356308 6500945 - •1 69E+00 -1 3βε+oo 2 Unchanged Medium
076008 A12cd6 Nef-associated factor 1 7202744 951 424 04 6984474 -7 64E-01 401 E-01 2 Unchanged Medium
Q9UPY4 K22ef3 nesca protein 4259149 469 621 9336 505 6782 546E-01 1 40E-01 2 Unchanged Medium
L19gh8 πeurabiπ II 1241 544 862 1023 077 1042081 -2 79E-01 -527E-01 2 Unchanged Medium
Q9g742 O07ab8 neuronal PAS domain protein 1 1076259 405 6063589 6958521 -8 28E-01 -1 41 E+00 2 Unchanged Medium
060448 P20ef3 neuronal thread protein 1831 592 1660 1490 624 1662 051 -297E-01 -1 38E 01 2 Unchanged Medium
Q9UNW9 O05ab8 πeuro-on∞logical ventral antiger 1049959 1050 1219792 1106 982 2 16E-01 1 70E-03 2 Unchanged Medium
Q9UGL9 C09gh3 NICE-1 protein 1026838 1360 381 058 9233423 -1 43E+00 408E 01 2 Unchanged Medium
Q9UGL6 M09ef4 NICE-5 protein 9127542 1390 955016 1086502 6 53E-02 609E-01 2 Unchanged Medium
Q929B2 I09ef7 ninjuπn 1 45823 689 4120181 5196952 -1 53E-01 588E-01 2 Unchanged Medium
Q9BPW8 N19cd3 nipsnap homolog 1 (C elegans) 8294266 529 562 9689 640 3075 -5 59E-01 -650E-01 2 Unchanged Medium
Q9NQR4 B13gh4 Nit protein 2 519 1587 868 6658532 6844701 3 59E-01 742ε-01 2 Unchanged Medium
Q9UF10 L08ef2 non-canonical ubquitin conjugatn 1336406 2000 1488 008 1608 811 1 55E-01 5 83E-01 2 Unchanged Medium
Q9Y385 H1 ef2 non-canonical ubquitin conjugatn 6256356 808 669 812 701 1992 9 84E-02 360E-01 2 Unchanged Medium
Q15233 O02ef1 πoπ-POU domain containing oct 1083363 1210 1234216 1174503 1 88E-01 1 55E-01 2 Unchanged Medium
Q13137 A03cd6 nuclear domain 10 protein 9107725 914 944 6079 923 1712 526E-02 531E-03 2 Unchanged Medium
Q16236 M03cd1 nuclear factor (erythr oid-denved 1233751 1180 1043638 1153088 -2 41 E-01 -620E-02 2 Unchanged Medium
P08651 B07ef1 nuclear factor l/C (CCAAT-biπdm 7260476 624 6596305 6698575 -1 38E-01 -2 19E-01 2 Unchanged Medium
095134 P10cd3 nuclear localization signal delete 4652933 522 5367333 50B 0938 2 06E-01 1 67E-01 2 Unchanged Medium
Q1S772 N19ab2 nuclear protein marker for differe 1473704 923 1157202 1184738 -349E-01 -675E 01 2 Unchanged Medium
Q9UHY1 L15cd8 nuclear receptor binding protein 515949 948 6197512 6944539 2 64E-01 877E 01 2 Unchanged Medium
Q9UPC9 H23ab2 nuclear receptor coactivator 3 8227768 1190 9329058 98277 1 81 E-01 536E 01 2 Unchanged Medium
Q15325 N22cd2 nuclease sensitive element bindi 1644 614 1720 2064 24 1808 771 3 28E-01 625E-02 2 Unchanged Medium
000567 D05cd6 nucleolar protein 5A (56kD with 1 6594335 608 6232536 630 2325 -8 14E-02 -1 17E-01 2 Unchanged Medium
Q9NX24 A10gh3 nucleolar protein family A, me b 4662539 625 5948443 561 9547 3 51 E-01 422E-01 2 Unchanged Medium
P06748 KOδghδ nucleophosmin (nucleolar phospl 1505368 1080 1136972 1275358 -4 98E-01 -567E-01 2 Unchanged Medium
P50583 B01ab2 nudix (nucleoside diphosphate In 1590 763 211 251 3768 684 354 -2 66E+00 -2 91 E+00 2 Unchanged Medium
Q9UHM6 N20gh8 opsm 4 (melanopsm) 107673 1200 1643887 1305 239 6 10E-01 1 50E-01 2 Unchanged Medium
Q9Y218 P22gh1 optineunn 1014697 1980 912 1917 1302823 -1 54E-01 966E-01 2 Unchanged Medium
Q16612 OOIcdS P311 protein 3227444 349 2231 846 967 7934 2 79E+00 1 12E 01 2 Unchanged Medium
P55771 J21cd7 paired box gene 9 692 506 380 573 135 5484374 -273E-01 -867E-01 2 Unchanged Medium
Q9UKJ1 N21cd8 paired immunoglobulin-like recer. 674 1862 450 558 3225 560 9087 -272E-01 -5 83E-01 2 Unchanged Medium
Q15165 P24ab7 paraoxonase 2 3385244 891 5837771 6044337 7 86E-01 1 40E+00 2 Unchanged Medium
Q07002 P06ef5 PCTAIRE protein kinase 3 8365659 916 6327298 795 1858 -4 03E-01 1 31 E-01 2 Unchanged Medium
QgY3C6 J07ef2 peptidylprolyl isomerase (cyclopt 5485938 731 526 6097 6020621 -5 90E-02 4 14E-01 2 Unchanged Medium
P30405 F14cd5 peptidylprolyl isomerase F (cyclo 843 1834 925 4676738 7452396 -850E-01 1 33E-01 2 Unchanged Medium
043924 G24ab8 phosphodiesterase 6D, cGMP-sp 373 1208 630 699 1887 5674949 906E-01 756E 01 2 Unchanged Medium
P17858 K10ab8 phσsphofructokinase liver 9505746 525 774727 750 1835 -295E-01 -8 56E-01 2 Unchanged Medium
Q01813 C17ef1 phosphofructokmase, platelet 5735211 646 555 9236 591 6879 -4 50E-02 1 71 E-01 2 Unchanged Medium
000511 N20cd3 phosphoprotein ennched in astro 1330005 1500 2288098 1704656 783E-01 1 70E-01 2 Unchanged Medium
P11216 B16ab8 phosphorylase, glycogen brain 5167884 495 988 163 666 5476 935E-01 -630E-02 2 Unchanged Medium
P00749 P19ef7 plasminogen activator, urokinass 1096052 3440 1051 513 1861 568 -5 98E-02 1 65E+00 2 Unchanged Medium
P13797 C13cd1 plastin 3 (T isoform) 990 1173 804 1393037 1062438 493E-01 -3 00E-01 2 Unchanged Medium
Q15102 E16ab8 platelet-activating factor acetylhy 4699778 674 4689765 5376672 -3 08E-03 520E-01 2 Unchanged Medium
P01 27 A08ef5 platelet-deπved growth factor bel 5006466 674 4564576 5435869 -1 33E-01 4 28E-01 2 Unchanged Medium
Q15795 C19ef6 pleckstπn homology, Sec7 and ci 578295 740 518 8327 61222 -1 57E-01 355E-01 2 Unchanged Medium
043660 018ab8 pleiotroplc regulator 1 (PRLIhorr 7437263 933 8043456 827 0995 1 13E-01 3 27E-01 2 Unchanged Medium
Q15155 G12ef3 pM5 protein 6642511 423 490295 525 8869 -4 38E-01 -6 51 E-01 2 Unchanged Medium
Q9H361 L04gh7 poly(A) binding protein, cytoplasi 7594566 491 710 0543 6538286 -9 52E-02 -629E-01 2 Unchanged Medium
Q15366 A11cd1 poly(rC) binding protein 2 1051 241 1490 2128585 1857745 1 26E-01 -386E-01 2 Unchanged Medium
P19388 B15ab8 polymerase (RNA) II (DNA direct 552 3545 529 βgβ 4965 5934201 339E-01 -6 12E 02 2 Unchanged Medium
P52434 F05gh6 polymerase (RNA) II (DNA direct 9497064 1480 1210411 1211 761 3 50E-01 635E-01 2 Unchanged Medium
P36954 A20cd1 polymerase (RNA) II (DNA direct 1603557 1820 1413573 1613004 -1 82E-01 1 84E-01 2 Unchanged Medium
P53803 C17cd1 polymerase (RNA) II (DNA direct 437 9544 893 5280144 6196184 270E-01 1 03E+00 2 Unchanged Medium Q9UQQ3 J08cd6 P0P4 (processing of precursor , 480 5848 645 551 3661 558 9966 1 98E-01 4 25E-01 2 Unchanged Medium
Q13670 B07ab8 postmeiotic segregation increase 812 7865 779 532 0548 7080473 -6 11 E-01 -6 07E-02 2 Unchanged Medium
Q9P0J7 L07gh4 potassium channel modulatory fa 1401 591 1720 1192204 1438482 -233E-01 297E-01 2 Unchanged Medium
060925 K02ab8 prefoldin 1 1631 996 1720 1860632 1737289 1.89E-01 7 51E-02 2 Unchanged Medium
Q9UHV9 J15ef4 prefoldln 2 5144897 882 833 1525 743 3158 6 95E-01 7.78E-01 2 Unchanged Medium
Q13519 J07ef6 preproπociceptin 5642079 464 887 4522 6384071 653E-01 -2 83E-01 2 Unchanged Medium
P04156 A!3ab8 pπon protein (p27-30) (Creutzfeli 7979495 631 701 8217 710 1438 -1 85E-01 -3 39E-01 2 Unchanged Medium
Q9UI73 K03ef8 PRO0246 protein 430412 535 5468599 5040018 345E-01 3 13E-01 2 Unchanged Medium
Q9P0T3 D14ef1 proapoptotic caspase adaptor pn 1261 463 1650 2553652 1820 221 1 02E+00 3 83E-01 2 Unchanged Medium
Q02809 P20ab7 procollagen -lysine, 2-oxoglutarat 5037557 477 1993232 991 2271 1 98E+00 -7 97E-02 2 Unchanged Medium
P07237 G13ab8 pracollagen-proline, 2-oxoglutarε 6338309 406 5756635 5383489 -1 39ε-01 -644E-01 2 Unchanged Medium
P09466 E12ab8 progestagen-associated endo e 3670939 625 7088717 5670247 949E-01 7 68E-01 2 Unchanged Medium
Q16342 G22ef6 programmed cell death 2 7350961 759 4903938 661 3332 -5 84E-01 452E-02 2 Unchanged Medium
075340 I02cd8 programmed cell death 6 1055886 1090 1356597 1167782 362E-01 470E-02 2 Unchanged Medium
P35232 C22ef5 prohibitin 2045693 1810 1600 236 1818 121 -3 54E-01 -1 78E-01 2 Unchanged Medium
Q9UQ80 003cd1 proliferation-associated 2G4, 38. 1902387 1390 2003 135 176359 744E-02 -458E-01 2 Unchanged Medium
Q12796 E05ab3 proline rich 2 192778 1530 1475973 1643691 -385E-01 -3 36E-01 2 Unchanged Medium
Q15188 P20cd2 proliπe-πch protein BstNI subfam 9975582 1290 1404 4 1232034 4 93E-01 376E-01 2 Unchanged Medium
P35998 L09ab8 proteasome (prosome, macropaii 1010463 1200 1059 594 1090 401 685E-02 249E-01 2 Unchanged Medium
P47210 N16cd2 proteasome (prosome, macropaii 1037339 1150 1193 1127 919 202E-01 1 53E-01 2 Unchanged Medium
000495 N03ab8 proteasome (prosome, macropaii 1043875 498 5637775 701 7628 -8 89E-01 -1 07E+00 2 Unchanged Medium
075831 N07ab8 proteasome (prosome, macropaii 763 7632 622 5068297 630 7237 -5 92E-01 -297E-01 2 Unchanged Medium
Q13200 L15ab8 proteasome (prosome, macropaii 6443008 594 331 4288 523 3702 -959E-01 -1 16E-01 2 Unchanged Medium
043242 L17ab8 proteasome (prosome, macropaii 2159327 1230 163767 1675 386 -3 99E-01 -8 13E-01 2 Unchanged Medium
P55036 N18cd2 proteasome (prosome, macropaii 4608093 724 588 5346 591 0419 353E-01 651 E-01 2 Unchanged Medium
P48556 L21ab8 proteasome (prosome, macropaii 1240243 1030 1665 116 131742 442E-01 -272E-01 2 Unchanged Medium
Q92530 G07cd6 proteasome (prosome, macropaii 1804 777 1570 1800731 1724253 -324E-03 -204E-01 2 Unchanged Medium
P28066 J13ab8 proteasome (prosome, macropaii 766589 767 7752704 7697417 1 62E-02 1 46E-03 2 Unchanged Medium
014818 J15ab8 proteasome (prosome, macropaii 1242517 1540 1139 994 1308 162 -1 24E-01 3 12E-01 2 Unchanged Medium
P49721 J19ab8 proteasome (prosome, macropaii 1832921 2110 1617062 1853 89 -1 81 E-01 204E-01 2 Unchanged Medium
P28062 H18ab8 proteasome (prosome, macropaii 7973912 905 505 3638 735 864 -6 58E-01 1 82E 01 2 Unchanged Medium
P28065 B0Sef7 proteasome (prosome, macrαpaii 771 1998 1630 100272 1133 626 3 79E-01 1 08E+00 2 Unchanged Medium
P10619 A07ab8 protective protein for beta-galacd 1539 157 907 980 3046 1142279 -651 E-01 -7 62E-01 2 Unchanged Medium
Q9UNN8 F03cd6 protein C receptor, endothelial (E 892 1589 702 4885084 6942014 -869E-01 -346E-01 2 Unchanged Medium
Q15084 H02cd5 protein disulfide isomerase-relate 1081 309 407 8590228 7824339 -332E-01 -1 41 E+00 2 Unchanged Medium
Q9Y2B9 C22cd7 protein kinase (cAMP-dependent 6509588 1040 754 6101 8144047 2 13E-01 673E-01 2 Unchanged Medium
Q13517 A09ef5 protein kinase C binding protein 380 9448 587 630 5497 5329442 727E-01 625E-01 2 Unchanged Medium
P54619 F15ab8 protein kinase, AMP-activated, g 4828359 572 841 1746 6320978 801 E-01 245E-01 2 Unchanged Medium
P17612 F13ab8 protein kinase, cAMP-dependent 6430385 629 901 5293 724 5168 4 87E-01 -3 19E-02 2 Unchanged Medium
P09131 F10gh1 Protein P3 5290069 607 6170621 5842407 222E-01 1 98E-01 2 Unchanged Medium
060927 P02gh1 protein phosphatase 1 , regulator 1728646 1760 1404 955 1630 486 -299E-01 242E-02 2 Unchanged Medium
P41236 C08cd1 protein phosphatase 1 , regulator 532 1136 621 583 7663 578 9436 1 34E-01 223E-01 2 Unchanged Medium
Q15435 D15ab8 protein phosphatase 1 , regulator 634975g 963 7539046 7840242 248E-01 601 E-01 2 Unchanged Medium
P05323 E13ef6 protein phosphatase 2 (formerly 1058276 1120 7966526 992 192 -4 10E-01 839E-02 2 Unchanged Medium
Q15257 G01ef5 protein phosphatase 2A, regulate 9254458 905 1160437 996 8116 326E-01 -329E-02 2 Unchanged Medium
P33172 F01ab8 protein phosphatase 4 (formerly 1791 171 1220 1064665 1357 256 -751 E-01 -559E-01 2 Unchanged Medium
000743 F03ab8 protein phosphatase 6, catalytic • 998 7 1070 7384815 9362693 -4 35E-01 1 02E-01 2 Unchanged Medium
P38391 E21cd7 protein translocation complex bei 1049306 1050 1428451 1175447 445E-01 -993E-04 2 Unchanged Medium
P78324 M17cd4 protein tyrosine phosphatase, no 6392381 741 591 4877 657 1953 -1 12E-01 2 13E-01 2 Unchanged Medium
Q13332 P21ab8 protein tyrosine phosphatase, rei 1882284 1880 2019865 1928827 1 02E-01 1 57E 03 2 Unchanged Medium
Q9HAD6 C08gh6 protocadhenn 16 dachsous-like ( 9672552 906 1070494 981 1143 1 46E-01 -950E-02 2 Unchanged Medium
043445 E11cd5 PRP4 pre-mRNA processing fact 7771081 549 569 3749 631 8368 -4 49E-01 -501 E-01 2 Unchanged Medium
QgY6B3 L19ef2 PTD013 protein 652 1251 701 1031 739 794 9108 6 62E-01 1 04E-01 2 Unchanged Medium
Q9HAN1 P19gh6 pumilio homolog 1 (Drosophila) 8424925 1170 1047 18 1019233 3 14E-01 4 71 E-01 2 Unchanged Medium
Q9NQA4 C23ef4 putative acid-sensing ion channe 742723 762 6783813 727 7123 -1 31 E-01 370E-02 2 Unchanged Medium
043598 J05cd6 putative c-Myc-responsive 4736498 621 459383 5179666 -441E-02 3 90E-01 2 Unchanged Medium
043257 M12cd6 putative cyclin G1 interacting pro 1118374 1190 1238925 1183655 1 48E-01 940E-02 2 Unchanged Medium
Q9NY06 M07ef4 putative integral membrane trans 9664384 544 569 8565 6934947 -762E-01 -8 29E-01 2 Unchanged Medium
P17152 H21cd4 putative receptor protein 3999305 650 591 3162 547 029 564E-01 7 00E-01 2 Unchanged Medium
Q9Y6I9 B13ef2 putative secreted protein 373307 485 742 537 533 7168 992E-01 379E-01 2 Unchanged Medium
P54886 B12ab8 pyrrolιne-5-carboxylate synthetas 4067128 302 905 8993 5380842 1 16E+00 -4 31 E-01 2 Unchanged Medium
Q13876 B03ef7 quiescin Q6 745299 585 8242489 718 0657 1 45E-01 -350E-01 2 Unchanged Medium
014679 K24ef5 quinoπe oxldoreductase homolog 710 5753 1160 651 2257 839 1208 -1 26E-01 7 02E-01 2 Unchanged Medium
P53611 N16ab8 Rab geranylgeranyltransferase, t 758 1496 727 g38 617g 807 7755 308E-01 -6 14E-02 2 Unchanged Medium
P47224 D06abβ RAB interacting factor 6455902 859 577 3956 693 8748 -1 61 E-01 4 11E-01 2 Unchanged Medium
Q15907 H04cd4 RAB11B, member RAS oncogeni 926 8757 1030 1224758 1060 693 4 02E-01 1 53E-01 2 Unchanged Medium
P51153 D04ab8 RAB13, member RAS oncogene 6190867 935 1131 86 8952783 870E-01 595E-01 2 Unchanged Medium
P35287 J24ef2 RAB14, member RAS oncogene 5437425 584 586 1635 571 2023 1 08E-01 1 02E-01 2 Unchanged Medium
Q9NP72 P02ef8 RAB18, member RAS oncogene 4594786 794 634 6616 629 3713 4 66E-01 7 89E-01 2 Unchanged Medium
P11476 H22ab8 RAB1A, member RAS oncogene 1039455 767 993 586 933 4801 -6 51E-02 -438E-01 2 Unchanged Medium
Q9H0U4 L08gh7 RAB1 B, member RAS oncogene 5269882 691 696 5292 638 0939 4 02E-01 390E-01 2 Unchanged Medium
P08886 B22ab8 RAB2, member RAS oncogene ft 1483703 1900 2195 304 1858 384 565E-01 3 54E-01 2 Unchanged Medium
095716 P04cd4 RAB3D, member RAS oncogene 9089015 638 5562242 701 181 -7 oβε-oi -5 10E-01 2 Unchanged Medium
P35239 D02ab8 RAB5B, member RAS oncogene 5985113 708 393 3892 566 5496 -605E-01 242E-01 2 Unchanged Medium
P20340 C07ef6 RAB6A, member RAS oncogene 503 1507 655 4167552 524 9788 -272E-01 3 81 E-01 2 Unchanged Medium
P43487 D16ab8 RAN binding protein 1 1438305 1180 1786 177 1468 585 3 13E-01 -284E-01 2 Unchanged Medium
Q9UI26 B20ef1 Ran binding protein 11 1505224 1180 1273 677 1319 368 -241 E-01 -3 52E-01 2 Unchanged Medium
P47736 D18ab8 RAP1 , GTPase activating proteir 8758692 414 461 3322 583 6391 -925E-01 -1 08E+00 2 Unchanged Medium
Q15382 F17cd2 Ras homolog ennched in brain 2 1435587 2190 1635792 175423 1 88E-01 6 10E-01 2 Unchanged Medium
P52199 B1βab2 ras homolog gene family, membe 5346169 1520 399 0517 816 6152 -422E-01 1 50E+00 2 Unchanged Medium
P35238 B20ab2 ras homolog gene family, membe 1022646 872 1019472 971 4616 -448E-03 -229E-01 2 Unchanged Medium
Q14644 J08ef7 RAS p21 protein activator (GTPa 615946 623 627 059 622 1475 258E-02 1 74E-02 2 Unchanged Medium
Q15404 A10cd8 Ras suppressor protein 1 1543953 1920 2317 155 1925 544 5 86E-01 3 11E-01 2 Unchanged Medium
Q13283 H14cd5 Ras-GTPase-activating protein S 8467267 789 571 1476 7355498 -568E-01 -1 02E-01 2 Unchanged Medium
Q9NVQ9 M05gh1 Recβp a melotic recombination . 1334371 1200 132585 1286027 -9 24E-03 -1 56E-01 2 Unchanged Medium
060895 K17cd6 receptor (calcitonin) activity modi 572 8174 519 899 2606 663 6562 6 51 E-01 -1 43E-01 2 Unchanged Medium P35244 I22ef6 replication protein A3 (14kD) 5440212 502 924 5385 656 7974 7 65E-01 -1 16E-01 2 Unchanged Medium
Q99623 D03cd7 repressor of estrogen receptor ai 1139283 689 1233 151 1020486 1 14E-01 -725E-01 2 Unchanged Medium
Q9UMQ4 C01gh1 ret proto-oπcogene (multiple end 7692484 602 803931 725 1999 636E-02 -353E-01 2 Unchanged Medium
Q9NQC3 M19cd7 reticulon 4 1459 586 586 927 9776 991 1835 -653E-01 ■ •1 32ε+00 2 Unchanged Medium
P47804 P03cd1 retinal G protein coupled receptα 403.1219 497 6274176 509 1489 638E-01 302E-01 2 Unchanged Medium
Q16576 P07ef6 retinoblastoma binding protein 7 1539006 1410 7988744 1250 347 -946E-01 -1 23E-01 2 Unchanged Medium
095357 D02cd4 retinoic acid induced 3 678 1926 713 206 6352 532.4837 1 71 E+00 7 14E-02 2 Unchanged Medium
Q15299 D20ef1 retinoic acid receptor-beta assoc 1060232 979 1013444 1017603 -651E-02 -1 15E-01 2 Unchanged Medium
Q9UMY1 P05ef2 retinoic acid repressive protein 610 5279 726 5862413 641 044 -586E-02 251 E-01 2 Unchanged Medium
Q13017 M15ef6 Rho GTPase activating protein 5 560443 807 514 6138 627 5049 -1 23E-01 527E-01 2 Unchanged Medium
043182 B24ab2 Rho GTPase activating protein 6 1257 146 806 8957191 9863979 -4 89E-01 -641 E-01 2 Unchanged Medium
060274 F04gh6 Rho-specific guanine nucleotide 651 9484 577 3664761 531 8448 -831 E-01 -1 76E-01 2 Unchanged Medium
P07998 P21cd1 πboπuclease, RNase A family, 1 1294476 3040 1592811 1976991 299E-01 1 23E+00 2 Unchanged Medium
P04843 B12cd1 ribophonn I 1493 814 1360 2248 214 1700 316 590E-01 -1 37E-01 2 Unchanged Medium
P04844 B14cd1 nbophoπn II 1574 181 1170 1880047 1540461 256E-01 -432E-01 2 Unchanged Medium
P26373 D11cd1 πbosomal protein L13 2091 256 1200 1924 546 1739922 -1 20E-01 -7 97E-01 2 Unchanged Medium
P40429 H12ef1 nbosomal protein L13a 1928 024 2060 1091 46 1694794 -821 E-01 9 89E-02 2 Unchanged Medium
P39019 J05cd1 nbosomal protein S19 1794644 1480 2253771 1841 785 329E-01 -281 E-01 2 Unchanged Medium
P78317 B04cd1 πng finger protein 4 7562395 661 6688027 695 4611 -1 77E-01 -1 93E-01 2 Unchanged Medium
Q9g942 F04cd2 πng finger protein 5 1016837 949 1126 187 1030 595 1 47E-01 -1 OOE-01 2 Unchanged Medium
043148 A15cd4 RNA (guanine-7-) methyltraπsfer 5726495 730 390498 564 3647 -552E-01 350E-01 2 Unchanged Medium
002916 FOδabβ RNA binding motif protein 4 5337121 628 430 5298 530 87 -3 10E-01 236E-01 2 Unchanged Medium
Q9Y580 J10gh6 RNA binding motif protein 7 368 8423 710 558043 5455838 597E-01 945E-01 2 Unchanged Medium
Q14621 H07cd7 RNA binding protein (autoantiger 4995699 737 506822 581 142 208E-02 561 E-01 2 Unchanged Medium
Q93062 K17cd7 RNA-biπding protein gene with rr 8450994 659 6404514 714 6837 -400E-01 -360E-01 2 Unchanged Medium
Q99497 B15cd7 RNA-binding protein regulatory s 191486 1400 2563974 1958 111 421 E-01 -4 56E-01 2 Unchanged Medium
Q99584 L17cd2 S100 calcium binding protein A1 492 6196 421 675 1457 529713 455E-01 -225E-01 2 Unchanged Medium
P23526 A06ef1 S-adenosylhomocysteme hydrolε 550 6181 603 478 692 544258 -202E-01 1 32E-01 2 Unchanged Medium
043865 H21ab2 S-adenosylhomocysteme hydrotε 1460 581 526 4664887 8178431 • ■1 65E+00 -1 47E+00 2 Unchanged Medium
014828 D02cd5 secretory earner membrane prate 661 3975 460 481 9262 534 3923 -457E-01 -524E-01 2 Unchanged Medium
075326 L05cd3 sema domain, immuπoglobulin di 7950564 768 943 1132 8352276 246E-01 -509E-02 2 Unchanged Medium
043278 H6cd2 serine protease Inhibitor, Kuπltz I 1295263 1260 641 0775 1066 162 • 1 01E+00 -374E-02 2 Unchanged Medium
000271 C05ef5 serine protease inhibitor, Kunitz I 1379 545 1740 8764128 1332552 -655E-01 336E-01 2 Unchanged Medium
Q9UEW8 N22ef5 seπne threonine kinase 39 (STE, 1230 117 1030 841 1872 1032 185 -548E-01 -263E-01 2 Unchanged Medium
Q13043 P15cd2 senne/threonine kinase 4 7507132 838 756 1662 781 5546 1 04E-02 1 58E-01 2 Unchanged Medium
Q9Y282 F01ef2 serologically defined breast cane 1279 414 1160 1907544 1448986 576E-01 -1 41 E-01 2 Unchanged Medium
P35542 A02gh1 serum amyloid A4, constitutive 754 5041 1310 811 5701 959 3499 1 05E-01 798E-01 2 Unchanged Medium
075790 I22cd6 seven transmembrane domain pr 761 3872 778 7990998 7795745 697E-02 3 16E-02 2 Unchanged Medium
Q9P0V3 H17ef3 SH3-domaιπ binding protein 4 1204 005 1710 1539363 1483624 354E-01 5 04ε-01 2 Unchanged Medium
Q99519 C13ab8 slalidase 1 (lysosomal sialidase) 7124593 680 4987449 630 4428 -5 15E-01 -670E-02 2 Unchanged Medium
Q92185 J20cd1 sialyltransferase 8A (alpha-N-ac( 6224236 478 4627941 520 9105 -428E 01 -382E-01 2 Unchanged Medium
Q9Y6A9 C05ef8 signal peptidase 12kDa 449125 742 8874615 6928575 983E-01 724E-01 2 Unchanged Medium
P21378 I04ef3 signal peptidase complex (18kD) 6305617 515 732 1592 6260198 2 16E-01 -291 E-01 2 Unchanged Medium
015302 P10ab3 signal recognition particle 72kD 1040 23 818 841 5078 899 9534 -3 06E-01 -347E-01 2 Unchanged Medium
076094 J02cd2 signal recognition particle 72kD 1473 56 965 14222 1286 822 -5 12E-02 -6 11 E-01 2 Unchanged Medium
Q9UNL2 J10cd2 signal sequence receptor, gam 1150 724 450 1654744 1085 128 5 24E-01 -1 35E+00 2 Unchanged Medium
P40763 K09ef5 signal transducer and activator o 671 5038 545 3480347 521 4351 -948E-01 -302E-01 2 Unchanged Medium
Q92783 M24cd3 signal transducing adaptor molec 8279851 1020 7257017 8578322 -1 90E-01 301E-01 2 Unchanged Medium
Q9H723 N01gh5 similar to rat nuclear ubiquitous c 7497661 530 125865 8462392 747E-01 -5 OOE-01 2 Unchanged Medium
015258 A04cd7 similar to S cerevisiae RER1 710 8499 635 9336382 7598427 393E-01 -1 63E-01 2 Unchanged Medium
014834 A11cd7 similar to S pombe dιm1+ 701 2292 753 9038926 7860877 366E-01 1 03E-01 2 Unchanged Medium
043617 H05ef3 similar to yeast BET3 (S cerevis 1759348 1750 1443578 1650 871 -285E-01 -7 94E-03 2 Unchanged Medium
Q04837 G11cd2 single-stranded DNA binding pro 1264 277 894 103475 1064292 -2 89E-01 -5 OOE-01 2 Unchanged Medium
P05455 E19gh1 Sjogren syndrome antigen B (aut 8509691 744 930 6428 841 9268 1 29E-01 -1 93E-01 2 Unchanged Medium
P43331 K08cd2 small nuclear πbonucleopratein [ 9163597 1260 1042335 107382 1 86E-01 463E-01 2 Unchanged Medium
P09012 M12cd2 small nuclear πbonucleoprotein p 5480261 310 6856636 5145708 323E-01 -822E-01 2 Unchanged Medium
P08579 A03cd2 small nuclear nbonucleoprotein p 502 6355 570 6699879 581 0279 4 15E-01 1 83E-01 2 Unchanged Medium
P09234 A05cd2 small nuclear ribonucleoprotein p 1054327 1450 1302742 126964 305E-01 462E-01 2 Unchanged Medium
P08578 A07cd2 small nuclear πbonucleoprotein p 1901 214 1740 1818557 1819876 -641E-02 -1 28E-01 2 Unchanged Medium
Q15357 A11cd2 small nuclear πbonucleoprotein p 3824892 734 593847 5702015 635E-01 941 E-01 2 Unchanged Medium
P14678 C23cd3 small nuclear πbonucleoprotein p 2036 574 1280 1737 398 1686 175 -229E-01 -665E 01 2 Unchanged Medium
Q13487 P08cd1 small nuclear RNA activating cor 517 5819 684 648 0121 616 6789 324E-01 4 03E-01 2 Unchanged Medium
P35326 E17cd3 small prolme-πch protein 2A 2906174 1030 839 3072 721 2318 1 53E+00 1 83E+00 2 Unchanged Medium
P55854 H04cd2 SMT3 suppressor of mlf two 3 ho 791 7437 658 962 4453 804 107 282E-01 -267E-01 2 Unchanged Medium
P14648 P19cd5 SNRPN upstream reading frame 1581 907 2270 1670 964 183936 7 90E-02 5 18E-01 2 Unchanged Medium
P55011 L17cd1 solute carrier family 12 (sodium/p 591 8676 740 517 2382 616 497 -1 94E-01 323E-01 2 Unchanged Medium
095258 P15cd4 solute carrier family 25 (mitochor 4763075 518 5778319 523 9535 279E-01 1 20E-01 2 Unchanged Medium
015431 A21ab5 solute earner family 31 (copper ti 1227 872 1010 1769026 1336 855 527E-01 -277E-01 2 Unchanged Medium
P04920 L04cd1 solute earner family 4, anion excl 1614 362 1560 1704 134 1624 765 7 81E-02 -533E-02 2 Unchanged Medium
Q01650 J11ef5 solute carrier family 7 (cationic ai 832 6996 632 1032 106 832 1088 3 10E-01 -399E-01 2 Unchanged Medium
Q07890 H23cd2 son of sevenless homolog 2 (Dro 4769505 568 680 8529 575 1528 5 14E-01 251 E-01 2 Unchanged Medium
060749 A19cd2 sorting nexin 2 364 9343 931 769 5782 6885915 1 08E+00 1 35E+00 2 Unchanged Medium
060493 A09cd4 sorting nexin 3 1008 916 1350 1180 469 1180 399 227E-01 4 22E-01 2 Unchanged Medium
Q9Y5X3 G06ef4 sorting nexin 5 6760975 647 6885568 670591 263E-02 -632E-02 2 Unchanged Medium
Q01082 E09cd2 spectπn, beta, πon-erythrocytic 1 571 4909 679 3870403 545 8922 -562E-01 249E-01 2 Unchanged Medium
P52788 M10cd2 spermine synthase 895 1994 854 770002 8397693 -217E-01 -678E-02 2 Unchanged Medium
P17947 C19cd2 spleen focus forming virus (SFF . 1307 418 1150 1646278 1366 573 332E-01 -1 90E-01 2 Unchanged Medium
Q14818 D10ef6 splicing factor 1 5470998 499 7822929 6093562 5 16E-01 -1 34E-01 2 Unchanged Medium
Q15427 K11cd6 splicing factor 3b, subunit 4, 49kl 441 2394 612 5400723 530 9445 292E-01 471 E-01 2 Unchanged Medium
Q15815 M06cd2 splicing factor, argiπine/serine-πc 738 2591 553 551 9082 614 261 -420E-01 -4 18E-01 2 Unchanged Medium
Q01130 H22cd1 splicing factor, argiπine/seπne-ric 553 5808 527 4885465 522 9409 -1 80E-01 -7 18E-02 2 Unchanged Medium
P23152 H24cd1 splicing factor, arglnine/serine-πc 1547 474 1460 1428273 1480 13 -1 16E-01 -7 94E-02 2 Unchanged Medium
Q13503 L22cd4 SRB7 suppressor of RNA polyme 7128859 574 7250591 670 5377 244E-02 -3 13E-01 2 Unchanged Medium
Q9P2R9 C23ef2 SRp25 nuclear protein 495796 558 515095 522 8318 551E-02 1 69E-01 2 Unchanged Medium
Q9H6I2 F07gh5 SRY (sex determining region Y)-l 774 5162 970 714 8666 819674 -1 16E-01 324ε-01 2 Unchanged Medium
Q9BTB1 I13gh8 SRY (sex determining region Y)-l 4970608 530 550 1706 525 7297 1 46E-01 925E-02 2 Unchanged Medium O60526 M03cd6 STIP1 homology and U-Box cont 7066078 538 5437559 596 1019 -378E-01 -3 93E-01 2 Unchanged Medium
Q9Y6X1 A21ef4 stress-associated endoplasmic it 1683 36 1220 2201 647 1700 638 3 87E-01 -468E-01 2 Unchanged Medium
P31948 M15ef3 slress-lnduced-phosphoproteln 1 436 1143 549 5175834 5009139 2 47E-01 332E-01 2 Unchanged Medium
P21912 E09gh1 succmate dehydrogenase compli 701 7228 902 751 7357 7853111 9 93E-02 363E-01 2 Unchanged Medium
014521 H04cd1 succmate dehydrogenase compli 6288405 505 672375 601 9355 9 66E-02 -3 18E-01 2 Unchanged Medium
P53597 I09gh1 succiπate-CoA llgase, GDP-formi 7044006 491 553 293 5327447 -348E-01 -522E-01 2 Unchanged Medium
095605 P15cd5 SUMO-1 activating enzyme subu 7764199 499 4332742 5694163 -842E-01 -639E-01 2 Unchanged Medium
Q16550 K01cd2 suppressor of Ty 4 homolog 1 (S 8135735 1440 991 3588 1081 744 2 B5E-01 824E-01 2 Unchanged Medium
Q15526 K07od2 surfeit 1 4633614 522 583 8097 524 7026 3 18E-01 1 56E-01 2 Unchanged Medium
043539 P02cd1 SWI/SNF related, matnx assocla 1047 14 1280 1212614 1178519 2 12E-01 285E-01 2 Unchanged Medium
Q9UPX1 D23cd7 synaptopodin 6834973 536 421 1841 546 8885 -6 98E-01 -3 51 E-01 2 Unchanged Medium
095721 O09cd5 synaptosomal-associated protein 8307721 1030 6866755 849 1506 -2 75E-01 3 10E-01 2 Unchanged Medium
043391 H09cd2 syndecan binding protein (synter 6256962 640 379 1899 548 1569 -723E-01 3 17E-02 2 Unchanged Medium
Q15B33 J04cd2 syntaxm binding protein 2 661 0175 556 840 6951 6860183 347E-01 -249E-01 2 Unchanged Medium
Q92804 O20cd3 TAF15 RNA polymerase II, TAT» 873 5584 605 1063 778 8474936 284E-01 -530E-01 2 Unchanged Medium
Q9Y490 B04cd2 talm 1 1342238 1170 2365625 1625 187 8 18E-01 -2 01 E-01 2 Unchanged Medium
094797 H20ef7 Tara-like protein 8990807 448 496 1404 614 3777 -858E-01 -1 01 E+00 2 Unchanged Medium
Q13311 C05cd6 Taxi (human T-cell leukemia viπ, 8999979 1190 9262314 1004 505 4 15E-02 4 OOE-01 2 Unchanged Medium
Q16650 F08cd6 T-box, brain, 1 1407 309 1750 1777 889 1645 184 337E-01 3 15E-01 2 Unchanged Medium
P51864 O04ef7 teratocarcinoma-derived growth I 2037 212 1590 1447 46 1690282 -4 93E-01 -361 E-01 2 Unchanged Medium
P55061 019cd2 iestis enhanced gene transcπpt ( 1540968 1330 1972323 1615 143 3 56E-01 -2 10E 01 2 Unchanged Medium
Q15569 P21cd2 testis-specific kinase 1 837 6269 796 708 1178 780 661 -242E-01 -7 31 E 02 2 Unchanged Medium
060636 F08cd5 tetraspan 2 468 1664 702 3753225 5152157 -3 19E-01 5 85E-01 2 Unchanged Medium
060637 F06cdS tetraspan 3 1025 362 742 5459662 770 9441 -909E-01 -4 68E-01 2 Unchanged Medium
095857 F13ef3 tetraspan NET-6 protein 702 1579 676 359 1921 5789636 -967ε-01 -558E-02 2 Unchanged Medium
Q99614 M03cd3 tetratncopeptide repeat domain 1 706 3536 891 6355379 744 2616 -1 52ε-01 335E-01 2 Unchanged Medium
Q13118 L05cd2 TGFB inducible early growth resj 4459691 601 6792931 5754732 607ε-01 4 31 E-01 2 Unchanged Medium
Q15583 A16cd2 TGFB-induced factor (TALE fami 8859 1290 1140439 1 05268 364E-01 542E-01 2 Unchanged Medium
Q9H3N1 N03gh7 thioredoxiπ domain-containing 4096333 426 6867997 507 428 746E-01 5 60E-02 2 Unchanged Medium
043396 017cd5 thioredoxin like 32kD 1821 595 1710 1548 596 1693 179 -234E-01 -9 18E-02 2 Unchanged Medium
P04216 B02cd2 Thy-1 cell surface antigen 1698064 298 4157357 1541 609 461 E+00 8 10E-01 2 Unchanged Medium
P12956 K10ef6 thyroid autoantigen 70kD (Ku anl 117256 1490 1395 803 1353001 2 5i -01 346E-01 2 Unchanged Medium
P16035 P11ef7 tissue inhibitor of metalloproteinε 3602533 354 913 1351 5424517 1 34ε+00 -2 54E-02 2 Unchanged Medium
Q9H2X8 I08gh8 TLH29 protein precursor 7102447 1000 1386 102 1033 648 965E-01 500E-01 2 Unchanged Medium
Q13077 L11cd2 TNF receptor-associated factor 1 1265 054 1270 756 401 1097 404 -742ε 01 649E-03 2 Unchanged Medium
Q9NZ34 P08gh4 TPA regulated locus 1074319 1090 128444 1148 575 258E-01 1 69E-02 2 Unchanged Medium
Q15369 D18ef6 transcription elongation factor B > 771 5598 1100 693 1767 8548396 -1 55E-01 5 11E-01 2 Unchanged Medium
Q15906 P11ef6 transcnption factor-like 1 436 5561 510 8789083 608 5936 1 01 E+00 225E-01 2 Unchanged Medium
P50616 H08cd5 transducer of ERBB2, 1 888 8059 874 518 1816 760 3803 -778E-01 -240E-02 2 Unchanged Medium
Q13595 N04ef7 transfor er-2 alpha (htra-2 alphε 2474437 612 698379 519219 1 50E+00 1 31 E+00 2 Unchanged Medium
P37802 F05cd3 transgelin 2 1986716 2240 1173434 1798473 -760E 01 1 70E-01 2 Unchanged Medium
Q9Y5Z9 D01cd8 transitional epitheiia response pr 1324284 875 1126793 1108824 -233E-01 -597E-01 2 Unchanged Medium
Q99595 K10cd6 translocase of inner mitochoπdπs 4506578 665 448 5161 521 2602 -687E-03 560E-01 2 Unchanged Medium
060830 A09cd6 translocase of inner mitochondπε 1646564 1590 1992 925 1744 175 275E-01 -477E-02 2 Unchanged Medium
014925 I24cd6 translocase of inner mitochondriε 745 8102 813 6534301 737451 -1 91 E-01 1 25E-01 2 Unchanged Medium
Q9Y5J9 EOβcdβ translocase of inner mitochondπε 1641 377 1550 1653524 1615991 1 06E-02 -798E-02 2 Unchanged Medium
Q15629 G18ef3 translocating chain-associating n 1003031 1060 6244499 897 0752 -684E 01 848E-02 2 Unchanged Medium
Q99442 C10cd2 translocation protein 1 526 8783 772 1065397 788001 1 02E+00 5 51 E-01 2 Unchanged Medium
Q99805 A18cd5 transmembrane 9 superfamily me 1023 368 1260 9572601 1081 028 -963E-02 3 03E-01 2 Unchanged Medium
Q9Y2B0 C20ef3 transmembrane protein 4 681 3857 1320 985 8397 995 6424 533E-01 9 54E-01 2 Unchanged Medium
P49755 J05ef4 transmembrane trafficking proteu 1311 203 469 700 7243 827066 -904E 01 -1 48E+00 2 Unchanged Medium
F03gh4 transmembrane, prostate androg 128798 841 6624165 930 4505 -959E-01 -6 15E-01 2 Unchanged Medium
Q03519 B07cd1 transporter 2 ATP-bmdiπg casse 851 2148 573 680 8519 701 534 -322E-01 -572E-01 2 Unchanged Medium
Q9NWF9 P02gh2 TRIAD3 protein 665 9772 444 6886646 5994053 483E-02 -5 86E-01 2 Unchanged Medium
Q15656 O07ef7 TRK-fused gene 1878254 1640 1858307 1792501 -1 54E-02 -1 95E-01 2 Unchanged Medium
Q92734 J17cd7 TRK-fused gene 1450307 1810 1609067 1624429 1 50E-01 323E 01 2 Unchanged Medium
Q12815 A21ef7 trophinin associated protein (tast 821 5601 1100 7228644 87996 -1 85E 01 4 15E-01 2 Unchanged Medium
P09493 O02cd1 tropomyosin 1 (alpha) 988 1694 429 1004982 807373 243E-02 -1 20E+00 2 Unchanged Medium
P49411 M11cd3 Tu translation elongation factor, I 5258572 555 4764592 519255 -1 42E-01 7 90E-02 2 Unchanged Medium
P05217 F03gh6 tubulin, beta, 2 1203686 705 920 1831 9428088 -3 87E-01 -773E-01 2 Unchanged Medium
P23258 K03cd3 tubulin, gamma 1 1733 971 1220 2149365 1702331 3 10E-01 -503E-01 2 Unchanged Medium
Q9UBN6 A16ef6 tumor necrosis factor receptor su 470 7412 751 531 524 5844772 1 75E-01 674E-01 2 Unchanged Medium
Q13829 L22ef4 tumor necrosis factor alpha-indu 849276 792 5527776 731 2933 620E-01 -1 01 E-01 2 Unchanged Medium
000496 K21cd3 tumor suppressing subtransferab 6283509 554 800 8751 661 0848 350E-01 -1 82E-01 2 Unchanged Medium
Q99816 G04cd4 tumor susceptibility gene 101 7238133 766 627 1295 7054904 -207E 01 808E-02 2 Unchanged Medium
P16422 C03ab7 tumor-associated calcium signal 1448512 791 373663 870 9367 -1 95E+00 -8 73E-01 2 Unchanged Medium
Q9NP84 K03ef2 type I transmembrane protein Fn 691 89 498 560 2824 583 2792 -304E 01 -4 75E-01 2 Unchanged Medium
Q9UJ47 O09cd8 type I transmembrane receptor (J 792 9873 819 8099055 8073703 305E-02 469E-02 2 Unchanged Medium
P31946 K21ef6 tyrosine 3-monooxygenase/tryptc 1220989 955 7249898 9669847 -7 52E-01 -355E-01 2 Unchanged Medium
P35214 J19ef4 tyrosine 3-monooxygenase/tryptc 881 0131 989 6825327 850 9964 -368E-01 1 67E-01 2 Unchanged Medium
P27348 G1Scd7 tyrosine 3-monooxygenase/tryptc 2196334 1540 1104 855 1615078 -991 E-01 -508E-01 2 Unchanged Medium
060704 J01cd3 tyrosylprotein sulfotr aπsferase 2 6583761 299 686 1339 5477036 596E-02 -1 14E+00 2 Unchanged Medium
Q9Y4Z0 G09cd8 U6 snRNA-associated Sm-like pr 837 5087 689 914 9547 813 8478 1 28E-01 -2 81 E-01 2 Unchanged Medium
P14927 G06cd4 ublquiπol-cytochrome c reductase 995 1237 817 9543085 922 1475 -604E-02 -285E-01 2 Unchanged Medium
Q9UI02 P18ef7 ublquinol-cytochrome c reductasi 9536884 1460 1546 568 132075 697E 01 6 16E-01 2 Unchanged Medium
P31930 A22cd3 ubiquiπol-cytochrome c reductasi 846 6396 849 6869864 7940747 -301 E 01 333E-03 2 Unchanged Medium
P22695 A24cd3 ubiqωπol-cytochrαme c reductasi 468 5936 636 581 791 5620633 3 12E-01 4 40E-01 2 Unchanged Medium
P07919 E08cd4 ubiquinol-cytochrome c reductasi 1328 532 1810 1005 378 1382391 -402E-01 449E-01 2 Unchanged Medium
P47985 E06cd4 ubiquinoi cytochrome c reductasi 1519763 1270 1127 575 1306086 -4 31 E-01 -2 58E-01 2 Unchanged Medium
Q9NZ09 N17ef1 ubiquitin associated protein 1588 1 7 1820 1392592 1598619 -1 90E 01 1 93E-01 2 Unchanged Medium
Q9UNP0 F09gh6 ubiquitin specific protease 15 5253364 492 5977817 5383523 1 86E 01 -9 48E 02 2 Unchanged Medium
Q9UHP3 L21cd8 ubiquitin specific protease 25 554 0657 724 561 5817 6130845 1 94E 02 3 85E 01 2 Unchanged Medium
P2231 O07cd3 ubiquitin-actlvating enzyme E1 (/ 1857238 1640 1863316 1788503 4 71E-03 -1 75E-01 2 Unchanged Medium
Q13404 023cd3 ubiquitin-conjugatmg enzyme E2 1073414 1210 1128962 1138559 728E-02 1 77E-01 2 Unchanged Medium
P51669 D05cd4 ubiquitin-conjugatmg enzyme E2 1266 25 1300 117373 1247427 -1 09E-01 405E-02 2 Unchanged Medium
P47986 011cd3 ubiquilin-con-ugatiπg enzyme E2 6163689 520 567 7317 5678765 -1 19E-01 -247E 01 2 Unchanged Medium 014933 H14cd4 ublquitlπ-conjugatlng enzyme E2 717 4244 893 5966415 7356835 -2 66E-01 3 16E-01 2 Unchanged Medium
Q16781 D07cd4 ubiquitin-conjugatmg enzyme E2 9236537 816 5337389 757964 -791 E-01 -1 78E-01 2 Unchanged Medium
Q93068 A02cd3 ubiqultm-like 1 (sentπn) 1376087 1530 1294307 139948 -8 84E-02 1 51E 01 2 Unchanged Medium
Q15386 I10gh1 ubiquitin-protein isopeptide ligas 531 8659 630 6282454 5968686 240E-01 245E-01 2 Unchanged Medium
Q9UBK9 I15cd4 ubiquitously-expressed traπscπpl 9362619 1060 1384764 1125743 565E-01 1 74E-01 2 Unchanged Medium
060512 E11ab3 UDP-Gal betaGlcNAc beta 1 ,4- ς 4367634 610 54239 5295839 3 12E-01 481 E-01 2 Unchanged Medium
P78383 P20cd5 UDP-galactose transporter relate 1570 135 1700 2180 117 1816963 474E-01 1 15E-01 2 Unchanged Medium
Q16851 I24cd4 UDP-glucose pyrophosphorylase 1324 08 1260 131878 1302468 -579E-03 -664E-02 2 Unchanged Medium
Q9NZ45 L02gh3 uncharactenzed hematopoietic si 6520685 670 6965692 6729895 952E-02 398E-02 2 Unchanged Medium
Q9NZ32 L20gh4 uncharactenzed hypothala us p 1035575 1250 1354231 1214412 3 87E-01 275E-01 2 Unchanged Medium
Q9NZ29 L16gh4 uncharactenzed hypothalamus p 659 53 992 1118776 923 518 762E-01 5 89E-01 2 Unchanged Medium
Q15853 C02cd3 upstream transcnption factor 2, c 601 6839 635 6980128 6449023 2 14E-01 778E-02 2 Unchanged Medium
Q92528 D02ef7 undine monophosphate kinase 5603976 685 6235243 6230076 1 54E-01 290E-01 2 Unchanged Medium
P15692 M04ef7 vascular endothelial growth facto 4609257 539 8573853 619202 895E-01 227E-01 2 Unchanged Medium
P50552 C08cd3 vasodilator-stimulated phosphopi 4684573 648 392 5569 5029122 -2 55E-01 4 67E-01 2 Unchanged Medium
060763 H16cd3 vesicle docking protein p115 639538 543 7454806 6427624 221 E-01 -2 35E-01 2 Unchanged Medium
Q15836 A15ef5 vesicle-associated membrane pn 8042648 1370 1060211 1076578 399E-01 7 63E-01 2 Unchanged Medium
Q9UEU0 022cd6 vesicle-associated soluble NSF i 4686024 697 6983534 621 1953 576E-01 572E-01 2 Unchanged Medium
P14921 E24ef5 v-ets erythroblastosis virus E26 c 913 893 765 291 1538 656 6528 -1 65E+00 -2 57E-01 2 Unchanged Medium
P18206 C14cd3 vinculin 580 3315 857 8657505 7675496 577E-01 562E-01 2 Unchanged Medium
P00540 G08ef5 v-mos Moloney muπne sarcoma 1115 145 728 6636747 8355051 -749E-01 -6 16E-01 2 Unchanged Medium
P01106 E18ef5 v-myc myelocytomatosis viral oni 537 8131 601 405 1047 5147639 -409E-01 1 61E-01 2 Unchanged Medium
P21796 C16cd3 voltage-dependent anion channe 483 8969 510 584201 5259036 272E-01 7 47E-02 2 Unchanged Medium
Q15765 C12cd3 von Hippel-Lmdau binding protei 689743 705 891 2621 7620788 370E-01 3 20E-02 2 Unchanged Medium
P10398 D01ab4 v-raf murine sarcoma 3611 viral i 1061 812 639 5322153 7444583 -996E-01 -7 32E-01 2 Unchanged Medium
P11233 A19ef6 v-ral simian leukemia viral oncog 8487099 1060 1081 428 958044 350E-01 3 17E-01 2 Unchanged Medium
Q9Y6W5 A22gh1 WAS protein family member 2 1283 077 1630 1493 145 1468514 2 19E-01 345E-01 2 Unchanged Medium
Q9UPY6 L06cd6 WAS protein family member 3 1503 584 1210 2151 643 1623 108 5 17E-01 -309E-01 2 Unchanged Medium
075083 D15cd5 WD repeat domain 1 892 4425 977 9633448 944 1492 1 10E-01 1 30E-01 2 Unchanged Medium
076071 A24cd5 WD40 protein Ciaol 609 8821 898 730 5311 746 1814 260E-01 5 58E-01 2 Unchanged Medium
Q9HCN4 H11gh6 XPA binding protein 1 , putative /> 119921 1070 5073277 923 9753 -1 24E+00 -1 71E 01 2 Unchanged Medium
Q9UM05 N17ef3 yeast Sec31p homolog 1887 447 1590 1542778 1672 59 -291 E-01 -250E-01 2 Unchanged Medium
Q9UQR1 P06gh1 zinc finger protein 148 (pHZ-52) 513 8639 737 5637625 6049201 1 34E-01 521E 01 2 Unchanged Medium
Q14119 G21ef5 zinc finger protein 161 1199 558 1760 1197 34 1387253 -2 67E-03 557E-01 2 Unchanged Medium
Q9NW07 F06gh2 zinc finger protein 358 4028342 575 6847069 5543431 765E-01 5 15E-01 2 Unchanged Medium
P20694 D04efβ zinc finger protein 9 (a cellular re 104265 1010 8565924 969 9823 -2 B4E-01 -4 49E-02 2 Unchanged Medium

Claims

WHAT IS CLAIMED IS;
1. A method for expanding mammalian acinar cells, comprising culturing said cells in a cell culture system comprising a cell culture medium and a cell attachment surface, under conditions wherein said acinar cells undergo a 3-4 fold expansion together with transdifferentiation into a modified cell phenotype (IP cells) showing characteristics of acinar cells and liver cells.
2. The method of claim 1, wherein said cells having a modified phenotype express cytokeratin 18 (CK18), CK8, CK19, CK7, HNF1, alpha-1 antitrypsin, pi- glutathione s transferase (pi-GST), liver-specific bHLH transcription factor, Thy- 1, C/EBP-alpha and C/EBP -beta, and express little if any carbonic anhydrase, cystic fibrosis transmembrane conductance regulator (CFTR), elastase and amylase.
3. The method of claim 1, wherein said culture medium comprises insulin, transferrin, selenium and epidermal growth factor (EGF) in a base medium suitable for maintaining epithelial cells.
4. The method of claim 1, wherein said culture medium comprises serum.
5. The method of claim 4, wherein said culture medium comprises up to 15% serum.
6. The method of claim 1 , wherein said culture medium is serum-free.
7. The method of claim 1, wherein said cell culture medium comprises an effective amount of at least one soluble active factor that promotes growth expansion and transdifferentiation of acinar cells to IP cells.
8. The method of claim 7, wherein said culture medium comprises an effective amount of at least one factor selected from the group consisting of heat inactivated bovine serum albumin (BSA) and the soluble active factors hepatocyte growth factor (HGF), insulin-like growth factor- 1 (IGF-1), transforming growth factor alpha (TGF-α), betacellulin, gastrin I and prolactin.
9. The method of claim 1, wherein said culture medium comprises an effective amount of at least one soluble active factor selected from the group consisting of HGF, betacellulin and prolactin.
10. The method of claim 1, wherein said cell attachment surface comprises one or more extracellular matrix molecules.
11. The method of claim 10, wherein said cell attachment surface comprises one or more extracellular matrix molecules selected from the group consisting of Collagen I, Collagen NI, Collagen IN, Vitronectin and Fibronectin.
12. The method of claim 1, wherein the cells are seeded at a density of 10 - 10 cells/cm2.
13. The method of claim 1 , wherein the cells are cultured for a period of 4-8 days.
14. The method of claim 1, wherein the acinar cells are human acinar cells.
15. The method of claim 1 wherein the acinar cells undergo transdifferentiation from an amylase-l- acinar phenotype to an amylase+/CK19+ mixed acinar/liver-specific phenotype.
16. A culture medium comprising a base medium suitable for maintaining mammalian epithelial cells that includes insulin, transferrin, selenium and EGF, wherein cultivation of human acinar cells in said medium under suitable conditions for 4-8 days results in expansion of said cells by 3-4 fold and transdifferentiation into a modified cell phenotype showing characteristics of acinar and liver cells.
17. The culture medium of claim 16, wherein the base medium comprises DMEM, Hams F12, MEM, M-199, or RPMI, or a combination thereof.
18. The culture medium of claim 17, wherein the base medium comprises 4 mM glutamine and a 1:1 mixture of DMEM and Hams 12.
19. The culture medium of claim 16, which additionally comprises serum.
20. The culture medium of claim 19, which additionally comprises up to 15% serum.
21. The culture medium of claim 16, which is serum-free.
22. The cell culture medium of claim 16, which comprises about 0.1-10 μg/ ml insulin, about 0.5-10 μg/ml transferrin, about 0.25 -5.0 ng/ml selenium, and about 1-20 ng/1 EGF.
23. The cell culture medium of claim 16, which additionally comprises an effective amount of at least one soluble active factor that promotes expansion and transdifferentiation of acinar cells into IP cells.
24. The cell culture medium of claim 16, which additionally comprises an effective amount of at least one factor selected from the group consisting of heat- inactivated BSA and the soluble active factors albumin, HGF, IGF-1, TGF-α, betacellulin, gastrin I and prolactin.
25. The cell culture medium of claim 24, wherein the concentration of BSA is 0.1- 2%, the concentration of HGF is 1-20 ng/ml, the concentration of IGF-1 is 0.5-50 ng/ml, the concentration of TGF-α is 1-10 ng/ml, the concentration of betacellulin is 0.0005-0.1 ug/ml , the concentration of gastrin I is 1-100 pg/ml, and the concentration of prolactin is 1-10 ng/ml.
26. The cell culture medium of claim 24, which comprises an effective amount of at least one soluble active factor selected from the group consisting of HGF, betacellulin and prolactin.
27. A cell culture system, which comprises the cell culture medium of claim 16 and a cell attachment surface.
28. The cell culture system of claim 27, wherein the cell attachment surface comprises a composition selected from the group consisting of collagen I, collagen VI, collagen IV, vitronectin and fibronectin.
29. An isolated mammalian cell having a phenotype comprising both acinar and liver- associated markers.
30. The isolated cell of claim 29 that expresses least one marker selected from the group consisting of CK18, CK8, CK19, CK7, HNF1, alpha-1 antitrypsin, pi- glutathione s transferase (pi-GST), liver-specific bHLH transcription factor, Thy- 1, C/EBP-alpha and C/EBP -beta; and that expresses little or none of the following markers: carbonic anhydrase, cystic fibrosis transmembrane conductance regulator (CFTR), elastase and amylase.
31. The isolated cell of claim 29 that expresses CK18, CK8, CK19, CK7, HNF1, alpha-1 antitrypsin, pi-glutathione s transferase (pi-GST), liver-specific bHLH transcription factor, Thy-1, C/EBP-alpha and C/EBP -beta.
32. The isolated cell of claim 29 that is derived from a primary culture of pancreatic acinar cells.
33. The isolated cell of claim 29 that is human.
34. The isolated cell of claim 29 having an expression profile after 8 days ex vivo as shown in Table 6.
35. An isolated cell prepared by the method of claim 1.
36. A kit suitable for expanding mammalian acinar cells, comprising a) a base medium suitable for the cultivation of mammalian epithelial cells, b) a collagen I coated culture substrate, and, separately packaged, c) a serum-free medium supplement containing one or more component selected from the group consisting of BSA, HGF, EGF, TGFA, betacellulin, gastrin I and IGF-1.
37. The kit of claim 36, wherein the serum-free medium supplement contains components in as suitable ratio for producing a medium containing 0.1-2% BSA, 1-20 ng/ml HGF, 1-20 ng/ml EGF, 1-10 ng/ml TGFA, 0.0005-0.10 ug/ml betacellulin, 1.0-100 pg/mL gastrinl, and 0.5-50 ng/mL IGFl, by the addition of a predetermined amount of base medium.
38. The kit of claim 36 wherein the cell culture substrate is on the surface of a flask, bottle, petri dish, plate or well, or is part of a scaffold, suitable for cell culture.
39. A method for transforming IP cells that express markers of acinar cells and liver- associated genes into insulin-producing cells in vitro, comprising culturing said IP cells in a cell culture medium comprising an effective amount of at least one differentiation promoting factor selected from the group consisting of Activin A, acidic FGF, basic FGF, C-Natriuretic Peptide (CNP), Calcitonin Gene Related Peptide, Cholera Toxin B Subunit, Dexamethasone, Gastrin-Releasing Peptide, Glucagon-like Peptide- 1 (GLP-1), Glucose, IGFl, IGF2, Insulin, Laminin, LIF, Met-Enkephalin, PDGFAA+PDGFBB, Prolactin, Sonic Hedgehog, Substance P, TGF-alpha, Trolox (alpha-tocopherol derivative), and VEGF, such that the IP cells are transformed into insulin-producing cells.
40. The method of claim 39, wherein the IP cells are derived from a culture of pancreatic acinar cells.
41. The method of claim 40, wherein the cells are human.
42. The method of claim 39, further comprising contacting said cells with a substrate that is coated with one or more extracellular matrix molecules.
43. The method of claim 42, wherein the extracellular matrix molecules are collagen I, collagen VI, collagen IV, vitronectin, and/or fibronectin.
44. The method of claim 42, wherein the substrate is on the surface of a flask, petri dish, plate, well or roller bottle, or is part of a scaffold.
45. The method of claim 39, wherein the medium is serum-free.
46. The method of claim 39, wherein the medium comprises serum.
47. The method of claim 46, wherein the medium comprises BSA, insulin, transferrin, selenium and epidermal growth factor (EGF).
48. The method of claim 39, wherein the cells are seeded on the substrate at a density of 5xl03 to 20xl05 cells/cm2.
49. An isolated insulin-producing cell generated by the method of claim 39.
50. An insulin-producing cell, prepared by differentiating a mammalian acinar cell in vitro, wherein said insulin-producing cell has an expression profile after 16 days ex vivo as shown in Table 6.
51. A serum-free medium comprising at least one active factor selected from the group consisting of Activin A, acidic FGF, basic FGF, C-Natriuretic Peptide (CNP), Calcitonin Gene Related Peptide, Cholera Toxin B Subunit, Dexamethasone, Gastrin-Releasing Peptide, Glucagon-like Peptide- 1 (GLP-1), Glucose, IGFl, IGF2, Insulin, Laminin, LIF, Met-Enkephalin, PDGFAA+PDGFBB, Prolactin, Sonic Hedgehog, Substance P, TGF-alpha, Trolox (alpha-tocopherol derivative), and VEGF, wherein said medium facilitates differentiation of IP cells into insulin-producing cells.
52. A serum-free medium comprising a 1 : 1 mixture of DMEM and Hams F12 plus the components listed in Table 2.
53. A kit suitable for differentiating IP cells to insulin-producing cells, comprising a) a base medium suitable for the cultivation of mammalian epithelial cells; b) a collagen I coated culture substrate, and, separately packaged, c) a serum-free medium supplement containing BSA, Activin A, acidic FGF, basic FGF, C-Natriuretic Peptide (CNP), Calcitonin Gene Related Peptide, Cholera Toxin B Subunit, Dexamethasone, Gastrin-Releasing Peptide, Glucagon- like Peptide-1 (GLP-1), Glucose, IGFl, IGF2, Insulin, Laminin, LIF, Met- Enkephalin, PDGFAA+PDGFBB, Prolactin, Sonic Hedgehog, Substance P, TGF- alpha, Trolox (alpha-tocopherol derivative), or VEGF, or two or more of these components in combination, in suitable amounts to yield final concentrations in the completed medium as indicated in Table 1 herein.
54. The kit of claim 53, wherein the cell culture substrate is contained on the surface of a flask, bottle, petri dish, plate or well suitable for cell culture.
55. A method for obtaining insulin-producing cells through culture and manipulation of pancreatic acinar cells in vitro comprising the steps of i) culturing pancreatic acinar cells in a cell culture system comprising a culture medium and a cell attachment surface, under conditions wherein said acinar cells undergo a 3-4 fold expansion together with transdifferentiation into partially differentiated IP cells that express cytokeratin 18 (CK18), CK8, CK19, CK7, HNF1, alpha-1 antitrypsin, pi-glutathione s transferase (pi-GST), liver-specific bHLH transcription factor, Thy-1, C/EBP-alpha and C/EBP-beta; and that express little if any of carbonic anhydrase, cystic fibrosis transmembrane conductance regulator (CFTR), elastase and amylase; and ii) culturing said IP cells in a cell culture system comprising a cell culture medium and a substrate, said culture medium comprising an effective amount of at least one differentiation promoting factor selected from the group consisting of Activin A, acidic FGF, basic FGF, C-Natriuretic Peptide (CNP), Calcitonin Gene Related Peptide, Cholera Toxin B Subunit, Dexamethasone, Gastrin-Releasing Peptide, Glucagon-like Peptide-1 (GLP-1), Glucose, IGFl, IGF2, Insulin, Laminin, LIF, Met-Enkephalin, PDGFAA+PDGFBB, Prolactin, Sonic Hedgehog, Substance P, TGF-alpha, Trolox (alpha-tocopherol derivative), and VEGF; such that the DP cells are transformed into insulin-producing cells.
56. The method of claim 55, wherein said insulin-producing cells release c-peptide and/or insulin in response to exposure to glucose.
57. The method of claim 55, wherein the medium of step i) comprises an HGF receptor activator and an EGF receptor activator.
58. The method of claim 55, wherein the medium of step ii) comprises an effective amount of at least one soluble active factor selected from the group consisting of C-Natriuretic Peptide (CNP), Calcitonin Gene Related Peptide, Cholera Toxin B Subunit, Dexamethasone, Gastrin-Releasing Peptide, Laminin, Met-Enkephalin, PDGFAA+PDGFBB, Sonic Hedgehog, and Substance P.
59. A method of obtaining insulin-producing cells, said method comprising culturing primary pancreatic cells in a two phase culture system whereby, in the first phase, the cells are cultured on a surface comprising an effective amount of at least one ECM in a medium comprising at least one active soluble factor selected from the group consisting of HGF, TGFα, EGF, IGFl, betacellulin, prolactin and gastrin 1 for 4-10 days; and in a second phase, the cells are cultured on a surface comprising at least one ECM in a medium comprising an effective amount of at least one differentiation promoting factor selected from the group consisting of Activin A, CGRP alpha, C naturiuretic peptide (CNP), Cholera Toxin B Subunit, Dexamethasone, aFGF, Glucagon-Like Peptide-1 (GLP-1), Glucose, Insulin, LIF, PDGFAA, PDGFBB, TGF-alpha, Prolactin, Trolox (Vitamin E), Gastrin Releasing Peptide (GRP), IGF-1, IGF-2, Laminin, Met- Enkephalin, Sonic hedgehog, Substance P, bFGF, and VEGF for 3-14 days to obtain insulin producing cells.
60. A primary culture of insulin-producing cells derived from glandular epithelial cells that expressed at least one marker selected from the group consisting of : cytokeratin 18 (CK18), CK8, CK19, CK7, HNF1, alpha-1 antitrypsin, pi-glutathione s transferase (pi- GST), liver-specific bHLH transcription factor, Thy-1, C/EBP-alpha and C/EBP-beta; and that expressed little if any of the markers carbonic anhydrase, cystic fibrosis transmembrane conductance regulator (CFTR), elastase and amylase, said insulin- producing cells having the characteristics of forming three-dimensional cell clusters that contain proinsulin and/or insulin and/or c-peptide.
61. The culture of claim 60 wherein the glandular epithelial cells are pancreatic cells.
62. The culture of claim 60 wherein the culture releases insulin and/or c-peptide in response to a glucose challenge.
63. The culture of claim 60, wherein the glandular epithelial cells are human.
PCT/US2003/016124 2002-05-28 2003-05-22 Pancreatic acinar cells into insulin producing cells WO2003102134A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2003228255A AU2003228255A1 (en) 2002-05-28 2003-05-22 Pancreatic acinar cells into insulin-producing cells
BR0311413A BR0311413A (en) 2002-05-28 2003-05-22 Development and transdifferentiation of human acinar cells
BR0311360A BR0311360A (en) 2002-05-28 2003-05-22 methods for in vitro expansion and transdifferentiation of human pancreatic acinar cells into insulin producing cells
US10/515,421 US20060122104A1 (en) 2002-05-28 2003-05-22 Methods for in vitro expansion and transdifferentiation of human pancreatic acinar cells into insulin-producing cells
EP03726954A EP1578925A4 (en) 2002-05-28 2003-05-22 Methods for in vitro expansion and transdifferentiation of human pancreatic acinar cells into insulin-producing cells
JP2004510376A JP2006512046A (en) 2002-05-28 2003-05-22 Methods for proliferation of human pancreatic acinar cells and transdifferentiation into insulin producing cells in vitro
CA 2487094 CA2487094A1 (en) 2002-05-28 2003-05-22 Methods for in vitro expansion and transdifferentiation of human pancreatic acinar cells into insulin-producing cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38400002P 2002-05-28 2002-05-28
US60/384,000 2002-05-28

Publications (2)

Publication Number Publication Date
WO2003102134A2 true WO2003102134A2 (en) 2003-12-11
WO2003102134A3 WO2003102134A3 (en) 2005-12-01

Family

ID=29584613

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2003/016124 WO2003102134A2 (en) 2002-05-28 2003-05-22 Pancreatic acinar cells into insulin producing cells
PCT/US2003/016096 WO2003102171A1 (en) 2002-05-28 2003-05-22 Expansion and transdifferentiation of human acinar cells
PCT/US2003/016713 WO2003100038A1 (en) 2002-05-28 2003-05-28 Methods and compositions for expanding and differentiating insulin-producing cells

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/US2003/016096 WO2003102171A1 (en) 2002-05-28 2003-05-22 Expansion and transdifferentiation of human acinar cells
PCT/US2003/016713 WO2003100038A1 (en) 2002-05-28 2003-05-28 Methods and compositions for expanding and differentiating insulin-producing cells

Country Status (8)

Country Link
US (5) US20060122104A1 (en)
EP (3) EP1578925A4 (en)
JP (2) JP2006512046A (en)
CN (2) CN1662643A (en)
AU (3) AU2003228255A1 (en)
BR (2) BR0311360A (en)
CA (2) CA2487094A1 (en)
WO (3) WO2003102134A2 (en)

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012508A1 (en) * 2003-07-28 2005-02-10 Queensland University Of Technology Skin regeneration system
WO2005118781A1 (en) * 2004-06-03 2005-12-15 Kyoto University Induction of insulin secreting cell
AU2004260815B2 (en) * 2003-07-28 2010-05-20 Queensland University Of Technology Skin regeneration system
US7875273B2 (en) 2004-12-23 2011-01-25 Ethicon, Incorporated Treatment of Parkinson's disease and related disorders using postpartum derived cells
US7875272B2 (en) 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
EP2302036A2 (en) 2005-05-27 2011-03-30 Lifescan, Inc. Amniotic fluid derived cells
US7939322B2 (en) 2008-04-24 2011-05-10 Centocor Ortho Biotech Inc. Cells expressing pluripotency markers and expressing markers characteristic of the definitive endoderm
US8318483B2 (en) 2003-06-27 2012-11-27 Advanced Technologies And Regenerative Medicine, Llc Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
EP2584034A1 (en) 2007-07-31 2013-04-24 Lifescan, Inc. Pluripotent stem cell differentiation by using human feeder cells
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
US8778673B2 (en) 2004-12-17 2014-07-15 Lifescan, Inc. Seeding cells on porous supports
US8785185B2 (en) 2009-07-20 2014-07-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US8785184B2 (en) 2009-07-20 2014-07-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US9012218B2 (en) 2008-10-31 2015-04-21 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US9062290B2 (en) 2007-11-27 2015-06-23 Lifescan, Inc. Differentiation of human embryonic stem cells
US9074189B2 (en) 2005-06-08 2015-07-07 Janssen Biotech, Inc. Cellular therapy for ocular degeneration
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
US9096832B2 (en) 2007-07-31 2015-08-04 Lifescan, Inc. Differentiation of human embryonic stem cells
US9133439B2 (en) 2009-12-23 2015-09-15 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US9150833B2 (en) 2009-12-23 2015-10-06 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US9175261B2 (en) 2005-12-16 2015-11-03 DePuy Synthes Products, Inc. Human umbilical cord tissue cells for inhibiting adverse immune response in histocompatibility-mismatched transplantation
US9181528B2 (en) 2010-08-31 2015-11-10 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
US9234178B2 (en) 2008-10-31 2016-01-12 Janssen Biotech, Inc. Differentiation of human pluripotent stem cells
US9434920B2 (en) 2012-03-07 2016-09-06 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
US9506036B2 (en) 2010-08-31 2016-11-29 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US9528090B2 (en) 2010-08-31 2016-12-27 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US9593305B2 (en) 2008-06-30 2017-03-14 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
US9611513B2 (en) 2011-12-23 2017-04-04 DePuy Synthes Products, Inc. Detection of human umbilical cord tissue derived cells
US9752125B2 (en) 2010-05-12 2017-09-05 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US9943552B2 (en) 2009-03-26 2018-04-17 DePuy Synthes Products, Inc. hUTC as therapy for Alzheimer's disease
US9969972B2 (en) 2008-11-20 2018-05-15 Janssen Biotech, Inc. Pluripotent stem cell culture on micro-carriers
US9969973B2 (en) 2008-11-20 2018-05-15 Janssen Biotech, Inc. Methods and compositions for cell attachment and cultivation on planar substrates
US9969981B2 (en) 2010-03-01 2018-05-15 Janssen Biotech, Inc. Methods for purifying cells derived from pluripotent stem cells
US10006006B2 (en) 2014-05-16 2018-06-26 Janssen Biotech, Inc. Use of small molecules to enhance MAFA expression in pancreatic endocrine cells
US10066203B2 (en) 2008-02-21 2018-09-04 Janssen Biotech Inc. Methods, surface modified plates and compositions for cell attachment, cultivation and detachment
US10066210B2 (en) 2012-06-08 2018-09-04 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
US10076544B2 (en) 2009-07-20 2018-09-18 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US10138465B2 (en) 2012-12-31 2018-11-27 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells using HB9 regulators
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
US10344264B2 (en) 2012-12-31 2019-07-09 Janssen Biotech, Inc. Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
US10358628B2 (en) 2011-12-22 2019-07-23 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into single hormonal insulin positive cells
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
US10377989B2 (en) 2012-12-31 2019-08-13 Janssen Biotech, Inc. Methods for suspension cultures of human pluripotent stem cells
US10420803B2 (en) 2016-04-14 2019-09-24 Janssen Biotech, Inc. Differentiation of pluripotent stem cells to intestinal midgut endoderm cells
KR20190112090A (en) * 2017-01-31 2019-10-02 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 Control of Differentiation of Pluripotent Stem Cells
US10557116B2 (en) 2008-12-19 2020-02-11 DePuy Synthes Products, Inc. Treatment of lung and pulmonary diseases and disorders
US10744164B2 (en) 2003-06-27 2020-08-18 DePuy Synthes Products, Inc. Repair and regeneration of ocular tissue using postpartum-derived cells

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2415432B (en) * 2001-12-07 2006-09-06 Geron Corp Islet cells from human embryonic stem cells
WO2003102134A2 (en) * 2002-05-28 2003-12-11 Becton, Dickinson And Company Pancreatic acinar cells into insulin producing cells
EP1636348B1 (en) * 2003-06-20 2009-07-29 Vrije Universiteit Brussel VUB Method of generating islet beta-cells from exocrine pancreatic cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US7985585B2 (en) 2004-07-09 2011-07-26 Viacyte, Inc. Preprimitive streak and mesendoderm cells
DK1709159T3 (en) * 2003-12-23 2019-07-29 Viacyte Inc DEFINITIVE ENDODERM
US8586357B2 (en) * 2003-12-23 2013-11-19 Viacyte, Inc. Markers of definitive endoderm
US7625753B2 (en) * 2003-12-23 2009-12-01 Cythera, Inc. Expansion of definitive endoderm cells
US8647873B2 (en) 2004-04-27 2014-02-11 Viacyte, Inc. PDX1 expressing endoderm
US7541185B2 (en) * 2003-12-23 2009-06-02 Cythera, Inc. Methods for identifying factors for differentiating definitive endoderm
US20050266554A1 (en) * 2004-04-27 2005-12-01 D Amour Kevin A PDX1 expressing endoderm
US8187878B2 (en) * 2004-08-13 2012-05-29 University Of Georgia Research Foundation, Inc. Methods for increasing definitive endoderm differentiation of pluripotent human embryonic stem cells with PI-3 kinase inhibitors
US8039254B2 (en) * 2004-11-22 2011-10-18 Ramot At Tel-Aviv University Ltd. Populations of expanded and re-differentiated adult islet beta cells capable of producing insulin and methods of generating same
JP5584875B2 (en) * 2005-04-13 2014-09-10 国立大学法人 千葉大学 Method for producing adult pancreatic stem cell
US9487755B2 (en) * 2005-10-06 2016-11-08 David Moscatello Cell culture media, kits and methods of use
DK2674485T3 (en) 2005-10-27 2019-08-26 Viacyte Inc PDX-1 EXPRESSING DORSAL AND VENTRAL FORTARM ENDODERM
EP2314670B1 (en) * 2005-11-18 2018-10-31 Lifescan, Inc. A method for creating pancreatic cell clusters
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
EP2650360B1 (en) * 2006-03-02 2019-07-24 Viacyte, Inc. Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
US7695965B2 (en) * 2006-03-02 2010-04-13 Cythera, Inc. Methods of producing pancreatic hormones
US11254916B2 (en) 2006-03-02 2022-02-22 Viacyte, Inc. Methods of making and using PDX1-positive pancreatic endoderm cells
US8415153B2 (en) 2006-06-19 2013-04-09 Geron Corporation Differentiation and enrichment of islet-like cells from human pluripotent stem cells
US20090286317A1 (en) * 2006-09-14 2009-11-19 Probiogen Ag Modular culture system for maintenance, differentiation and proliferation of cells
WO2008048647A1 (en) * 2006-10-17 2008-04-24 Cythera, Inc. Modulation of the phosphatidylinositol-3-kinase pathway in the differentiation of human embryonic stem cells
WO2008124169A2 (en) * 2007-04-10 2008-10-16 The Trustees Of The University Of Pennsylvania Islet cells composition and methods
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
US7846974B2 (en) * 2007-10-24 2010-12-07 National University Corporation Gunma University Method of lowering blood glucose and method of treating diabetes and obesity
KR20090051695A (en) * 2007-11-19 2009-05-22 배용석 Method of differentiation into cells producing insulin from islet-neighboring cell
US8728812B2 (en) * 2008-04-22 2014-05-20 President And Fellows Of Harvard College Compositions and methods for promoting the generation of PDX1+ pancreatic cells
EA020490B1 (en) * 2008-08-30 2014-11-28 Тарганта Терапьютикс Корп. Method of treatment of bacterial infection
JP5307489B2 (en) * 2008-09-19 2013-10-02 株式会社クラレ Method for producing three-dimensional cell structure
EP2356227B1 (en) 2008-11-14 2018-03-28 Viacyte, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells
IL196820A0 (en) 2009-02-01 2009-11-18 Yissum Res Dev Co Devitalized, acellular scaffold matrices derived from micro-organs seeded with various cells
US9328331B2 (en) * 2009-05-21 2016-05-03 Joslin Diabetes Center, Inc. Compositions and methods for promoting beta cell maturity
CN101880648B (en) * 2010-06-25 2012-10-03 广东药学院 Primary culture method for pancreas acinar cells
US9404087B2 (en) * 2010-12-15 2016-08-02 Kadimastem Ltd. Insulin producing cells derived from pluripotent stem cells
US20140242038A1 (en) * 2011-10-11 2014-08-28 The Trustees Of Columbia University In The City Of New York Method for generating beta cells
KR20140099269A (en) * 2011-11-11 2014-08-11 이센셜 파마수티컬스 엘엘씨 Kit comprising serum replacement and labile factors
MX2015017103A (en) 2013-06-11 2016-11-07 Harvard College Sc-î² cells and compositions and methods for generating the same.
CA2915143C (en) 2013-06-13 2021-08-03 Orgenesis Ltd. Cell populations, methods of transdifferentiation and methods of use thereof
WO2016100930A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Methods for generating stem cell-derived b cells and methods of use thereof
US10190096B2 (en) 2014-12-18 2019-01-29 President And Fellows Of Harvard College Methods for generating stem cell-derived β cells and uses thereof
US10443042B2 (en) 2014-12-18 2019-10-15 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived beta cells and uses thereof
CN104593399A (en) * 2014-12-22 2015-05-06 广西大学 Process for synthesizing transgenic insulin
MA41296A (en) 2014-12-30 2017-11-07 Orgenesis Ltd TRANSDIFFERENTIATION PROCESSES AND METHODS FOR USING THE SAME
CN106680510B (en) * 2016-12-27 2018-02-27 中南大学湘雅医院 Application of Myoferlin and specific antibody thereof in preparation of kit for detecting nasopharyngeal carcinoma
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
EP3635106A4 (en) 2017-05-08 2021-01-06 Orgenesis Ltd. Transdifferentiated cell populations and methods of use thereof
CN107034177B (en) * 2017-06-02 2021-01-19 北京市农林科学院 Bovine vacuolar membrane cell in-vitro culture regulator and application thereof
EP3694985A1 (en) 2017-10-13 2020-08-19 IMBA-Institut für Molekulare Biotechnologie GmbH Enhanced reprogramming of somatic cells
BR112020009275A2 (en) 2017-11-15 2020-10-27 Semma Therapeutics, Inc. islet cell manufacturing compositions and methods of use
EP3833365A4 (en) 2018-08-10 2022-05-11 Vertex Pharmaceuticals Incorporated Stem cell derived islet differentiation
CN110579457B (en) * 2019-09-20 2021-11-02 郑州大学第一附属医院 Vimentin specific responsiveness fluorescent probe and preparation method and application thereof
CN112956453B (en) * 2021-04-07 2022-10-11 华北理工大学 Method for establishing drosophila melanogaster insulin antidiabetic model
CN113341152B (en) * 2021-04-27 2022-04-26 华南农业大学 Application of RPS9 protein in prediction of good response of crab eating monkey to superovulation
US11735303B2 (en) 2021-06-22 2023-08-22 David Haase Apparatus and method for determining a composition of a replacement therapy treatment
CN114250194B (en) * 2021-11-30 2023-04-11 四川大学华西医院 Construction method and application of acute pancreatitis cell model
WO2023123299A1 (en) * 2021-12-31 2023-07-06 Beijing Theraxyte Bioscience Co., Ltd. Compositions and methods for culturing stem cells
CN115282065B (en) * 2022-08-11 2024-03-15 顾帅 Freeze-dried powder containing mesenchymal stem cell exosomes and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127406A1 (en) * 2002-05-28 2004-07-01 Presnell Sharon C. Methods for in vitro expansion and transdifferentiation of human pancreatic acinar cells into insulin-producing cells

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4332893A (en) * 1980-06-13 1982-06-01 Rosenberg Ralph A Process for the production of an insulin-producing cell line of pancreatic beta cells
DE3801236A1 (en) * 1988-01-18 1989-07-27 Boehringer Mannheim Gmbh PENTOSANE SULFATE MEDIUM
US6001647A (en) * 1994-04-28 1999-12-14 Ixion Biotechnology, Inc. In vitro growth of functional islets of Langerhans and in vivo uses thereof
US5834308A (en) * 1994-04-28 1998-11-10 University Of Florida Research Foundation, Inc. In vitro growth of functional islets of Langerhans
US6043092A (en) * 1996-03-18 2000-03-28 University Of Pittsburgh Cell culture media for mammalian cells
US5935852A (en) * 1997-07-03 1999-08-10 Genetics Institute, Inc. DNA molecules encoding mammalian cerberus-like proteins
ES2335066T3 (en) * 1998-08-10 2010-03-18 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services DIFFERENTIATION OF NON-INSULIN CELL PRODUCTS IN GLP-1 OR EXENDIN-4 INSULIN CELLS AND USING THEMSELVES.
US6242666B1 (en) * 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
US6946293B1 (en) * 1999-02-10 2005-09-20 Es Cell International Pte Ltd. Progenitor cells, methods and uses related thereto
IL144654A0 (en) * 1999-02-10 2002-05-23 Curis Inc Pancreatic progenitor cells, methods and uses related thereto
US6362201B1 (en) * 1999-03-02 2002-03-26 Merck & Co., Inc. 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity
US6967019B2 (en) * 1999-04-06 2005-11-22 The Regents Of The University Of California Production of pancreatic islet cells and delivery of insulin
US6815203B1 (en) * 1999-06-23 2004-11-09 Joslin Diabetes Center, Inc. Methods of making pancreatic islet cells
JP2003513624A (en) * 1999-10-29 2003-04-15 マクギル・ユニヴァーシティ Medium for preparing dedifferentiated cells
US6382201B1 (en) * 1999-11-17 2002-05-07 Mathew A. McPherson Bow vibration damper
US6610535B1 (en) * 2000-02-10 2003-08-26 Es Cell International Pte Ltd. Progenitor cells and methods and uses related thereto
AU3350201A (en) * 2000-02-18 2001-08-27 Inst Medical W & E Hall Pancreatic islet cell growth factors
US6436704B1 (en) * 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
US6759039B2 (en) * 2000-06-30 2004-07-06 Amcyte, Inc. Culturing pancreatic stem cells having a specified, intermediate stage of development
FR2814752A1 (en) * 2000-10-02 2002-04-05 Chru Lille METHOD FOR OBTAINING IN VITRO INSULIN-SECRETORY MAMMAL CELLS AND USES THEREOF
US6642003B2 (en) * 2001-08-02 2003-11-04 Cedars-Sinai Medical Center Human glucose-dependent insulin-secreting cell line
US7524492B2 (en) * 2001-08-31 2009-04-28 Joslin Diabetes Center, Inc. Insulin related transcription factor and uses thereof
WO2003033697A1 (en) * 2001-10-18 2003-04-24 Ixion Biotechnology, Inc. Conversion of liver stem and progenitor cells to pancreatic functional cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127406A1 (en) * 2002-05-28 2004-07-01 Presnell Sharon C. Methods for in vitro expansion and transdifferentiation of human pancreatic acinar cells into insulin-producing cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1578925A2 *

Cited By (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11191789B2 (en) 2003-06-27 2021-12-07 DePuy Synthes Products, Inc. Cartilage and bone repair and regeneration using postpartum-derived cells
US11179422B2 (en) 2003-06-27 2021-11-23 DePuy Synthes Products, Inc. Method of differentiating umbilical cord tissue into a chondrogenic phenotype
US10220059B2 (en) 2003-06-27 2019-03-05 DePuy Synthes Products, Inc. Postpartum cells derived from placental tissue, and methods of making and using the same
US10039793B2 (en) 2003-06-27 2018-08-07 DePuy Synthes Products, Inc. Soft tissue repair and regeneration using postpartum-derived cells and cell products
US10758576B2 (en) 2003-06-27 2020-09-01 DePuy Synthes Products, Inc. Soft tissue repair and regeneration using postpartum-derived cells and cell products
US9579351B2 (en) 2003-06-27 2017-02-28 DePuy Synthes Products, Inc. Postpartum cells derived from placental tissue, and methods of making and using the same
US10744164B2 (en) 2003-06-27 2020-08-18 DePuy Synthes Products, Inc. Repair and regeneration of ocular tissue using postpartum-derived cells
US7875272B2 (en) 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
US10500234B2 (en) 2003-06-27 2019-12-10 DePuy Synthes Products, Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US10195233B2 (en) 2003-06-27 2019-02-05 DePuy Synthes Products, Inc. Postpartum cells derived from placental tissue, and methods of making and using the same
US11000554B2 (en) 2003-06-27 2021-05-11 DePuy Synthes Products, Inc. Postpartum cells derived from placental tissue, and methods of making and using the same
US8703121B2 (en) 2003-06-27 2014-04-22 DePuy Synthes Products, LLC Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
US10383898B2 (en) 2003-06-27 2019-08-20 DePuy Synthes Products, Inc. Postpartum cells derived from placental tissue, and methods of making and using the same
US8318483B2 (en) 2003-06-27 2012-11-27 Advanced Technologies And Regenerative Medicine, Llc Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US9717763B2 (en) 2003-06-27 2017-08-01 DePuy Synthes Products, Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US9504719B2 (en) 2003-06-27 2016-11-29 DePuy Synthes Products, Inc. Soft tissue repair and regeneration using postpartum-derived cells and cell products
US8911997B2 (en) 2003-07-28 2014-12-16 Queensland University Of Technology Mammalian cell culture medium
AU2004260815B2 (en) * 2003-07-28 2010-05-20 Queensland University Of Technology Skin regeneration system
WO2005012508A1 (en) * 2003-07-28 2005-02-10 Queensland University Of Technology Skin regeneration system
JPWO2005118781A1 (en) * 2004-06-03 2008-04-03 国立大学法人京都大学 Insulin secretory cell induction
WO2005118781A1 (en) * 2004-06-03 2005-12-15 Kyoto University Induction of insulin secreting cell
US8778673B2 (en) 2004-12-17 2014-07-15 Lifescan, Inc. Seeding cells on porous supports
US7875273B2 (en) 2004-12-23 2011-01-25 Ethicon, Incorporated Treatment of Parkinson's disease and related disorders using postpartum derived cells
EP2302036A2 (en) 2005-05-27 2011-03-30 Lifescan, Inc. Amniotic fluid derived cells
US9074189B2 (en) 2005-06-08 2015-07-07 Janssen Biotech, Inc. Cellular therapy for ocular degeneration
US9175261B2 (en) 2005-12-16 2015-11-03 DePuy Synthes Products, Inc. Human umbilical cord tissue cells for inhibiting adverse immune response in histocompatibility-mismatched transplantation
US9725699B2 (en) 2006-04-28 2017-08-08 Lifescan, Inc. Differentiation of human embryonic stem cells
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
US10316293B2 (en) 2007-07-01 2019-06-11 Janssen Biotech, Inc. Methods for producing single pluripotent stem cells and differentiation thereof
EP2584034A1 (en) 2007-07-31 2013-04-24 Lifescan, Inc. Pluripotent stem cell differentiation by using human feeder cells
US10456424B2 (en) 2007-07-31 2019-10-29 Janssen Biotech, Inc. Pancreatic endocrine cells and methods thereof
US9096832B2 (en) 2007-07-31 2015-08-04 Lifescan, Inc. Differentiation of human embryonic stem cells
US9744195B2 (en) 2007-07-31 2017-08-29 Lifescan, Inc. Differentiation of human embryonic stem cells
US9062290B2 (en) 2007-11-27 2015-06-23 Lifescan, Inc. Differentiation of human embryonic stem cells
US9969982B2 (en) 2007-11-27 2018-05-15 Lifescan, Inc. Differentiation of human embryonic stem cells
US11001802B2 (en) 2008-02-21 2021-05-11 Nunc A/S Surface of a vessel with polystyrene, nitrogen, oxygen and a static sessile contact angle for attachment and cultivation of cells
US10066203B2 (en) 2008-02-21 2018-09-04 Janssen Biotech Inc. Methods, surface modified plates and compositions for cell attachment, cultivation and detachment
USRE43876E1 (en) 2008-04-24 2012-12-25 Centocor Ortho Biotech Inc. Cells expressing pluripotency markers and expressing markers characteristic of the definitive endoderm
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
US9845460B2 (en) 2008-04-24 2017-12-19 Janssen Biotech, Inc. Treatment of pluripotent cells
US7939322B2 (en) 2008-04-24 2011-05-10 Centocor Ortho Biotech Inc. Cells expressing pluripotency markers and expressing markers characteristic of the definitive endoderm
US9593306B2 (en) 2008-06-30 2017-03-14 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
US9593305B2 (en) 2008-06-30 2017-03-14 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
US10233421B2 (en) 2008-06-30 2019-03-19 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
US10351820B2 (en) 2008-06-30 2019-07-16 Janssen Biotech, Inc. Methods for making definitive endoderm using at least GDF-8
US9752126B2 (en) 2008-10-31 2017-09-05 Janssen Biotech, Inc. Differentiation of human pluripotent stem cells
US9234178B2 (en) 2008-10-31 2016-01-12 Janssen Biotech, Inc. Differentiation of human pluripotent stem cells
US9388387B2 (en) 2008-10-31 2016-07-12 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US9012218B2 (en) 2008-10-31 2015-04-21 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US9969973B2 (en) 2008-11-20 2018-05-15 Janssen Biotech, Inc. Methods and compositions for cell attachment and cultivation on planar substrates
US9969972B2 (en) 2008-11-20 2018-05-15 Janssen Biotech, Inc. Pluripotent stem cell culture on micro-carriers
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
US10557116B2 (en) 2008-12-19 2020-02-11 DePuy Synthes Products, Inc. Treatment of lung and pulmonary diseases and disorders
US9943552B2 (en) 2009-03-26 2018-04-17 DePuy Synthes Products, Inc. hUTC as therapy for Alzheimer's disease
US8785184B2 (en) 2009-07-20 2014-07-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US10076544B2 (en) 2009-07-20 2018-09-18 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US8785185B2 (en) 2009-07-20 2014-07-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US10471104B2 (en) 2009-07-20 2019-11-12 Janssen Biotech, Inc. Lowering blood glucose
US9133439B2 (en) 2009-12-23 2015-09-15 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US9150833B2 (en) 2009-12-23 2015-10-06 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US9969981B2 (en) 2010-03-01 2018-05-15 Janssen Biotech, Inc. Methods for purifying cells derived from pluripotent stem cells
US10329534B2 (en) 2010-03-01 2019-06-25 Janssen Biotech, Inc. Methods for purifying cells derived from pluripotent stem cells
US9752125B2 (en) 2010-05-12 2017-09-05 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US9181528B2 (en) 2010-08-31 2015-11-10 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
US9506036B2 (en) 2010-08-31 2016-11-29 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US9951314B2 (en) 2010-08-31 2018-04-24 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US9458430B2 (en) 2010-08-31 2016-10-04 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
US9528090B2 (en) 2010-08-31 2016-12-27 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US10358628B2 (en) 2011-12-22 2019-07-23 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into single hormonal insulin positive cells
US11377640B2 (en) 2011-12-22 2022-07-05 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into single hormonal insulin positive cells
US9611513B2 (en) 2011-12-23 2017-04-04 DePuy Synthes Products, Inc. Detection of human umbilical cord tissue derived cells
US10724105B2 (en) 2011-12-23 2020-07-28 DePuy Synthes Products, Inc. Detection of human umbilical cord tissue-derived cells
US9434920B2 (en) 2012-03-07 2016-09-06 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
US9593307B2 (en) 2012-03-07 2017-03-14 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
US10208288B2 (en) 2012-06-08 2019-02-19 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
US10066210B2 (en) 2012-06-08 2018-09-04 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
US10344264B2 (en) 2012-12-31 2019-07-09 Janssen Biotech, Inc. Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
US10377989B2 (en) 2012-12-31 2019-08-13 Janssen Biotech, Inc. Methods for suspension cultures of human pluripotent stem cells
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
US10947511B2 (en) 2012-12-31 2021-03-16 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells using thyroid hormone and/or alk5, an inhibitor of tgf-beta type 1 receptor
US10138465B2 (en) 2012-12-31 2018-11-27 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells using HB9 regulators
US10006006B2 (en) 2014-05-16 2018-06-26 Janssen Biotech, Inc. Use of small molecules to enhance MAFA expression in pancreatic endocrine cells
US10870832B2 (en) 2014-05-16 2020-12-22 Janssen Biotech, Inc. Use of small molecules to enhance MAFA expression in pancreatic endocrine cells
US10420803B2 (en) 2016-04-14 2019-09-24 Janssen Biotech, Inc. Differentiation of pluripotent stem cells to intestinal midgut endoderm cells
KR102208889B1 (en) 2017-01-31 2021-01-27 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 Method for controlling the differentiation of pluripotent stem cells
KR20190112090A (en) * 2017-01-31 2019-10-02 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 Control of Differentiation of Pluripotent Stem Cells

Also Published As

Publication number Publication date
EP1507848A1 (en) 2005-02-23
WO2003102171A9 (en) 2005-01-20
US20060122104A1 (en) 2006-06-08
CN1662643A (en) 2005-08-31
EP1507849A4 (en) 2006-05-03
US20040259244A1 (en) 2004-12-23
AU2003228255A1 (en) 2003-12-19
JP2006512046A (en) 2006-04-13
BR0311413A (en) 2005-03-22
JP2005527241A (en) 2005-09-15
EP1507849A1 (en) 2005-02-23
WO2003100038A1 (en) 2003-12-04
AU2003273573A1 (en) 2003-12-19
CN1819838A (en) 2006-08-16
US20040127406A1 (en) 2004-07-01
AU2003234666A1 (en) 2003-12-12
CA2487094A1 (en) 2003-12-11
EP1507848A4 (en) 2005-11-23
WO2003102171A1 (en) 2003-12-11
US20060275900A1 (en) 2006-12-07
US20040132183A1 (en) 2004-07-08
WO2003102134A3 (en) 2005-12-01
CA2485862A1 (en) 2003-12-11
EP1578925A2 (en) 2005-09-28
BR0311360A (en) 2006-06-06
EP1578925A4 (en) 2006-10-11

Similar Documents

Publication Publication Date Title
EP1578925A2 (en) Methods for in vitro expansion and transdifferentiation of human pancreatic acinar cells into insulin-producing cells
US6759039B2 (en) Culturing pancreatic stem cells having a specified, intermediate stage of development
US11708562B2 (en) Differentiation of human embryonic stem cells
CA2722619C (en) Pluripotent cells
ES2627419T3 (en) Adult stromal cells derived from the pancreas
US9068169B2 (en) CD56 positive human adult pancreatic endocrine progenitor cells
US8377689B2 (en) EPHA4-positive human adult pancreatic endocrine progenitor cells
CN100465268C (en) Culture method for human embryonic stem cell and special culture medium thereof
WO2022183740A1 (en) Method for preparing pancreatic beta cell, and use thereof
EP1301589A1 (en) Culturing pancreatic stem cells having a specified, intermediate stage of development
AU2013201439A1 (en) Adult pancreatic derived stromal cells
RezaSadeghi et al. Journal Information Journal ID (publisher-id): JRI
UA95733C2 (en) Method for producing endothelial cells (variants)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2006122104

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10515421

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2487094

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003726954

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004510376

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003228255

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20038170884

Country of ref document: CN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003726954

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0311360

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10515421

Country of ref document: US